Vanderbilt University Medical Center

Reports on Federal Awards in Accordance with the OMB Uniform Guidance
June 30, 2017
EIN # 35-2528741

Vanderbilt University Medical Center
Reports on Federal Awards in Accordance with the OMB Uniform Guidance
Index
June 30, 2017

Page

Part I – Financial Statements and Schedule of Expenditures of Federal Awards

Report of Independent Auditors 1

Consolidated Financial Statements 3

Notes to Consolidated Financial Statements 7

Schedule of Expenditures of Federal Awards 45

Notes to the Schedule of Expenditures of Federal Awards 103

Part II – Reports on Internal Control and Compliance

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards* 106

Report of Independent Auditors on Compliance with Requirements that Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the Uniform Guidance 108

Part III – Findings

Schedule of Findings and Questioned Costs 111

Summary Schedule of Prior Audit Findings 114

Management's Views and Corrective Action Plan 115

Part I
Financial Statements and
Schedule of Expenditures of Federal Awards

Vanderbilt University Medical Center

Consolidated Financial Statements
As of June 30, 2017 and
For the period April 29, 2016 through June 30, 2017

Vanderbilt University Medical Center
Table of Contents
June 30, 2017

Page

Report of Independent Auditors 1

Consolidated Balance Sheet 3

Consolidated Statement of Operations 4

Consolidated Statement of Changes in Net Assets 5

Consolidated Statement of Cash Flows 6

Notes to Consolidated Financial Statements 7

Report of Independent Auditors

To the Board of Directors of
Vanderbilt University Medical Center

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Vanderbilt University Medical Center (the "Medical Center"), which comprise the consolidated balance sheet as of June 30, 2017, and the related consolidated statement of operations, statement of changes in net assets, and statement of cash flows for the fourteen months ended June 30, 2017, and the related notes to the financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the Medical Center's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Medical Center's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Vanderbilt University Medical Center as of June 30, 2017, and the results of its operations and its cash flows for the fourteen months ended June 30, 2017 in accordance with accounting principles generally accepted in the United States of America.

PricewaterhouseCoopers LLP, 150 3rd Avenue South, Suite 1400, Nashville, TN 37201
T: (615) 503 2860, F: (615) 503 2870, www.pwc.com/us

Other Matters

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the fourteen months ended June 30, 2017 is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated December 7, 2017 on our consideration of the Medical Center's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the fourteen months ended June 30, 2017. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the operating effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Medical Center's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

December 7, 2017

Vanderbilt University Medical Center
Consolidated Balance Sheet
June 30, 2017

($ in thousands)

	2017
Assets	
Current	
Cash and cash equivalents	$ 520,857
Current investments	133,977
Patient accounts receivable, net of allowance for bad debts of $130.5 million as of June 30, 2017	378,704
Estimated receivables under third-party programs	12,642
Grants and contracts receivable, net	67,249
Inventories	67,478
Other current assets	69,058
Total current assets	1,249,965
Non-current investments	94,412
Non-current investments limited as to use	202,592
Property, plant, and equipment, net	1,219,768
Other non-current assets	34,593
Total assets	$ 2,801,330
Liabilities and Net Assets	
Current	
Current installments of long-term debt	$ 5,753
Accounts payable and other accrued expenses	272,641
Bank overdrafts	-
Estimated payables under third-party programs	37,072
Accrued compensation and benefits	194,739
Current portion of deferred revenue	39,353
Current portion of medical malpractice self-insurance reserves	17,161
Total current liabilities	566,719
Long-term debt, net of current installments	1,288,346
Fair value of interest rate exchange agreements	65,203
Non-current portion of medical malpractice self-insurance reserves	54,373
Non-current portion of deferred revenue	10,694
Other non-current liabilities	15,093
Total liabilities	2,000,428
Net assets	
Unrestricted net assets controlled by Vanderbilt University Medical Center	708,088
Unrestricted net assets related to noncontrolling interests	5,891
Total unrestricted net assets	713,979
Temporarily restricted net assets	69,058
Permanently restricted net assets	17,865
Total net assets	800,902
Total liabilities and net assets	$ 2,801,330

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statement of Operations
For the Period April 29, 2016 through June 30, 2017

($ in thousands)

Operating Revenues	
Patient service revenue, net of contractual adjustments and discounts	$ 4,000,729
Provision for bad debts	(130,476)
Patient service revenue, net	3,870,253
Academic and research revenue	479,372
Other operating revenue	179,922
Total operating revenues	4,529,547
Operating Expenses	
Salaries, wages, and benefits	2,350,780
Supplies and drugs	814,532
Facilities and equipment	285,043
Services and other	703,947
Depreciation and amortization	105,723
Interest	56,832
Total operating expenses	4,316,857
Income from operations	212,690
Non-operating Revenues & Expenses	
Income from investments	23,247
Gift income	10,985
Earnings of unconsolidated organizations	4,677
Unrealized gain on interest rate exchange agreements, net of cash settlements	8,286
Inherent contribution from VU	476,895
Other non-operating gains (losses), net	(861)
Total non-operating revenues & expenses	523,229
Excess of revenues over expenses	735,919
Excess of revenues over expense attributable to noncontrolling interests	(5,532)
Excess of revenues over expense attributable to VUMC	730,387
Other Changes in Unrestricted Net Assets	
Change in noncontrolling interest's net assets	5,891
Net asset reclassification	(22,234)
Other changes	(65)
Total changes in unrestricted net assets	$ 713,979

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statement of Changes in Net Assets
For the Period April 29, 2016 through June 30, 2017

($ in thousands)

Unrestricted Net Assets	
Unrestricted net assets at the beginning of the period	$ -
Excess of revenue over expense	730,387
Change in noncontrolling interest's net assets	5,891
Net asset reclassification	(22,234)
Other changes	(65)
Change in unrestricted net assets	713,979
Unrestricted net assets at the end of the period	$ 713,979
Temporarily Restricted Net Assets	
Temporarily restricted net assets at the beginning of the period	$ -
Contributions	31,072
Endowment appreciation	749
Net assets released from restrictions	(7,880)
Inherent contribution from VU	25,360
Net asset reclassification	19,757
Change in temporarily restricted net assets	69,058
Temporarily restricted net assets at the end of the period	$ 69,058
Permanently Restricted Net Assets	
Permanently restricted net assets at the beginning of the period	$ -
Contributions	8,628
Inherent contribution from VU	6,761
Net asset reclassification	2,476
Change in permanently restricted net assets	17,865
Permanently restricted net assets at the end of the period	$ 17,865
Total net assets at the beginning of the period	$ -
Change in total net assets	800,902
Total net assets at the end of the period	$ 800,902

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statement of Cash Flows
For the Period April 29, 2016 through June 30, 2017

($ in thousands)

Cash Flows from Operating Activities:	
Change in total net assets	$ 800,902
Adjustments to reconcile change in total net assets to net cash provided by operating activities:	
Inherent contribution	(509,016)
Depreciation and amortization	105,723
Amortization of debt issuance costs, and original issue premium and discount	(1,102)
Provision for bad debts	130,476
Loss on disposal of assets	3,398
Undistributed equity in earnings of equity method affiliates	1,714
Net realized and unrealized gain on investments	(17,397)
Purchases of trading securities	(312,072)
Sales of trading securities	111,995
Change in split-interest trusts	(963)
Unrealized gain on interest rate exchange agreements	(14,765)
Restricted contributions for endowments and property, plant, and equipment	(24,512)
(Decrease) increase in cash due to changes in:	
Patient accounts receivable	(163,556)
Inventories	(3,793)
Other assets and other liabilities, net	(66,784)
Accounts payable and other accrued expenses	73,342
Estimated net receivables and payables under third-party programs	(6,081)
Accrued compensation and benefits	100,299
Net cash provided by operating activities	207,808
Cash Flows from Investing Activities:	
Acquisition of Medical Center	(600,971)
Purchase of property, plant, and equipment	(176,383)
Purchases of long-term securities	(176,934)
Sales and maturities of long-term securities	92,859
Change in restricted cash for property, plant, and equipment contributions	(15,893)
Net cash used in investing activities	(877,322)
Cash Flows from Financing Activities:	
Proceeds from issuance of long-term debt	1,189,644
Debt issuance costs	(12,532)
Repayment of long-term debt	(5,417)
Principal payments under capital lease obligations	(693)
Restricted contributions for endowments and property, plant, and equipment	24,512
Distributions to noncontrolling interests	(5,143)
Net cash provided by financing activities	1,190,371
Net change in cash and cash equivalents	520,857
Cash and cash equivalents at the beginning of the period	-
Cash and cash equivalents at the end of the period	$ 520,857

The accompanying notes are an integral part of these consolidated financial statements.

1. Description of Organization

Vanderbilt University Medical Center ("VUMC") is a Tennessee not-for-profit corporation incorporated in March of 2015 to operate an academic medical center including a comprehensive research, teaching, and patient care health system (the "Medical Center"). Until April 29, 2016, the Medical Center operated as a unit within Vanderbilt University ("the University" or "VU"), as a part of the University's administrative structure, with the same governing board, legal, financial, and other shared services.

VUMC began operations effective April 30, 2016, following the closing of the sale of the Medical Center by the University (the "Acquisition"). VUMC owns and operates three hospitals primarily located on the main campus of the University in Nashville, Tennessee: Vanderbilt University Adult Hospital ("VUAH"), Monroe Carell Junior Children's Hospital at Vanderbilt ("MCJCHV"), and Vanderbilt Psychiatric Hospital ("VPH"). In addition, VUMC partially owns Vanderbilt Stallworth Rehabilitation Hospital ("VSRH"), also located on the main campus of the University, through a joint venture with HealthSouth Corp. in which VUMC holds a 50% interest, which includes a 1% interest held by Vanderbilt Health Services, LLC, ("VHS"), a VUMC wholly owned subsidiary. VUAH, MCJCHV, and VPH are licensed for 1,025 beds, and VSRH is licensed for 80 beds.

VUMC consists of two major operating divisions and an administrative overhead division. The operating divisions include the Clinical Enterprise and Academic Enterprise divisions. The administrative overhead division is referred to as Medical Center Administration ("MCA").

The Clinical Enterprise division includes the professional clinical practice revenues and related expenses of the Vanderbilt Medical Group ("VMG"), and technical revenues and associated expenses for the operation of VUMC's hospitals and clinic facilities, including VUAH, MCJCHV, and VPH. The Clinical Enterprise also includes VHS.

- VUAH is a quaternary care teaching hospital licensed for 670 acute care and specialty beds. VUAH, a Level I trauma center, provides advanced patient care and serves as a key site for medical education and clinical research conducted by physician faculty. VUAH includes a comprehensive burn center, the Vanderbilt Transplant Center, the Vanderbilt Heart and Vascular Institute, and the Vanderbilt Ingram Cancer Center.

- MCJCHV is a pediatric quaternary care teaching hospital licensed for 129 acute and specialty beds, 42 pediatric intensive care beds, and 96 neonatal intensive care beds. MCJCHV is the region's only full-service pediatric hospital, with over 30 pediatric specialties. MCJCHV serves as a site for medical education and clinical research conducted by pediatric physician faculty, houses the only Level IV neonatal intensive care center and the only Level 1 pediatric trauma center within the region, and is a regional referral center for extracorporeal membrane oxygenation (heart and lung failure).

- VPH is a psychiatric hospital licensed for 88 beds and provides both inpatient and outpatient partial hospitalization psychiatric services to both adult and adolescent patients. Also, VPH provides psychiatric assessment services and neuromodulation procedures through electroconvulsive therapy and transcranial magnetic stimulation.

- The VMG is the practice group of physicians and advanced practice nurses employed by VUMC, with faculty appointments from the University, who perform billable professional medical services. The VMG is not a separate legal entity. The VMG has a board which consists of the VUMC clinical service chiefs, who also serve as clinical department chairs.

The accompanying notes are an integral part of these consolidated financial statements.

Under the oversight of VUMC executive leadership, the VMG sets professional practice standards, bylaws, policies, and procedures for the administration of a group practice. VUMC bills for services rendered by the VMG clinicians in both inpatient and outpatient locations. Collected fees derive a component of each VMG clinician's compensation.

- The VMG includes nationally recognized physicians whose expertise spans the spectrum from primary care to the most specialized quaternary discipline. The entire clinical faculty is "board certified" or eligible for board certification. All staff members are re-credentialed every two years by the National Committee for Quality Assurance standards. All specialties and subspecialties currently recognized by the various national specialty boards are represented on the clinical faculty.

- VHS serves as a holding company for 13 health care related subsidiaries and joint ventures owned with various entities, including, but not limited to, VSRH and the Vanderbilt Health Affiliated Network ("VHAN"). VHS operations primarily consist of community physician practices, imaging services, outpatient surgery centers, radiation oncology centers, a home health care agency, a home infusion and respiratory service, an affiliated health network, and a rehabilitation hospital. These subsidiaries include clinics managed in multiple outpatient locations throughout middle Tennessee and southwestern Kentucky.

The Academic Enterprise division includes all clinically-related research, research-support activities, and faculty endeavors supporting post-graduate training programs. A significant funding source for VUMC's research has historically been the federal government. Federal funding is received from the Department of Health and Human Services, the National Institutes of Health, the Department of Defense, NASA, and other federal agencies. Sponsored research awards, including multiple-year grants and contracts from government sources, foundations, associations, and corporations signify future research commitments. Also, core activities supporting research, including advanced computing and grant administration, are included in this division.

The terms "Company," "VUMC," "we," "our" or "us" as used herein and unless otherwise stated or indicated by context, refer to Vanderbilt University Medical Center and its affiliates. The term "facilities" or "hospitals" refer to entities owned and operated by VUMC and its affiliates and the term "employees" refers to employees of VUMC and its affiliates.

VUMC operates on a fiscal year which ends on June 30. References to the period from April 29, 2016 to June 30, 2017 are referred to as the Fourteen Month Period.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the U.S. (GAAP). Based on the existence or absence of donor-imposed restrictions, VUMC classifies resources into three categories: unrestricted, temporarily restricted, and permanently restricted net assets.

Principles of Consolidation

The consolidated financial statements include the accounts of VUMC and its wholly owned, majority-owned, and controlled organizations. Noncontrolling interests in less-than-wholly owned consolidated subsidiaries of VUMC are presented as a component of net assets to distinguish between the interests of VUMC and the interests of the noncontrolling owners. All material intercompany transactions and account balances among the various entities have been eliminated.

VUMC uses the equity method to account for its interests in unconsolidated partnerships, joint ventures, and limited liability entities over which it exercises significant influence. Investment carrying amounts are adjusted for VUMC's share of investee earnings or losses based on percentage of ownership. Distributions received from unconsolidated entities that represent returns on the investor's investment (i.e., dividends) are reported as cash flows from operating activities in the investor's statement of cash flows.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. These estimates affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results ultimately could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents are liquid assets with minimal interest rate risk and maturities of three months or less when purchased. VUMC invests operating assets in a diversified manner. At times, VUMC may have cash and cash equivalents at a financial institution in excess of federally insured limits, and therefore, bear a risk of loss. VUMC maintains certain cash balances within the non-current investments limited as to use caption in the consolidated balance sheet which are not included in the cash and cash equivalents section.

Revenue Recognition—Healthcare Services

VUMC recognizes revenues from patient services in the period those services are provided and reports these revenues at the net realizable amount expected to be collected from patients or through the assignment or other entitlement to receive patients' benefits payable under patients' health insurance programs, plans or policies. Amounts realized from patient services are generally less than standard billing charges, due to contractual agreements with third-party payors, state-mandated discounts, governmental programs that require reduced billing rates, or amounts which prove uncollectible.

In addition to patient payments, VUMC earns revenue and reimbursements from certain services provided under federal healthcare programs, and other contracts with third-party payors. These

compensation arrangements are complex programs which extend over multiple accounting periods, are subject to the interpretation of federal and state-specific reimbursement rates, new or changing legislation, and final cost report settlements. Estimated settlements under these programs are recorded in the period the related services are performed and are subsequently adjusted, as needed, based on new information.

VUMC receives periodic interim payments from Medicare in lieu of individual payments for patient claims processed by VUMC's fiscal intermediary. These payments are applied against claims processed, with the final settlement of amounts owed for a fiscal year included in the applicable Medicare cost report.

In evaluating the collectability of accounts receivable, VUMC analyzes its history and identifies trends for each of its major revenue categories to estimate the appropriate allowance for bad debts and related provision. Management regularly reviews data about these major revenue categories in evaluating the sufficiency of the allowance for bad debts, taking into consideration recent write-off experience by payor category, payor agreement rate changes, and other factors. For third-party payors, the provision is determined by analyzing contractually due amounts from payors who are known to be having financial difficulties. For self-pay patients, the provision is based on an analysis of experience related to patients' payments. The difference between the standard rate charged (less contractual adjustments and discounts) and the amount collected (after reasonable collection efforts have been exhausted) are charged against the allowance for doubtful accounts. VUMC follows established guidelines, Centers for Medicare & Medicaid Services (CMS) regulations, and IRS Reg. §1.501(r)-6 for placing certain past-due patient balances with external collection agencies. During the Fourteen Month Period, cash collections related to the professional and technical component of our patient accounts receivable balance exceeded the receivable recorded as of April 29, 2016 by $30.2 million.

VUMC provides care to patients who meet the criteria under its financial assistance policy for no payment, or at payment amounts less than its established charge rates. VUMC does not recognize the charges that qualify as charity care as revenue because VUMC does not pursue collection of these amounts.

Revenue Recognition— Academic and Research
VUMC receives funding through grants and contracts issued by departments and agencies of the U.S. government, industry, and other foundation sponsors who restrict the use of such funds to academic and research purposes. VUMC recognizes revenue from these grants and contracts upon the incurrence of allowable expenditures, as defined in the agreements governing that funding. VUMC recognizes facilities and administrative (F&A) costs recovery as revenue when revenue is recognized on the associated grant or contract. This activity represents reimbursement, primarily from the federal government, of F&A costs on sponsored activities.

Research grants and contracts receivable includes amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor. These receivables are reported net of reserves for uncollectible accounts.

Deferred Revenue
The majority of deferred revenue relates to grants and contracts whereby certain grantors pay in advance of incurring eligible costs. In these cases, VUMC records the amount received in excess of reimbursable costs incurred as deferred revenue.

The accompanying notes are an integral part of these consolidated financial statements.

Gift Income and Pledges
VUMC recognizes unconditional promises to give cash and other assets, referred to as pledges, as gift income at fair value when the pledge is received. Conditional promises to give are recognized as pledges once the conditions are substantially met. Gifts received with donor stipulations limiting the use of the donated assets are reported as either temporarily or permanently restricted support, depending on the nature of the restriction. Donor-restricted contributions whose restrictions are met within the same year as received are reported as gift income in the accompanying consolidated statement of operations. Gift income is recognized when a donor restriction expires, that is, when a stipulated time restriction ends, or purpose restriction is accomplished. Pledges are treated as unrestricted, temporarily restricted, or permanently restricted net assets depending on the donor instructions associated with the pledge. Gifts of cash or other assets that must be used to acquire long-lived assets are reported as temporarily restricted net assets until the assets are placed in service, at which point they are reclassified to unrestricted net assets.

Pledges receivable are reported net of allowances for uncollectible amounts based on an analysis of past collection experience and other judgmental factors. Pledges receivable are reflected as current or non-current assets in the consolidated balance sheet based on the expected timing of cash flows. VUMC discounts the non-current portion of pledges receivables at a rate commensurate with the scheduled timing of receipt. VUMC applied discount rates ranging from 0.5% to 1.5% to amounts outstanding as of June 30, 2017.

Concentrations of Credit Risk
VUMC grants unsecured credit to its patients, primarily residing in Nashville, Tennessee and the surrounding areas of middle Tennessee, most of whom are insured under commercial, Medicare, or TennCare agreements. Medicare, Blue Cross Blue Shield (“BCBS”), and TennCare (which includes BCBS, United, and Amerigroup) represent VUMC’s significant concentrations of credit risk from payors.

Inventories
VUMC reports inventories at the lower of cost or market, with cost being determined on the first-in, first-out method. Inventories consist primarily of medical supplies, surgical implants, and pharmaceuticals.

Investments
VUMC has elected the fair value option related to investments, including investments limited as to use, and reports investments held at fair value on the consolidated balance sheets. VUMC records purchases and sales of securities on the trade dates and realized gains and losses are determined based on the average historical cost of the securities sold. VUMC reports net receivables and payables arising from unsettled trades as a component of investments.

Property, Plant, and Equipment, Net
VUMC records purchases of property, plant, and equipment at cost, and expenses repairs and maintenance costs as incurred. VUMC capitalizes interest cost incurred on borrowed funds during the period of construction of capital assets as a component of the cost of acquiring those assets. VUMC capitalizes donated assets at fair value on the date of donation.

Capitalized software for internal use is recorded during the application development stage. These costs include fees paid to third parties for direct costs of materials and services consumed in developing or obtaining the software; payroll related costs and capitalized interest costs. Costs for training and application maintenance in the post-implementation operation stage are expensed as incurred.

VUMC computes depreciation using the straight-line method over the estimated useful life of land improvements (3 to 18 years), buildings and leasehold improvements (2 to 37 years) and equipment (1 to 20 years). Equipment costs also include capitalized internal use software costs, which are expensed over the expected useful life, which is generally 1.5 to 12 years. VUMC assigns useful lives in accordance with American Hospital Association guidelines.

Software for internal use is amortized on a straight-line basis over its estimated useful life. In determining the estimated useful life, management considers the effects of obsolescence, technology, competition, other economic factors and rapid changes that may be occurring in the development of software products, operating systems, and computer hardware. Amortization begins once the software is ready for its intended use, regardless of when the software is placed into service.

Impairment of Long-Lived Assets
VUMC reviews long-lived assets, such as property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. VUMC measures the recoverability of assets to be held and used by comparing the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, VUMC recognizes an impairment charge to the extent the carrying amount of the asset exceeds its fair value.

Conditional Asset Retirement Costs and Obligations
VUMC recognizes the estimated fair value of liabilities for existing legal obligations to perform certain activities, primarily asbestos removal, in connection with the retirement, disposal, or abandonment of assets. These liabilities are included in accounts payable and other accrued expenses and total $6.0 million as of June 30, 2017. VUMC measures these liabilities using estimated cash flows with an inflation rate applied of 3.0% as of June 30, 2017. VUMC discounts those cash flow estimates at a credit-adjusted, risk-free rate, which ranged from 2.9% to 4.2% as of June 30, 2017, and adjusts these liabilities for accretion costs and revisions in estimated cash flows.

Long-Term Debt
The carrying value of VUMC's debt is the par amount adjusted for the net unamortized amount of debt issuance costs, and bond premiums and discounts.

Interest Rate Exchange Agreements
VUMC reports interest rate exchange agreements at fair value, which is determined to be the present value sum of future net cash settlements that reflect market yields as of the measurement date and estimated amounts that VUMC would pay, or receive, to terminate the contracts as of the report date. VUMC considers current interest rates and creditworthiness of the interest rate exchange counterparties when estimating termination settlements.

Self-Insurance Reserves
VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability coverage via an irrevocable self-insurance trust. The maximum annual self-insurance retention was $5.5 million per occurrence, up to $43.0 million in the aggregate for the Fourteen Month Period. Actuarial firms determine expected losses on an annual basis, at which time VUMC records medical malpractice, professional, and general liability expense within the limits of the program. These liabilities were classified as current or non-current based on the expected timing of cash flows and were measured at the net present value of those cash flows using a discount rate of 2.5% as of June 30, 2017. Throughout the Fourteen Month Period, VUMC carried excess medical malpractice, professional, and general liability coverage from commercial insurance carriers for claims in excess of $5.5 million per occurrence, up to $100.0 million. These policies would also provide coverage up to $100.0 million if any claims in the aggregate exceed $43.0 million.

VUMC also elects to self-insure for employee health and workers' compensation expenses. Actuarial firms determine expected losses on an annual basis. The maximum retention for workers' compensation was $0.8 million per occurrence for the Fourteen Month Period. There is no stop loss insurance on health plan claims.

Income Taxes
VUMC is a tax-exempt organization as described in Section 501(c)(3) of the Internal Revenue Code (the Code) and is generally exempt from federal income taxes under Section 501(a) of the Code.

Excess of Revenues Over Expenses
The consolidated statements of operations include excess of revenues over expenses as a performance indicator. Excess of revenues over expenses includes all changes in unrestricted net assets except for changes in noncontrolling interest holders' share of consolidated entities, reclassifications of net assets from the prior period presentation, and certain other adjustments.

Recent Accounting Pronouncements
Periodically, the Financial Accounting Standards Board ("FASB") issues Accounting Standards Updates ("ASU") that may impact the recognition, measurement, and presentation of balances and activity in VUMC's consolidated financial statements, or the disclosures contained within those statements. As part of preparing financial statements, VUMC evaluates the effects of the ASUs, and applies the updated guidance within the required effective dates.

During the Fourteen Month Period, VUMC adopted ASU 2014-15, *Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern*. The amendments require management to assess an entity's ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (i) provide a definition of the term substantial doubt, (ii) provide principles for considering the mitigating effect of management's plans, (iii) require certain disclosures when substantial doubt is alleviated as a result of consideration of management's plans, (iv) require an express statement and other disclosures when substantial doubt is not alleviated, and (v) require an assessment for a

period of one year after the date that the financial statements are issued, or available to be issued. The adoption of ASU No. 2014-15 had no effect on VUMC's financial statements

Following is a summary of ASUs which VUMC believes have a reasonably possible likelihood of having a material effect on the recognition, measurement, and presentation of balances and activity in VUMC's consolidated financial statements:

- In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, which is a principles-based standard on revenue recognition. Companies across all industries will use a five-step model to recognize revenue from customer contracts. The new standard, which replaces nearly all existing GAAP revenue recognition guidance, will require significant management judgment in addition to changing the way many companies recognize revenue in their financial statements. The FASB subsequently issued ASU No. 2016-08, *Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations,* ASU No. 2016-10, *Revenue from Contracts with Customer (Topic 606) Identifying Performance Obligations and Licensing*, and ASU No. 2016-12, *Narrow-Scope Improvements and Practical Expedients* to address issues arising from implementation of the new revenue recognition standard. For VUMC, the revised ASU will be adopted for Fiscal 2019. VUMC continues to evaluate the effects the adoption of this standard will have on our consolidated financial statements and disclosures.

- In February 2016, the FASB issued ASU 2016-02, *Leases*, which requires lessees to recognize assets and liabilities for most leases. ASU 2016-02's transition provisions will be applied using a modified retrospective approach at the beginning of the earliest comparative period presented in the financial statements. For VUMC, the amendments in ASU 2016-02 are effective for Fiscal 2020, although early adoption is permitted. VUMC expects the primary effect of adopting the new standard to be a requirement to record assets and offsetting obligations for current operating leases.

- In August 2016, the FASB issued ASU 2016-14, *Presentation of Financial Statements for Not-for-Profit Entities,* which, among other things, replaces the existing three-category classification of net assets (i.e., unrestricted, temporarily restricted, and permanently restricted) with a model that combines temporarily restricted and permanently restricted into a single category called "net assets with donor restrictions." Differences in the nature of donor restrictions will be disclosed in the notes, with an emphasis on how and when the resources can be used. ASU 2016-14 also provides guidance for classifying deficiencies in endowment funds, accounting for the lapsing of restrictions on gifts to acquire property, plant, and equipment, and providing information about how the nature of expenses relates to programs and supporting activities. For VUMC, ASU 2016-14 is effective for Fiscal 2019, although early adoption is permitted. ASU 2016-14's requirements must be applied retrospectively; however, entities can elect not to provide certain comparative disclosures in the year of adoption.

- In January 2017, the FASB issued ASU 2017-02, *Clarifying When a Not-for-Profit Entity That Is a General Partner or a Limited Partner Should Consolidate a For-Profit Limited Partnership or Similar Entity.* Under the new guidance, Not-for-Profit (NFP) investors in a limited partnership or similar entity will continue to apply a presumption that the general partner has control and should consolidate the investment unless substantive kick-out or participating rights held by any limited partners overcome that presumption. If

the general partner does not have control, the limited partners have to evaluate whether they have control. If a limited partner has control, consolidation is required unless the investment is part of a portfolio for which the NFP "portfolio-wide" fair value option has been elected. In that situation, the limited partner can instead report its interest at fair value, mirroring an exception that already exists for NFP general partners. For VUMC, ASU 2017-02 is effective for Fiscal 2018.

3. Acquisitions

On April 29, 2016, VUMC acquired the assets, liabilities, rights, and obligations of the clinical enterprise, post-graduate medical training programs and clinically-related research of the University owned and operated Medical Center for consideration of $1.23 billion ("the Acquisition"). To fund the Acquisition, VUMC entered into certain debt agreements to borrow $1.13 billion of publically and privately placed debt and committed to a $100.0 million subordinate note to the University payable over twenty years (May 2016 through April 2036). VUMC paid VU cash of $1.13 billion to acquire the Medical Center assets and liabilities which included $529.0 million of cash. The net cash paid of $601.0 million represents the $1.13 billion of cash paid to VU net of the $529.0 million of cash included in the assets acquired. In addition to the cash consideration paid and subordinate note payable, VUMC committed to additional consideration in the form of other payables of $31.7 million; a $12.0 million commitment to fund trans-institutional programs and a $19.7 million memorandum of understanding ("MOU") to fund certain University capital projects both of which were previously agreed to be funded by the Medical Center. These Medical Center assets and operations were used to form the two major operating divisions of VUMC.

VUMC accounted for the Acquisition using the acquisition method of accounting under ASC 805-10-05-4 as modified by ASC 958-805-25, whereby the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date VUMC obtained control of the Medical Center. The Acquisition resulted in an inherent contribution from the University totaling $509.0 million. The inherent contribution is a result of the University's interest in the success of VUMC and the shared missions of the two organizations which are memorialized in the agreements discussed within this note. No goodwill was recorded as a result of this transaction.

The table below summarized the allocation of the purchase price (including assumed liabilities) for the Medical Center as of the acquisition date ($ in thousands):

Identifiable net assets contributed:	
Current assets	$ 492,709
Property, plant, and equipment	1,121,845
Other non-current assets	207,101
Liabilities	(574,466)
Noncontrolling interests	(5,502)
Total identifiable net assets contributed	1,241,687
Less: Total consideration paid to VU	
Net cash consideration paid	600,971
Note payable to VU	100,000
Other VU payables	31,700
Total consideration	732,671
Inherent contribution from VU	$ 509,016

The inherent contribution from VU is included in the following fund balances from April 29, 2016, the date of the Acquisition ($ in thousands):

Unrestricted	$ 476,895
Temporarily restricted	25,360
Permanently restricted	6,761
Total inherent contribution from VU	$ 509,016

The assets acquired and liabilities assumed from the Acquisition were detailed in a Master Transfer and Separation Agreement (“MTSA”). In addition to the explanation of the transaction details pertaining to the Medical Center assets and liabilities, the MTSA contains the framework for the ongoing economic relationship between VUMC and the University. The relationship is memorialized in the form of an Academic Affiliation Agreement (“AAA”), a Trademark License Agreement (“TMLA”), a Ground Lease, and a Reciprocal Master Services Agreement (“MSA”).

4. Related Parties

After the Acquisition, when control of the assets necessary to operate VUMC transferred from VU, VUMC has operated as a 501(c)(3) not-for-profit corporation, governed by a separate and autonomous board apart from the governance of VU; VUMC is responsible for its debt and liabilities, separate and apart from the University. At legal separation, VUMC and VU entered into several agreements that govern the relationship between the two entities moving forward as described below.

- The AAA outlines the ongoing academic, research, and clinical affiliation between the University and VUMC for all of the University's degree-granting, certificate and research programs. The AAA allocates responsibility between the University and VUMC for jointly administered academic and residency programs and is an exclusive agreement between VUMC and VU requiring VUMC to be organized, governed, and operated in a manner that supports VU's academic and research mission. The agreement provides that VU will be the exclusive academic affiliate of VUMC and VUMC will be the exclusive clinical affiliate of VU.

  The AAA requires VUMC to pay VU an annualized fee of $70.0 million in equal monthly payments adjusted annually for inflation based upon the Biomedical Research and Development Price Index (BRDPI) in perpetuity under certain mutually agreed upon termination or default clauses. During the Fourteen Month Period, VUMC recorded operating expenses totaling $83.2 million in connection with fees due under the AAA.

  The AAA required a one-time $12.0 million commitment to fund trans-institutional programs with the University. VUMC paid this commitment in June 2017. This commitment was recorded as additional consideration in the Acquisition, as discussed in Note 3—Acquisitions.

- Under the TMLA, the University grants, subject to certain consents and approvals, a perpetual license to use various University-owned licensed marks in connection with VUMC's fundamental activities after the Acquisition date. The licensed marks, which VUMC will continue to use as its primary brands, include virtually all those currently in use by VUMC. This agreement requires VUMC to pay VU a monthly royalty payment equal to 1.0% of all operating revenues (as defined in the TMLA) of VUMC and a percentage of net income (0% in Fiscal 2017, 5% in Fiscal 2018, 10% in Fiscal 2019, and 15% in Fiscal 2020 and beyond) from operations (as defined in the TMLA). Also, VUMC is required to pay VU, in equal monthly installments, an annualized fee of $61.8 million, increasing by 3% annually, and reduced by the amount of principal payments made under the subordinate note payable to VU discussed in Note 12—Long-Term Debt. This agreement is in force in perpetuity under certain mutually agreed upon termination or default clauses. During the Fourteen Month Period, VUMC recorded operating expenses totaling $110.6 million in connection with fees due under the TMLA.

- The Ground Lease is an agreement between VU and VUMC that allows VUMC to use the land on which VUMC's campus and related buildings are located. The initial term of the Ground Lease ends June 30, 2114, with the option to extend the lease for two additional terms of up to fifty to ninety-nine years each with agreement between VU and VUMC. The lease covers 1.7 million square feet or 38.75 acres of space with an annual base rent of $18.0 million payable monthly and CPI adjusted annually beginning in Fiscal 2017. During the Fourteen Month Period, VUMC recorded operating expenses totaling $21.1 million in connection with fees due under the Ground Lease.

- The University and VUMC provide services to one another for agreed-upon consideration as outlined in the MSA. VU will provide services to VUMC such as information technology infrastructure support, utilities, and law enforcement staffing. VUMC will provide various operational services for the University such as student health centers, a psychological counseling center, and animal care. Additionally, the MSA encompasses an Employee Matters Agreement (EMA) and specific Employee Service Agreements (ESAs). The EMA and ESAs govern employee transitions and on-going sharing between VU and VUMC in various capacities, such as research, teaching, clinical, and other administrative services. Services under the MSA can be terminated by either party subject to pre-determined cancellation notification periods. In connection with the MSA, during the Fourteen Month Period, VUMC recognized revenue totaling $58.4 million and recorded operating expenses totaling $142.1 million.

- Also, as part of the Acquisition, VUMC issued to VU a $100.0 million subordinate promissory note payable, which is further described in Note 12—Long-Term Debt, with a balance of $94.6 million as of June 30, 2017. During the Fourteen Month Period, VUMC recorded interest expense totaling $3.7 million associated with this subordinate promissory note payable to VU.

The impact of these related party agreements in the statement of operations during the Fourteen Month Period is as follows ($ in thousands):

Other operating revenues	$ 58,383
Operating Expenses	
Salaries, wages, and benefits	$ 700
Supplies and drugs	387
Facilities and equipment	62,936
Services and other	293,019
Interest	3,689
Total operating expenses	$ 360,731

Other current assets include amounts receivable from VU, which totaled $5.8 million as of June 30, 2017. Accounts payable and other accrued expenses include amounts payable to VU, which totaled $30.0 million as of June 30, 2017, for services provided to VUMC under the MSA. As of June 30, 2017, the receivable from VU relates to services provided by VUMC to VU under the MSA.

The accompanying notes are an integral part of these consolidated financial statements.

In the normal course of business, members of VUMC's Board of Directors or VUMC employees may be directly or indirectly associated with companies engaged in business activities with VUMC. VUMC has a written conflict of interest policy that requires, among other things, that members of the VUMC community (including trustees) may not review, approve, or administratively control contracts or business relationships when (i) the contract or business relationship is between VUMC and a business in which the individual or a family member has a material financial interest or (ii) the individual or a family member is an employee of the business and is directly involved with activities pertaining to VUMC.

Furthermore, VUMC's conflict of interest policy extends beyond the foregoing business activities in that disclosure is required for any situation in which an applicable individual's financial, professional, or other personal activities may directly or indirectly affect, or have the appearance of affecting, an individual's professional judgment in exercising any VUMC duty or responsibility, including the conduct or reporting of research.

The policy extends to all members of the VUMC community (including trustees, faculty, and staff and their immediate family members). Each applicable person is required to certify compliance with the conflict of interest policy on an annual basis. This certification includes specifically disclosing whether VUMC conducts business with an entity in which he or she (or an immediate family member) has a material financial interest as well as any other situation that could appear to present a conflict with VUMC's best interests.

When situations exist relative to the conflict of interest policy, VUMC takes active measures to manage appropriately the actual or perceived conflict in the best interests of VUMC, including periodic reporting of the measures taken to the Board of Directors Audit Committee.

5. Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-party Settlements

The sources of patient service revenues, net, for the Fourteen Month Period are as follows:

Commercial/managed care	63.2%
Medicare/Managed Medicare	23.3%
TennCare/Medicaid	11.9%
Uninsured (self-pay)	1.6%
	100.0%

Patient service receivables, net, comprise the following as of June 30, 2017 ($ in thousands):

Patient accounts receivable, net of contractual adjustments and discounts[1]	$ 509,180
Allowance for bad debts	(130,476)
Patient accounts receivable, net	$ 378,704

Patient accounts receivable, net of related contractual adjustments, discounts, and bad debt allowances comprise amounts due from the following sources as of June 30, 2017 ($ in thousands):

Medicare	$ 56,890
TennCare/Medicaid	55,207
Blue Cross	77,514
Other third-party payors, primarily commercial carriers	149,049
Patient responsibility[1]	40,044
Patient accounts receivable, net	$ 378,704

[1] Includes self-pay after insurance.

The accompanying notes are an integral part of these consolidated financial statements.

Estimated third-party settlements by major payor category as of June 30, 2017, are as follows ($ in thousands):

Receivables under third-party programs:		
Tricare/Champus	$	4,712
Medicare		7,930
Total receivables under third-party programs	$	12,642
Payables under third-party programs:		
TennCare/Medicaid	$	37,072
Medicare		-
Other		-
Total payables under third-party programs	$	37,072

Certain contracts require pay for performance or episode of care settlements whereby VUMC receives additional payment or pays a penalty based on ability to achieve certain clinical measures or manage the cost of care for patients within various thresholds. VUMC estimates and accrues these adjustments in the period the related services are rendered, and adjusts these estimates in future periods as settlements are finalized. The aggregate liability associated with pay for performance and episode of care settlements at June 30, 2017, was $1.7 million, with the ultimate resolution of such financial arrangements not expected to have a material impact on the operating results of VUMC.

Medicare

Amounts received under Medicare are subject to review and final determination by program intermediaries or their agents. Final settlements have been reached for program periods ended June 30, 2011. Final settlements have not been reached for more recent years due to audit delays experienced with the Medicare Administrative Contractor. VUMC expects final settlements relative to periods through June 30, 2013, to be complete during Fiscal 2018. Years without final settlement determinations are subject to audit by program representatives. VUMC records provisions in the financial statements for the effects of estimated final settlements. The receivable above is presented net of these provisions.

TennCare

TennCare is a Medicaid managed care program implemented by the State of Tennessee to provide healthcare coverage to those patients eligible for Medicaid, through the Federal 1115 Waiver Program. VUMC contracts with each of the three TennCare managed care organizations (MCOs), which offer health maintenance organization (HMO) and Medicare Special Needs Products for Dual Eligible Enrollees. VUMC receives inpatient reimbursement through payments that are primarily based on the Medicare severity diagnostic related group system (MS-DRG) for these plans. VUMC receives outpatient payments generally based on an ambulatory payment classification system (APC), and/or a payor-developed fee schedule.

The accompanying notes are an integral part of these consolidated financial statements.

In accordance with the Tennessee Hospital Assessment Act, VUMC receives a payment of a portion of its unreimbursed TennCare costs based upon VUMC's share of uninsured TennCare costs for all of the covered hospitals.

There is no assurance that this program will be continued or will not be materially modified in the future. In the Fourteen Month Period, patient service revenues, net, include the following supplemental amounts from TennCare ($ in thousands):

Essential access	$	15,954
Disproportionate share		17,198
Trauma fund		2,131
Graduate medical education		16,681
Reserve for disproportionate share audit		(27,593)
Total supplemental TennCare revenue, net of audit reserves	$	24,371

The accompanying notes are an integral part of these consolidated financial statements.

6. Charity Care Assistance, Community Benefits, and Other Unrecovered Costs

VUMC maintains a policy which sets forth the criteria under which health care services are provided to patients who have minimal financial resources to pay for medical care. Additionally, VUMC provides other services that benefit the economically disadvantaged for which little or no payment is expected.

Charity care is determined by examining patient and family income relative to the federal poverty guidelines. VUMC provides additional discounts based on the income level of the patient household using a sliding scale for those patients with a major catastrophic medical event not qualifying for full charity assistance. Tennessee law mandates that all uninsured patients receive a discount from billed charges for medically necessary services. These amounts are classified as charity care if the patient meets charity care criteria, for which no revenue is recorded, or as a discount, and included as a part of discounts and contractual adjustments.

VUMC maintains records to identify and monitor the level of charity care provided, and these records include gross charges and patient deductibles, coinsurance and copayments forgone for services furnished under its charity care policy, and the estimated cost of those services. VUMC calculates a ratio of total costs to gross charges and then multiplies the ratio by foregone charity care charges in determining the estimated cost of charity care. The gross amount of foregone charity care revenues in the Fourteen Month Period total $304.9 million. The estimated cost of providing care to charity patients in the Fourteen Month Period totals $82.2 million, an amount which has been reduced by any reimbursements from governmental assistance programs to subsidize its care of indigent patients.

In addition to the charity care services described above, TennCare/Medicaid and state indigent programs do not cover the full cost of providing care to beneficiaries of those programs. As a result, in addition to direct charity care costs, VUMC provided services related to TennCare/Medicaid and state indigent programs and was reimbursed substantially below the cost of rendering such services. VUMC also provides public health education and training for new health professionals and provides, without charge, services to the community at large, together with support groups for many patients with special needs.

7. Academic and Research Revenue, and Grants and Contracts Receivable, Net

Academic and research revenue comprises the following for the Fourteen Month Period ($ in thousands):

Grants and contracts revenue:	
Federally funded	$ 270,712
Non-federally funded	107,086
	377,798
Facilities and administrative costs recovery	101,574
Total academic and research revenue	$ 479,372

Grants and contracts receivable comprise the following as of June 30, 2017 ($ in thousands):

Federally funded	$ 31,603
Non-federally funded	37,192
	68,795
Allowance for bad debts	(1,546)
Total grants and contracts receivable, net	$ 67,249

The accompanying notes are an integral part of these consolidated financial statements.

8. Pledges Receivable, net

Pledges receivable, net of applied discounts and allowance for uncollectible pledges as of June 30, 2017 were as follows ($ in thousands):

Amounts due:		
Within one year	$	7,022
In one to five years		12,417
Total pledges receivable		19,439
Unamortized discount		(449)
		18,990
Allowance for uncollectible pledges		(1,934)
Net pledges receivable	$	17,056
Net pledges receivable classified as:		
Current	$	5,785
Non-current		11,271
	$	17,056
Net pledges receivable by asset class:		
Unrestricted	$	105
Temporarily restricted		14,475
Permanently restricted		2,476
	$	17,056

In addition to pledges reported as pledges receivable, VUMC had cumulative bequest intentions and conditional promises to give totaling $43.0 million as of June 30, 2017. Due to their conditional nature, VUMC does not recognize intentions to give as assets.

9. Other Relevant Financial Information

Other current assets comprise the following as of June 30, 2017 ($ in thousands):

Prepaid expenses	$ 20,137
Other receivables	27,363
Amounts due from VU (see Note 4—Related Parties)	5,814
Current pledges receivable, net (see Note 8— Pledges Receivable, net)	5,785
Expected recoveries from commercial insurance carriers	4,028
Other	5,931
Total other current assets	$ 69,058

Other non-current assets comprise the following as of June 30, 2017 ($ in thousands):

Equity in unconsolidated organizations	$ 20,184
Non-current pledges receivable (see Note 8— Pledges Receivable, net)	11,271
Other	3,138
Total other non-current assets	$ 34,593

Other operating revenue comprises the following for the Fourteen Month Period ($ in thousands):

Amounts recognized under MSA with VU (see Note 3—Acquisitions and Note 4—Related Parties)	$ 58,383
Clinical contracts	28,778
Medical services provided during air transports	12,187
Resident and house staff rotations	12,749
Other	67,825
Total other operating revenue	$ 179,922

In the Fourteen Month Period, non-cash investing and financing activities totaled $10.0 million related to property, plant, and equipment expenditures financed through the product financing arrangement and capital leases discussed in Note 12—Long-Term Debt.

The accompanying notes are an integral part of these consolidated financial statements.

10. Investments

VUMC investment balances are as follows as of June 30, 2017 ($ in thousands):

Current:	
Unrestricted investments	$ 133,977
	133,977
Non-current:	
Unrestricted investments	94,412
Investments limited as to use	202,592
	297,004
	$ 430,981

VUMC investments include assets limited as to use related to the following specified purposes as of June 30, 2017 ($ in thousands):

Assets held in trust:	
Self-insured malpractice program	$ 69,849
Internally designated	85,865
Externally designated:	
Donor-designated gifts for capital assets	31,248
Donor endowments	8,283
Split-interest trusts	7,347
	46,878
	$ 202,592

Endowment-related assets include both donor-restricted endowment funds, included in externally designated, and board designated institutional funds, included in internally designated. VUMC's endowment does not include gift annuities, interests in trusts held by others, contributions pending donor designation, or contributions receivable.

The Board of Director's interpretation of its fiduciary responsibilities for donor-restricted endowments under the Uniform Prudent Management of Institutional Funds Act (UPMIFA) requirements is to preserve intergenerational equity, barring the existence of any donor-specific provisions. Under this broad guideline, future endowment beneficiaries should receive at least the same level of real economic support as the current generation. The overarching objective is to preserve and enhance the real (inflation-adjusted) purchasing power of the endowment in perpetuity. VUMC invests assets to provide a relatively predictable and stable stream of earnings to meet spending needs and attain long-term return objectives without the assumption of undue risks.

Investments were as follows as of June 30, 2017 ($ in thousands):

Corporate bonds	$ 119,045
Equity mutual funds	112,704
Restricted cash	32,569
Split-interest trusts	7,347
Hedged equity funds	14,759
Fixed income mutual funds	38,211
Certificates of deposit	38,657
Asset-backed securities	21,779
Real estate mutual funds	16,206
Commercial paper	11,609
Government bonds	9,097
Hedged debt funds	5,178
Commodities and managed futures mutual funds	3,820
Total investments, at fair value	$ 430,981

Investment returns comprise the following elements for the Fourteen Month Period ($ in thousands):

Interest and dividend income	$ 9,385
Net realized gains on sales of securities	2,292
Realized investment gains, before fees	11,677
Unrealized investment gains and losses, net	15,108
Total investment returns before fees	26,785
Investment manager and trustee fees and other	(3,538)
Total income from investments	$ 23,247

VUMC has exposure to risks including liquidity, interest rate, counterparty, basis, regulatory, market, and credit risks for marketable securities. Due to the level of risk exposure, it is possible that material near-term valuation changes for investment securities may occur.

VUMC manages all investments, including endowments, as an investment pool.

The accompanying notes are an integral part of these consolidated financial statements.

11. Property, Plant, and Equipment, Net

Property, plant, and equipment comprise the following as of June 30, 2017 ($ in thousands):

Land and land improvements	$ 27,762
Buildings and improvements	893,728
Equipment	205,357
Construction in progress	196,828
Property, plant, and equipment at cost	1,323,675
Accumulated depreciation and amortization	(103,907)
Property, plant, and equipment, net	$ 1,219,768

As part of the MTSA, VUMC acquired land and land improvements, and buildings and improvements which are not allowed to be repurposed without the express consent of VU.

Property, plant, and equipment balances above include the following amounts related to capitalized internal use software ($ in thousands):

Equipment	$ 6,287
Construction in progress[(1)]	92,478
	98,765
Accumulated amortization	(2,230)
Internal use software, carrying value	$ 96,535

(1) As of June 30, 2017, construction in progress includes $24.9 million, of internal costs, primarily payroll and payroll-related costs for employees directly associated with and who devoted time to internal use software.

As of June 30, 2017, internal use software capitalized includes $92.5 million of costs related to the implementation of an integrated electronic health record and revenue cycle system. The system is scheduled to go-live in November 2017. Once the software is ready for its intended use, these costs will be amortized over the estimated 12 year life. VUMC anticipates approximately $130 million of capitalizable internal software costs related to this project. In addition to internal use software, VUMC has capitalized $23.8 million of hardware costs related to this project and does not anticipate incurring material amounts of additional hardware costs through the go-live date.

Depreciation and amortization comprised the following amounts in the Fourteen Month Period ($ in thousands):

Depreciation of tangible assets	$ 95,786
Amortization of capital leases, leasehold improvements, and internal use software	9,937
Total depreciation and amortization	$ 105,723

The accompanying notes are an integral part of these consolidated financial statements.

In the Fourteen Month Period, VUMC capitalized interest of $1.1 million related to long-term capital projects, primarily internal use software costs. As of June 30, 2017, there were $16.7 million of capital expenditures incurred but not yet paid. These costs are included in accounts payable and other accrued expenses on the consolidated balance sheet.

12. Long-Term Debt

Long-term debt comprises the following as of June 30, 2017 ($ in thousands):

	Carrying Amount	Effective Interest Rate
2016 Series Debt, at par		
Fixed-rate debt:		
Series 2016A	$ 476,930	4.8%
Series 2016B	300,000	4.8%
Total fixed-rate debt	776,930	4.8%
Variable-rate debt:		
Series 2016C	50,000	2.5%
Series 2016D	100,000	3.8%
Series 2016E	128,070	3.7%
Series 2016F	75,000	3.8%
Total variable-rate debt	353,070	3.6%
Total 2016 Series Debt, par	1,130,000	
Other long-term debt		
Note payable to VU	94,583	3.8%
Product financing arrangement	22,273	4.6%
Capital leases	1,448	4.5%
Subtotal[(1)]	1,248,304	4.4%
Net unamortized premiums	57,467	
Net unamortized issuance costs	(11,672)	
Total long-term debt	$ 1,294,099	
Current portion	(5,753)	
Long-term debt, net	$ 1,288,346	

(1) The effective interest rate, 4.4% as of June 30, 2017, is presented exclusive of interest rate exchange agreements discussed in Note 13—Interest Rate Exchange Agreements. Inclusive of these agreements, the overall portfolio effective interest rate was 4.9%. Effective interest rate calculations are based on interest expense for the 14 month period.

The accompanying notes are an integral part of these consolidated financial statements.

On April 29, 2016, VUMC issued the Series 2016 A,B,C,D,E, and F bonds ("2016 Series Debt") and notes aggregating $1.278 billion of proceeds for the purpose of financing the Medical Center Acquisition and paying a portion of the costs of issuance associated with the 2016 Series Debt.

The bonds and notes comprising the 2016 Series Debt were issued by the Health and Educational Facilities Board of The Metropolitan Government of Nashville and Davidson County, Tennessee (HEFB). As a conduit issuer, the HEFB loaned the debt proceeds to VUMC. VUMC's debt service requirements under these loan agreements coincide with required debt service of the actual HEFB bonds.

- The Series 2016A tax-exempt fixed-rate revenue bonds were issued in the par amount of $476.9 million and include an original issue premium of $59.6 million. The Series 2016A bonds have a final maturity date of July 1, 2046, and can be optionally redeemed at par on or after July 1, 2026. The 2016A bonds were structured as serial bonds with maturities from fiscal 2030 through 2032, as well as three term bonds maturing fiscal 2036 through 2047 which are subject to mandatory sinking fund redemption in lots. The Series 2016A bonds bear interest at 5% per annum and pay interest semi-annually on July 1st and January 1st.

- The Series 2016B taxable fixed-rate revenue bonds were issued in the par amount of $300.0 million bear interest at 4.1% per annum, and have a bullet maturity of July 1, 2026. VUMC is entitled, at its option, to redeem all or a portion of the Series 2016B bonds before April 1, 2026, at a make-whole redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate 35 basis points above rates for U.S. Treasury securities with comparable maturities.

- The Series 2016C taxable variable-rate revenue bonds (R-FLOATs) were issued in the par amount of $50.0 million and bear interest initially at a fixed spread to weekly LIBOR of 1.6%. The R-FLOATs have an optional tender provision whereby the bondholder can tender the bond to the trustee for purchase in whole or part. The funds for optional redemption are derived solely from remarketing proceeds or funds provided by VUMC; however, VUMC is not required to provide such funds. If the bonds cannot be remarketed at optional redemption, they are returned to the bondholder and enter a term out period of 24 months. If bonds cannot be successfully remarketed by the end of the 24-month term out period, they are subject to mandatory redemption. In addition to optional redemption of all or a portion of the bonds, the Series 2016C bonds are subject to mandatory sinking fund redemption starting on July 1, 2030 through final maturity of July 1, 2046.

- The Series 2016D taxable variable-rate revenue notes (floating rate notes) were issued in the par amount of $100.0 million and bear interest initially at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2021, and a final maturity of July 1, 2046. Beginning six months prior to the mandatory tender date of July 1, 2021, the bonds have an optional redemption feature. If the Series 2016D bonds are successfully remarketed at the mandatory tender date, they are subject to mandatory redemption in lots commencing on July 1, 2021, and each July thereafter until final maturity.

The accompanying notes are an integral part of these consolidated financial statements.

- The Series 2016E taxable term loan revenue notes were issued in the par amount of $128.1 million and were placed privately with a bank. The notes bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.4% through the initial mandatory tender date of July 1, 2022, and a final maturity of July 1, 2046. In addition to optional redemption of all or a portion of the notes at any time, subject to notice, the Series 2016E notes are subject to principal amortization commencing on July 1, 2022, as defined in the Series 2016E loan agreement between VUMC and the lender.

- The Series 2016F taxable variable-rate revenue bonds were issued in the par amount of $75.0 million and were placed privately with a bank. The bonds bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2022. If the Series 2016F bonds are successfully remarketed, the bonds can be optionally redeemed in-part or in-whole in the current interest mode at par on or after July 1, 2022, at which time the bonds are also subject to mandatory sinking fund redemption until the final maturity date of July 1, 2041.

Each of the bonds and notes comprising the 2016 Series Debt represent separate obligations under a Master Trust Indenture (MTI) structure. The MTI provides the flexibility for multiple parties to participate in debt issuances as part of an obligated group; presently, VUMC has no other members participating in the obligated group. All debt issued under the MTI are general obligations of the obligated group. Under the provisions of the Leasehold Deed of Trust, Security Agreement, Assignment of Rents and Leases, and Fixture Filing ("the Security Agreement") within the MTI, gross receivables of the obligated group are pledged as collateral. Additionally, the Security Agreement established a mortgage lien on (i) the leasehold interest of the land subject to the Ground Lease; (ii) the buildings, structures, improvements, and fixtures now or hereafter located on the land subject to the Ground Lease; and (iii) certain other collateral.

Trust indentures for certain bond issues contain covenants and restrictions, the most material of which include limitations on the issuance of additional debt, maintenance of a specified debt service coverage ratio, and a minimum amount of days cash on hand. VUMC complied with such covenants and restrictions as of June 30, 2017.

On April 29, 2016, VUMC delivered a secured subordinated promissory note in the amount of $100.0 million to Vanderbilt University to finance the Acquisition ("the VU subordinated note"). The note was issued at a fixed rate of 3.25% with monthly principal payments totaling $5.0 million annually commencing on May 31, 2016, for a period of twenty years ending on April 30, 2036. VUMC may, at any time and from time to time, without premium or penalty, prepay all or any portion of the unpaid principal amount of the VU subordinated note. This note is secured by the gross receivables and mortgaged property described in the Security Agreement subject to the requirements of the 2016 Series Debt and the MTI.

As part of the Acquisition, VUMC assumed a 10 year, unsecured, noninterest bearing product financing arrangement with a vendor for the purchase and implementation of internal use software. As part of this agreement, VUMC has committed to an annual payment of $0.5 million payable in monthly installments through November of 2019. These payments will be considered imputed interest. During Fiscal 2020, the annual payment increases to $4.9 million payable in monthly installments. These payments are considered principal and imputed interest and continue through Fiscal 2026. The balance due under the Product Financing Arrangement is $22.3 million as of June 30, 2017, and is included in the long-term debt caption of the consolidated balance sheets.

The accompanying notes are an integral part of these consolidated financial statements.

Interest paid on all obligations, net of amounts capitalized was $38.0 million in the Fourteen Month Period.

Principal retirements and scheduled sinking fund requirements based on nominal maturity schedules for long-term debt due in subsequent fiscal years ending June 30 are as follows:

2018	$ 5,753
2019	5,391
2020	7,486
2021	8,866
2022	109,030
Thereafter	1,111,778
Total	$ 1,248,304

VUMC has entered into an agreement with a bank to provide a general use line of credit with a maximum available commitment totaling $100.0 million. The line of credit, which may be drawn upon for general operating purposes, expires on April 27, 2018, and can be renewed. Interest on each advance under this line of credit accrues at a rate of 0.75% plus LIBOR, and a commitment fee of 0.20% per annum accrues on any unused portion of the line of credit. Commitment fees for the line of credit totaled $0.2 million in the Fourteen Month Period. No amounts were drawn under this credit facility as of June 30, 2017.

13. Interest Rate Exchange Agreements

On April 29, 2016, the University transferred an interest rate exchange agreement to VUMC with a total notional amount of $150.0 million with a maturity date of May 1, 2040. VUMC split the transferred notional amount into two agreements, with key features summarized below:

Notional Amount	Pay Fixed Rate	Receive Variable Rate	Maturity
$75.0 million	4.12%	68% of one-month LIBOR	April 29, 2021
$75.0 million	4.18%	68% of one-month LIBOR	April 29, 2023

VUMC incorporated these interest rate exchange agreements into its debt portfolio management strategy. Collateral pledging requirements were removed from the novated agreements, and the agreements were modified to terminate automatically on April 29, 2021 and 2023, at which point the exchange agreements will be settled at fair value.

VUMC recorded the following activity related to the interest rate exchange agreements during the Fourteen Month Period ($ in thousands):

Mark-to-market adjustments	$ 14,766
Cash settlements	(6,480)
Unrealized gain on interest rate exchange agreements, net of cash settlements	$ 8,286

The accompanying notes are an integral part of these consolidated financial statements.

14. Operating Leases

VUMC has entered into certain long-term agreements with respect to facilities and equipment, both as a lessee and a lessor, which VUMC classifies as operating leases. Rental expense and rental income in the Fourteen Month Period are as follows ($ in thousands):

		Location in Consolidated Statement of Operations
Operating lease rental expense	$ 124,925	Operating Expenses—Facilities and equipment
Operating lease rental income, including related party income	9,069	Operating Revenues—Other operating revenue

The following is a schedule by fiscal year of future minimum rentals on non-cancelable operating leases as of June 30, 2017 ($ in thousands):

	Equipment	Property	Ground Lease	Total
2018	$ 18,794	$ 46,053	$ 18,602	$ 83,449
2019	14,684	44,159	18,602	77,445
2020	10,406	43,016	18,602	72,024
2021	6,392	35,899	18,602	60,893
2022	5,234	28,167	18,602	52,003
Thereafter	4,652	170,149	1,730,023	1,904,824
Total minimum rentals	$ 60,162	$ 367,443	$ 1,823,033	$ 2,250,638

Essential provisions of leases considered by management to be material are as follows:

- On April 29, 2016, VUMC entered into a Ground Lease with VU for approximately 1.7 million square feet of space for an initial term ending June 30, 2114, and an option to extend for up to two additional terms of fifty to ninety-nine years each upon agreement by VU and VUMC. The initial annual base rent of $18.0 million is payable monthly and CPI adjusted annually. The Ground Lease allows VUMC to use the land on which its campus and related buildings are located. The $1.8 billion in ground lease payments in the table above represents future minimum rentals based on current payments.

- In July 2007, VU entered an agreement to lease approximately 50% of the space in the 850,000 square foot One Hundred Oaks shopping center located approximately five miles from the main campus (“100 Oaks Lease”). VU redeveloped this leased space primarily for medical and office uses. This operating lease commenced during Fiscal 2009 with an initial lease term of twelve years. In October 2014, VU agreed to an amendment which extends the original lease term by an additional fifteen years, with an option to renew the lease further for four additional ten-year periods. As part of the lease agreement, the lessee also has first rights on leasing additional space in the shopping center and first rights on purchasing if the landlord desires to sell. On April 29, 2016, the

100 Oaks Lease was assigned to VUMC. As a condition of the assignment, amendments to the 100 Oaks Lease were added which required VUMC to provide the landlord a $25.0 million irrevocable standby letter of credit, pay a $13.2 million refinancing penalty payable to the landlord, and pay $7.8 million of the landlord's closing costs, financing fees, and prepayment penalties associated with a refinancing of the landlord's debt. The prepayment penalty and closing costs were recorded as part of the Acquisition. The irrevocable standby letter of credit must remain in place through April 29, 2026. The amounts related to this standby letter of credit are recorded as facilities and equipment expense and totaled $0.3 million in the Fourteen Month Period. VUMC included minimum property rental payments totaling $138.8 million related to this space in the above future minimum property rentals.

- On April 29, 2016, VU assigned to VUMC a lease for approximately 231,000 square feet of office space at 2525 West End Avenue with expiration dates primarily in 2026 through 2030, with options to renew for two additional five-year periods. VUMC included minimum property rental payments totaling $90.9 million related to this space in the above future minimum property rentals.

- On April 29, 2016, VUMC and VU entered into certain lease agreements for the use of space in buildings owned by both entities. As of June 30, 2017, VUMC's estimated future minimum property lease payments to VU totaled $34.3 million, and estimated future lease receipts from VU totaled $61.4 million. For the fiscal years ended June 30, 2018 through 2022, the minimum rental receipts from VU are $6.8 million.

The accompanying notes are an integral part of these consolidated financial statements.

15. Net Assets

Net assets restrictions relate to the following purposes as of June 30, 2017 ($ in thousands):

Temporarily restricted:	
Property, plant, and equipment	$ 31,248
Research and education	35,807
Operations	2,003
Total temporarily restricted net assets	$ 69,058
Permanently restricted:	
Research and education	$ 17,865

Unrestricted net assets are free of donor-imposed restrictions. This classification includes all revenues, gains, and losses not temporarily or permanently restricted by donors. VUMC reports all expenditures in the unrestricted class of net assets since the use of restricted contributions in accordance with donors' stipulations results in the release of the restriction.

Temporarily restricted net assets contain donor-imposed stipulations that expire with the passage of time, or that can be satisfied by the action of VUMC. These net assets may include unconditional pledges, split-interest agreements, interests in trusts held by others, and accumulated appreciation on donor-restricted endowments not yet appropriated by the Board of Directors for distribution.

Permanently restricted net assets are amounts held in perpetuity as requested by donors. These net assets may include unconditional pledges, donor-restricted endowments (at historical value), split-interest agreements, and interests in trusts held by others. Generally, the donors of these assets permit VUMC to use a portion of the income earned on related investments for specific purposes.

UPMIFA specifies that unless stated otherwise in a gift instrument, donor-restricted assets in an endowment fund are restricted assets until appropriated for expenditure. Barring the existence of specific instructions in gift agreements for donor-restricted endowments, VUMC reports the historical value of such endowments as permanently restricted net assets and the net accumulated appreciation as temporarily restricted net assets. In this context, the historical value represents the original value of initial contributions restricted as permanent endowments plus the original value of subsequent contributions and, if applicable, the value of accumulations made in accordance with the direction of specific donor gift agreements.

16. Fair Value Measurements

Fair value measurements represent the amount at which the instrument could be exchanged in an orderly transaction between market participants at the measurement date. VUMC utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels:

Level 1 - Inputs to the valuation methodology are unadjusted quoted prices for identical asset or liabilities in active markets that VUMC has the ability to access.

Level 2 - Inputs to the valuation methodology include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in inactive markets; inputs other than quoted prices that are observable for the assets or liabilities; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect VUMC's assumptions about the inputs market participants would use in pricing the asset or liability, including assumptions about risk. Unobservable inputs are developed based on the best information available in the circumstances and may include VUMC's own data.

VUMC's principal assets and liabilities subject to fair value measurement are cash and cash equivalents, investments, patient accounts receivable, estimated receivables and payables under third-party programs, grants and contracts receivable, pledges receivable, accounts payable and other accrued expenses, self-insurance reserves, long-term debt, and interest rate exchange agreements. Except for long-term debt, the carrying amount of these assets and liabilities approximate fair value.

As of June 30, 2017, the carrying value and estimated fair value of total long-term debt totaled $1.294 billion and $1.319 billion, respectively. VUMC bases estimated fair value of long-term debt on market conditions prevailing at fiscal year-end reporting dates. Besides potentially volatile market conditions, fair value estimates typically reflect limited secondary market trading. The fair values of the fixed rate 2016 Series Debt, as defined in Note 12—Long-Term Debt, were based on a Level 2 computation using quoted prices for similar liabilities in inactive markets as of June 30, 2017, as applicable. The carrying amounts related to VUMC's variable rate 2016 Series Debt and other long-term debt obligations approximate their fair values as of June 30, 2017. As of June 30, 2017, the fair values of the promissory note payable to VU and the product financing arrangement were based on a level 2 discounted cash flow approach applying a risk-adjusted spread for issuers of similar credit quality to U.S. Treasury yields for securities with comparable maturities.

For financial instruments measured at fair value on a recurring basis, the following tables summarize valuation hierarchy levels as of June 30, 2017, determined by the nature of the financial instrument, and the least observable input significant to the fair value measurement, ($ in thousands):

	Fair Value Measurements as of June 30, 2017			
	Level 1	Level 2	Level 3	Total Carrying Amount
Assets				
Corporate bonds	$ 60,214	$ 58,831	$ -	$ 119,045
Equity mutual funds	38,637	74,067	-	112,704
Restricted cash	32,569	-	-	32,569
Beneficial interests in split-interest trusts	7,347	-	-	7,347
Hedged equity funds	4,267	10,492	-	14,759
Fixed income mutual funds	2,080	36,131	-	38,211
Certificates of deposit	-	38,657	-	38,657
Asset-backed securities	-	21,779	-	21,779
Real estate mutual funds	-	16,206	-	16,206
Commercial paper	-	11,609	-	11,609
Government bonds	-	9,097	-	9,097
Hedged debt funds	-	5,178	-	5,178
Commodities and managed futures mutual funds	-	3,820	-	3,820
Total assets reported at fair value	$ 145,114	$ 285,867	$ -	$ 430,981
Liabilities				
Interest rate exchange agreements	$ -	$ 65,203	$ -	$ 65,203
Total liabilities reported at fair value	$ -	$ 65,203	$ -	$ 65,203

VUMC employs derivatives, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable-rate debt. In addition to the credit risk of the counterparty owing a balance, VUMC calculates the fair value of interest rate exchange agreements based on the present value sum of future net cash settlements that reflect market yields as of the measurement date.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates as well as the risk of credit loss in the event of nonperformance by the counterparty. VUMC deals only with high-quality counterparties that meet rating criteria for financial stability and credit worthiness.

17. Retirement Plans

VUMC's full-time employees participate in a 403(b) defined contribution retirement plan administered by a third-party. For eligible employees with one year of continuous service, these plans require employer matching of employee contributions up to 5% of eligible compensation. The employee immediately vests in these contributions.

VUMC funds the obligations under these plans through monthly transfers to the respective retirement plan administrators with the corresponding expenses recognized in the year incurred. During the Fourteen Month Period, VUMC recognized $65.7 million of expense in connection with these plans.

18. Functional Expenses

Total operating expenses by function for the Fourteen Month Period were as follows ($ in thousands):

Healthcare services	$ 3,437,216
Academic research and education	697,208
Administrative and other	182,433
Total operating expenses	$ 4,316,857

The accompanying notes are an integral part of these consolidated financial statements.

19. Commitments and Contingencies

Management has policies, procedures, and a compliance overview organizational structure to enforce and monitor compliance with government statutes and regulations. VUMC's compliance with such laws and regulations is subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time.

- Litigation. VUMC is a defendant in certain lawsuits alleging medical malpractice and civil action.

  One such legal action was a qui tam civil action related to billing and government reimbursement for certain professional health care services provided by VUMC, which was filed in 2011. The parties agreed to settlement terms prior to June 30, 2017; VUMC has accrued an amount equal to the agreed upon settlement, which is not material to VUMC's overall financial position.

  In February 2015, VUMC received a letter from the Office of Audit Services (OAS) of the Office of Inspector General (OIG) in connection with its nationwide review to determine whether, in certain cases, services were provided to certain Medicare beneficiaries in accordance with national coverage criteria. OAS has issued their final report regarding their audit which contains an overpayment amount. VUMC resolved the matter by repaying certain funds previously received prior to June 30, 2017; the repayment amount was not material to VUMC's overall financial position.

  On August 16, 2016, VUMC received written notice from VU of a third-party claim which may, if determined adversely to VU, require indemnification by VUMC pursuant to the provisions of the MTSA, dated as of April 29, 2016. That third-party claim is a lawsuit (Cassell v. Vanderbilt University, et al., No. 3:16-cv-02086 (U.S.D.C. M.D. TN)) brought by current and former employees of VU which alleges claims relating to administration of the Vanderbilt University Retirement Plan and New Faculty Plan. Due to the early stage of the litigation, it is not possible to assess the likely outcome of the litigation or to estimate the amount of the indemnification obligation which VUMC might have, were the matter decided adversely to VU.

  Through the operation of its compliance program, VUMC from time to time initiates the review of billing for clinical services provided by VUMC and its affiliated providers. VUMC has established a liability reserve relating to certain matters under review as of June 30, 2017, which is not material to VUMC's overall financial position.

- Regulations. VUMC's compliance with regulations and laws is subject to future government reviews and interpretations, as well as regulatory actions unknown at this time. VUMC believes that the liability, if any, from such reviews will not have a significant effect on VUMC's consolidated financial position.

- Medical Malpractice Liability Insurance. The consolidated balance sheet includes reserves for medical malpractice, professional, and general liability coverage totaling $71.5 million as of June 30, 2017. These liabilities are measured at the net present value of those cash flows using a discount rate of 2.5% as of June 30, 2017 and are classified as current or non-current based on the expected timing of cash flows. The $15.2 million reduction in total medical malpractice self-insurance reserves from the date of the acquisition to June 30, 2017 primarily

reflects an $11.4 million change in estimate recorded during the fourteen months ended June 30, 2017 to reflect improved claims experience observed during that period. Other current assets include expected recoveries from commercial insurance carriers under excess coverage arrangements totaling $4.0 million as of June 30, 2017.

- Employee Health and Workers' Compensation Insurance. Accrued compensation and benefits included actuarially determined liabilities for employee health and workers' compensation claims totaling $16.0 million and $7.3 million, respectively, as of June 30, 2017. During the Fourteen Month Period, VUMC recorded expenses totaling $183.3 million for self-insured employee health benefit plans, net of employee premiums, and $4.1 million for self-insured workers' compensation insurance plans.

- Federal and State Contracts and Other Requirements. Expenditures related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. Amounts of expenditures that granting agencies might disallow cannot be determined at this time. These amounts affect government grants and contracts revenue as well as facilities and administrative costs recovery. VUMC would not expect these costs to influence the consolidated financial position by material amounts.

- Health Care Services. In the Fourteen Month Period, 85% of VUMC's operating revenue was generated by providing health care services, where revenue is affected by reimbursement arrangements with federal and state healthcare programs, commercial insurance, and other managed care payors. If reimbursement rates from third-party payors decrease or if contract terms become less favorable in future periods, VUMC's net operating revenues may decline. See Note 5—Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-party Settlements, for further information regarding healthcare revenues and related receivables

- HIPAA Compliance. Under the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the federal government has authority to complete fraud and abuse investigations. HIPAA has established substantial fines and penalties for offenders. VUMC maintains policies, procedures, and organizational structures to enforce and monitor compliance with HIPAA, as well as other applicable local, state, and federal statutes and regulations.

- Construction. VUMC had contractual commitments under major construction and equipment contracts totaling $109.2 million as of June 30, 2017.

- Letter of Credit. As a requirement of the assignment of the 100 Oaks Lease described in Note 14—Operating Leases, VUMC provided an irrevocable standby letter of credit of $25.0 million to the landlord of the property dated June 10, 2016.

The accompanying notes are an integral part of these consolidated financial statements.

20. Subsequent Events

Management evaluated events after June 30, 2017, through December 7, 2017, the date on which the financial statements were available for issuance. During this period, there were no subsequent events requiring recognition in the consolidated financial statements that have not been recorded.

On July 26, 2017, VUMC issued the Series 2017A tax-exempt and Series 2017 taxable fixed-rate bonds in the aggregate amount of $221.3 million to provide new project funding to finance the construction, expansion, and renovation of various facilities and related equipment. The Series 2017A bonds were issued by the HEFB, as VUMC's conduit, at a par amount of $121.3 million, include an original issue premium of $5.1 million, and have an average coupon of 4.38%. Of the $121.3 million par amount, $75.0 million mature in 2047, with the remainder maturing in 2048. The Series 2017 taxable bonds were issued by VUMC at a par amount of $100.0 million, bear interest at 4.172% per annum, and mature in 2037.

On August 1, 2017, VUMC issued the Series 2017B taxable notes through the HEFB at a par amount of $50.0 million for fully redeeming the Series 2016C taxable variable-rate revenue bonds (R-FLOATs). The Series 2017B notes were placed privately with a bank and were issued in a variable-rate mode to bear interest at a fixed spread to one-month LIBOR of 1.15%.

On August 1, 2017, VUMC restructured certain terms of its Series 2016E and F variable rates bonds which are placed privately with two banks. The credit spread on the Series 2016E bonds was reduced to 1.75% from 2.4%, while the credit spread for the Series 2016F bonds was reduced to 1.15% from 2.5%. Additionally, the mandatory tender date of the Series 2016F bonds was extended two years to July 1, 2024.

Subsequent to June 30, 2017, the previously disclosed qui tam civil action was settled for an amount not material to VUMC's overall financial position.

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
Research and Development Cluster - Direct Awards					
Department Of Agriculture					
2017-68001-26352 CHILDREN EATING WELL (CHEW) SMARTPHONE APPL	10.310	2017-68001-26352		26,787	
Subtotal 10.310				**26,787**	
Total Department Of Agriculture				**26,787**	
Department Of Defense					
HDTRA1-13-1-0034: HUMAN MONOCLONAL ANTIBODIES AGAINST EBO	12.351	HDTRA1-13-1-0034		892,189	280,782
Subtotal 12.351				**892,189**	**280,782**
W81XWH-10-2-0133:TREATMENT OF EARLY POST-OP WOUND	12.420	W81XWH-10-2-0133		412,328	190,477
W81XWH-12-1-0159 SCREENING & MONITORING RESPONSE TO TREATMEN	12.420	W81XWH-12-1-0159		379,286	
W81XWH-12-1-0245 EVALUATION OF MULTIMODAL IMAGING	12.420	W81XWH-12-1-0245		1,884	
W81XWH-12-1-0335: RESTORATION OF STANDING AND WALKING THROUG	12.420	W81XWH-12-1-0335		135,247	22,306
W81XWH-13:7T MAGNETIZATION TRANSFER AND CHEMICAL EXCHANGE	12.420	W81XWH-13-1-0073		28,615	
W81XWH-13-1-0287:BC123219:INTEG OF GENOMIC,BIOLOGIC	12.420	W81XWH-13-1-0287		169,755	13,116
W81XWH-13-1-0399- USING ANITBODIES AS NANPARTICLE TARGETING	12.420	W81XWH-13-1-0399		78,495	
W81XWH-13-1-0447: DEVELOPMENT OF CLASS II MEDICAL DEVICE	12.420	W81XWH-13-1-0447		65,997	
W81XWH-14-1-0104 PHARMACOGENETICS OVARIAN CANCER KNOWLEDGE	12.420	W81XWH-14-1-0104		120,397	
W81XWH-14-1-0140 DOD - AMP. OF JAK2 IN BREAST CANCER	12.420	W81XWH-14-1-0140		162,771	
W81XWH-15-1-0096 DIETARY APPROACHES TO PROTECT AGAINST EYE	12.420	W81XWH-15-1-0096		21,685	
W81XWH-15-1-0110 LCRP-IDA:NON INVASIVE CHARACTERIZ OF INDET	12.420	W81XWH-15-1-0110		187,904	132,456
W81XWH-15-1-0259 MAGNESIUM PREDICTS PROSTATE CANCER, POOR	12.420	W81XWH-15-1-0259		285,279	21,788
W81XWH-15-1-0271:LOW-COST, HIGH-THROUGHPUT 3D PULMONARY IMAG	12.420	W81XWH-15-1-0271		390,507	
W81XWH-15-1-0328 TARGETING PERIPHERAL-DERIVED REGULATORY T	12.420	W81XWH-15-1-0328		229,526	
W81XWH-15-1-0559:NEUROPROTECTIVE STRATEGIES FOR THE TREATMEN	12.420	W81XWH-15-1-0559		614,198	400
W81XWH-15-1-0622 TARGET DRUG NANOCARRIERS FOR INHIB	12.420	W81XWH-15-1-0622		202,697	800
W81XWH-15-1-0622:TARGETED DRUG NANOCARRIERS FOR INHIBITING	12.420	W81XWH-15-1-0622		5,281	
W81XWH-16-1-0057 REGULATION OF PROGRAMMED NECROSIS AND BONE	12.420	W81XWH-16-1-0057		340,821	
W81XWH-16-1-0554:PATIENT-CENTERED TREATMENT DECISION-MAKING	12.420	W81XWH-16-1-0554		163,913	
W81XWH-16-1-0605: MRI DIFFUSION TENSOR TRACTOGRAPHY TO TRACK	12.420	W81XWH-16-1-0605		295,397	
W81XWH-16-1-0622:CELLULAR PLASTICITY IN THE DIABETIC MYOCARD	12.420	W81XWH-16-1-0622		177,342	
W81XWH-16-2-0061:MORE RESILIENCY IN THE REHABILITATION OF AC	12.420	W81XWH-16-2-0061		11,392	
W81XWH-17-2-0003:PHOTOSENSITIZATION OF BACTERIAL PATHOG	12.420	W81XWH-17-2-0003		197,123	
Subtotal 12.420				**4,677,840**	**381,342**
Total Department Of Defense				**5,570,029**	**662,124**
Department Of Education					
R324A140006 FATIGUE AND LISTENING EFFORT IN SCHOOL-	84.324	R324A140006		48,623	
R324A160300 MEASUREMENT OF LISTENING FATIGUE IN CHI	84.324	R324A160300		405,444	480
Subtotal 84.324				**454,067**	**480**
Total Department Of Education				**454,067**	**480**

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
Department Of Health And Human Services					
GH00812-04AVANTE ZAMB ZIA: TECHNICAL ASSISTANCE T	93.067	5 U2G GH00812-04		20,244,849	
Subtotal 93.067				**20,244,849**	
DD000001-01-00 ENHANCING P H SURVEILLANCE OF AUTISM SPE	93.073	1 NU53 DD000001-01-00		368,968	
Subtotal 93.073				**368,968**	
IP00979-01 DETERMINING INFLUENZA VACCINE EFFECTIVEN	93.083	1 U01 IP00979-01		501,073	8,021
Subtotal 93.083				**501,073**	**8,021**
IIR160029-01 GROWING RESEARCH INTEGRITY TOGETHER CONFERENCE	93.085	1 OR IIR160024-01		16,591	
Subtotal 93.085				**16,591**	
FD04117-05 PHASE 2 STUDY OF MONTELUKAST FOR THE TR	93.103	7 R01 FD004117-05		288,715	53,366
FD04778-02 PHASE 2 NOREPINEPHRINE TRANSPORTER BLOCK	93.103	7 R01 FD04778-02		286,484	6,338
Subtotal 93.103				**575,199**	**59,704**
MC30769-01:01 MINDFULNESS TRAINING ENHANCE EARLY EVIDENCE	93.110	6 R40MC30769-01-01		454,663	
Subtotal 93.110				**454,663**	
ES016931-10 GENE-NEUROTOXICANT INTERACTIONS IN HUNTINGT	93.113	5 R01 ES016931-10		113,519	200
ES14942-11 DIOXIN EXPOSURE AND THE INVASIVE PATH	93.113	5 R01 ES14942-11		306,580	16,009
ES16931-09 GENE-NEUROTOXICANT INTERACTIONS- HUN	93.113	6 R01 ES16931-09		287,682	540
ES19969-01:3 PESTICIDE-MEDIATED INHIBITION OF UBA1	93.113	1 R01 ES19969-01A1		(336)	
ES22936-04:05 ASK SIGNALOSOMES AND ENVIR	93.113	6 R01 ES22936-04		374,901	5,038
Subtotal 93.113				**1,082,346**	**21,788**
HA30535-01 SOUTHEAST REGIONAL AIDS EDUCATION AND TR	93.145	7 U1O HA30535-01		4,635,999	3,513,282
Subtotal 93.145				**4,635,999**	**3,513,282**
HG007253-04 INTEGRATED, INDIVIDUALIZED, INTELLIGENT PRESCRIB	93.172	5 U01 HG007253-04		17,329	
HG008672-03 VGER,THE VANDERBILT GENOME-ELECTRONIC RECORDS PR	93.172	5 U01 HG008672-03		58,817	
HG008701-03 ELEC. MED. RECORDS AND GENOMICS(EMERGE)PHASEI	93.172	5 U01 HG008701-03		120,125	
HG009034-02 GENETIC PRIVACY AND IDENTITY IN COMMUNITY SETTIN	93.172	5 RM1 HG009034-02		29,557	
HG06844-01:05 A RISK MANAGEMENT FRAMEWORK FOR IND	93.172	6 R01 HG06844-05		35,058	7,544
HG06844-06 A RISK MANAGEMENT FRAMEWORK FOR IDENTIFIABILITY	93.172	2 R01 HG06844-06		54,796	
HG07253-03 INTEGRATED, INDIVIDUALIZED, INTELLIGENT PRESCRIBI	93.172	6 U01 HG07253-03		761,841	382,259
HG07253-03S1 INTEGRATED, INDIVIDUALIZED, INTELLIGENT PRESCRI	93.172	3 U01 HG07253-03S1		58,030	
HG08341-01A1 VGM: VANDERBILT GENOMIC MEDICINE TRAINING PROGR	93.172	1 T32 HG08341-01A1		47,814	
HG08672-02 VGER, THE VANDERBILT GENOME-ELECTRONIC RECORDS PR	93.172	6 U01 HG08672-02		1,049,379	
HG08701-02 ELECTRONIC MEDICAL RECORDS AND GENOMICS (EMERGE)N	93.172	6 U01 HG08701-02		1,168,374	472,230
HG09034-01 GENETIC PRIVACY AND IDENTITY IN COMMUNITY SETT	93.172	1 RM1 HG09034-01		396,041	
Subtotal 93.172				**3,797,160**	**862,034**
DC00523-19 EMOTIONAL AND LINGUISTIC CONTRIBUTIONS -	93.173	6 R01 DC00523-19		104,333	63,143
DC08408-09 CLINICAL VALIDATION & TESTING OF PER	93.173	6 R01 DC08408-09		207,912	
DC08763-11 DEVELOPING RESEARCH CAREERS IN THE HEARI	93.173	6 T35 DC08763-11		30,142	8,103
DC09404-08 COCHLEAR IMPLANTS: COMBINED ELECTRIC	93.173	6 R01 DC09404-08		391,938	14,262

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
DC11092-07 SUBCORTICAL NEURAL BASIS OF HEARING IN	93.173	6 R01 DC11092-07		19,666	
DC11548-07 TEMPORAL WEIGHTING OF AUDITORY SPATIA	93.173	6 R01 DC11548-07		398,402	5,980
DC11755-06 LANGUAGE PROCESSING AND THE HIPPOCAMPAL DECLARATI	93.173	7 R01 DC11755-06		91,710	38,828
DC11777-04 MODELING AUDITORY RESPONSES AND BEHA	93.173	5 R01 DC11777-04		578,873	306,711
DC12865-03 QUANTIFYING THE FATIGUE FACTOR: HEA	93.173	6 R21 DC12865-03		34,444	
DC13117-05 CLINICAL APPLICATION OF SPECTRAL ENVE	93.173	5 R01 DC13117-05		299,838	46,758
DC13270-03:04 NEURAL CORRELATES OF RECOVERY FROM APHASIA AFT	93.173	5 R01 DC13270-04		281,669	15,574
DC13559-04:05 DEVELOPING AN OUTCOME MEASURING UNILATERAL VOC	93.173	6 K23 DC13559-04		178,092	
DC14802-03 RHYTHM IN ATYPICAL LANGUAGE DEVELOPMENT: MECHAN	93.173	5 R03 DC14802-03		190,999	
DC14809-02 THE MECHANISM OF INFLAMMATION-MEDIATED	93.173	6 R03 DC14809-02		196,523	
DC15075-01A1 TONGUE- AND JAW-SPECIFIC CONTRIBUTIONS TO VOWEL	93.173	1 R03 DC15075-01A1		133,609	9,733
DC15388-02 IDENTIFICATION OF CELLULAR PHENOTYPES IN THE A	93.173	6 R01 DC15388-02		275,502	3,910
DC15405-01A1 PRE-CLINICAL TESTING OF THE SAFETY AND EFFICACY	93.173	1 R01 DC15405-01A1		448,268	
DC15726-01 VOCAL FOLD VIBRATORY FUNCTION DURING DEVELOPMENT	93.173	1 F32 DC15726-01		43,113	
DC16080-01 AN ADAPTIVE SEMANTIC PARADIGM FOR VALID AND RELI	93.173	1 R21 DC16080-01		15,965	
DC16144-01 SENSORY PROJECT IN INFANT/TODDLER SIBLINGS OF CH	93.173	1 R21 DC16144-01		19,112	
Subtotal 93.173				**3,940,111**	**513,002**
IP01063-01 ENHANCED SURVEILLANCE FOR NEW VACCINE PREVENTABLE	93.185	1 U01 IP01063-01		724,355	
Subtotal 93.185				**724,355**	
AT04821-08 IMMUNOMODULATORY EFFECTS OF ARGININE S	93.213	6 R01 AT04821-08		518,289	
AT06965-06 MIND-BODY THERAPIES FOR PATIENTS WITH EN	93.213	5 K23 AT06965-06		153,861	
AT09340-01 BREATHING INTERVENTIONS FOR RELAXATION: DOSING TH	93.213	1 R61 AT09340-01		285,856	11,786
Subtotal 93.213				**958,006**	**11,786**
HHSA290201500003I T05 MEDIUM SR UPDATE	93.226	HHSA290201500003I T05		88,321	
HS21496-04 PERSONAL HEALTH INFORMATION NEEDS AND PRACTICES F	93.226	6 R01 HS21496-04		284,944	
HS22093-02 REAL-WORLD PATIENT RESPONSIVENESS & SA	93.226	6 R01 HS22093-02		310,349	65,101
HS22342-03 THE IMPACT OF INFANT VACCINATION WITH A	93.226	6 R03 HS22342-03		7,684	
HS22640-02 YR 02 COMPARATIVE EFFECTIVENESS OF MODER	93.226	6 R01 HS22640-02		541,781	238,810
HS22990-03 VPOCKET BACHMANN	93.226	6 K12 HS22990-03		599,106	213,366
Subtotal 93.226				**1,832,185**	**517,276**
MH100096-05:06 SUBSTRATE-SELECTIVE INHIBITION OF COX-02 TO T	93.242	6 R01 MH100096-05		523,607	
MH101321-03 MAPPING THALAMOCORTICAL NETWORKS ACRO	93.242	6 R21 MH101321-03		112,749	
MH102246-03 NEUTRAL CONNECTIVITY AFFECTING THE	93.242	6 R01 MH102246-03		603,252	
MH102266-03:04 THALAMOCORTICAL NETWORKS IN PSYCHOSIS	93.242	6 R01 MH102266-03		531,049	30,911
MH102272-03:04 NEURAL NETWORKS OR ATTENTION TO INTERNAL AND	93.242	6 R01 MH102272-03		424,444	
MH103500-03 AUTISM SPECTRUM DISORDERS AND DEPR	93.242	6 K01 MH103500-03		194,391	
MH104428-03 ADAPTING A PARENT ADVOCACY PROGRAM T	93.242	6 R34 MH104428-03		240,603	42,503
MH106998-03 BNST NEUROCIRCUITRY IN PTSD	93.242	6 R21 MH106998-03		162,741	
MH107255-02:03 TRADITIONAL HEALERS AS ADHERENCE PAR	93.242	5 K01 MH107255-03		173,239	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
MH107256-02:03 POPULATION MOBILITY AND RETENTION IN	93.242	6 K01 MH107256-02		154,051	
MH107435-01A1:02 ARCHIDONOYLGLYCEROL SIGNALING IN ANXIETY DE	93.242	1 R01 MH107435-01A1		428,314	27,642
MH109105-02:04 NEURON SELECTIVE MODULATION OF BR	93.242	5 R24 MH109105-04		369,003	23,560
MH109225-02:03 PERIPERSONAL SPACE REPRESENTATI	93.242	6 R21 MH109225-02		145,818	37,881
MH110598-01 MENTORING AND RESEARCH ON NEUROBIOLOGICAL MARKER	93.242	1 K24 MH110598-01		103,558	
MH111567-01 AN INTELLIGENT THREE DIMENSIONAL LEARNING ENVIRO	93.242	1 R21 MH111567-01		10,344	
MH111776-01:02 TRANSCRIPTIONAL CONSEQUENCES OF STRUCTURAL VA	93.242	5 R01 MH111776-02		98,065	
MH111877-01:02 ESTABLISHING A DOSE RESPONSE FOR ULTRASOUND N	93.242	5 R01 MH111877-02		67,343	
MH112783-01 WOMEN WITH AUTISM SPECTRUM DISORDERS DURING ADOL	93.242	1 R03 MH112783-01		8,357	
MH113478-01 PARTNERS-BASED HIV TREATMENT FOR SERO-CONCORDANT	93.242	1 R01 MH113478-01		7,008	
MH70560-10:11 IMAGING HIPPOCAMPAL FUNCTION IN PSYCHOSIS	93.242	6 R01 MH70560-10		445,112	
MH77298-11 DOPAMINERGIC REGULATION OF PYRAMIDAL	93.242	6 R01 MH77298-11		399,945	4,629
MH92598-05 REVISED RISK AND RESILIENCY FOR YOUTH	93.242	6 K01 MH92598-05		50,777	
MH95621-06 IRON AND MITOCHONDRIAL GENOMICS IN NEURO	93.242	6 R01 MH95621-06		111,198	55,309
MH97793-04 PEERS PLAY & PERFORMANCE TO IMPROVE S	93.242	6 R34 MH97793-04		173,340	
MH99218-03 FRONTAL HYPO PERFUSION EFFECTS ON ANT	93.242	6 R21 MH99218-03		35,519	
Subtotal 93.242				**5,573,827**	**222,436**
1 R21 AA021443-02:03 HEPATOCYTE CLOCK GENES IN ALCO	93.273	6 R21 AA21443-03		8,035	
AA13514-16 GENE-TARGETED MOUSE CORE	93.273	6 U01 AA13514-16		186,768	
AA25385-01 INVESTIGATING THE ROLE OF THE HUMAN BNST CIRCUIT	93.273	1 R21 AA25385-01		24,220	
Subtotal 93.273				**219,024**	
DA31699-06 SYNAPTIC MECHANISMS OF ADDICTION-RELA	93.279	6 R00 DA31699-06		34,182	
DA31726-06 PREDICTORS OF OPIOID ANALGESIC RESPONSE	93.279	6 R01 DA31726-06		278,656	130,989
DA37891-03:04 REDUCED OPIOD ANALGESIC REQUIRMENTS	93.279	6 R01 DA37891-03		593,091	197,047
DA38720-03:04 NEONATAL ABSTINENCE SYNDROME:RISK	93.279	6 K23 DA38720-03		209,336	
DA39743-03 CHARACTERIZING NON-MEDICAL PRESCRIPTI	93.279	6 R03 DA39743-03		182,416	
DA40630-01A1:02 PARVALBUMIN INTERNEURONS REGULATE NUCLEUS AC	93.279	1 R01 DA40630-01A1		210,990	5,591
Subtotal 93.279				**1,508,671**	**333,627**
EB001628-15 POSTDOCTORAL TRAINING IN BIOMEDICAL MRI AND MRS	93.286	5 T32 EB001628-15		43,183	
EB01628-14 POSTDOCTORAL TRAINING IN BIOMEDICAL MRI AND MR	93.286	6 T32 EB01628-14		188,700	
EB021840-03 ULTRA-FAST MOLECULAR MRI OF HUMAN ADIPOSE TISSUE	93.286	5 F32 EB021840-03		8,390	
EB09106-06 IN VIVO AMYLOID-BETA IMAGING MOUSE BR	93.286	6 R00 EB09106-06		270,498	
EB13659-05 QUANTITATIVE MRI OF THE HUMAN PER	93.286	6 K25 EB13659-05		137,711	50
EB13677-05 SYNTHETIC-COLLIMATOR SPECT WITH SEMICON	93.286	6 R01 EB13677-05		45,416	8,882
EB16689-03 FUNCTIONAL IMAGING AND RESTING STATE	93.286	6 K99 EB16689-03		6,268	
EB17767-04:05 CERT IMAGING OF MUSC	93.286	5 R01 EB17767-05		365,741	23,022
EB18033-03 HIGH LIGHT OUTPUT SCINTILLATOR CAME	93.286	6 R21 EB18033-03		100,757	24,839
EB18992-03 A MAGNETIC CAPSULE ENDOSCOPE FOR COLONOSCOPY IN P	93.286	6 R01 EB18992-03		102,642	
EB19509-02 THERMOSENSITIVE INJECTABLE POLYMER-BA	93.286	6 R21 EB19509-02		200,956	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
EB20666-02:03 IDENTIFICATION EXTRACTION AND DI	93.286	5 R01 EB20666-03		459,267	
EB21012-01A1 FAST VOLUMETRIC TREATMENT USING MULTI-FOCUS INS	93.286	1 R21 EB21012-01A1		35,510	
EB21840-02 ULTRA-FAST MOLECULAR MRI OF HUMAN AD	93.286	6 F32 EB21840-02		51,450	
Subtotal 93.286				**2,016,489**	**56,792**
MD10722-01 CTR OF EXCELLENCE IN PRECISION MEDICINE-OVERALL-P	93.307	1 U54 MD10722-01		1,612,876	964,763
MD10722-02 CTR. OF EXCELLENCE PREC. MED-ADMIN CORE	93.307	5 U54 MD10722-02		176,319	
Subtotal 93.307				**1,789,194**	**964,763**
CA203708-01 CROWD SOURCING LABELS FROM ELECTRONIC MEDICAL	93.310	1 UH2 CA203708-01		120,947	
CA203708-02 CROWD SOURCING LABELS FROM ELECTRONIC MEDICAL RE	93.310	5 UH2 CA203708-02		26,458	
DK85712-06 INSULIN REGULATION OF MONOAMINE SIGNALI	93.310	6 R01 DK85712-06		5,487	
DK97678-02 POSITIVE PSYCHOLOGY TO PROMOTE ADHERE	93.310	6 DP3 DK97678-02		456,338	24,461
GM118944-01:02 MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF	93.310	1 R21 GM118944-01		237,121	
HG07674-04 VANDERBILT CENTER FOR UNDIAGNOSED DISEA	93.310	6 U01 HG07674-04		1,407,383	
HG07674-05 VANDERBILT CENTER FOR UNDIAGNOSED DISEASES (VCUD	93.310	5 U01 HG07674-05		490,576	16,411
OD23132-02 PMI PARTI PREP/PROTO: MILESTONE 1	93.310	6 OT2 OD23132-02		2,664,314	43,742
OD23196-01 PMI DATA CORE-1U2COD023196-01	93.310	1 U2C OD23196-01		8,560,502	4,474,948
OD23850-01 ENSMAP: MOLECULAR AND FUNCTIONAL MAPPING OF THE	93.310	1 OT2 OD23850-01		349,715	57,471
Subtotal 93.310				**14,318,841**	**4,617,034**
DD01073-03 COMP B NATIONAL SB PATIENT REGISTRY	93.315	6 U01 DD01073-03		27,034	
DD01073-04 COMP B-NATIONAL SB PATIENT REGISTRY AT VANDERBILT	93.315	5 U01 DD01073-04		56,788	
DD01075-03 COMP C-NATIONAL SPINA BIFIDA UROLOGIC PR	93.315	6 U01 DD01075-03		6,405	
DD01075-04 COMP C-NATIONAL SB UROLOGIC PROTOCOL AT VANDERBIL	93.315	5 U01 DD01075-04		17,016	
Subtotal 93.315				**107,243**	
6TL1TR000447-11 VICTR TL1	93.350	6TL1TR000447-11		254,961	39,449
GM100183-06 PHARMACOGENOMICS OF TACROLIMUS AND N	93.350	6 K23 GM100183-06		125,187	
TR000123-06 C4 7-1-16	93.350	6 U54 TR000123-06		1,700,703	
TR000123-07 CLINICAL AND TRANSLATIONAL COORDINATING CENTER	93.350	4 U54 TR000123-07		62,820	
TR002243-01 VICTR UL1-ADMIN	93.350	1 UL1 TR002243-01		485,387	
TR002245-01 KL2 ADMIN	93.350	1 KL2 TR002245-01		19,070	
TR00445-11 VICTR GOVERNANCE	93.350	6 UL1 TR00445-11		8,182,444	761,217
TR00446-11 KL2-NATHAN BRUMMEL	93.350	6 KL2 TR00446-11		617,600	115,217
TR01579-01 RIC IMPROVING CLIN TRIAL ED.,RECRUIT.	93.350	1 U24 TR01579-01		2,000,168	71,673
TR01723-01 REPURPOSING MISOPROSTOL FOR CLOSTRIDIUM DIFFICILE	93.350	1 R21 TR01723-01		233,596	
Subtotal 93.350				**13,681,937**	**987,555**
OD019963-01A1 RADIOFLUORINATION EQUIPMENT FOR PET IMAGING RE	93.351	1 S10 OD019963-01A1		291,475	
OD021804-01A1: REPLACEMENT AND UPGRADE OF AN OPTICAL IMAGI	93.351	1 S10 OD021804-01A1		409,279	
Subtotal 93.351				**700,754**	
NR15079-03:04 IMAGING LYMPHATIC FUNCTION IN PATIENTS	93.361	5 R01 NR15079-04		380,179	1,159
Subtotal 93.361				**380,179**	**1,159**

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
CA116087-09HPYLORI-INDUCED INFLAMMATION & GAS	93.393	6 P01 CA116087-09		842,957	86,015
CA116087-10 H. PYLORI-INDUCED INFLAMMATION PROJECT 1	93.393	5 P01 CA116087-10		577,154	320
CA137026-06 IEI - CANCER MORTALITY AMONG MIL PARTIC	93.393	6 U01 CA137026-06		7,102	
CA138833-06 A1:07 REGULATION OF THE ONCOGENIC STRESS RESPONSE	93.393	2 R01 CA138833-06A1		(44)	
CA138833-06A1:07 REGULATION OF THE ONCOGENIC STRESS RESPONSE	93.393	2 R01 CA138833-06A1		443,183	
CA141596-07 CONNECT TO QUIT: COORDINATED CARE FOR S	93.393	6 R01 CA141596-07		42,333	5,838
CA148667-06 CONSORTIUM STUDY TO IDENTIFY	93.393	6 R01 CA148667-06		274,376	
CA158141-06 GENETIC BASIS OF FAMILIAL COLORECTAL	93.393	6 R00 CA158141-06		17,048	
CA158473-06 GENOME SEQUENCING TO IDENTIFY NOVEL	93.393	6 R01 CA158473-06		212,199	10,472
CA160938-05 FATTY ACID DESATURASE ACTIVITY, FISH	93.393	6 R01 CA160938-05		10,445	
CA161045-05 EXOME SEQUENCING TO IDENTIFY NOVEL G	93.393	6 U01 CA161045-05		11,928	
CA161045-06 EXOME SEQUENCING TO IDENTIFY NOVEL GENETIC FACT	93.393	5 U01 CA161045-06		162,257	
CA173640-04 SHANGHAI MEN'S HEALTH ST	93.393	6 UM1 CA173640-04		283,190	64,101
CA173640-05 SHANGHAI MEN'S HEALTH STUDY	93.393	5 UM1 CA173640-05		420,302	
CA174853-05 HELICOBACTER PYLORI BLOOD BIOMARK	93.393	5 R01 CA174853-05		517,051	194,749
CA176757-03 SEARCHING FOR NEW RISK VARIANTS IN	93.393	6 R03 CA176757-03		41,725	
CA178680-03 DEVELOPMENT & EVALUATION - PREDICTIO	93.393	6 R03 CA178680-03		2,892	
CA182063-02:03 PERSISTENT SIX2 EXPRESSION AS A FI	93.393	5 R03 CA182063-03		43,828	
CA182910-03 SHANGAI WOMEN'S HEALTH STUDY	93.393	6 UM1 CA182910-03		525,635	137,943
CA182910-04 SHANGHAI WOMEN'S HEALTH STUDY	93.393	5 UM1 CA182910-04		508,861	
CA183019-03 REPRODUCIBILITY/VALIDITY OF MICRO	93.393	6 R03 CA183019-03		3,869	
CA183021-03 CALCIUM INTAKE AND LUNG CANCER: EF	93.393	6 R03 CA183021-03		37,976	
CA187495-03 PREVENTION OF COX-2 DERIVED DNA	93.393	6 R21 CA187495-03		213,817	42,859
CA188214-03:04 COLORECTAL CANCER RISK LOCI: GWAS, FINE MAPPI	93.393	5 R01 CA188214-04		728,991	
CA189152-02 EFFECTS OF EXPANDED COVERAGE ON ACCE	93.393	6 R01 CA189152-02		1,816,678	678,777
CA189455-03 EFFECT OF MAGNESIUM TREATMENT ON VIT	93.393	6 R03 CA189455-03		55,347	20,707
CA190428-02 HELICOBACTER PYLORI PROTEIN SPECIFIC	93.393	6 R01 CA190428-02		680,704	461,811
CA190612-04 TARGETED CHEMOPREVENTION OF GASTRIC	93.393	5 R01 CA190612-04		800,810	75,628
CA194829-03 METABOLIC REGULATION OF T-ALL CELL	93.393	5 R21 CA194829-03		350,779	400
CA195660-02:03 METHIONINE METABOLISM IN ESOPH	93.393	5 R03 CA195660-03		103,290	
CA197344-02:03 ADAPTATION OF A PREVENTION-TREATME(A	93.393	6 R21 CA197344-02		195,130	
CA198482-02 CHROMATIN MAINTENANCE IN CANCER PROG	93.393	6 R01 CA198482-02		738,094	206,829
CA200999-02:03 SEX HORMONES PHYTOEESTROGENS	93.393	6 R01 CA200999-02		309,609	57,092
CA201856-02:03 PREVENTION OF GENOMIC INSTABIL	93.393	5 R21 CA201856-03		204,886	13,705
CA202936-02:03 METHLYLOMIC BIOMAKERS FOR MAGNE	93.393	6 R01 CA202936-02		718,099	301,537
CA202979-01 -SOUTHERN COMMUNITY COHORT STUDY-VANDERBILT	93.393	1 U01 CA202979-01		2,243,693	50,602
CA202981-01 BREAST CANCER GENETIC STUDY IN AFRICAN-ANCESTRY	93.393	1 R01 CA202981-01		1,270,112	128,841
CA203012-01A1 METHYLTRANSFERASE CONTRIBUTIONS TO GENOMIC STA	93.393	1 R01 CA203012-01A1		96,686	
CA206563-02 MOLECULAR FUNCTIONS OF APE1 IN BARRE	93.393	6 R01 CA206563-02		501,381	5,709

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
CA206564-02 MECHANISMS OF TUMORIGNENIC TRANSFORM	93.393	6 R01 CA206564-02		459,170	
CA207401-01A1 INCREASING HPV VACCINE UPTAKE IN COMMUNITY-BAS	93.393	1 R01 CA207401-01A1		184,693	79,253
CA207466-01 ORAL MICROBIOME AND LUNG CANCER RISK	93.393	1 R01 CA207466-01		342,516	62,843
CA28842-30 ETIOLOGICAL STUDIES OF GASTRIC CARCINOMA	93.393	6 P01 CA28842-30		349,965	192,394
CA28842-31 ETIOLOGICAL STUDIES OF GASTRIC CARCINOMA-PROJ 1	93.393	5 P01 CA28842-31		690,813	169,675
CA70867-17 CANCER RISK REDUCTION AND DIET: A COH	93.393	6 R37 CA70867-17		41,543	
CA77955-20:21 H. PYLORI RELATIONSHIP TO DIGESTIVE DISEASE AN	93.393	5 R01 CA77955-21		287,926	
CA92447-15 SOUTHERN COMMUNITY COHORT STUDY -VAND	93.393	6 R01 CA92447-15		2,026,530	575,687
Subtotal 93.393				**20,397,529**	**3,623,787**
CA109106-11 MRI DIFFUSION IN TUMORS USING OSCI	93.394	6 R01 CA109106-11		141,796	
CA138599-07 EVALUATION AND VALIDATION	93.394	6 R01 CA138599-07		69,851	
CA142565-07 QUANTITATIVE MRI FOR PREDICTING RESP	93.394	6 U01 CA142565-07		292,460	238,286
CA142565-08 QUANTITATIVE MRI FOR PREDICTING RESPONSE OF BREA	93.394	5 U01 CA142565-08		336,957	168,724
CA152662-06 VALIDATION OF BIOMARKERS OF RISK FOR THE EARLY	93.394	2 U01 CA152662-06		506,945	30,006
CA152662-07 VALIDATION OF BIOMARKERS OF RISK FOR THE EARLY D	93.394	5 U01 CA152662-07		126,216	
CA159988-06 VANDERBILT PROTEOME CHARACTERIZATION	93.394	6 U24 CA159988-06		616,016	264,498
CA163806-05:06 TSPO LIGANDS FOR CANCER IMAGING	93.394	5 R01 CA163806-06		435,699	
CA173593-05:06 COMPHREHENSIVE EVALUATION OF OGSE	93.394	5 R01 CA173593-06		337,800	
CA177372-04 THE ROLE OF MIRNA NETWORK IN GASTRIC	93.394	6 R01 CA177372-04		115,608	
CA182364-03 TRANSLATING GENE CALCIUM INTERACTION	93.394	6 U01 CA182364-03		566,532	400
CA182364-04 TRANSLATING GENE-CALCIUM INTERACTIONS TO PRECISI	93.394	5 U01 CA182364-04		162,120	
CA183727-04 TN VALLEY COOPERATIVE HUMAN TISSUE N	93.394	6 UM1 CA183727-04		1,093,121	
CA183727-05 TENNESSEE VALLEY COOPERATIVE HUMAN TISSUE NETWOR	93.394	5 UM1 CA183727-05		166,179	
CA184693-03:04 CERT IMAGING OF CANCER	93.394	5 R01 CA184693-04		311,135	28,125
CA186145-02 NON-INVASIVE EVALUATION- INDETERMINA	93.394	6 U01 CA186145-02		119,429	41,539
CA186145-03 NON-INVASIVE EVALUATION OF INDETERMINATE PULMONA	93.394	5 U01 CA186145-03		221,244	1,049
Subtotal 93.394				**5,619,109**	**772,627**
CA121210-10 OVERCOMING ACQUIRED RESISTANCE TO EG	93.395	6 R01 CA121210-10		192,634	69,411
CA131225-08 THE ROLE OF AURORA KINASE A IN UPPER	93.395	6 R01 CA131225-08		430,121	
CA160700-05 MULTIFUNCTIONAL NANOPARTICLES FOR IM	93.395	6 R01 CA160700-05		45,584	
CA166492-04:06 TARGETING RADIATION RESISTANCE GL	93.395	5 R01 CA166492-06		405,853	
CA178613-05 CYCLIC DINUCLEOTIDES IN COMBINATORIAL IMMUNOTH	93.395	7 R01 CA178613-05		14,868	
CA180847-04 VANDERBILT NETWORK LEAD ACADEMIC PAR	93.395	6 U10 CA180847-04		501,954	
CA180847-05 VANDERBILT NETWORK LEAD ACADEMIC PARTICIPATING S	93.395	5 U01 CA180847-05		197,664	
CA181491-03:04 DUSP4 IN BREAST CANCER: TUMOR SUPPRESSO*NE	93.395	5 R00 CA181491-04		166,498	
CA184387-03 EXPLOITING NOTCH INHIBITION AS A ME	93.395	6 R21 CA184387-03		176,616	18,944
CA208631-01 (PQ9) DUAL ACTION RSK INHIBITOR: TARGETING METAS	93.395	1 R21 CA208631-01		104,031	600
Subtotal 93.395				**2,235,824**	**88,955**
CA148934-06 EPHA2 RECEPTOR IN ENDOTHELIAL CELL-ME	93.396	6 R01 CA148934-06		165,048	12,095

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
CA151566-06 ROLES FOR LRIG1 IN INTESTINAL NE	93.396	2 R01 CA151566-06		409,857	41,127
CA162433-06 THE P450 EPOXYGENASES AS PRO-ONCO	93.396	5 R01 CA162433-06		444,172	
CA163056-06 BARRETT'S ESOPHAGUS TRANSLATIONAL RE	93.396	6 U01 CA163056-06		351,634	
CA163056-07 BARRETT'S ESOPHAGUS TRANSLATIONAL RESEARCH NETWO	93.396	2 U24 CA163056-07		23,474	
CA163563-04:05 ROLE OF EGFR LIGAND-CONTAINING EXOSOMES IN CO	93.396	6 R01 CA163563-04		424,416	717
CA177681-03:05 HRIN-A1 IN LIPOGENESIS AND BREAST CANCER META	93.396	5 R01 CA177681-05		442,984	100
CA179514-04 SECRETED RNA DURING CRC PROGRESSION	93.396	6 U19 CA179514-04		410,649	167,187
CA179514-05 SECRETED RNA DURING CRC PROGRESSION: BIOGENESIS,	93.396	5 U19 CA179514-05		549,965	194,770
CA187307-03 MOUSE MODEL OF INVASIVE COLON CANCE	93.396	6 R21 CA187307-03		169,028	
CA193219-02:03 THE ROLE OF AXL-ABLE AXIS IN BARR	93.396	6 R01 CA193219-02		397,859	
CA194198-02 CHARACTERIZATION OF BREAST CANCER DORMANCY IN BO	93.396	4 R00 CA194198-02		201,512	200
CA196405-02 CELLULAR MOLECULAR AND QUANTITATIVE	93.396	6 U01 CA196405-02		226,424	129,386
CA196405-03 CELLULAR, MOLECULAR AND QUANTITATIVE IMAGING ANA	93.396	5 U01 CA196405-03		260,502	16,650
CA197570-01A1 INTEGRATED APPROACH TO STUDY EARLY AND LATE EV	93.396	1 R35 CA197570-01A1		206,315	
CA200681-01A1:02 ROLE OF ADENOSINE IN TGF-BETA EFFECTS IN C	93.396	5 R01 CA200681-02		296,081	
CA46413-29 ROLE OF EGFR LIGANDS IN NEOPLASIA	93.396	6 R01 CA46413-29		392,341	196
CA69457-20S1 EMT REGULATION IN GASTROINTESTINAL	93.396	3 R01 CA69457-20S1		365,134	8,215
CA93999-15 TARGETS OF GENE OVEREXPRESSION AT 1	93.396	6 R01 CA93999-15		394,020	
CA95004-13:14 ENDOTHELIAL MTOR SIGNALING IN TU-B	93.396	6 R01 CA95004-13		307,993	
Subtotal 93.396				**6,439,408**	**570,643**
CA163072-06 ADMIN - MCC,VICC & TSU: PARTNERS IN	93.397	6 U54 CA163072-06		507,157	51,759
CA163072-07 - MCC,VICC & TSU: ADMIN	93.397	2 U54 CA163072-07		833,232	
CA210300-01 REGIONAL CENTER OF RESEARCH EXCELLENCE IN CANCER	93.397	1 P20 CA210300-01		143,354	53,455
CA68485-20 CANCER CTR SUPP GRANT: SENIOR LEADERS	93.397	6 P30 CA68485-20		2,427,126	541,560
CA68485-21 CANCER CTR SUPP GRANT: SENIOR LEADERS	93.397	5 P30 CA68485-21		4,953,672	1,105,760
CA95103-15 SPORE IN GI CANCER - PROJECT 1	93.397	6 P50 CA95103-15		1,990,160	353,615
CA98131-14 SPORE IN BREAST CANCER - PROJECT 1	93.397	6 P50 CA98131-14		699,169	38,178
CA98131-15 BREAST SPORE PROJECT 1	93.397	5 P50 CA98131-15		2,420,257	350,495
Subtotal 93.397				**13,974,126**	**2,494,822**
CA106183-12 SURGICAL ONCOLOGY TRAINING GR	93.398	6 T32 CA106183-12		56,250	
CA106183-13 SURGICAL ONCOLOGY TRAINING GRANT	93.398	5 T32 CA106183-13		290,119	
CA148912-06 HIGH-THROUGHPUT ANALYSIS OF MUTATI	93.398	6 K08 CA148912-06		189,112	200
CA151782-06 HELICOBACTER PYLORI SUBSTYPES, INFLA	93.398	6 K07 CA151782-06		14,924	
CA154267-06 CONDUCTING RESEARCH IN PEDIATRIC HEM	93.398	6 T32 CA154267-06		31,113	
CA160056-05 VANDERBILT TRAINING PROGRAM IN MOLEC	93.398	6 R25 CA160056-05		267,294	
CA160056-06 VANDERBILT TRAINING PROGRAM IN MOLECULAR AND GEN	93.398	5 R25 CA160056-06		300,129	5,398
CA168936-05:06 ASSESSMENT OF TUMOR EARLY RESPONSE	93.398	5 K25 CA168936-06		146,964	
CA172294-04:05 UNRAVELING GENETIC DETERMINANTS OF	93.398	5 K07 CA172294-05		164,636	14,835
CA172355-06 ENHANCING TANSLATIONAL SCIENCE VI	93.398	5 K24 CA172355-06		159,863	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
CA172957-05 CANCER CELL SIGNALING THROUGH LIPIDS CO	93.398	6 K01 CA172957-05		50,943	
CA176219-03:04 APPLYING COMPRESSED SENSING DYNAM	93.398	6 K25 CA176219-03		116,055	
CA184257-03 DNA REPAIR PATHWAYS IN TRIPLE NEGATIV	93.398	6 K07 CA184257-03		76,206	10,649
CA197315-03 NUCLEAR FACTOR I/B ACTION IN CASTRAT	93.398	5 K99 CA197315-03		40,150	
CA204726-01A1 PREDICTING AND PROFILING LONG-TERM SURVIVAL AF	93.398	1 K23 CA204726-01A1		113,415	
CA207848-01 VITAMIN D AND COLORECTAL CANCER RISK: AN INTEGRA	93.398	1 K99 CA207848-01		86,686	
CA90625-16 VANDERBILT CLINICAL ONCOLOGY RESEARCH CA	93.398	6 K12 CA90625-16		116,534	
CA90625-17 VANDERBILT CLINICAL ONCOLOGY RESEARCH CAREER DEVE	93.398	2 K12 CA90625-17		400,929	
CA92043-16 MULTIDISCIPLINARY TRAINING BASIC AND	93.398	6 R25 CA92043-16		52,061	2,058
CA93240-15 TRAINING GRANT IN RADIATION BIOL	93.398	6 T32 CA93240-15		42,400	22,311
CA93240-16 TRAINING GRANT IN RADIATION BIOLOGY	93.398	5 T32 CA93240-16		162,948	56,718
Subtotal 93.398				**2,878,731**	**112,169**
90IF0024-01 IMPROVING TRAUMA OUTCOMES	93.433	90 IF0024-01		39,753	
Subtotal 93.433				**39,753**	
DD00825-01-00 UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPME	93.632	90 DD00825-01-00		451,213	
Subtotal 93.632				**451,213**	
CMS331549-01-00 TRANSFORMING CLINICAL PRACTICE (TCPI) YR 2	93.638	1 L1 CMS331461-02		3,561,188	412,870
Subtotal 93.638				**3,561,188**	**412,870**
HL100398-08 PROJECT 1 OPTIMIZING CARDIO	93.837	6 U01 HL100398-08		185,762	15,271
HL102387-06 ALDOSTERON AND SODIUM REGULATION IN	93.837	6 R01 HL102387-06		59,176	
HL103620-07 GROWING RIGHT ONTO WELLNESS (GROW): CH	93.837	6 U01 HL103620-07		1,553,819	34,424
HL103836-06 MIDCAREER INVESTIGATOR AWARD IN PATIEN	93.837	2 K24 HL103836-06		127,333	
HL103976-05:06 OBESITY HYPERTENSION IN AFRICAN AMER	93.837	6 K23 HL103976-06		4,736	
HL105334-07 DEVELOPMENTAL DETERMINANTS OF CARDIOVASCULAR DI	93.837	2 T32 HL105334-07		132,446	
HL105678-07 HEPATIC LIPASE, PPAR-DELTA AND FATTY AC	93.837	6 K08 HL105678-07		9,316	
HL105731-05 METHODS TO REDUCE VEIN HARVEST INJ	93.837	6 R01 HL105731-05		169,329	
HL109019-06 THE VANDERBILT EMERGENCY MEDICINE RE	93.837	6 K12 HL109019-06		401,290	
HL109388-06 HEALTH LITERACY, HOSPITAL DISCHARGE, A	93.837	6 R01 HL109388-06		157,999	11,603
HL111420-05 CARDIAC REPAIR BY REPROGRAMMING FIBR	93.837	6 K08 HL111420-05		140,916	
HL111516-05 VASCULAR FACTORS UNDERLYING ABNORMAL	93.837	6 R01 HL111516-05		583,889	400
HL112746-05 IMPACT OF VITAMIN D	93.837	6 R01 HL112746-05		32,240	
HL116263-03 PROJ 1 HDL FUNCTION	93.837	6 P01 HL116263-03		2,655,520	605,980
HL116263-04 HDL FUNCTION IN HUMAN DISEASE (PROJ 1)	93.837	5 P01 HL116263-04		329,929	
HL116803-05 THE ROLE OF RAF-MEK SIGNALING IN THE	93.837	6 K08 HL116803-05		163,728	
HL118386-04:05 TIE TEK MODULATION OF CARDIAC DEVELO	93.837	6 R01 HL118386-04		558,863	800
HL118392-04:05 OPTIMAL DESIGN: CHALLENGE-RESPONSE -	93.837	5 R01 HL118392-05		198,669	42,139
HL118579-04:05 LYMPHATIC REGULATION OF SKIN ELECTR	93.837	6 R01 HL118579-04		465,768	
HL118952-05 REVISED SCN5A MUTATIONS AND DIALTED	93.837	5 R01 HL118952-05		584,904	12,239
HL119234-03:04 HEART FAILURE IN CANCER PATIENTS	93.837	6 R01 HL119234-03		530,388	400

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
HL119602-04:05 EFFECT OF DIPEPTIDYL PEPTIDASE 4 I	93.837	6 K23 HL119602-04		257,276	
HL121045-04:05 THE ANTI-FIBROTIC EFFECTS OF NEUR	93.837	5 K01 HL121045-05		193,697	
HL121139-04:05 PROCESSING & PRESENTATION OF MINOR	93.837	5 R01 HL121139-05		362,917	
HL121429-03 COGENT CONSORTIUM META-ANALYSIS OF B	93.837	6 R21 HL121429-03		37,163	13,080
HL121671-04:05 DIVERSE ROLES OF INTERLEUKIN 17 ISOFORM	93.837	5 K08 HL121671-05		181,870	
HL122847-03:04 SPLANCHNIC CIRCULATION AND BLOOD PRES	93.837	6 R01 HL122847-03		355,096	
HL122904-04 RATIONAL INTEGRATION OF GENOMIC HEALTHCARE TESTI	93.837	6 U01 HL122904-04		518,234	32,447
HL123829-03 RSV IMMUNOPROPHYLAXIS IMPACT ON RSV	93.837	6 R21 HL123829-03		90,629	13,416
HL123938-03 QUANTITATIVE ASSESSMENT- CARDIAC DIS	93.837	6 K23 HL123938-03		264,563	
HL124116-02:03 SIRTUIN 3 IMPAIRMENT AND SOD2 ACETYLA	93.837	5 R01 HL124116-03		655,274	
HL124935-03:04 TOWARD MECHANISM BASED APPROACH TO T	93.837	5 R01 HL124935-04		694,797	138,176
HL125032-03 IMMUNE FUNCTION AND THE RISK OF	93.837	6 R01 HL125032-03		69,274	29,215
HL125032-04 IMMUNE FUNCTION & THE RISK OF CVD AMONG HIV	93.837	5 R01 HL125032-04		924,806	661,517
HL125426-03:04 CARDIOVASCULAR CONSEQUENCES OF PEPTID	93.837	6 R01 HL125426-03		712,125	
HL125670-02:03 RANDOMIZED, ED-BASED INTERVENTION T	93.837	5 K23 HL125670-03		256,381	
HL125865-03:04 THE ROLE OF THE T CELL IN THE GENESI	93.837	6 R01 HL125865-03		456,008	
HL127104-02:03 GROW BABY IMPROVING MATERNAL GES	93.837	6 K23 HL127104-02		219,624	
HL127130-02:03 ENHANCING INTERFACILITYTRANSF	93.837	5 K23 HL127130-03		167,752	
HL127173-02:03 MACROPHAGE SR-BI REGULATES AUTO	93.837	5 R01 HL127173-03		631,944	
HL127218-01A1 PGE2 SIGNALING IN HYPERTENSION: THE ROLE OF EP	93.837	1 R56 HL127218-01A1		286,321	
HL127368-02 CHARACTERIZING LIFE-SPAN SOCIOBEHAVI	93.837	6 R21 HL127368-02		9,112	9,112
HL127704-02:03 ATRIAL FIBRILLATION SUSCEPTIBILITY	93.837	5 K23 HL127704-03		243,369	
HL128044-01 PANNEXIN CHANNELS IN CARDIAC ARRHYTHMIA	93.837	1 R01 HL128044-01		(224)	
HL128203-01A1 PROJ 1 VUMC 1MULTIDISCIPLINARY APPROACHES TO H	93.837	1 P01 HL128203-01A1		937,221	589,266
HL128386-01A1 DUCTUS ARTERIOSUS REGULATION BY ANION CHANNELS	93.837	1 R01 HL128386-01A1		349,255	
HL128928-01A1 THE NATRIURETIC PEPTIDE SYSTEM IN AFRICAN-AMER	93.837	1 K23 HL128928-01A1		180,586	
HL128983-01A1 PDE5 INHIBITION FOR OBESITY-RELATED CARDIOMETA	93.837	1 R01 HL128983-01A1		761,475	
HL128983-02 PDE5 INHIBITION FOR OBESITY-RELATED CARDIOMETABO	93.837	5 R01 HL128983-02		61,547	
HL128996-02:03 HDL-MICRORNA INTERCELLULAR COMMUNICATION IN A	93.837	6 R01 HL128996-02		512,747	200
HL129941-01A1 THE ROLE OF INFLAMMATION IN CARDIOVASCUL ADMIN	93.837	1 P01 HL129941-01A1		1,513,121	445,410
HL130497-03 ROLE OF SALT, ISOKETAL-MODIFIED PROTEIN	93.837	5 K01 HL130497-03		194,456	
HL131906-02:03 IMAGING ACTIVATED MACROPHAGES IN THE LUNGS	93.837	5 R01 HL131906-03		564,955	9,352
HL131911-02 ROLE OF GENETIC VARIANTS IN SUDDEN DEATH IN T	93.837	6 U01 HL131911-02		426,295	
HL131911-03 ROLE OF GENETIC VARIANTS IN SUDDEN DEATH IN THE	93.837	5 U01 HL131911-03		135,701	
HL131977-01 VUMC THE IMPACT OF DIABETES ON REVASCULARIZATION	93.837	1 R01 HL131977-01		144,908	23,880
HL131977-02 THE IMPACT OF DIABETES ON REVASCULARIZATION I	93.837	5 R01 HL131977-02		18,264	
HL132338-01A1 MATERNAL TRAUMATIC STRESS, OXIDATIVE STRESS, A	93.837	1 R01 HL132338-01A1		17,093	
HL132805-01 KATP CHANNELS AS BIOMECHANICAL SENSORS IN THE RE	93.837	1 R21 HL132805-01		119,105	
HL133117-01 THE VANDERBILT EMERGENCY CARE RESEARCH TRAINING	93.837	1 K12 HL133117-01		67,528	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
HL133127-01A1 NOVEL PATHOPHYSIOLOGICAL TARGETS IN ATRIAL FIB	93.837	1 R01 HL133127-01A1		94,958	
HL133290-01A1 SIGNALING MECHANISMS GOVERNING MYOCARDIAL FIBR	93.837	1 R01 HL133290-01A1		191,621	200
HL133786-01A1 EXPLORING STATIN PLEIOTROPIC EFFECTS WITHIN A	93.837	1 R01 HL133786-01A1		43,644	
HL133860-01 TISSUE SODIUM, INFLAMMATION, AND BLOOD PRESSURE	93.837	1 R01 HL133860-01		198,028	101,496
HL135442-01 SCN5A (NAV1.5): PREDICTING THE CONSEQUENCE OF MI	93.837	1 K99 HL135442-01		36,570	
HL135453-01 TRAJECTORY OF ANTI-MULLERIAN HORMONE DECLINE AND	93.837	1 R03 HL135453-01		42,014	
HL135461-01 SOX6 ROLE IN RENIN EXPRESSION DURING JUXTAGLOMER	93.837	1 K01 HL135461-01		81,862	
HL137166-01 IMMUNOPHENOTYPING OF HUMAN HYPERTENSION USING SI	93.837	1 DP2 HL137166-01		199,581	
HL137392-01 NOVEL MECHANISMS OF ARRHYTHMOGENESIS AND DILATED	93.837	1 F32 HL137392-01		9,472	
HL37675-26 REGULATION OF CARDIAC MYOCATE DIFFERE	93.837	5 R01 HL37675-26		475,034	44,595
HL39006-28:29 IMMUNITY, INFLAMMATION AND HYPERTEN	93.837	6 R01 HL39006-28		514,278	11,661
HL49989-22 MODULATION OF CARDIAC	93.837	6 R01 HL49989-22		398,186	9,081
HL56693-20 AUTONOMIC CARDIOVASCULAR REGULATION	93.837	6 P01 HL56693-20		1,634,014	266,545
HL65962-14:15 PHARMACOGENOMICS OF ARRHYTHMIA THERAP	93.837	6 U19 HL65962-15		1,221,971	134,920
HL70715-12 PREVENTION OF VEIN GRAFT FAILURE	93.837	6 R01 HL70715-12		367,126	
HL71670-14 ARRHYTHMIA MECHANISMS IN SAR	93.837	5 R01 HL71670-14		582,421	
HL79184-06A1:11 PHARMACOGENETICS OF ACE INHIBITOR-A	93.837	6 R01 HL79184-11		2,714	
HL81326-11 FACTOR XI IN THROMBOSIS	93.837	5 R01 HL81326-11		513,579	
HL81707-11 MEDICATIONS AND THE RISK OF SUDDEN CA	93.837	6 R01 HL81707-11		154,544	
HL88635-09 REVISED CALSEQUESTRIN IN VENTRICULAR	93.837	6 R01 HL88635-09		219,390	
HL92870-06 MECHANISMS FIBR- PROJECT 1	93.837	2 P01 HL92870-06		1,858,774	374,409
HL94786-05A1 OUTCOME DEPENDENT SAMPLING OF LONGITUDINAL DATA	93.837	2 R01 HL94786-05A1		390,673	123,392
HL96223-07:08 SHORT TERM TRAINING FOR MIN	93.837	6 R25 HL96223-07		51,471	5,609
HL96223-08 NIH - SHORT TERM TRAINING FOR MINORITY STUDE	93.837	5 R25 HL096223-08		36,895	
Subtotal 93.837				**31,957,104**	**3,760,234**
HL087738-12 CLINICAL AND TRANSLATIONAL TRAINING PROGRAM IN P	93.838	2 T32 HL087738-12		29,412	
HL092870-07 MECHANISMS OF FAMILIAL PULMONARY FIBRO-PROJECT 1	93.838	5 P01 HL092870-07		242,247	
HL102020-06 ROLE OF BMPR2 EXPRESSION IN HPAH; IMP	93.838	6 R01 HL102020-06		214,172	
HL105479-06 REGULATION OF FIBROTIC REMODELING	93.838	6 R01 HL105479-06		136,465	
HL108800-05 PROJ1:HORMONAL METABOLIC AND SIGNALI	93.838	6 P01 HL108800-05		476,306	2,884
HL108800-06 PROJECT 1: HORMONAL, METABOLIC AND SIGNALING	93.838	5 P01 HL108800-06		2,841,704	131,952
HL109977-06 PREGNANCY FOLATE STATUS & EARLY CHIL	93.838	6 R01 HL109977-06		478,211	254,917
HL111111-05 ALTERING SEDATION PARADIGMS TO IMPROVE BRAIN INJ	93.838	6 R01 HL111111-05		660,694	139,751
HL111259-06 MINORITY SUPPLEMENT - CAVELOAR DEFE	93.838	6 R01 HL111259-06		471,935	
HL112286-05 NRF2 AND RADIATION-INDUCED PULMONARY	93.838	6 R01 HL112286-05		394,975	
HL116597-04 ROLE OF LUNG MSC IN EMPHYSEMA	93.838	6 R01 HL116597-04		515,932	
HL117074-04 MICROBIAL INDUCTION OF SARCOIDOSIS C	93.838	6 R01 HL117074-04		184,229	31,684
HL117074-05 MICROBIAL INDUCTION OF SARCOIDOSIS CD4+ T CELL D	93.838	5 R01 HL117074-05		636,958	33,700
HL119503-04 MECHANISMS OF PULMONARY FIBROSIS IN	93.838	6 R01 HL119503-04		401,126	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
HL119503-05 MECHANISMS OF PULMONARY FIBROSIS IN HERMANSKY-PU	93.838	5 R01 HL119503-05		22,420	
HL121174-03:04 METABOLIC REPROGRAMMING IN PULMONARY	93.838	6 K08 HL121174-03		195,453	
HL122417-03:04 LIPID DEPOSITION IN THE RIGHT VEN	93.838	5 R01 HL122417-04		685,669	4,647
HL122554-03 ROLE OF GENDER IN TH17-MEDIATED INFLA	93.838	6 R01 HL122554-03		686,527	34,162
HL123033-03 PREVENTION AND EARLY TREATMENT OF AC	93.838	6 U01 HL123033-03		373,416	58,938
HL123033-04 PREVENTION AND EARLY TREATMENT OF ACUTE LUNG INJ	93.838	5 U01 HL123033-04		56,571	
HL125212-04 A MOLECULAR PHENOTYPE OF COMBINED PULMONARY HYPE	93.838	5 U01 HL125212-04		291,300	
HL125212-04 MOLECULAR PHENOTYPE OF COMBINED P	93.838	6 U01 HL125212-03		56,867	
HL126176-03 THE GOLD STUDY: GOAL OF OPEN LUNG VE	93.838	6 R01 HL126176-03		440,874	153,759
HL126492-04 USING REAL WORLD DECISIONS TO DEV	93.838	6 R01 HL126492-03		258,021	34,010
HL126671-03:04 HEMOGLOBIN IN ARDS: A NOVEL MEDIATOR OF AVEOL	93.838	6 R01 HL126671-03		626,153	
HL127102-02:03 BETA 1 IN THE LUNG	93.838	6 K08 HL127102-02		172,349	
HL127301-02:03 MENTORING IN TRANSLATIONAL	93.838	6 K24 HL127301-02		108,967	
HL129020-03 STATISTICAL METHODS FOR RECURRENT EV	93.838	5 R21 HL129020-03		140,295	18,003
HL130595-02:03DNA-DAMAGE REPAIR IN PULMONARY FIBRO	93.838	6 K08 HL130595-02		243,513	
HL133742-01 ANTIBIOTIC TIMING, SPECTRUM, AND CUMULATIVE DOSE	93.838	1 R21 HL133742-01		59,515	
HL136664-01 TARGETING TH17 CELL METABOLISM IN STEROID RESIST	93.838	1 R01 HL136664-01		54,492	
HL136748-01 ROLE OF BONE MARROW CELLS IN PATHOGENESIS AND TH	93.838	1 R01 HL136748-01		30,181	
HL136888-01 MECHANISMS OF AIRSPACE INFLAMMATION CAUSED BY CE	93.838	1 K08 HL136888-01		25,662	
HL79937-09 ASTHMA AND NOCTURNAL HYPOXEMIA IN SICKLE	93.838	6 R01 HL79937-09		32,472	
HL87738-11 CLINICAL AND TRANSLATIONAL RESEARCH T	93.838	6 T32 HL87738-11		363,127	
HL94296-09 INTERDISCIPLINARY TRAINING PROGRAM IN LUNG RESEAR	93.838	6 T32 HL94296-09		284,102	
HL95797-07:08 INTERVENTIONS AGAINST MOLECULAR ET	93.838	6 R01 HL95797-07		529,099	
Subtotal 93.838				**13,421,409**	**898,408**
HL106812-07:08 DISTRICT CONTRIBUTIONS OF MTOR COMPLEXES 1 A	93.839	5 R01 HL106812-08		450,786	
HL114518-04 PREVENTING GASTRODUODENAL BLEEDING I	93.839	6 R01 HL114518-04		486,541	
HL117676-01:03 FREE HEMOGLOBIN POTENTIATES PULMONAR	93.839	6 R21 HL117676-03		(847)	
HL122143-03 METABOLIC AND CD4+ T CELL DYSREGUL	93.839	6 K23 HL122143-03		178,055	
HL124159-03 PHOSPHATASE AND TENSIN HOMOLOG PTEN ACTIONS IN P	93.839	7 R01 HL124159-03		255,179	12,377
HL130018-01A1 MECHANISMS OF GLYCOSAMINOGLYCAN-CATALYZED PROT	93.839	1 R01 HL130018-01A1		127,557	20,922
HL58837-20 PHYSIOLOGY & MOLECULAR BIOLOGY OF FACT	93.839	6 R01 HL58837-20		399,444	
HL71544-14 MECHANISM OF STAPHYLOCAGULASE-ACTIVAT	93.839	6 R01 HL71544-14		322,097	39,173
Subtotal 93.839				**2,218,813**	**72,472**
AR63157-05 THE ROLES OF COLLAGEN AND WATER IN TH	93.846	6 R01 AR63157-05		345,949	
AR64768-04:05 DRUG-DRUG INTERACTIONS & PREVENTAB	93.846	6 K23 AR64768-04		157,271	
AR65762-03 PLASMIN IS ESSENTIAL TO PREVENT AND	93.846	6 R03 AR65762-03		10,241	
AR66875-03:04 THE MECHANICAL PHENOTYPE OF FETA	93.846	6 R03 AR66875-03		103,951	
AR66971-03 HDL-MEDIATED TRANSFER OF MICRORNA REGULA	93.846	6 R21 AR66971-03		39,591	
AR67871-01A1 THE ROLE OF TISSUE MATRIX IN THE FRACTURE RESIS	93.846	1 R21 AR67871-01A1		185,447	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
AR67901-03 IMMUNE CELLS & CYTOKINES MEDIATING FIBRODYSPLASIA	93.846	6 R21 AR67901-03		229,046	
AR67938-01A1 EVALUATING GENETIC RISK FOR KELOIDS IN AFRICAN	93.846	1 R21 AR67938-01A1		82,393	
AR68443-02:03 FUNCTIONAL IMPACT OF HDLANSPORT OF MI	93.846	6 K23 AR68443-02		107,608	
AR69201-01A1 OPERATIVE VERSUS NON-OPERATIVE TREATMENTS FOR A	93.846	1 U34 AR69201-01A1		196,506	
AR71267-01 STEVENS-JOHNSON SYNDROME/TOXIC EPIDURAL NECROLYS	93.846	1 R13 AR71267-01		35,018	
Subtotal 93.846				**1,493,022**	
DK007383-38 SHORT TERM RESEARCH TRAINING - STIPENDS	93.847	5 T35 DK007383-38		74,184	
DK020593-40 DRTC ADMIN	93.847	2 P30 DK020593-40		442,375	
DK062794-14:15 ROLE OF CYCLOOXYGENASE2 SALETSENSI	93.847	5 R01 DK062794-15		348,825	
DK065138-15A1 GLUCOSE MODIFICATIONS OF PROTEINS IN DIABET	93.847	2 R01 DK065138-15A1		117,573	
DK07061-42 RESEARCH TRAINING IN DIABETES AND END	93.847	6 T32 DK07061-42		52,681	
DK07061-43 RESEARCH TRAINING IN DIABETES AND ENDOCRINOLO-	93.847	2 T32 DK07061-43		231,210	46,296
DK07383-37:38 SHORT TERM RESEARCH TRAINING	93.847	6 T35 DK07383-37		176,627	
DK07569-27 RENAL BIOLOGY AND DISEASE TRAINING PRO	93.847	6 T32 DK07569-27		44,972	
DK07569-28 RENAL BIOLOGY AND DISEASE TRAINING PROGRAM	93.847	5 T32 DK07569-28		244,275	
DK07673-23 TRAINING IN GASTROENTEROL	93.847	6 T32 DK07673-23		43,615	
DK07673-24 TRAINING IN GASTROENTEROLOGY - MINORITY SUPPLEMEN	93.847	5 T32 DK07673-24		229,267	
DK084246-07:08 BRUTON'S TYROSINE KINASE & IMM	93.847	5 R01 DK84246-08		467,106	400
DK085465-09 VANDERBILT UNIVERSITY: CLINICAL CENTER APPLICAT	93.847	5 U01 DK085465-09		71,099	
DK096999-06S1 UNDERGRADUATE RESEARCH INTERNSHIPS IN PATHOBIO	93.847	3 R25 DK096999-06S1		5,555	
DK100431-03:04 ROLE OF FOREGUT IN NUTRIENT METABOLI	93.847	6 R01 DK100431-03		321,299	
DK100533-04:06 MITOCHONDRIAL DYSFUNCTION IN CHRONI	93.847	5 K23 DK100533-06		205,406	
DK100694-04:05 IMPROVING MEDICATION ADHERENCE AMONG UNDERSER	93.847	6 R01 DK100694-04		765,278	45,076
DK101038-02 MAPPING SEROTONIN RECEPTORS IN LOWER	93.847	6 U01 DK101038-02		27,950	
DK101332-03:04 INDUCTION & EVOLUTION OF METAPLASIA IN THE ST	93.847	6 R01 DK101332-03		390,477	
DK101342-03 MITOCHONDRIAL DNA HAPLOGROUPS AND	93.847	6 R21 DK101342-03		31,820	13,422
DK101689-04 EARLY ONSET OBESITY AND COGNITIVE	93.847	5 K23 DK101689-04		184,464	
DK101791-04 METABOLIC REPROGRAMMING IN ACUTE K	93.847	5 R01 DK101791-04		571,780	2,516
DK103067-04 HARRIS-NOVEL INTEGRATED ANALYSES OF	93.847	5 R24 DK103067-04		1,421,137	19,152
DK103474-03 MECHANISMS OF BILE ACID SIGNALING	93.847	6 F32 DK103474-03		20,217	
DK103474-04 MECHANISMS OF BILE ACID SIGNALING AND METABOLISM	93.847	5 F32 DK103474-04		54,928	
DK103910-02 AFFERENT HYPERACTIVITY MECH IN OVERAC	93.847	6 K23 DK103910-02		147,522	
DK103935-03:04 DETERMINING KEY ORGANIZATIONAL HEALTH	93.847	6 R01 DK103935-03		342,841	56,739
DK104211-02 MOLECULAR MECHANISMS OF PHYSIOLOGIC PAN	93.847	6 UC4 DK104211-02		833,190	462,047
DK104817-03:04 ICD8ALPHA CELLS AS NOVEL INNATE-TYPE LYMPHOID	93.847	5 R01 DK104817-04		251,771	
DK105371-02:04 NON-INVASIVE ASSESSMENT OF HUMAN BROWN ADIPOS	93.847	5 R01 DK105371-04		453,237	
DK105550-04:05 EXPLOITING METABOLIC VULNERABILITIES	93.847	5 R01 DK105550-05		524,198	35,920
DK105720-02 DETERMINING THE ROLE OF THE CVPA	93.847	6 F32 DK105720-02		21,007	
DK105847-03:04 BILE DIVERSION SIMPLE AND EFFECTIVE	93.847	6 R01 DK105847-03		429,573	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
DK106306-02 TARGETING FAMILY BEHAVIORS TO IMPROV	93.847	6 K01 DK106306-02		171,776	
DK106472-02:03 MECHANISMS OF CELLULAR ADAPTATION IN CYSTITIS	93.847	6 K08 DK106472-02		152,458	
DK106511-02:03 ENHANCING PATIENT ACTIVIATION IN DIABETES CAR	93.847	6 K23 DK106511-02		189,860	
DK106755-02:03 PANCREATIC SIGNATURES IN T2D MELLITU	93.847	6 R24 DK106755-02		822,489	356,935
DK108159-02:03 METABOLITE PROFILES AND THE RISK	93.847	5 R01 DK108159-03		424,991	125,615
DK108352-02 INNATE AND ADAPTIVE IMMUNITY IN HIV-ASS	93.847	6 R56 DK108352-02		390,720	112,935
DK108448-01A1 PRESERVATION OF DIALYSIS ACCESS PATENCY	93.847	1 F32 DK108448-01A1		50,717	
DK108492-02 TISSUE-SPECIFIC CONTRIBUTION OF SELE	93.847	6 F32 DK108492-02		50,481	
DK108492-03 TISSUE-SPECIFIC CONTRIBUTION OF SELENOPROTEIN P	93.847	5 F32 DK108492-03		6,623	
DK108968-02 TGF-BETA PATHWAYS THAT PROTECT EPITHELIA IN CHRO	93.847	6 R01 DK108968-02		377,563	10,159
DK109019-02 PARATHYROID HORMONE: GENETIC ARCHITECTURE AND CL	93.847	7 K01 DK109019-02		9,135	
DK109102-02:03 ESTROGEN AND COORDINATED CARBOHYDRAT	93.847	6 R01 DK109102-02		350,319	14,560
DK110166-01A1 CALCIUM: MAGNESIUM BALANCE, MICROBIOTA, AND NE	93.847	1 R01 DK110166-01A1		46,705	
DK110399-02 GLUCOSE-INDUCED STIFFENING OF EXTRACELLULAR MATR	93.847	6 R03 DK110399-02		2,892	
DK110657-01 SLEEP PROMOTION TO IMPROVE DIABETES MANAGEMENT I	93.847	1 R21 DK110657-01		129,594	
DK110804-02 ATLAS OF AUTONOMIC AND NEUROMODULATORY LINEAGES	93.847	6 U01 DK110804-02		226,965	11,395
DK110804-03 ATLAS OF AUTONOMIC AND NEUROMODULATORY LINEAGES	93.847	5 U01 DK110804-03		8,037	
DK111101-01A1 DEFICITS IN ENTEROCYTE APICAL TRANSPORTERS ASS	93.847	1 F32 DK111101-01A1		27,782	
DK111554-01 THE NF-KAPPAB-ANDROGEN RECEPTOR AXIS DRIVES FAIL	93.847	1 R01 DK111554-01		213,495	5,845
DK112080-01 VANDERBILT DEVELOPMENTAL CENTER FOR TRANSLATIONA	93.847	1 P20 DK112080-01		87,618	20,084
DK112232-01 HPPAP POWERS PARENT CENTER	93.847	1 UC4 DK112232-01		324,188	196,171
DK112262-02 THE ROLE OF ADIPOSE-RESIDENT T CELLS IN HIV	93.847	6 R01 DK112262-02		106,669	
DK112688-01A1 MECHANISMS AND THERAPEUTIC MANIPULATION OF RET	93.847	1 R01 DK112688-01A1		128,120	
DK113329-01 DIABETES-SPECIFIC FAMILY FUNCTIONING AMONG ADULT	93.847	1 R03 DK113329-01		13,514	
DK18381-45 STUDIES ON THE STRUCTURE OF BASEMENT	93.847	5 R01 DK18381-45		816,972	
DK20593-39 DRTC ADMINISTRATIVE COMPON	93.847	6 P30 DK20593-39		2,563,573	431,662
DK38226-28 ROLE OF EICOSANOIDS IN RENAL FUNCTION	93.847	6 P01 DK38226-28		148,098	144,730
DK48370-22 SMALL GTP BINDING PROTEINS IN GASTROINTE	93.847	6 R01 DK48370-22		280,555	
DK50435-20 ASCORBIC ACID FUNCTION AND METABOLISM	93.847	6 R01 DK50435-20		125,531	
DK51265-21:22 MECHANISMS OF EGFR ACTIVATION AND SIG	93.847	6 R01 DK51265-21		804,196	
DK53620-15 H PYLORI INDUCED DNA DAMAGE AND IMMUN	93.847	6 R01 DK53620-15		30,064	
DK56942-14 RESOLUTION OF GLOMERULOSCLEROS	93.847	6 R01 DK56942-14		413,383	
DK58404-15 MOLECULAR AND CELLULAR BASIS FOR DIGESTIVE DISEAS	93.847	6 P30 DK58404-15		1,289,977	202,102
DK58587-10:15 HELICOBACTER PYLORI AND GASTROINTESTI	93.847	6 R01 DK58587-15		2,120	
DK58587-16 HELICOBACTER PYLORI AND GASTROINTESTINAL BIOL	93.847	2 R01 DK58587-16		461,068	
DK58697-12 BIOMAGNETIC CHARACTERIZATION OF GASTRI	93.847	6 R01 DK58697-12		76,736	
DK61470-13:14 SURGICAL STUDIES ON THE ROLE ON GASTRIN-	93.847	5 R01 DK61470-14		361,457	
DK64775-11 REALISTIC MODELS OF GASTROINTESTINAL	93.847	6 R01 DK64775-11		150,146	39,574
DK65138-14 GLUCOSE MODIFICATIONS OF PROTEINS IN	93.847	6 R01 DK65138-14		60,606	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
DK69921-13:14 THE LAMININ RECEPTORS IN KIDNEY DEVEL	93.847	6 R01 DK69921-13		461,842	111,516
DK75594-06 BETAL INTEGRIN AND RENAL TUBULOGENISIS	93.847	2 R01 DK75594-05		(616)	
DK78158-07:08 NEURAL CREST CONTRIBS TO LOWER URINARY	93.847	5 R01 DK78158-08		365,729	
DK81134-08:09 REGULATION OF INTESTINAL DEVELOPMENT B	93.847	6 R01 DK81134-08		356,654	
DK81646-09 MOLECULAR MECHANISMS OF RENAL INJURY	93.847	6 R01 DK81646-09		89,087	
DK82192-09 IMPACT OF ACUTE KIDNEY INJURY ON KIDNEY	93.847	6 U01 DK82192-09		118,871	
DK82192-10 IMPACT OF ACUTE KIDNEY INJURY ON KIDNEY DISEASE P	93.847	5 U01 DK82192-10		475,244	
DK83187-05 STRUCTURE FUNCTION ANALYSIS OF INEGR	93.847	6 R01 DK83187-05		537	
DK83264-06 PUBLIC-PRIVATE PARTNERSHIP ADDRESSING LI	93.847	6 R18 DK83264-06		92,339	2,411
DK85465-08 VANDERBILT UNIVERSITY: CLINICAL CENTER APPLICA	93.847	6 U01 DK85465-08		498,591	
DK87894-06 LEVERAGING PATIENT PORTAL TO IMPROVE	93.847	6 K01 DK87894-06		37,217	
DK87962-05 BIOMARKERS OF OBESITY, PROSTATE TISSUE	93.847	6 R01 DK87962-05		6,272	
DK90304-06 DEVELOPING, VALIDATING, AND IMPLEMENT	93.847	6 K23 DK90304-06		126,614	11,479
DK91748-06 RYGB IMPROVES METABOLISM BY INTERUPTIN	93.847	6 R01 DK91748-06		268,042	10,499
DK92357-06 PROTEIN HANDLING BY RENAL TUBULE EPITHEL	93.847	6 K01 DK92357-06		128,246	
DK92986-06 CDTR ADMINISTRATIVE CORE	93.847	6 P30 DK92986-06		205,901	79,308
DK92986-07 CDTR ADMIN	93.847	2 P30 DK92986-07		300,434	14,168
DK93501-05 KINASE MODULATION OF NA+-DEPENDENT C	93.847	6 R01 DK93501-05		297,362	173,277
DK93501-06 WNK-SPAK SIGNALING IN THE DISTAL NEPHRON	93.847	2 R01 DK93501-06		548,191	174,794
DK93660-07 NOVEL CELL THERAPY FOR ANEMIA OF CKD-	93.847	5 R01 DK93660-07		389,050	
DK94199-05 ISLET IMAGING WITH MONOCLONAL ANTIBOD	93.847	6 R01 DK94199-05		161,367	267
DK95761-05 INTEGRIN/TGF-BETA AXIS IN TUBULOINTER	93.847	6 R01 DK95761-05		281,937	
DK95785-05 ROLE OF RENAL MACROPHAGES IN RECOVERY	93.847	5 R01 DK95785-05		417,094	
DK96994-05 ENDOGENOUS ALDOSTERONE AND GLUCOSE	93.847	5 R01 DK96994-05		395,653	47,623
DK96999-06 UNDERGRADUATE RESEARCH INTERNSHIPS IN	93.847	5 R25 DK96999-06		161,660	
DK97306-04:05 ROLE OF PEROXIDASIN IN GLOMERULAR MATRIX HOMEO	93.847	6 K08 DK97306-04		156,522	
DK97332-06 ROLE OF CD148 TYROSINE PHOSPHASE I	93.847	5 R01 DK97332-06		427,807	933
DK99204-04:05 SELENIUM IN GASTROINTESTINAL INFLAMMA	93.847	5 R01 DK99204-05		428,256	
DK99467-04 COLLAGEN IV NETOWRKS OF BASEMENT MEMB	93.847	6 R01 DK99467-04		470,864	
DK99473-04 PROXIMAL TUBULE KIM-1 EXPRESSION MODULATES ACUTE	93.847	7 K01 DK99473-04		149,575	
DK99923-04 ANTI-INFLAMMATORY INTERVENTIONS IN MA	93.847	6 U01 DK99923-04		90,588	54,882
DK99923-05 ANTI-INFLAMMATORY INTERVENTIONS IN MAINTENANCE HE	93.847	5 U01 DK99923-05		454,882	178,985
Subtotal 93.847				**29,806,464**	**3,213,476**
NS007491-17 TRAINING PROGRAM IN ION CHANNEL AND TRANSPORTER	93.853	5 T32 NS007491-17		504	
NS07491-16 TRAINING PROGRAM IN ION CHANNEL AND TRANSPORTER B	93.853	2 T32 NS07491-16		137,638	26,126
NS33300-22 GABA (A) RECEPTOR ASSEMBLY/TRAFFICKIN	93.853	6 R01 NS33300-22		240,370	
NS65736-08 AUTONOMIC RARE DISEASES CLINICAL RESEARCH ADMIN	93.853	6 U54 NS65736-08		1,210,252	738,212
NS66927-08:09 PATHOPHYSIOLOGY OF CONDUCTION BLOC	93.853	5 R01 NS66927-09		360,931	48,830
NS69909-06 REPRESENTATION OF NOCICEPTION IN SII	93.853	6 R01 NS69909-06		334,230	2,450

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
NS75270-06 MRI STRUCTRUAL AND FUNCTIONAL CONNECTI	93.853	6 R01 NS75270-06		307,163	39,678
NS77318-06 VANDERBILT SITE FOR NETWORK OF EXCELL	93.853	6 U10 NS77318-06		364,773	
NS78289-05 REGULATION OF NEUROGENESIS IN TSC BY MTORC1 AND M	93.853	6 R01 NS78289-05		392,380	600
NS78680-06 BIOPHYSICAL BASIS OF FUNCATIONAL CO	93.853	6 R01 NS78680-06		346,904	
NS78828-05 CHARACTERIZING HEMODYNAMIC COMPENSAT	93.853	6 R01 NS78828-05		239,598	
NS80988-04:05 DOPAMINE EFFECTS ON MESOCORTICOLIMB	93.853	5 K23 NS80988-05		276,185	
NS82635-04:05 ALTERED SYNAPSE FORMATION AND FUNCT	93.853	5 R01 NS82635-05		393,752	9,940
NS82736-03 SOX10 ALLELES FOR FUNCTIONAL ANALYSIS OF	93.853	6 R21 NS82736-03		62,631	
NS83710-05 MTOR MODULATION OF MYELINATION	93.853	6 K08 NS83710-05		221,186	
NS86492-04 THE VANDERBILT STROKE TRIALS NETWORK REGIONAL COO	93.853	4 U10 NS86492-04		355,302	
NS92961-02:03 RESTING STATE CONNECTIVITY IN PRI	93.853	6 R01 NS92961-02		626,218	14,072
NS93669-02:03 RESTING STATE CONNECTIVITY IN WHITE MATTER	93.853	6 R01 NS93669-02		440,937	78,402
NS94041-02 PRIMARY PREVENTION OF STROKE IN CHILDREN	93.853	6 R01 NS94041-02		1,054,157	343,712
NS96127-02:03 MRIBASED QUANTITATIVE BRAIN OXYGE	93.853	5 R01 NS96127-03		321,813	
NS96483-01A1 IMPAIRED HOMEOSTATIC POTENTIATION OF GABAERGIC	93.853	1 R21 NS96483-01A1		146,632	
NS97618-01 MULTIMODAL MAPPING OF SUBCORTICAL AND CORTICAL FU	93.853	1 K99 NS97618-01		74,718	
NS97763-01:02 IMAGING COLLATERALS AND TISSUE METABOLISM IN P	93.853	5 R01 NS97763-02		206,857	
NS97783-01:02 BIOLOGICAL DETERMINANTS OF IMPULSIVITY IN PARK	93.853	1 R01 NS97783-01		256,575	43,550
NS97821-01:02 QUANTITATIVE ASSESSMENT OF PERIPHERAL NERVE IN	93.853	5 R01 NS97821-02		267,085	15,574
Subtotal 93.853				**8,638,790**	**1,361,147**
AI07474-22 VANDERBILT INFECTION PATHOGENESIS AND	93.855	6 T32 AI07474-22		71,184	
AI07474-23 VANDERBILT INFECTION PATHOGENESIS AND EPIDEMIOLOG	93.855	5 T32 AI07474-23		246,688	
AI100700-05 THE ROLE OF OBESITY AND ADIPOCYTES	93.855	6 K23 AI100700-05		132,203	
AI101171-05:06 HOST-MEDIATED ZINC SEQUESTRATION	93.855	5 R01 AI101171-06		344,454	88,802
AI103038-05:06 KEY DETERMINANTS OF DENGUE VIRUS	93.855	6 K08 AI103038-05		159,811	
AI104336-05 CHRONIC GRAFT DESTRUCTION: INTERPLAY OF	93.855	6 U01 AI104336-05		878,504	820,381
AI104336-06 CHRONIC GRAFT DESTRUCTION: INTERPLAY OF ALLO- AN	93.855	5 U01 AI104336-06		93,007	45,240
AI104352-04 TUBERCULOSIS RISK & HIGHLY ACTIVE AN	93.855	6 K08 AI104352-04		128,797	
AI104779-05 DEVELOPMENT & VALIDATION OF A CLINIC	93.855	6 K23 AI104779-05		125,494	
AI105197-01A1 SIGNALNG PATHWAYS - INTERFACE WITH KL	93.855	1 R21 AI105197-01A1		(267)	
AI106002-05 MOLECULAR DETERMINANTS OF CROSS-REAC	93.855	6 R01 AI106002-05		49,187	
AI106406-05 DECREASING INTERRUPTIONS & LOSSES HIV CARE	93.855	7 K23 AI106406-05		105,493	
AI106420-03 FLUOROQUINOLONE RESISTANCE IN PATI	93.855	6 K08 AI106420-03		170,445	11,519
AI107052-03:04 TWO-COMPONENT SYSTEM INTERACTIONS A	93.855	5 R01 AI107052-04		425,663	8,587
AI108197-05 DETERMINANTS OF CORONAVIRUS FIDELITY IN	93.855	5 R01 AI108197-05		536,740	322,523
AI109690-03 NOVEL BIOCHEMICAL AND FUNATIONAL TAR	93.855	6 R21 AI109690-03		172,091	
AI110527-02 TN-CFAR - ADMIN CORE	93.855	6 P30 AI110527-02		1,760,900	615,297
AI110527-03 TN-CFAR - ADMIN CORE	93.855	5 P30 AI110527-03		330,688	
AI111820-04:05 PGI2 REGULATION OF TSLP-MEDIATED ALL	93.855	5 R01 AI111820-05		454,952	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
AI113107-03:04 HOST-PATHOGEN INTERACTIONS DURING OS	93.855	5 K08 AI113107-04		169,127	
AI113150-04 EVALUATING THE FUNCTIONAL ANTIBODY R	93.855	5 K23 AI113150-04		187,429	
AI113292-03:04 FIT TO REMEMBER? B CELL METABOLIC	93.855	5 R01 AI113292-04		443,859	
AI113858-03 HOSPITAL ADMISSIONS & EMERGENCY ROOM	93.855	6 R03 AI113858-03		20,912	
AI114339-03 A COMPETITION BINDING ASSAY FOR IDENTIF	93.855	6 R01 AI114339-03		324,963	
AI114816-03:04 STRUCTURAL AND FUNCTIONAL BASIS OF	93.855	5 R01 AI114816-04		806,159	576,211
AI115419-03 CHARACTERIZATION OF CD8A CELLS AS A	93.855	6 R21 AI115419-03		130,802	
AI117905-02 -ADMINCORE- STRUCTURE BASED DESIGN OF A	93.855	6 U19 AI117905-02		2,686,116	2,009,361
AI117905-03 STRUCTURE BASED DESIGN OF ANTIBODIES AND VACCINE	93.855	5 U19 AI117905-03		187,170	47,198
AI117905-03 STRUCTURE BASED DESIGN OF ANTIBODIES IOF CROWE	93.855	5 U19 AI117905-03		67,015	
AI118361-01A1 FLUOROQUINOLONES AND EFFLUX-MEDIATED CROSS RES	93.855	1 R56 AI118361-01A1		278,344	58,226
AI118887-02 REOVIRUS ATTACHMENT MECHANI	93.855	6 R01 AI118887-02		28,022	
AI118932-02 TYPE IV PROTECIN SECRETION IN HELIC	93.855	6 R01 AI118932-02		(65,671)	
AI118932-02:03 TYPE IV PROTEIN SECRETION IN HELI	93.855	5 R01 AI118932-03		608,914	47,480
AI119224-02 HIGH THROUGHPUT IDENTIFICATION OF TR	93.855	6 R21 AI119224-02		251,755	
AI120553-02 THE IMPACT OF DIETARY METALS	93.855	6 F32 AI120553-02		11,324	
AI120553-03S1 IMPACT OF DIETARY METALS ON THE GUT MICROBIOME	93.855	5 F32 AI120553-03		49,341	
AI120790-01A1 PREDICTORS OF TREATMENT TOXICITY, FAILURE	93.855	1 R01 AI120790-01A1		388,027	222,652
AI120875-02:03 THE DYNAMICS OF HIV AGNG AND T LYM	93.855	6 K23 AI120875-02		147,403	
AI121420-02:03 THE ROLE OF OVARIAN HORMONES ON ALL	93.855	6 R21 AI121420-02		230,427	
AI121549-01A1:02 THE CONTRIBUTION OF B LYMPHOCYTE TO T1D	93.855	1 R21 AI121549-01A1		148,592	
AI121796-01A1:02 PROSTAGLANDINS AS PROTECTIVE MEDIATORS IN C	93.855	5 R21 AI121796-02		143,683	
AI122516-02S1 DEFINING THE MOLECULAR BETWEEN ZINC DEFICIENCY	93.855	6 F32 AI122516-02		55,694	
AI123307-01A1 GENERATION AND CHARACTERIZATION OF FULL-LENGTH	93.855	1 R21 AI123307-01A1		110,406	
AI123348-02 CHIKUNGUNYA VIRUS REPLICATI	93.855	6 R01 AI123348-02		21,507	
AI124190-01A1 TARGETING THE T CELL IMMUNE SYNAPSE IN AUTOIMM	93.855	1 R03 AI124190-01A1		39,238	
AI124456-01A1 GLP-1R SIGNALING IN ALLERGIC INFLAMMATION	93.855	1 R01 AI124456-01A1		262,007	
AI124613-01 ANAEROBE 2016: THE 13TH BIENNIAL CONGRESS OF THE	93.855	1 R13 AI124613-01		9,312	
AI124872-02:03 HARMONIST:A SCALABLE TOOLKIT FOR STA	93.855	6 R24 AI124872-02		493,518	71,874
AI125135-01 COMPARISON OF HIGH VS. STANDARD DOSE FLU VACC	93.855	1 U01 AI125135-01		937,597	302,982
AI125642-01A1 RISK STRATIFICATION AND DECISION SUPPORT TO IM	93.855	1 R01 AI125642-01A1		105,260	
AI127129-01 MOLECULAR ANALYSIS OF THE ADAPTIVE IMMUNE RESPON	93.855	1 R21 AI127129-01		141,157	
AI127205-02 THE RISK OF HIV SEROCONVERSION FOLLOWING AN HPV	93.855	7 R01 AI127205-02		9,955	2,058
AI127828-01 VUMC HUMAN NEUTRALIZING ANTIBODIES FOR ZIKA VIR	93.855	1 R01 AI127828-01		160,580	51,382
AI130459-01 ANTIGENIC LANDSCAPE OF THE HUMAN HELMINTH IGE AN	93.855	1 R01 AI130459-01		72,520	
AI131722-01A1 NEUTRALIZATION FINGERPRINTING ANALYSIS OF POLY	93.855	1 R01 AI131722-01A1		18,225	
AI132560-01 THE IMPACT OF HYPOXIA ON STAPHYLOCOCCUS AUREUS M	93.855	1 R01 AI132560-01		1,873	
AI26603-26 POLYMERASE PROTEINS CORNAVIRUS REPL	93.855	6 R01 AI26603-26		54,440	
AI32539-24 CELL BIOLOGY OF REOVIRUS INFECTION	93.855	6 R01 AI32539-24		47,606	28,334

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
AI38296-21 MOLECULAR BASIS OF REOVIRUS PATHOGEN	93.855	6 R37 AI38296-21		93,421	416
AI39657-20S1 STRUCTURE AND FUNCTION OF HELICOBACTER PYLORI V	93.855	3 R01 AI39657-20S1		271,290	15,471
AI44924-16:17 IFN GAMMA GENE REGULATION IN T CEL	93.855	6 R01 AI44924-16		395,794	15,294
AI51448-14 SELECTION & REGULATION OF B LYMPHOCYT	93.855	6 R01 AI51448-14		520,845	
AI69233-12:13 MECHANISM AND FUNCTION OF HEME-IRON UTILIZATIO	93.855	6 R01 AI69233-12		445,759	800
AI69439-11 VANDERBILT HIV CLINICAL TRIALS UNIT	93.855	6 UM1 AI69439-11		1,140,764	378,839
AI69439-12 VANDERBILT HIV CLINICAL TRIALS UNIT - ADMIN CORE	93.855	5 UM1 AI69439-12		533,241	
AI69923-11 CARIBBEAN, CENTRAL AND SOUTH AMERICAN	93.855	6 U01 AI69923-11		455,213	283,283
AI69923-12 CARIBBEAN, CENTRAL AND SOUTH AMERICA NETWORK FOR	93.855	2 U01 AI69923-12		1,346,408	520,837
AI73843-08:09 PATHOBIOLOGY OF HEME INDUCIBLE TRANS	93.855	6 R01 AI73843-08		444,997	400
AI76121-09 MECHANISM AND REGULATION OF HIV-1	93.855	6 R01 AI76121-09		361,944	800
AI77505-08 PHARMACOGENOMICS OF HIV THERAP	93.855	6 R01 AI77505-08		814,201	95,094
AI77930-09:10 MIDCAREER INVESTIGATOR PATIENT-ORIENT	93.855	5 K24 AI77930-10		156,434	
AI91692-06 TOLL-LIKE RECEPTOR 2, VITAMIN D AND EX	93.855	6 K23 AI91692-06		15,519	
AI93234-06 STATISTICAL METHODS FOR ORDINAL VARIA	93.855	6 R01 AI093234-06		402,198	200,621
AI94562-05 MULTI-COMPONENT HIV INTERVENTION	93.855	6 R01 AI94562-05		87,909	11,602
AI95202-06 CHILDHOOD INFECTION RESEARCH PROGR	93.855	6 T32 AI95202-06		66,904	
AI95202-07 CHILDHOOD INFECTIONS RESEARCH PROGRAM	93.855	2 T32 AI95202-07		139,448	
AI95227-06 HOST AND VIRAL DETERMINANTS OF INF	93.855	6 U19 AI95227-06		168,775	31,614
AI95227-07 VIRAL & HOST DETERMINANTS OF INFANT PROJECT 1	93.855	2 U19 AI95227-07		1,834,751	371,614
AI95346-05 STUDIES ON EMERGENCT DIARRHEAGENIC	93.855	6 R01 AI95346-05		42,643	9,710
AI95755-07:08 STRUCTURAL MECHANISMS OF CLOSTRIDIUM DIFFICILE	93.855	6 R01 AI95755-07		370,500	1,200
AI96186-06 IEDEA NETWORKS COORDINATING CENTER AT VA	93.855	6 U01 AI96186-06		70,698	
HHSN272201400024C B-CELL EPIOPE - CROWE	93.855	HHSN272201400024C		657,317	465,852
HHSN272201400024C UNIVERSAL FLU SUPP CROWE	93.855	HHSN272201400024C		1,785,897	35,210
Subtotal 93.855				**28,593,510**	**7,768,763**
GM007569-42 CLINICAL PHARMACOLOGY TRAINING PROGRAM	93.859	2 T32 GM007569-42		1,034	
GM07569-40 CLINICAL PHARMACOLOGY TRAINING PROGRAM	93.859	6 T32 GM07569-40		88,307	
GM07569-41 CLINICAL PHARMACOLOGY TRAINING PROGRAM	93.859	5 T32 GM07569-41		545,468	
GM102676-05 MITOCHONDRIAL DYSFUNCTION, OXIDATIVE	93.859	6 K23 GM102676-05		156,248	
GM103859-03:04 INFORMATICS TOOLS FOR PHARMACOGENOMI	93.859	6 R01 GM103859-03		668,431	436,850
GM104306-05 AUGMENTATION OF INNATE ANTI-MICROBIA	93.859	5 R01 GM104306-05		416,642	45,280
GM106232-04 ALLOSTERIC MODULATORS GLP1 RECEP- NI	93.859	6 R01 GM106232-04		188,997	74,340
GM107947-04 ULTRA COMPACT POLARIZER PROBE - IMAG	93.859	6 R21 GM107947-04		(291)	
GM108554-03 TIPS: TRAINING IN PERIOPERATIVE SCIENCE	93.859	6 T32 GM108554-03		42,960	
GM108554-04 TIPS: TRAINING IN PERIOPERATIVE SCIENCE	93.859	5 T32 GM108554-04		239,480	
GM109145-04 DRUG METABOLISM GENOTYPES IN CLINICAL	93.859	6 R01 GM109145-04		327,667	5,340
GM110469-03:04 SALIVARY CORTISOL AS A MARKER OF CO	93.859	5 K23 GM110469-04		187,282	
GM112871-02:03 HYPER-OXYGENATION, OXIDATIVE STRESS, AN*NE	93.859	6 R01 GM112871-02		336,146	2,317

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
GM115305-01 IMPROVING PREDICTION OF DRUG ACTION-ADM	93.859	3 R50 GM115305-02		1,262,398	135,860
GM115305-03 IMPROVING PREDICTION OF DRUG ACTION - AC	93.859	5 P50 GM115305-03		2,567,194	191,723
GM115353-02:03 SERIAL NON-INVASIVE MOLECULAR ANALYSIS OF EXH	93.859	6 R01 GM115353-02		407,007	
GM117367-02 PREVENTION OF ENDOTHELIAL INJURY BY	93.859	6 K08 GM117367-02		192,220	
GM117395-03 PHARMACOGENETIC DETERMINANTS OF VARI	93.859	6 K23 GM117395-03		143,636	
GM118300-01:02 ELUCIDATING FIBROBLAST HETEROGENEITY AS	93.859	5 R01 GM118300-02		249,134	
GM118557-01:02 CHEMICAL GENETIC ANALYSIS OF VERTEBRA	93.859	5 R01 GM118557-02		580,582	35,331
GM120484-01A1 THE INSIGHT-ICU STUDY: ILLUMINATING NEUROPSYCH	93.859	1 R01 GM120484-01A1		94,239	
GM120523-01:02 PLEITROPY OF PCSK9 INHIBITION	93.859	5 R01 GM120523-02		230,841	
GM121711-01 ENHANCING RESISTANCE TO INFECTION AFTER BURN INJ	93.859	1 R01 GM121711-01		104,698	
GM66885-15 RESISTANCE OF BETA 2 MICROGLOBULIN NU	93.859	5 R01 GM66885-15		478,751	400
GM74771-05A1:7 KINASES IN ION COTRANSPORTER FUNCTIO	93.859	6 R01 GM74771-09		8,506	
GM99924-06 HEPATIC OATP DRUG TRANSPORTERS AND	93.859	5 R01 GM99924-06		401,577	
Subtotal 93.859				**9,919,153**	**927,442**
HD060554-08 CONDUCTING CHILD HEALTH CARE RESEARCH IN VULNERA	93.865	5 T32 HD060554-08		18,366	
HD083211-04 EUNICE KENNEDY SHRIVER INTELLECTUAL AND DEVELOPM	93.865	5 U54 HD083211-04		82,159	
HD088830-01A1 IDENTIFYING SMALL MOLECULES THAT REGULATE UTE	93.865	1 R21 HD088830-01A1		11,897	
HD35684-14:16 PREDICTING PHENOTYPIC TRAJECTORIES IN	93.865	5 R01 HD35684-14		(20)	
HD43483-15 BIRCWH - ADMIN (PARENT	93.865	6 K12 HD43483-15		110,453	
HD43483-16 BIRCWH -ADMIN	93.865	5 K12 HD43483-16		375,799	
HD59794-09:10 ROLE OF PARENT HEALTH LITERACY PR	93.865	6 R01 HD59794-09		739,360	440,916
HD60554-07L CONDUCTING CHILD HEALTH CARE RESEARCH IN VULNERA	93.865	6 T32 HD60554-07		423,864	
HD60850-06 DYSLEXIA IN POST-SECONDARY STUDENT	93.865	6 K08 HD60850-06		24,533	
HD68256-05 PREVENTING PREMATURITY AND POOR PREGNANC	93.865	5 T32 HD68256-05		51,340	
HD74584-05: PRESCRIBED OPIOD SAFETY IN CHILDREN	93.865	5 R01 HD74584-06		454,451	
HD74711-04:05 UNDERSTANDING THE GENETIC RISK UNDERLYING RACI	93.865	6 R01 HD74711-04		793,330	29,503
HD76733-01A1 TIMING OF INGUINAL HERNIA REPAIR IN PR	93.865	1 R01 HD76733-01A1		31,117	10,907
HD76733-04 TIMING OF INGUINAL HERNIA REPAIR IN PREMATURE INF	93.865	5 U01 HD76733-04		325,965	130,055
HD76983-04:05 PREDICTING TREATMENT RESPONSE IN PEDI	93.865	6 R01 HD76983-04		525,286	29,850
HD80148-02:03 PAROUS MOUSE UNIQUE MODEL TO DEFINE	93.865	6 R21 HD80148-02		165,859	
HD81121-02:04 DETECTING BIOCHEMICAL CHANGES IN THE	93.865	1 R01 HD81121-01		247,292	
HD83211-01A1 E.K SHRIVER INTELLECTUAL DEVELOPMENT C	93.865	6 U54 HD83211-02		103,188	27,444
HD83211-03 EUNICE KENNEDY SHRIVER INTELLECTUAL AND DEVELO	93.865	5 U54 HD83211-03		955,257	
HD84461-02 PHARMACOGENETICS AND PERSONALIZED MEDICINE AFTER	93.865	6 R01 HD84461-02		523,368	
HD84500-02 MARKERS OF DISEASE PROGRESSION IN	93.865	6 R01 HD84500-02		174,181	
HD86792-02:03 THE IMPACT OF NONROUTINE EVENTS ON	93.865	6 R01 HD86792-02		438,809	
HD87023-02 PATHOGENESIS TARGETED THERAPEUTIC	93.865	6 K12 HD87023-02		259,291	
HD87023-03 PATHOGENESIS, TARGETED THERAPEUTICS, AND NEW VACC	93.865	5 K12 HD87023-03		193,623	
Subtotal 93.865				**7,028,767**	**668,675**

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
AG047992-04 LONG-TERM NICOTINE TREATMENT OF MILD COGNITIVE I	93.866	5 R01 AG047992-04		24,889	
AG048915-01A1 PSYCHOSOCIAL AND OXIDATIVE STRESS MECHANISMS O	93.866	1 R01 AG048915-01A1		67,002	
AG33679-05:06 SYSTEMIC INFLAMMATION AND CENTRAL NER	93.866	6 R01 AG33679-06		22,267	
AG33828-05 COST EFFECTIVENESS OF TWO NUTRITION I	93.866	6 R01 AG33828-05		16,858	
AG34962-06S1 MAP ADMINISTRATIVE SUPPLEMENT 06S1	93.866	3 R01 AG34962-06S1		20,432	
AG34962-07 MAP YEAR 6	93.866	6 R01 AG34962-07		807,999	42,347
AG35117-06 THE MIND USA STUDY	93.866	6 R01 AG35117-06		1,094,481	52,309
AG38471-06 COGNATIVE AND NEURAL CORRELATES OF T	93.866	6 R01 AG38471-06		60,456	
AG38481-06 ORGANIZATIONAL FACTORS & THE DELIVERY	93.866	6 K01 AG38481-06		42,960	
AG40157-06 PREDICTING ACUTE BRAIN DYSFUNCTION IN	93.866	6 K23 AG40157-06		52,564	
AG43419-04 EFFECTIVENESS OF THE INFLUENZE VACCIN	93.866	6 R01 AG43419-04		66,601	
AG43471-05 OPIOD SELECTIONS & THE RISK OF SERI	93.866	5 R01 AG43471-05		563,192	
AG45085-02:03 ROLE OF ENDOTHELIAL AND BRAIN INJURY	93.866	6 R03 AG45085-03		20,984	
AG45095-01 EARLY PREDICTION OF LONG-TERM COGNITIVE	93.866	1 R03 AG45095-01		(34)	
AG45966-02:04 COGNITIVE COMPLAINTS IN AGING ADULTS	93.866	5 K23 AG45966-04		148,153	
AG46093-04 INSULIN RESISTANCE, VASCULAR REACTIVI	93.866	6 F32 AG46093-04		14,966	
AG46373-04:05 RISK FACTORS & PREVENTION TARGETGE	93.866	5 K24 AG46373-05		213,615	
AG47992-01 LONG TERM NICOTENE TREATMENT OF MILD	93.866	1 R01 AG47992-01A1		77,160	57,615
AG47992-03 LONG-TERM NICOTINE TREATMENT OF MILD COGNITIVE IM	93.866	5 R01 AG47992-03		938,312	577,080
AG48347-03 LONGITUDINAL HEMODYNAMIC AND VASCUL	93.866	6 K23 AG48347-03		180,246	
AG49164-02:03 GENETIC RESILENSE TO THE CLINICAL MANIFESTA	93.866	6 K01 AG49164-02		144,226	
AG53264-02:03 RADNDOMIZED CONTROLLED TRIAL TO DEPRESCRIBE FO	93.866	6 R01 AG53264-02		216,307	
AG54864-01:02 LONG TERM OUTCOMES OF PHYSICAL ACTIVITY IN OLD	93.866	5 K76 AG54864-02		118,630	
Subtotal 93.866				**4,912,266**	**729,351**
EY07533-28A1 MOLECULAR MECHANISMS OF RETINAL VASCULAR DISEAS	93.867	2 R01 EY07533-28A1		79,337	
EY08126-27:28 CORE GRANT IN VISION RESEARCH PARENT	93.867	6 P30 EY08126-28		118,146	61,792
EY08126-29 CORE GRANT IN VISION RESEARCH	93.867	5 P30 EY08126-29		744,770	412,182
EY13760-12:13 REGULATION OF RETINAL PROGENITOR CE	93.867	5 R01 EY13760-13		450,281	
EY17427-08 TRANSIENT RECEPTOR POTENTIAL CHANNEL	93.867	6 R01 EY17427-08		38,866	
EY20496-06 INTERIEUKIN-6 AND RETINAL GANGLION CE	93.867	2 R01 EY20496-06A1		350,171	400
EY20894-07 MICROFIBRIL DEFICIENCY IN GLAUCOMA	93.867	5 R01 EY20894-07		829,728	
EY22349-07 NOVEL THERAPY AND MECHANISMS IN GLAUC	93.867	6 R01 EY22349-07		308,203	
EY22618-05 METABOLOMIC AND GENETIC INTERACTION	93.867	5 R01 EY22618-05		578,194	224,609
EY23240-04:05 MICROSTRUCTURAL CHARACTERIZATION O	93.867	5 R01 EY23240-05		316,720	44,281
EY23397-05:06 IN VIVO MOLECULAR IMAGING OF - CHEMIS	93.867	5 R01 EY23397-06		453,096	8,305
EY23639-04:05 CALCINEURIN/NFAT SIGNALING AXIS IN BIABETIC RE	93.867	6 R01 EY23639-04		458,406	
EY24373-02:04 REGULATION OF EYE MORPHOGENESIS	93.867	5 R01 EY24373-04		498,992	
EY24997-03 MECHANISMS OF SYNAPTIC REMODELING AND	93.867	6 R01 EY24997-03		448,411	
EY27265-01 NOVEL ACTIVATORS OF REGENERATION IN MULLER GLIA	93.867	1 U01 EY27265-01		238,150	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
EY27464-01 DEVELOPING ALTERNATIVE APPROACHES TO REDUCE RETIN	93.867	1 K08 EY27464-01		56,498	
EY27746-01 INVESTIGATION OF ADAMTS IN GLAUCOMA PATHOGENESIS	93.867	1 R01 EY27746-01		49,666	
Subtotal 93.867				**6,017,635**	**751,570**
LM09989-07 TECHNOLOGIES TO ENABLE PRIVACY IN BIO	93.879	6 R01 LM09989-07		273,669	76,025
LM10207-07:08 AUTOMATED DETECTION OF ANOMALOUS	93.879	5 R01 LM10207-08		203,159	11,680
LM10685-07 FROM GWAS TO PHEWAS: SCANNIN THE EMR	93.879	5 R01 LM10685-07		636,901	
LM11174-06 VANDERBILT BIOMEDICAL INFORMATICS SUM	93.879	6 R25 LM11174-06		39,941	1,302
LM11382-04 DEVELOPING NEW APPROACHES TO CHRONIC D	93.879	6 K22 LM11382-04		2,402	
LM11664-03 SCALABLE BIOMEDICAL PATTERN RECOGNITI	93.879	6 R21 LM11664-03		31,799	
LM11933-02:03 LEARNING PATTERNS OF COLLABORATION TO OPTIMIZE	93.879	4 R00 LM11933-02		265,737	
Subtotal 93.879				**1,453,609**	**89,007**
TW009337-07 VANDERBILT-EMORY-CORNELL-DUKE CONSORTIUM FOR GLO	93.989	2 D43 TW009337-07		46	
TW009744-04 UNZA-VANDERBILT PARTNERSHIP FOR HIV-NUTRITION RE	93.989	5 D43 TW009744-04		7,633	
TW009745-04 UEM PARTNERSHIP FOR RESEARCH IN IMPLEMENTATION S	93.989	5 D43 TW009745-04		23,478	
TW09337-06 VANDERBILT-EMORY-CORNELL-DUKE CONSORTIUM FOR GLOB	93.989	5 R25 TW09337-06		1,336,166	822,281
TW09722-04 VU-MOZAMBIQUE COLLABORATIVE RESEARCH	93.989	6 R25 TW09722-04		168,929	36,073
TW09722-05 VU-MOZAMBIQUE COLLABORATIVE RESEARCH ETHICS EDUCA	93.989	5 R25 TW09722-05		203,331	65,293
TW09744-02 UNZA VANDERBILT PARTNERSHIP HIV NUTRI	93.989	6 D43 TW09744-02		14,225	
TW09744-03 UNZA-VANDERBILT PARTNERSHIP FOR HIV-NUTRITION	93.989	5 D43 TW09744-03		318,002	124,641
TW09745-01:02 UEM PARTNERSHIP FOR RESEARCH IN SCIEN	93.989	6 D43 TW09745-02		23,900	8,289
TW09745-03 UEM PARTNERSHIP FOR RESERACH IN IMPLEMENTATION	93.989	5 D43 TW09745-03		271,953	30,518
TW10411-01 RESEARCH CAPACITY BUILDING IN POST EBOLA COUNTRIE	93.989	1 D71 TW10411-01		27,989	10,363
TW9337-05 VANDERBILT-EMORY-CORNELL-DUKE CONSORTIUM	93.989	6 R25 TW09337-05		173,516	116,716
Subtotal 93.989				**2,569,168**	**1,214,174**
200-2012-50430 TASK OR CISA TDAP INFANT FOLLOW UP CLIN 0002	93.RD	200-2012-50430 TO 3-3		57,687	
200-2012-50430 TASK OR CISA TDAP INFANT FOLLOW UP CLIN 0003	93.RD	200-2012-50430 TO 3-3		56,688	
200-2012-50430:CISA LAIV & ASTHMA STUDY - BASE	93.RD	200-2012-50430		94,394	
200-2012-50430:CISA LAIV & ASTHMA STUDY - TASK 2	93.RD	200-2012-50430		37,098	
200-2012-50430:CISA TASK ORDER 1 OPTION 3 YEAR 4	93.RD	200-2012-50430		213,856	
200-2012-50430:CISA TASK ORDER 1 YEAR 5	93.RD	200-2012-50430		328,160	
200-2015-63553:MONITORING AND COORDINATING PERSONAL PROTECT	93.RD	200-2015-63553:CDC		1,284,605	
AI80007 VTEU- 09-0016: ZOSTAVAX IN RENAL TRANSPLANT	93.RD	N01 AI80007 VTEU		297,587	
CDC 200-2012-50430: TO #3 - CISA TDAP SAFETY IN PREGANT WOME	93.RD	CDC 200-2012-50430		106,864	
HHSA2902015000031 TO3 MEDIUM SR	93.RD	HHSA2902015000031 TO3		65,506	
HHSA290201500003I TO 1: METHODS AND DISSEMINATION, COLLABORA	93.RD	HHSA290201500003I TO 1		12,411	
HHSA290201500003I TO3: TONSILLECTOMY	93.RD	HHSA290201500003I TO3		(6,466)	
HHSA29020150003I TO5 COMPARATIVE EFFECTIVENESS OF THERAPIES	93.RD	HHSA29020150003I TO5		191	
HHSA29032001T: TO1:METHODS AND DISSEMINATION:COLLABORATIO	93.RD	HHSA290201500003I TO 1		31,924	
HHSA29032002T TO#2, MOD #01 UTERINE FIBROIDS LARGE SR	93.RD	HHSA290201500003I		36,000	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
HHSF223010000011I: MEDICATION EXPOSURE IN PREGNANCY RISK EVAL	93.RD	HHSF223010000011I		11,290	
HHSN261201600027I:HELICOBACTER PYLORI GENOME PROJECT	93.RD	HHSN261201600027I		13,601	
HHSN268201500053P:STUDY OF PLXNB3 FUNCTION USING HUMAN IPS	93.RD	HHSN268201500053P		10,103	
HHSN27200011 15-0066:B1C1D1.0041 VTEU TASK AREA B-BASE PERIO	93.RD	HHSN272201300023I TO11		126,803	
HHSN27200012 16-0078.B2C2D2.0053 VTEU TASK AREA B BASE PERIO	93.RD	HHSN272201300023I TO12		71,554	
HHSN27200014-13-0045 C1D1 0062(CDIF) TASK AREA C BASE	93.RD	HHSN272201300023I		12,168	
HHSN272201300023I - HHSN27200006 TASK A	93.RD	HHSN272201300015		62,184	
HHSN272201300023I - HHSN27200006 TASK B - 2A	93.RD	HHSN272201300015		35,273	
HHSN272201300023I VTEU 10-15-0060.C1.0045 TASK AREAS C BASE	93.RD	HHSN272201300023I		211,052	
HHSN272201300023I VTEU 13-0089 RSV TASK B PROTOCOL DEVELOPME	93.RD	HHSN272201300023ITO2-		395,375	
HHSN272201300023I -VTEU 14-0015.C1 CLINICAL TRIAL H7N9	93.RD	HHSN272201300023I		808,405	
HHSN272201300023I VTEU 14-0079 TASK AREA B SCOUT CAP PROTOCO	93.RD	HHSN272201300023I		622,332	395,616
HHSN272201300023I VTEU TASK B 13-0090 FOR PERTUSSIS IN PERU	93.RD	HHSN272201300023ITO5-		95	
HHSN272201300023I VTEU TASK C 13-0090 FOR PERTUSSIS IN PERU	93.RD	HHSN272201300023ITO5-		337,232	291,664
HHSN272201300023I VTEU TASK D-2 13-0090 PERU ELISA SEROLOGY	93.RD	HHSN272201300023ITO5-		2,725	
HHSN272201300023I VTEU TASK D-3 13-0090 PERU B CELL & CYTOKI	93.RD	HHSN272201300023ITO5-		27,949	22,500
HHSN272201300023I VTEU TASK D-4 13-0090 PERU SYSTEMS BIOLOGY	93.RD	HHSN272201300023ITO5-		425	
HHSN272201300023I: TASK 13 B & C1	93.RD	HHSN272201300023I		31,401	
HHSN272201300023I:VTEU FY 2017 TASK AREA A - BASE	93.RD	HHSN272201300023I TO 9		321,330	
HHSN272201300023I:VTEU TO #8 SUB STUDY 10-0074	93.RD	HHSN272201300023I		122,843	83,812
HHSN272201400024C B-CELL - SUPPLEMENT UNIVERSAL INFLUENZA	93.RD	HHSN272201400024C		544,021	
HHSN272201400024C B-CELL - SUPPLEMENT ZIKA VIRUS	93.RD	HHSN272201400024C		530,667	
HHSN311201600276P: PROVIDE NOVEL ANALYSES OF SEX DIFFERENCES	93.RD	HHSN311201600276P		14,025	
HHSP233201500026C:TRACKING THE IMPACT OF OWNERSHIP CHANGES	93.RD	HHSP233201500026C		94,822	63,253
MACP16114:HOSPITAL COMMUNITY BENEFIT DATA ANALYSIS	93.RD	MACP16114		9,078	
Subtotal 93.RD				**7,033,258**	**856,845**
Total Department Of Health And Human Services				**290,087,511**	**43,077,696**
National Science Foundation					
NSF 1416268 PROPOSAL INTERNATIONAL COLLABORATION IN CHE	47.049	NSF 1416268 PROPOSAL		14,779	
Subtotal 47.049				**14,779**	
CNS1526014 TWC: SMALL: ANALYSIS AND TOOLS FOR AUD	47.070	CNS-1526014		190,205	5,980
CNS1536871 MANAGING INFORMATION RISK AND BREACH	47.070	CNS-1536871		112,186	36,929
NSF IIS-1418504 SCH:INT:COLLABORATIVE RESEARCH	47.070	NSF IIS-1418504		105,240	7,787
Subtotal 47.070				**407,631**	**50,695**
NSF IOS-1121758 IMMUNE MECHANISMS OF DISEASE	47.074	NSF IOS-1121758		55,725	
NSF IOS-1121758 IMMUNE MECHANISMS OF DISEASE RESISTANCE I	47.074	NSF IOS-1121758		3,245	
NSF IOS-1557634 COLLABORATIVE RESEARCH: HOST AND PATHOGEN IN	47.074	NSF IOS-1557634		136,982	
Subtotal 47.074				**195,952**	
Total National Science Foundation				**618,362**	**50,695**

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
Total Research and Development Cluster - Direct Awards				**296,756,755**	**43,790,996**
Research and Development Cluster - Pass-Through Grantor					
Agency For International Development					
AURUM INSTITUTE NPC-AID-OAA-A-14-00029: AURUM-3HP A RANDOMIZED PRAGMATIC, OPEN-L	98.001		AID-OAA-A-14-00029	3,498	
Subtotal 98.001				**3,498**	
Total Agency For International Development				**3,498**	
Department Of Agriculture					
TENNESSEE STATE UNIVERSITY-NASHVILLE CHILDREN EATING WELL (CHEW) FOR HEALTH	10.310		2011-68001-30113	39,873	
Subtotal 10.310				**39,873**	
Total Department Of Agriculture				**39,873**	
Department Of Defense					
UNIVERSITY OF PITTSBURGH-PITTSBURGH:EFFECTS OF CLIMATE ON HOST-PATHOGEN INTERACTIONS	12.114		W912HQ-16-C-0033	73,259	
Subtotal 12.114				**73,259**	
VANDERBILT UNIVERSITY-INTEGRATION OF NOVEL TECHNOLOGIES FOR ORGAN DEVELOPMENT	12.351		SUBCONTRACT 219709-1	(61)	
Subtotal 12.351				**(61)**	
BAYLOR COLLEGE-W81XWH-15-1-0714:TARGETING RAF1 WITH C-TYPE NATRIURETIC PEPT	12.420		W81XWH-15-1-0714	31,858	
CEDARS-SINAI MEDICAL CENTER-W81XWH-16-1-0750:RACIAL DIFFERENCES IN SYSTEMIC AND PROSTATI	12.420		W81XWH-16-1-0750	30,464	
CHARLES RIVER ANALYTICS INC.-W81XWH-14-C-0018:MONITORING, EXTRACTING, AND DECODING INDICA	12.420		W81XWH-14-C-0018	34,683	
DUKE UNIVERSITY-W81XWH-15-2-0046:VIPER: CHRONIC PAIN AFTER AMPUTATION	12.420		W81XWH-15-2-0046	123,541	
GENEVA FOUNDATION-VALIDATION OF METABOLOMIC DIAGNOSTIC AND PROGNOSTIC CLASSIFI	12.420		W81XWH-15-2-0053	27,111	
GENEVA FOUNDATION-W81XWH-13-1-0345: IDENTIFYING METASTATSIS SUSCEPTIBILITY GEN	12.420		W81XWH-13-1-0345	16,438	
JOHNS HOPKINS UNIVERSITY-W81XWH-09-2-0108 - THE MAJORITY TRAUMA RESEARCH CONSORTIUM	12.420		W81XWH-09-2-0108	(15,565)	
JOHNS HOPKINS UNIVERSITY-W81XWH-10-2-0090 THE MAJOR EXTREMITY TRAUMA RESEARCH CONSOR	12.420		W81XWH-10-2-0090	77,046	
JOHNS HOPKINS UNIVERSITY-W81XWH-10-2-0090: METRC PATIENT REIMBURSEMENT	12.420		W81XWH-10-2-0090	115,410	
JOHNS HOPKINS UNIVERSITY-W81XWH-15-2-0074:NERVE REPAIR AND RECONSTRUCTION - LEE	12.420		W81XWH-15-2-0074	198	
NATIONAL ASSOCIATION OF VETERANS' RESEARCH & EDUCATION FDNS-W81XWH-11-2-0161 DECAMP-DET	12.420		W81XWH-11-2-0161	308,426	
UNIVERSITY OF MISSOURI-W81XWH-14-1-0604:IMPROVING HEALTH CARE TRANSITION PLANNING	12.420		W81XWH-14-1-0604	9,858	
UNIVERSITY OF PITTSBURGH-W81XWH-12-2-0023: PREHOSP AIR MEDICAL PLASMA - PER PT BILL	12.420		W81XWH-12-2-0023	44,941	
UNIVERSITY OF PITTSBURGH-W81XWH-12-2-0023: PREHOSPITAL AIR MEDICAL PLASMA TRIAL (P	12.420		W81XWH-12-2-0023	161,284	
VANDERBILT UNIVERSITY-AMBULATORY & NON-AMBULATORY BENEFITS OF LOWER LIIMB EXOSKELE	12.420		W81XWH-15-2-0068 HAS	23,403	
VANDERBILT UNIVERSITY-AMBULATORY & NON-AMBULATORY BENEFITS OF LOWER LIMB EXOSKELET	12.420		W81XWH-15-2-0068 CTC	9,872	
VANDERBILT UNIVERSITY-IN VIVO ASSESSMENT OF TOXICANT EXPOSURE IN REATS USING MULTI	12.420		W81XWH-14-C-0058	12,103	
VANDERBILT UNIVERSITY-OPTICALLY BASED RAPID SCREENING METHOD FOR PROVEN OPTIMAL	12.420		W81XWH-13-1-0194 SUB	5,705	
VANDERBILT UNIVERSITY-W81WH-16-2-0052:DEVELOPMENT OF AN INJECTABLE, SETTABLE, RES	12.420		W81XWH-16-2-0052	1,018	
VANDERBILT UNIVERSITY-W81XWH-14-1-0139 AMPLIFICATION OF JAK2 IN BREAST CANCER	12.420		W81XWH-14-1-0139	98,773	
VANDERBILT UNIVERSITY-W81XWH-14-C-1422 ASSESSMENT OF CHEMICAL EXPOSURE IN ANIMAL	12.420		W81XWH-14-C-1422	18,805	
VANDERBILT UNIVERSITY-W81XWH-16-1-0063:INSIDE-OUT IMMUNOTHERAPY: PREVENTING METAS	12.420		W81XWH-16-1-0063	7,456	
VANDERBILT UNIVERSITY-W81XWH-16-1-0559:TARGETING THE EPITHELIAL TYPE II INTERLEUK	12.420		W81XWH-16-1-0559	24,608	
Subtotal 12.420				**1,167,436**	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-W911NF-14-2-0022 WIKSWO/PHYSICS PERIOD ONE, 3 OF 4	12.431		W911NF-14-2-0022	7,470	
VANDERBILT UNIVERSITY-W911NF-14-2-0022:CHEMICAL THREAT ASSESSMENT BY RAPID MOLECUL	12.431		W911NF-14-2-0022	598,201	
Subtotal 12.431				**605,671**	
DUKE UNIVERSITY-FA8650-13-2-6374:GENETIC RISK TESTING AND HEALTH COACHING	12.800		FA8650-13-2-6374	37,451	
Subtotal 12.800				**37,451**	
EMORY UNIVERSITY-DARPA-BAA-14-38 EBOLA SPECIFIC ANTIBODIES FM SURVIVORS	12.910		DARPA-BAA-14-38	456,825	
INOVIO PHARMACEUTICALS-W31P4Q-15-1-0003:DARPA II-IMMEDIATE PROTECTION AGAINST EBOLA	12.910		W31P4Q-15-1-0003	432,523	
INSTITUT PASTEUR-DARPA-BAA-16-35:DEFECTIVE INTERFERENCE OF VIRAL INFECTIOUS	12.910		DARPA-BAA-16-35	85,010	
MODERNA THERAPEUTICS, INC.-W911NF-13-1-0417:CHIKUNGUNYA COLLABORATION RESERACH PROGRA	12.910		W911NF-13-1-0417	71,263	
UNIVERSITY OF PENNSYLVANIA-W31P4Q-13-0003 DARPA I:HUMAN MONOCLONAL ANTIBODIES-CROWE	12.910		W31P4Q-13-0003	284,272	34
Subtotal 12.910				**1,329,894**	**34**
VANDERBILT UNIVERSITY-W911NF-14-2-0022:RENEWAL FOR CHEMICAL THREAT ASSESSMEN	12.RD		W911NF-14-2-0022	13,460	
Subtotal 12.RD				**13,460**	
Total Department Of Defense				**3,227,110**	**34**
Department Of Education					
VANDERBILT UNIVERSITY-4D130003-16:IMPROVING READING AND MATHEMATICS OUTCOMES	84.324		R32 4D130003-16	16,285	
VANDERBILT UNIVERSITY-4D130003-16IMPROVING READING AND MATHEMATICS OUTCOMES FOR ST	84.324		R32 4D130003-16	8,403	
VANDERBILT UNIVERSITY-R324A110266 FATIGUE AND LISTENING EFFORT IN SCHOOL-AGE CHI	84.324		R32 4A110266	(77)	
VANDERBILT UNIVERSITY-R324A150029 MEASUREMENT OF LISTENING FATIGUE IN CHILDREN	84.324		R32 4A150029	(372)	
Subtotal 84.324				**24,239**	
VANDERBILT UNIVERSITY-P407A150058:NEXT STEPS FOR INCLUSIVE HIGHER EDUCATION	84.407		P407A150058	19,564	
Subtotal 84.407				**19,564**	
Total Department Of Education				**43,803**	
Department Of Energy					
VANDERBILT UNIVERSITY-DE-NE0008267 META-LEVEL DESIGN GUIDANCE AND OPERATOR PERFORM	81.121		DE-NE0008267	290,536	89,076
VANDERBILT UNIVERSITY-DE-NE0008267 META-LEVEL DESIGN GUIDANCE& OPERATOR PERFORMANC	81.121		DE-NE0008267	(257)	
Subtotal 81.121				**290,279**	**89,076**
Total Department Of Energy				**290,279**	**89,076**
Department Of Health And Human Services					
UNIVERSITY OF MICHIGAN-RRC8098401-08-00:RETIREMENT RESEARCH CONSORTIUM	93.007		5 RRC8098401-08-00	4,062	
Subtotal 93.007				**4,062**	
UNIVERSITY OF WASHINGTON-GGH01449-02:HIS EVALUATION FRAMEWORK FOR CDC PROJECT HQ BUI	93.067		5 NU2 GGH01449-02	53,747	
VANDERBILT UNIVERSITY-GH00812-04:S1 ZAMB ZIA: TECHNICAL ASSISTANCE TO THE MINISTRY	93.067		5 U2G GH00812-04	301,781	
Subtotal 93.067				**355,528**	
UNIVERSITY OF NORTH CAROLINA-DD01155-00:COMMUNITY COUNTS PUBLIC HEALTH SURVEILLANCE FOR	93.080		1 U27 DD01155-00	8,947	
Subtotal 93.080				**8,947**	
VANDERBILT UNIVERSITY-IP00979-01 DETERMINING INFLUENZA VACCINE EFFECTIVENESS- DIVE	93.083		1 U01 IP00979-01	(240)	
Subtotal 93.083				**(240)**	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
DUKE UNIVERSITY-FD05292:PROSPECTIVE OBSERVATIONAL STUDY OF THE RISK FACTORS	93.103		5 R18 FD05292	24,903	
ICON CLINICAL RESEARCH (FORMERLY OVATION RESEARCH GROUP)-EVALUATION OF THE MEASUREMENT	93.103		FDA-ICON	1,375	
VANDERBILT UNIVERSITY-FD004117-03 PHASE 2 STUDY OF MONTELUKAST FOR THE TREATMENT	93.103		5 R01 FD004117-03	19,365	15,204
Subtotal 93.103				**45,642**	**15,204**
HEMPHILIA OF GEORGIA, INC.-MC24046-04-00: COMPREHENSIVE HEMOPHILLIA DIAGNOSTIC AND TREA	93.110		5 H30 MC24046-04-00	1,392	
HEMPHILIA OF GEORGIA, INC.-MC24046-04-00:PROGRAM INCOME- COMPREHENSIVE HEMOPHILIA DIAGN	93.110		5 H30 MC24046-04-00	2,000,252	
HEMPHILIA OF GEORGIA, INC.-MC24046-05-00:COMPREHENSIVE HEMOPHILIA DIAGNOSTIC AND TREATM	93.110		5 H30 MC24046-05-00	14,507	
MASSACHUSETTS GENERAL HOSPITAL-MC11054:AUTISM INTERVENTION RESEARCH NETWORK (AIR)	93.110		6 UAC MC11054-07-01	13,823	
MASSACHUSETTS GENERAL HOSPITAL-MC11054-07: TREATMENT OF OVERWEIGHT INDUCED BY ANTIPSYC	93.110		5 UA3 MC11054-07	(1,249)	
MASSACHUSETTS GENERAL HOSPITAL-MC11054-07-02:AUTISM TREATMENT NETWORK - ECHO AUTISM	93.110		2 UA3 MC11054-07-02	5,124	
MASSACHUSETTS GENERAL HOSPITAL-MC11054-07-04:IMPROVING HOSPITALIZATIONS FOR CHILDFEN WIT	93.110		6 UA3 MC110504:06-04	(1,669)	
MASSACHUSETTS GENERAL HOSPITAL-MC11054-08-00:AUTISM INTERVENTION NETWORKS -ECHO AUTISM	93.110		5 UA3 MC11054-08-00	28,422	
UNIVERSITY OF ROCHESTER-MC277505:INVESTIGATION OF A TEACHER-MEDIATED TOILET TRAIN	93.110		1 R40 MC277505	28,406	
UNIVERSITY OF ROCHESTER-MC277505-03:INVESTIGATION OF A TEACHER-MEDIATED TOILET TRAIN	93.110		1 R40 MC277505-03	76,470	
VANDERBILT UNIVERSITY-MC22220-04 MID TENN SICKLE CELL NETWORK-COORDINATED HEALTH	93.110		5 U38 MC22220-04-00	1,906	
Subtotal 93.110				**2,167,382**	
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY-ES07331-22A1: MECHANISIMS OF METH	93.113		2 R01 ES07331-22A1	327,433	
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY-ES10563-15:MECHANISMS OF MANGAN	93.113		5 R01 ES10563-15	252,848	320
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY-ES10563-16:MECHANISMS OF MANGAN	93.113		5 R01 ES10563-16	176,763	340
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY-ES7331-23:MECHANISMS OF METHYLME	93.113		5 R01 ES07331-23	11,020	
CUMBERLAND PHARMACEUTICALS, INC.-ES25596-01A1 TARGETING DNA DAMAGE RESPONSE PATHWAYS	93.113		1 R41 ES25596-01A1	2,542	
JOHNS HOPKINS UNIVERSITY-ES19560:STATISTICAL METHODS FOR COMPLEX ENVIRONMENTAL HEALTH	93.113		5 R01 ES19560	22,981	
VANDERBILT UNIVERSITY-ES00267-47 CENTER IN MOLECULAR TOXICOLOGY - PILOT #6 TBA	93.113		5 P30 ES00267-47	(60)	
VANDERBILT UNIVERSITY-ES02497-31:35 NUTRITIONAL AND METABOLIC SIGNIFICANE OF SELEN	93.113		4 R37 ES02497-31	1,199	
VANDERBILT UNIVERSITY-ES07028-42:TRAINING PROGRAM IN ENVIRONMENTAL TOXICOLOGY	93.113		5 T32 ES07028-42	38,220	
VANDERBILT UNIVERSITY-ES14942-06:-9 DIOXIN EXPOSURE AND THE INVASIVE PATHOGENESIS	93.113		2 R01 ES14942-06	2,673	2,660
VANDERBILT UNIVERSITY-ES16931-06:08 GENE-NEUROTOXICANT INTERACTIONS- HUNTINGTON	93.113		5 R01 ES16931-07	(7,040)	2,037
VANDERBILT UNIVERSITY-ES22936-01:03 ASK SIGNALOSOMES & ENVIRONMENTAL SENSING	93.113		5 R01 ES22936-03	(25,644)	
VANDERBILT UNIVERSITY-ES24133-STEROLS, NEUROGENESIS AND ENVIRONMENTAL AGENTS	93.113		1 R01 ES24133-01A1	15,985	
Subtotal 93.113				**818,922**	**5,357**
VANDERBILT UNIVERSITY-DE024982-02 LYMPHEDEMA & FIBROSIS MEASURES IN ORAL CA - MED	93.121		5 R01 DE024982-02	108,795	
Subtotal 93.121				**108,795**	
TULANE UNIVERSITY-CE02327-03:A SELECTIVE PREVENTION RCT TO ADDRESS PARENTING	93.136		5 R01 CE02327-03	13,877	
Subtotal 93.136				**13,877**	
VANDERBILT UNIVERSITY-HA29297-01 SOUTHEAST REGIONAL AIDS EDUCATION AND TRAINING	93.145		1 U10 HA29297-01	856,285	840,585
Subtotal 93.145				**856,285**	**840,585**
UNIVERSITY OF MINNESOTA-HG08605-01A1:LAWSEQ: BUILDING A SOUND LEGAL FOUNDATION	93.172		1 R01 HG08605-01A1	105,549	
UNIVERSITY OF WASHINGTON-HG07879-01A1:COMMUNITY-BASED EVALUATION OF APOL1 GENETIC TES	93.172		1 R01 HG07879-01A1	111,770	
VANDERBILT UNIVERSITY-HG06844-01:04 A RISK MANAGEMENT FRAMEWORK FOR INDENTIFIABILI	93.172		1 R01 HG06844-04	(36)	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-HG07253-02 INTEGRATED, INDIVIDUALIZED, INTELLIGENT PRESCRIBI	93.172		5 U01 HG07253-02	113,857	113,853
VANDERBILT UNIVERSITY-HG08055-02:ELASTIC NET ANALYSIS OF PENOTYPE RELATIONSHIPS	93.172		5 R03 HG-08055-02	6,989	
VANDERBILT UNIVERSITY-HG08672-01 VGER, THE VANDERBILT GENOME-ELECTRONIC RECORDS PR	93.172		1 U01 HG08672-01	(81)	
VANDERBILT UNIVERSITY-HG08701-01 THE ELECTRONIC MEDICAL RECORDS AND GENOMICS(EMERG	93.172		1 U01 HG08701-01	203,933	140,608
VANDERBILT UNIVERSITY-HG09086-01-ANALYSIS, VALIDATION AND RESOURCE CREATION FOR GE	93.172		1 UO1 HG09086-01	286,940	
VANDERBILT UNIVERSITY-HG09086-02:ANALYSIS, VALIDATION AND RESOURCE CREATION FOR G	93.172		1 U01 HG09086-02	73,489	
WAKE FOREST SCHOOL OF MEDICINE BOWMAN GRAY CAMPUS-HL07112-05: EXOME SEQUENCING TO IDE	93.172		5 R01 HL07112-04	104,232	
Subtotal 93.172				**1,006,642**	**254,461**
BRIGHAM AND WOMEN'S HOSPITAL-DC10811-05 RISK FACTORS OF HEARING LOSS	93.173		5 U01 DC10811-05	1,294	
CHILDREN'S HOSPITAL OF PHILADELPHIA-DC12270-04: AUDIOLOGICAL & GENETIC RESOURCE FOR PEDIATRI	93.173		5 R24 DC12270-04	33,046	
CHILDREN'S HOSPITAL OF PHILADELPHIA-DC122707-05:AUDIOLOGICAL AND GENETIC RESOURCE FOR PEDI	93.173		4 R24 DC122707-05	89,025	
INTELLIGENT HEARING SYSTEMS, INC.-DC11432-02A1 BONE CONDUCTION TESTING-NEWBORN HEARING S	93.173		2 R44 DC11432-02A1	247,278	
INTELLIGENT HEARING SYSTEMS, INC.-DC15920-01A1:AUTOMATED OBJECTIVE AUDIOMETRY USING LONG	93.173		1 R44 DC15920-01A	16,055	
NATHAN S. KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH (NKI)-DC15780-01:NEUROPHYSIOLOGY, BEHAVIO	93.173		1 R01 DC15780-01	17,508	
NEW YORK UNIVERSITY-DC03937-17:ADAPTATION TO FREQUENCY-PLACE FUNCTIONS IN COCHLE	93.173		2 R01 DC03937-17	25,867	
NEW YORK UNIVERSITY-DC03937-18:ADAPTATION TO FREQUENCY-PLACE FUNCTIONS IN COCHLE	93.173		2 R01 DC03937-18	2,554	
PURDUE UNIVERSITY-DC11759-0A1: CHALLENGES TO VOCAL FOLD EPITHELIA: FUNCTIONAL	93.173		1 R01 DC11759-0A1	32,178	
RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.-DK11490-15: SOMO-AUDITORY CONVERGENCE: SUP	93.173		5 R01 DK11490-15	25,314	
VANDERBILT UNIVERSITY-DC00523-18 EMOTIONAL AND LINGUISTIC CONTRIBUTIONS -MED	93.173		2 R01 DC000523-18	(774)	
VANDERBILT UNIVERSITY-DC00523-20A1:IMPACT OF EMOTION AND ATTENTION ON CHILDHOOD	93.173		2 R56 DC00523-20A1	17,689	
VANDERBILT UNIVERSITY-DC08408-05A1:6 CLINICAL VALIDATION & TESTING OF PERCUTANEOUS	93.173		2 R01 DC08408-05A1	(9)	
VANDERBILT UNIVERSITY-DC09404-06 COCHLEAR IMPLANTS: COMBINED ELECTRIC & BINAURAL	93.173		2 R01 DC09404-06	4,104	
VANDERBILT UNIVERSITY-DC11092-2:6 SUBCORTICAL NEURAL BASIS OF HEARING IN NOISE	93.173		7 R01 DC11092-06	3,785	
VANDERBILT UNIVERSITY-DC11548-03:06 TEMPORAL WEIGHTING OF AUDITORY SPATIAL	93.173		5 R01 DC11548-06	962	
VANDERBILT UNIVERSITY-DC11777-01A1:2 MODELING AUDITORY RESPONSES AND BEHAVIORAL	93.173		1 R01 DC11777-01A1	28,685	28,567
VANDERBILT UNIVERSITY-DC12593-04:SAFE, RAPID ACCESS TO INTERNAL AUDITORY CANAL	93.173		4 R01 DC12593-04	20,394	
VANDERBILT UNIVERSITY-DC12865-01A1:02 QUANTIFYING THE FATIGUE FACTOR: HEARING LOSS	93.173		5 R21 DC12865-02	(245)	
VANDERBILT UNIVERSITY-DC13117-01:03 CLINICAL APPLICATION OF SPECTRAL ENVELOPE PERC	93.173		1 R01 DC13117-03	54,500	54,831
VANDERBILT UNIVERSITY-DC13767:EFFICACY OF PARENT-IMPLEMENTED TREATMENT IN INFANT	93.173		5 R01 DC13767	851	
VANDERBILT UNIVERSITY-DC13767-02:EFFICACY OF PARENT-IMPLEMENTED TREATMENT IN INFAN	93.173		5 RO1 DC13767-02	7,125	
VANDERBILT UNIVERSITY-DC13767-03:EFFICACY OF PARENT-IMPLEMENTED TREATMENT IN INFAN	93.173		5 R01 DC13767-03	22,467	
VANDERBILT UNIVERSITY-DC13797:EFFICACY OF PARENT-IMPLEMENTED TREATMENT IN INFANT	93.173		5 R01 DC13767	2,627	
VANDERBILT UNIVERSITY-DC14027-IMAGE-GUIDED COCHLEAR PROGRAM-OTOLARYNGOLOGY	93.173		1 R01 DC14037-YR01-05	164,221	
VANDERBILT UNIVERSITY-DC14037-03:IMAGE-GUIDED COCHLEAR IMPLANT PROGRAMMING TECHNIQ	93.173		5 R01 DC14037-03	(93)	
VANDERBILT UNIVERSITY-DC14114-02:NEURONAL CORRELATES OF THE VISUAL MODELATION	93.173		5 R21 DC14114-02	52,409	
VANDERBILT UNIVERSITY-DC14462-01A1:COMPUTER-ASSISTED, IMAGE-GUIDED PROGRAMMING	93.173		1 R01 DC14462-01A1	62,464	
VANDERBILT UNIVERSITY-DC14462-02:COMPUTER-ASSISTED, IMAGE-GUIDED PROGRAMMING OF CO	93.173		1 R01 DC14462-02	79,336	
VANDERBILT UNIVERSITY-RHYTHM IN ATYPICAL LANGUAGE DEVELOPMENT: MECHANISMS AND IN	93.173		1 R03 DC14802-01	1,038	
VANDERBILT UNIVERSITY-THE MECHANISM OF INFLAMMATION-MEDIATED OLFACTORY DYSFUNCTION	93.173		1 R03 DC014809-01	(6)	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
Subtotal 93.173				**1,011,649**	**83,398**
VANDERBILT UNIVERSITY-IP00464-05 NEW VACCINE SURVEILLANCE NETWORK - NSVN	93.185		5 U01 IP00464-05	30,266	
VANDERBILT UNIVERSITY-IP00464-05 YEAR 04 CARRYFORWARD	93.185		5 U01 IP00464-05	41,161	
Subtotal 93.185				**71,427**	
BROWN UNIVERSITY-AT09145-02S1:MINDFULNESS INFLUENCES ON SELF-REGULATION:MENTA	93.213		3 UH2 AT09145-02S1	7,983	
DUKE UNIVERSITY-AT07748-05S1:HEALTH CARE SYSTEMS RESEARCH COLLABORATORY-ADMI	93.213		3 U54 AT07748-05S1	6,184	
VANDERBILT UNIVERSITY-AT04821-05 IMMUNOMODULATORY EFFECTS OF ARGININE SUPPLEMEN	93.213		1 R01 AT04821-05	(37,410)	
VANDERBILT UNIVERSITY-AT06965-04 MIND-BODY THERAPIES FOR PATIENTS WITH END-STAGE	93.213		5 K23 AT06965-04	2,362	
VANDERBILT UNIVERSITY-AT07830-04:THERAPEUTICALLY MODIFIED GUT BACTERIA FOR TREA	93.213		4 R01 AT07830-04	45,814	
Subtotal 93.213				**24,933**	
BRIGHAM AND WOMEN'S HOSPITAL-HS23757-01A1:IMPLEMENTATION OF A MEDICATION RECONCILIATIO	93.226		1 R18 H223757-01A1	12,116	522
EMORY UNIVERSITY-HS25102-01:ANNUAL HEALTH ECONOMICS CONFERENCE GRANT	93.226		1 R13 HS25102-01	27,816	
INDIANA UNIVERSITY-HS23306-01A1:DESIGNING USER-CENTERED DECISION SUPPORT TOOLS	93.226		1 R01 HS23306-01A1	7,654	
INDIANA UNIVERSITY-HS23306-02: DESIGNING USER-CENTERED DECISION SUPPORT TOOLS F	93.226		5 R01 HS23306-02	26,014	
SEATTLE CHILDREN'S HOSPITAL-HS25291-01:PEDIATRIC HOSPITAL CARE IMPROVEMENT PROJECT	93.226		1 U18 HS25291-01	36,464	
UNIVERSITY OF MARYLAND-HS18975-01A1: TELEMEDICINE IN PATIENTS WITH INFLAMMATORY BOW	93.226		1 R01 HS18975-01A1	5,036	
VANDERBILT UNIVERSITY-HS21496-03 PERSONAL HEALTH INFORMATION NEE YR 2 CARRYFORWARD	93.226		5 R01 HS21496-03	70,398	
VANDERBILT UNIVERSITY-HS22093-01A1 REAL-WORLD PATIENT RESPONSIVENESS & SAFETY OF L	93.226		1 R01 HS22093-01A1	3,762	3,762
VANDERBILT UNIVERSITY-HS22640-01 COMPARATIVE EFFECTIVENESS OF MODERN	93.226		1 R01 HS22640-01	21,298	13,566
VANDERBILT UNIVERSITY-HS22990-02 THE VANDERBILT PCOR CAREER KNOWLEDGE, EDUCATION	93.226		5 K12 HS22990-02	311	
Subtotal 93.226				**210,869**	**17,850**
MASSACHUSETTS GENERAL HOSPITAL-MH106013-02:MAPPING NEURONAL CHLORIDE MICRODOMAINS	93.242		1 U01 MH106013-02	22,400	
MASSACHUSETTS GENERAL HOSPITAL-MH106013-03:MAPPING NEURONAL CHLORIDE MICRODOMAINS	93.242		5 U01 MH106013-03	375,587	
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO-MH107467-01A1:USING EQTL NETWORKS TO GAIN BIOLO	93.242		1 R01 MH107467-01A1	91,124	
UNIVERSITY OF CALIFORNIA, DAVIS-MH100030-03: TODDLER INTERVENTIONS FOR ASD: TESTING - MC	93.242		5 R01 MH100030-03	2	
UNIVERSITY OF CALIFORNIA, DAVIS-MH100030-04: TODDLER INTERVENTIONS FOR ASD: TESTING - UNIV	93.242		4 R01 MH100030-04	519,134	
UNIVERSITY OF CALIFORNIA, DAVIS-MH10030-05:INTERVENTION EFFECTS OF INTENSITY AND DELIVERY	93.242		4 RO1 MH100030-05	196,477	
UNIVERSITY OF CHICAGO-MH107666-01:PREDICTED GENE EXPRESSION: HIGH POWER, MECHANISM	93.242		1 R01 MH107666-01	20,629	
UNIVERSITY OF CHICAGO-MH94267 CONTE CENTER FOR COMPUTATIONAL SYSTEMS GENOMICS OF N	93.242		1 P50 MH94267-05	20,903	
UNIVERSITY OF NORTH CAROLINA-MH73402: RESTRICTED REPETITIVE BEHAVIOR IN AUTISM	93.242		5 R01 MH73402	24,390	7,636
UNIVERSITY OF PENNSYLVANIA-MH98260-03:STRESS AND INFLAMMATION IN THE PATHOLOGY OF LATE	93.242		4 R01 MH98260-03	44,843	
VANDERBILT UNIVERSITY-MH100096-01:03 SUBSTRATE-SELECTIVE INHIBITION OF COX-2 TO TA	93.242		5 R01 MH100096-03	(180)	
VANDERBILT UNIVERSITY-MH101321-01A1 MAPPING THALAMOCORTICAL NETWORKS ACROSS	93.242		1 R21 MH101321-01A1	1,914	
VANDERBILT UNIVERSITY-MH102246-01A1:02 NEUTRAL CONNECTIVITY AFFECTING THE ANTIDEPR	93.242		1 R01 MH102246-01A1	1,724	
VANDERBILT UNIVERSITY-MH102266-01A1:02 THALAMOCORTICAL NETWORKS IN PSYCHOSIS	93.242		1 R01 MH102266-01A1	10,215	
VANDERBILT UNIVERSITY-MH102272-02 NEURAL NETWORKS FOR ATTENTION TO INTERNAL AND	93.242		1 R01 MH102272-01A1	(211)	
VANDERBILT UNIVERSITY-MH103500-01A1:02 AUTISM SPECTRUM DISORDERS AND DEPRESSION: S	93.242		1 K01 MH103500-01A1	(143)	
VANDERBILT UNIVERSITY-MH103515-01:02 AFFERENT-SPECIFIC ENDOCANNABINOID SIGNALING I	93.242		5 R21 MH103515-02	(2,167)	
VANDERBILT UNIVERSITY-MH103518-TRANSFORMATIVE CO-ROBOTIC TECH FOR AUTISM VKC	93.242		1 R21 MH103518-01/02	64,735	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-MH104428-01:02 ADAPTING A PARENT ADVOCACY PROGRAM TO IMPROV	93.242		1 R34 MH104428-01	2,015	1,244
VANDERBILT UNIVERSITY-MH106839-01 DEVELOPMENT OF AN M1 PAM - LEAD OFF	93.242		1 U19 MH106839-01	5,342	
VANDERBILT UNIVERSITY-MH106998-01:02 BNST NEUROCIRCUITRY IN PTSD	93.242		1 R21 MH106998-01	(24,528)	
VANDERBILT UNIVERSITY-MH107255-01 TRADITIONAL HEALERS AS ADHERENCE PARTNERS FOR PL	93.242		1 K01 MH107255-01	1,591	
VANDERBILT UNIVERSITY-MH108657-01A1:IMPROVING DEPRESSION OUTCOME BY ENHANCING MEMO	93.242		1 R01 MH108657-01A1	10,486	
VANDERBILT UNIVERSITY-MH109105-01 REVISED NEURON SELECTIVE MODULATION OF BRAIN CIR	93.242		1 R24 MH109105-01	(49,496)	
VANDERBILT UNIVERSITY-MH109225-01 PERIPERSONAL SPACE REPRESENTATION AS A BASIS FOR	93.242		1 R21 MH109225-01	(18,190)	
VANDERBILT UNIVERSITY-MH70560-07A1:09 IMAGING HIPPOCAMPAL FUNCTION IN PSYCHOSIS	93.242		2 R01 MH70560-07A1	(10,575)	
VANDERBILT UNIVERSITY-MH77298-07 DOPAMINERGIC REGULATION OF PYRAMIDAL CELLS	93.242		2 R01 MH77298-06A1	29	
VANDERBILT UNIVERSITY-MH85717-01A2:05 PSYCHOBIOLOGICAL INVESTIGATION OF THE SOCIO	93.242		5 R01 MH85717-05	81	
VANDERBILT UNIVERSITY-MH91102-05:ADAPTAIVE RESPONSE TECHNOLOGY FOR AUTISM SPECTRUM	93.242		5 R01 MH91102-05	19,718	
VANDERBILT UNIVERSITY-MH92598-04 REVISED RISK AND RESILIENCY FOR YOUTH WITH AUTIS	93.242		5 K01 MH92598-04	(745)	
VANDERBILT UNIVERSITY-MH95621-02:03 IRON & MITOCHONDRIAL GENOMICS IN NEURO-INFLAM	93.242		5 R01 MH95621-02	217,828	218,456
VANDERBILT UNIVERSITY-MH96972-04:ENDURING EFFECTS OF EARLY-LIFE SERONTONIN SIGNALI	93.242		5 P50 MH96972-04	35,494	
VANDERBILT UNIVERSITY-MH96972-04:ENDURING EFFECTS OF EARLY-LIFE SEROTONIN SIGNALIN	93.242		5 P50 MH96972-04	23,857	
VANDERBILT UNIVERSITY-MH96972-04:PHOTOPERIODIC PROGRAMMING OF SEROT	93.242		5 P50 MH96972-04	2,933	
VANDERBILT UNIVERSITY-MH97793-01A1 PEERS, PLAY & PERFORMANCE TO IMPROVE SOCIAL	93.242		1 R34 MH97793-01A1	(3,651)	
VANDERBILT UNIVERSITY-MH99218-01A1 FRONTAL HYPO PERFUSION EFFECTS ON ANTIDEPRESSAN	93.242		1 R21 MH99218-01A1	(14,910)	
Subtotal 93.242				**1,588,656**	**227,336**
MEHARRY MEDICAL COLLEGE-SP21359-01:REDUCING HIV & SA AMONG MSMS ON HBCU CAMPUSES	93.243		1 H79 SP21359-01	16,207	
MEHARRY MEDICAL COLLEGE-SP21359-02:REDUCING HIV & SA AMONG MSMS ON HBCU CAMPUSES	93.243		1 H79 SP21359-02	13,215	
TENNESSEE ASSOCIATION OF ALCOHOL, DRUG & OTHER ADDICTION SVC-SBIRT CHAMPION PROGRAM - IN	93.243		SBIRT CHAMPION PROGR	1,079	
Subtotal 93.243				**30,500**	
BOSTON MEDICAL CENTER-AA20780-05:ALCOHOL AND ZINC IMPACT ON INFLAMMATORY MARKERS	93.273		5 U01 AA20780-05	1,158	
BOSTON MEDICAL CENTER-AA20780-06:URBAN ARCH (4/5) RUSSIA COHORT-TARGETING HIV-COMO	93.273		2 U01 AA20780-06	85,013	
BOSTON MEDICAL CENTER-AA21989-04:ZINC FOR HIV DISEASE AMONG ALCOHOL USERS -AN RCT	93.273		5 U01 AA21989-04	27,017	
BOSTON MEDICAL CENTER-AA21989-05:ZINC FOR HIV DISEASE AMONG ALCOHOL USERS -AN RCT	93.273		5 U01 AA21989-05	90,229	
VANDERBILT UNIVERSITY-1 R21 AA021443-02 HEPATOCYTE CLOCK GENES IN ALCOHOL AND HI	93.273		1 R21 AA021443-01A1	(2,821)	
VANDERBILT UNIVERSITY-AA13514-15 GENE-TARGETED MOUSE CORE	93.273		5 U01 AA13514-15	(4,390)	
YALE UNIVERSITY-AA22001-04:TRANSLATIONAL RESEARCH ON ALCOHOL,IMMUNODEFICIEN	93.273		5 U24 AA22001-04	25,346	
Subtotal 93.273				**221,552**	
DUKE UNIVERSITY-DA40317-01:MID SOUTHERN PRIMARY CARE NETWORKS NODE	93.279		1 UG1 DA40317-01	1,864	
DUKE UNIVERSITY-DA40317-02:MID SOUTHERN PRIMARY CARE NETWORKS NODE	93.279		5 UG1 DA40317-03	1,376	
DUKE UNIVERSITY-DA40317-02:MID SOUTHERN PRIMARY CARE NETWORKS NODE	93.279		1 UG1 DA40317-02	16,332	
RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.-DA38739-01 CYCOOXYGENASE-2 INHIBITION FOR CA	93.279		1 R21 DA38739-01	17,616	
RUSH UNIVERSITY MEDICAL CENTER-DA39522-01A1:DEVELOPMENT OF CO-MORBID PTSD AND CHRONIC P	93.279		1 R01 DA39522-01A1	41,198	
TUFTS UNIVERSITY-DA32889-04:IMPROVING OUTCOMES IN NAS - SOM	93.279		1 R01 DA32889-04	517	
UNIVERSITY OF PITTSBURGH-DA34629-02: CESSATION IN NON-DAILY SMOKERS: A RCT OF NRT	93.279		5 R01 DA34629-02	61,432	
VANDERBILT UNIVERSITY-DA38720-01:02 NEONATAL ABSTINENCE SYNDROM: RISK OF DRUG WITH	93.279		1 K23 DA38720-01	257	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-DA39743-01:02 CHARACTERIZING NON-MEDICAL PRESCRIPTION OPIOID	93.279		5 R03 DA39743-02	(2,855)	
Subtotal 93.279				**137,737**	
AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK-DD00761-03:A CROSS-SECTIONAL ANALYSIS OF CAR	93.283		5 U10 DD00761-03	827	
TN DEPARTMENT OF HEALTH-GR-15-44026-00: EMERGING INFECTIONS PRGM - MRSA	93.283		GR-15-44026-00	(64)	
TN DEPARTMENT OF HEALTH-GR-16-47952-00: EIP ACTIVE BACTERIA CORE (ABC)	93.283		GR-16-47952-00	2,058,183	14,450
TN DEPARTMENT OF HEALTH-GR-17-52614:EIP - ABC CORE CONTINUATION	93.283		GR-17-52614:ST TN	1,153,744	7,787
Subtotal 93.283				**3,212,690**	**22,236**
SOUTHERN ILLINOIS UNIVERSITY-EB18014 PURE PARAHYDROGEN-ENHANCED METABOLIC MRI CONTRAST	93.286		1 R21 EB18014	79,696	
SOUTHERN ILLINOIS UNIVERSITY-EB20323-01:PURE PARAHYDROGEN-ENHANCED METABOLIC MRI CONTRA	93.286		1 R21 EB20323-01	97,881	
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO-EB21214-01:SCALE-UP OF IMPLANTABLE ARTIFICIAL KIDNE	93.286		1 U01 EB21214-01	152,169	
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO-EB21214-02:SCALE-UP OF IMPLANTABLE ARTIFICIAL KIDNE	93.286		1 U01 EB21214-02	622,421	
VANDERBILT UNIVERSITY-EB014308-BONE FRACTURE RISK ASSESSMENT-ORTHOPEICS	93.286		1 R01 EB14308-01A1/04	43,444	
VANDERBILT UNIVERSITY-EB01628-13 POSTDOCTORAL TRAINING IN BIOMEDICAL MRI AND MRS	93.286		5 T32 EB01628-13	(3,856)	
VANDERBILT UNIVERSITY-EB017230-CONTROLLING QUALITY AND CAPTURING UNCERTAINTY IN	93.286		1 R01 EB17230	(22)	
VANDERBILT UNIVERSITY-EB017230-CONTROLLING QUALITY AND CAPTURING UNCERTAINTY-EECS	93.286		1 R01 EB17230 YR 1-4	127,812	
VANDERBILT UNIVERSITY-EB017467 ROBOTIC NATURAL ORIFICE SKULL BASE OTOLARYNGOLOGY	93.286		1 R01 EB17467 01/04	17,547	
VANDERBILT UNIVERSITY-EB017467 ROBOTIC NATURAL ORIFICE SKULL BASE SURGERY-NEUROLOG	93.286		1 R01 EB17467 01/04	(17)	
VANDERBILT UNIVERSITY-EB018521-RF ENCODING FOR GRADIENT-FREE MRI-RADIOLOGY	93.286		1 R21 EB18521-01/02	69,044	
VANDERBILT UNIVERSITY-EB018992-03 MAGNETIC CAPSULE ENDOSCOPE FOR COLONOSCOPY IN PA	93.286		1 R01 EB018992-01	(107)	
VANDERBILT UNIVERSITY-EB019409-SUBSTRATE MEDICATED SIRNA DELIVERY -SURGERY	93.286		1 R01 EB19409 01/04	2,158	
VANDERBILT UNIVERSITY-EB019409-SUBSTRATE SIRNA DELIVERY FROM SCAFFOLDS -PATHOLOGY	93.286		1 R01 EB19409-01/04	55,063	
VANDERBILT UNIVERSITY-EB019409-SUBSTRATEMEDIATED SIRNA DELIVERY FROM SCAFFOLDS	93.286		1 R01 EB19409 01/04	(148)	
VANDERBILT UNIVERSITY-EB019880-MRI TOOLBOX FOR RODENT MICROSTRUCTURE IMAGING	93.286		1 R01 EB19980	(13)	
VANDERBILT UNIVERSITY-EB0199880-MRI TOOLBOX FOR RODENT BRAIN MICROSTRUCTURE IMAGIN	93.286		1 R01 EB19980	(23)	
VANDERBILT UNIVERSITY-EB09106-05 IN VIVO AMYLOID-BETA IMAGING MOUSE BRAIN USING	93.286		5 R00 EB09106-05	(537)	
VANDERBILT UNIVERSITY-EB13659-01A1:04 QUANTITATIVE MRI OF THE HUMAN PERIPHERAL	93.286		5 K25 EB13659-04	(107)	
VANDERBILT UNIVERSITY-EB16695-03:THREE-DIMENSIONAL PATIENT-TAILORED RF PULSES	93.286		5 R01 EB16695-03	80,577	
VANDERBILT UNIVERSITY-EB17767-01:03 CERT IMAGING OF MUSCLE	93.286		5 R01 EB17767-03	77	
VANDERBILT UNIVERSITY-EB19509-01A1 THERMOSENSITIVE INJECTABLE POLYMER-BASED STEM C	93.286		1 R21 EB19509-01A1	1,561	
VANDERBILT UNIVERSITY-EB19980-01A1:MRI TOOLBOX FOR RODENT BRAIN MICROSTRUCTURE	93.286		1 R01 EB19980-01A1	12,805	
VANDERBILT UNIVERSITY-EB20666-01A1 IDENTIFICA, EXTRACTION AND DISPLAY OF CLINICAL	93.286		1 R01 EB20666-01A1	1,300	
VANDERBILT UNIVERSITY-EB22380-01:A COMPUTATIONAL MODEL-ENHANCED APPROACH FOR TUMOR	93.286		1 R21 EB22380-01	27,094	
Subtotal 93.286				**1,385,819**	
MEHARRY MEDICAL COLLEGE-MD07593-07:THE ROLE OF PLACENTAL INFLAMMATION IN HCMV ASSOCI	93.307		2 U54 MD07593-07	1,071	
MEHARRY MEDICAL COLLEGE-NS07593:MEHARRY CLINICAL AND TRANSLATIONAL RESEARCH CENTER	93.307		2 U54 NS07593	19,037	
MOREHOUSE SCHOOL OF MEDICINE-MD08173:04:UNDERSTANDING THE IMPACT OF FEDERAL EHR INCENTI	93.307		5 U54 MD08173-04	34,265	
WAYNE STATE UNIVERSITY-MD05849 ADJUNCT VITAMIN D THERAPY AS A MEANS TO REDUCE	93.307		5 R02 MD05849	327	
Subtotal 93.307				**54,701**	
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY-OD23320:DEVELOPMENTAL IMPACT OF	93.310		UG3 OD23320	55,804	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
DUKE UNIVERSITY-OD23375-1:ECHO COORDINATING CENTER	93.310		1 U2C OD23375-01	142,390	
FISK UNIVERSITY-GM119023-02:NRMN FOR A DIVERSE BIOMEDICAL WORKFORCE	93.310		8 U54 GM119023-02	29,529	
FISK UNIVERSITY-GM119023-03:NRMN-LINK PROJECT DEVELOPING/IMPLEMENTING MENTOR	93.310		8 U54 GM119023-03	234,024	
GENERAL ELECTRIC COMPANY-CA174377-04: ACCELERATING THE INTEGRATION AND TRANSLATION	93.310		5 R01 CA174377-04	161,841	
GENERAL ELECTRIC COMPANY-CA174377-05: ACCELERATING THE INTEGRATION AND TRANSLATION	93.310		1 R01 CA174377-05	377,253	
UNIVERSITY OF CHICAGO-MH101820-02S1 UN OF CHI HARNESSING GTEX TO CREATE TRANSCRIP	93.310		5 R01 MH101820-02S1	57,350	
UNIVERSITY OF WASHINGTON-OD23271-01:PRENATAL AND EARLY CHILDHOOD PATHWAYS TO HEALTH	93.310		1 UG3 OD23271-01	52,386	
UNIVERSITY OF WISCONSIN-OD23282-01:CHILDREN'S RESPIRATORY RESEARCH AND ENVIRONMENT	93.310		1 UG3 OD23282-01	39,982	
VANDERBILT UNIVERSITY-CA183492-01 MULTISENSORY PROCESSING ACROSS LIFESPAN	93.310		1 R21 CA183492-01	758	
VANDERBILT UNIVERSITY-CA183492-01 MULTISENSORY PROCESSING ACROSS LIFESPAN & LIN	93.310		1 R21 CA183492-01	(754)	
VANDERBILT UNIVERSITY-DK97678-01 POSITIVE PSYCHOLOGY TO PROMOTE ADHERENCE IN AD	93.310		1 DP3 DK97678-01	(24,819)	
VANDERBILT UNIVERSITY-HG07674-02 VANDERBILT CENTER FOR UNDIAGNOSED DISEASES (VCUD)	93.310		5 U01 HG07674-02	(10,135)	
VANDERBILT UNIVERSITY-HG07674-03 VANDERBILT CENTER FOR UNDIAGNOSED DISEASES (VCUD)	93.310		5 U01 HG07674-03	8,875	
VANDERBILT UNIVERSITY-OD18423:VANDERBILT ASPIRE PROGRAM - BILLING AGREEMENT AIRFAR	93.310		DP7 OD18423	277	
VANDERBILT UNIVERSITY-OD23132-01 PMI PARTI PREP/PROTYPING INITIATIVE: MILESTONE 1	93.310		1 OT2 OD23132-01	82,998	22,824
Subtotal 93.310				**1,207,761**	**22,824**
TN DEPARTMENT OF HEALTH-GR-16-47450-00:EMERGING INFECTIONS PROGRAM (EIP) 2016 INFRAS	93.317		GR-16-47450-00	81,320	
Subtotal 93.317				**81,320**	
VANDERBILT UNIVERSITY-MH99649-01:2 IMAGING THE ANTIPSYCHOTIC ACTIONS OF METABOTR	93.342		1 R01 MH99649-01	(50)	
Subtotal 93.342				**(50)**	
DARTMOUTH COLLEGE-TR01086-02S2 - DARTMOUTH - IRB CHOICE: EMPOWERING IRBS TO SE	93.350		3 UL1 TR01086-02S2	59	
DUKE UNIVERSITY-TR01608-01:CENTER FOR INNOVATIVE TRIALS IN CHILDREN AND ADUL	93.350		1 U24 TR01608-01	1,623,938	
DUKE UNIVERSITY-TR01803-01:LEVERAGING EXISTING REGISTRY RESOURCES TO FACILIT	93.350		1 U01 TR01803-01	81,303	
UNIVERSITY OF MASSACHUSETTS-TR01812-01:STRENGTHENING TRANSLATIONAL RESEARCH(STRIDE)	93.350		1 U01 TR01812-01	126,506	
VANDERBILT UNIVERSITY-GM100183-01:05 PHARMACOGENOMICS OF TACROLIMUS AND NEW ONSET	93.350		1 K23 GM100183-01	122	
VANDERBILT UNIVERSITY-TR00123-05 CTSA COORDINATING CENTER-C4	93.350		5 U54 TR00123-05	334,825	
VANDERBILT UNIVERSITY-TR00445-09 VICTR GOVERNANCE	93.350		5 UL1 TR00445-09	369,555	226,900
VANDERBILT UNIVERSITY-TR00446-09 KL2 - NATHAN BRUMMEL	93.350		5 KL2 TR00446-09	38,009	
VANDERBILT UNIVERSITY-TR00447-09 VICTR TL1	93.350		5 TL1 TR00447-09	15,291	
VANDERBILT UNIVERSITY-TR00491-05 NEUROVASCULAR UNIT ON A CHIP:REGIONAL CHEMICAL CO	93.350		5 UH3 TR00491-05	3,206	
VANDERBILT UNIVERSITY-TR00491-05 NEUROVASCULAR UNIT ON A CHIP-NEUROLOGY	93.350		5 UH3 TR00491-05	101,103	
VANDERBILT UNIVERSITY-TR00491-05S1:NEUROVASCULAR UNIT ON A CHIP: REGIONAL CHEMICAL	93.350		3 UH3 TR00491-05S1	60,373	
VANDERBILT UNIVERSITY-TR00491-06:NEUROVASCULAR UNIT ON A CHIP: REGIONAL CHEMICAL	93.350		5 UH3 TR00491-06	19,601	
Subtotal 93.350				**2,773,889**	**226,900**
TULANE UNIVERSITY-OD11109-14:TULANE NATIONAL PRIMATE RESEARCH CENTER U24 AIDS	93.351		4 U24 OD11109-14	85,411	
Subtotal 93.351				**85,411**	
VANDERBILT UNIVERSITY-NR15079-1:2 IMAGING LYMPHATIC FUNCTION IN PATIENTS W/ BREAST	93.361		5 R01 NR15079-02	126	
VANDERBILT UNIVERSITY-NR15353-03:IMPACT-PCRC-SUPPORTED LEGACY INTERVENTION	93.361		5 R01 NR15353-03	38,120	
Subtotal 93.361				**38,246**	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
BOSTON MEDICAL CENTER-CA187508-01A1:PROSPECTIVE INVESTIGATION OF THE ORAL MICROBIO	93.393		1 U01 CA187508-01A1	59,528	
BOSTON MEDICAL CENTER-CA187508-02:A PROSPECTIVE INVESTIGATION OF THE ORAL MICROBI	93.393		5 U01 CA187508-02	35,792	
FRED HUTCHINSON CANCER RESEARCH CENTER-CA183570-03: PROMISS:PROSTATE MODELING TO IDENTIF	93.393		5 R01 CA183570-03	12,345	
FRED HUTCHINSON CANCER RESEARCH CENTER-CA183570-04:PROMISS:PROSTATE MODELING TO IDENTIFY	93.393		4 R01 CA183570-04	39,404	
INDIANA UNIVERSITY-CA157823-04:GENETIC SUSCEPTIBILITY AND BIOMARKERS OF PLATINU	93.393		1 R01 CA157823-04	16,280	
INDIANA UNIVERSITY-CA157823-05:GENETIC SUSCEPTIBILITY AND BIOMARKERS OF PLATINU	93.393		5 R01 CA157823-05	11,867	
INDIANA UNIVERSITY-CA207530-01:THE ROLE OF LMO2 IN THE PATHOGENESIS OF T-CELL	93.393		1 R01 CA207530-01	6,290	
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (FRANCE)-CA155340-04: ONE-CARBON METABOLISM	93.393		5 U01 CA155340-04	13,660	
KAISER FOUNDATION-CA140377-02: INEGRATING GENETIC TESTING FOR LYNCH SYNDROME I	93.393		5 R01 CA140377-02	1,093	
MEHARRY MEDICAL COLLEGE-CA199214-01-A1:UNDERSTANDING BREAST CANCER SUBTYPES IN BLACK	93.393		1 RO3 CA199214-01-A1	1,724	
MEHARRY MEDICAL COLLEGE-CA199214-02:UNDERSTANDING BREAST CANCER SUBTYPES IN BLACK	93.393		1 R03 CA199214-02	10,722	
NEW YORK UNIVERSITY-CA204113-01:FOREGUT MICROBIOME, GASTRIC INTESTINAL METAPLASI	93.393		1 R01 CA204113-01	252,803	
NEW YORK UNIVERSITY-CA204113-02:FOREGUT MICROBIOME, GASTRIC INTESTINAL METAPLASI	93.393		1 R01 CA204113-02	7,025	
THOMAS JEFFERSON UNIVERSITY-CA177786-03:NOVEL MECHANISMS OF ONCOGENIC TRANSFORMATION	93.393		5 R01 CA177786-03	91,272	
THOMAS JEFFERSON UNIVERSITY-TJU:CA160432-04:SMARCAL1 FUNCTION IN REPLICATION STRESS...	93.393		5 R01 CA160432-04	62,638	
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO-CA197422-01A1:CANADIAN FLUOROSCOPY COHORT STUD	93.393		1 R01 CA197422-01A1	24,483	
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO-CA197422-02:CANADIAN FLUOROSCOPY COHORT STUDY: L	93.393		1 R01 CA197422-02	14,778	
UNIVERSITY OF CALIFORNIA, SYSTEMWIDE-CA192156-01A1:PHARMACOGENOMICS OF MICROTUBULE TAR	93.393		1 R01 CA192156-01A1	3,666	
UNIVERSITY OF CALIFORNIA, SYSTEMWIDE-CA192156-02:PHARMACOGENOMICS OF MICROBULE TARGETIN	93.393		5 R01 CA192156-02	37,339	
UNIVERSITY OF MARYLAND-CA163018-03 PROSPECTIVE STUDY OF SERUM MIS AND GYNECOLOGIC	93.393		5 R01 CA163018-03	1,416	
UNIVERSITY OF SOUTHERN CALIFORNIA-CA138338-06:MECHANISMS OF ETHNIC/RACIAL DIFFERENCES IN L	93.393		2 P01 CA138338-06	2,685	
VANDERBILT UNIVERSITY-CA116087-08 H.PYLORI-INDUCED INFLAMMATION AND GASTRIC CANCER	93.393		5 P01 CA116087-08	(16,091)	
VANDERBILT UNIVERSITY-CA118332-09:PARENT-CHILD COMMUNICATION ABOUT CANCER	93.393		4 R01 CA118332-09	11,476	
VANDERBILT UNIVERSITY-CA124558-01A2:5 GENETIC FACTORS FOR BREAST CANCER-A GENOME	93.393		5 R01 CA124558-05	(937)	
VANDERBILT UNIVERSITY-CA137013-01:4 GENOME-WIDE COPY NUMBER VARIATION & BREAST CAN	93.393		1 R01 CA137013-01A1	(1,004)	
VANDERBILT UNIVERSITY-CA137026-05 CANCER MORTALITY AMONG MILITARY PARTICIPAN	93.393		5 U01 CA137026-05	(14,902)	
VANDERBILT UNIVERSITY-CA141596-05 CONNECT TO QUIT: COORDINATED CARE FOR SMOKING	93.393		7 R01 CA141596-05	85,567	85,567
VANDERBILT UNIVERSITY-CA148667-01:05 CONSORTIUM STUDY TO IDENTIFY BREAST CANCER	93.393		5 R01 CA148667-05	4,560	
VANDERBILT UNIVERSITY-CA158473-01:04 GENOME SEQUENCING TO IDENTIFY NOVEL GENETIC	93.393		5 R01 CA158473-04	(3,212)	
VANDERBILT UNIVERSITY-CA158473-05 GENOME SEQUENCING TO IDENTIFY NOVEL GENETIC FACT	93.393		4 R01 CA158473-05	964	
VANDERBILT UNIVERSITY-CA160938-02:4 FATTY ACID DESATURASE ACTIVITY, FISH OIL AND	93.393		1 R01 CA160938-01	(3,981)	
VANDERBILT UNIVERSITY-CA167773-01:02 H. PYLORI ANCESTRAL HAPLOTYPE A GASTRIC CAN	93.393		5 R03 CA167773-02	5,715	
VANDERBILT UNIVERSITY-CA171013-01:02 MODIFIABLE LIFESTYLE-RELATED FACTORS & TRIP	93.393		5 R03 CA171013-02	2,200	
VANDERBILT UNIVERSITY-CA173640-03 SHANGHAI MEN'S HEALTH STUDY	93.393		5 UM1 CA173640-03	7	
VANDERBILT UNIVERSITY-CA177786-01A1:02 NOVEL MECHANISMS OF ONCOGENCI TRANSFORMATIO	93.393		1 R01 CA177786-01A1	(4,054)	
VANDERBILT UNIVERSITY-CA182910-02 SHANGHAI WOMEN'S HEALTH STUDY	93.393		5 UM1 CA182910-02	(93,543)	19,624
VANDERBILT UNIVERSITY-CA183021-01A1:02 CALCIUM INTAKE AND LUNG CANCER: EFFECT MODI	93.393		1 R03 CA183021-01A1:02	5	
VANDERBILT UNIVERSITY-CA187495-01:02 PREVENTION OF COX-2 DERIVED DNA AND HISTO	93.393		1 R21 CA187495-01A1	6,583	6,583
VANDERBILT UNIVERSITY-CA189152-01A1 EFFECTS OF EXPANDED COVERAGE ON ACCESS, HEALTH	93.393		1 R01 CA189152-01A1	(392,600)	(307,270)

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-CA190428-01A1 HELICOBACTER PYLORI PROTEIN-SPECIFIC ANTIBODIE	93.393		1 R01 CA190428-01A1	37,983	27,996
VANDERBILT UNIVERSITY-CA190612-01:02 TARGETED CHEMOPREVENTION OF GASTRIC CARCINO	93.393		1 R01 CA190612-01	(23,591)	(10,335)
VANDERBILT UNIVERSITY-CA195660-01A1 METHIONINE METABOLISM IN ESOPH ADENO CARCINOGE	93.393		1 R03 CA195660-01A1	(5,841)	
VANDERBILT UNIVERSITY-CA197344-01 ADAPTATION OF A PREVENTION-TREATMENT (ADAPT) PRO	93.393		1 R21 CA197344-01	(26,881)	
VANDERBILT UNIVERSITY-CA200709-01:FACILITATED RECRUITMENT OF MYC TO CHROMATIN	93.393		1 R01CA200709-01	37,320	
VANDERBILT UNIVERSITY-CA201856-01 PREVENTION OF GENOMIC INSTABILITY BY A SCAVENGER	93.393		1 R21 CA201856-01	(16)	
VANDERBILT UNIVERSITY-CA206563-01 MOLECULAR FUNCTIONS OF APE1 IN BARRETT'S TUMORIG	93.393		1 R01 CA206563-01	17	
VANDERBILT UNIVERSITY-CA206564-01 MECHANISMS OF TUMORIGENIC TRANSFORMATION OF BARR	93.393		1 R01 CA206564-01	(33,853)	
VANDERBILT UNIVERSITY-CA28842-29 ETIOLOGICAL STUDIES OF GASTRIC CARCINOMA PROJ 1 M	93.393		2 P01 CA28842-29	(7,649)	
VANDERBILT UNIVERSITY-CA77955-16:18 HELICOBACTER PYLORI RELATIONSHIP TO DIGESTIVE	93.393		5 R01 CA77955-18	11,915	
VANDERBILT UNIVERSITY-CA77955-19 H. PYLORI RELATIONSHIP TO DIGESTIVE DISEASES AND	93.393		4 R01 CA77955-19	15,901	
VANDERBILT UNIVERSITY-CA89450-15 FUNCTIONAL ANALYSIS OF CYCLOOXYGENASE-2	93.393		4 R01 CA89450-15	11,851	
VANDERBILT UNIVERSITY-CA92447-14 SOUTHERN COMMUNITY COHORT STUDY - VANDERBILT	93.393		5 R01 CA92447-14	560	
Subtotal 93.393				**311,278**	**(177,835)**
CASE WESTERN RESERVE UNIVERSITY-CA179327-01 CASE WESTN HISTOLOGIC IMAGE-BASED AGGRESSI	93.394		1 R21 CA179327-01 CASE	2,636	
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (FRANCE)-CA195603-01:BIOMARKERS OF HPV INFECT	93.394		1 U01 CA195603-01	25,621	
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (FRANCE)-CA195603-02:BIOMARKERS OF HPV INFECT	93.394		1 U01 CA195603-02	10,488	
MOUNT SINAI SCHOOL OF MEDICINE-CA163772-01A1: LUNG ADENOCARCINOMA INVASION GENOMICS	93.394		1 R01 CA163772-01A1	(6,890)	
MOUNT SINAI SCHOOL OF MEDICINE-CA163772-04:LUNG ADENOCARCINOMA INVASION GENOMICS	93.394		4 R01 CA163772-04	62,329	
MOUNT SINAI SCHOOL OF MEDICINE-CA163772-05:LUNG ADENOCARCINOMA INVASION GENOMICS	93.394		5 R01 CA163772-05	13,154	
NORTHWESTERN UNIVERSITY-CA159178-04: QUANTITATIVE MRI-GUIDED NANOEMBOLIZIATION FOR L	93.394		1 RO1 CA159178-04	8,524	
STANFORD UNIVERSITY-CA190214-01:QUALIFICATION AND DEPLOYMENT OF IMAGING BIOMARKE	93.394		1 U01 CA190214-01	5,149	
THOMAS JEFFERSON UNIVERSITY-CA194307-01A1:2D AND 3D CONTRAST-ENHANCED ULTRASOUND EVALU	93.394		1 R01 CA194307-01A1	70,053	
UNIVERSITY OF MIAMI-CA158472-05:INTEGRATIVE PREDICTION MODELS FOR METASTASIS	93.394		7 R01 CA158472-05	254,502	
UNIVERSITY OF MIAMI-CA200987-01A1:INTEGRATIVE STATISTICAL MODELS FOR TNCBC BIOMA	93.394		1 RO1 CA200987-01A1	58,453	
UNIVERSITY OF MICHIGAN-CA205414-01:VALIDATION OF 4-MIRRNA SIGNATURE FOR EARLY LUNG	93.394		1 R21 CA205414-01	15,329	
UNIVERSITY OF TEXAS HEALTH SCIENCES CENTER AT SAN ANTONIO-CA86402 UTHSCSA SUBCONTRACT: VAL	93.394		1 U01 CA86402-15S2	8,168	
VANDERBILT UNIVERSITY-CA138599-01A1:06 EVALUATION AND VALIDATION OF IMAGING BIOMAR	93.394		5 R01 CA138599-06	(23,656)	
VANDERBILT UNIVERSITY-CA152662-05 VALIDATION OF BIOMARKERS OF RISK FOR THE EARLY D	93.394		5 U01 CA152662-05	13,875	21,385
VANDERBILT UNIVERSITY-CA159988-05 VANDERBILT PROTEOME CHARACTERIZATION CENTER-MAIN	93.394		5 U24 CA159988-05	(201,984)	24,927
VANDERBILT UNIVERSITY-CA159988-07:VANDERBILT PROTEOME CHARACTERIZATION CENTER	93.394		7 U24 CA159988-07	3,896	
VANDERBILT UNIVERSITY-CA173593-04 COMPREHENSIVE EVALUATION OF OGSE DWI FOR ASSESSI	93.394		4 R01 CA173593-04	(63,254)	
VANDERBILT UNIVERSITY-CA174706-03 IMAGE DRIVEN MULTI-SCALE MODELING - PARENT	93.394		5 U01 CA174706-03	(32)	
VANDERBILT UNIVERSITY-CA177372-01:03 THE ROLE OF MIRNA NETWORK IN GASTRIC CANCER	93.394		1 R01 CA177372-01	38	
VANDERBILT UNIVERSITY-CA183727-02 TN VALLEY COOPERATIVE HUMAN TISSUE NETWORK	93.394		5 UM1 CA183727-02	(12,155)	
VANDERBILT UNIVERSITY-CA183727-03 TN VALLEY COOPERATIVE HUMAN TISSUE NETWORK	93.394		5 UM1 CA183727-03	(1,494)	
VANDERBILT UNIVERSITY-CA184693-01:02 CERT IMAGING OF CANCER	93.394		1 R01 CA184693-01	(1,461)	
VANDERBILT UNIVERSITY-CA185747-01/05 CELLULAR LEVEL METABOLIC IMAGING TOPREDICT	93.394		1 R01 CA185747	1,072	
VANDERBILT UNIVERSITY-CA186145-01A1 NON-INVASIVE EVALUATION - INDETERMINATE PULMON	93.394		1 R01 CA186145-01	(1,906)	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-CA186193-01: 02 QUANTITATIVE MULTISCALE IMAGING - QUARANTA	93.394		5 R01 CA186193-02	3,314	
Subtotal 93.394				**243,768**	**46,313**
CHILDREN'S HOSPITAL OF PHILADELPHIA-CA180886-01 COG CHILD H OF PHILADELPHIA NETWK GRP OPS CE	93.395		1 U01 CA180886-01	99,821	
CHILDREN'S HOSPITAL OF PHILADELPHIA-CA180886-01: COG NCTN WORKLOAD INTENSITY	93.395		1 U10 CA180886-01	37,334	
CHILDREN'S HOSPITAL OF PHILADELPHIA-CA180886-02S7:BIQSFP-COG AALL1131 PER CASE REIMBURSEME	93.395		1 U10 CA180886-02S7	4,501	
CHILDREN'S HOSPITAL OF PHILADELPHIA-CA189955-01 COG PER CASE REIMBURSEMENT: NCORP RESEARC	93.395		1 UG1 CA189955-01	25,032	
CHILDREN'S HOSPITAL OF PHILADELPHIA-CA196854:PHARMACOLOGIC REVERSAL OF VENTRICULAR REMOD	93.395		1 R01 CA196854	1,560	
CHILDREN'S HOSPITAL OF PHILADELPHIA-N02-CM-62212 CANCER TRIALS SUPPORT UNIT (CTSU) PHASE II SU	93.395		N02-CM-62212	9,862	
DUKE UNIVERSITY-CA184173-01A1: LIVE SYSTEM FOR SBRT TREATMENTS	93.395		1 R01 CA184173-01A1	25,496	
EASTERN COOPERATIVE ONCOLOGY GROUP-CA180820-03: ECOG-ACRIN NETWORK GROUP OPERATIONS CE	93.395		1 U10 CA180820-03	18,829	
EASTERN COOPERATIVE ONCOLOGY GROUP-CA180820-04:ECOG-ACRIN NETWORK GROUP OPERATIONS CE	93.395		U10 CA180820-04	6,216	
EASTERN COOPERATIVE ONCOLOGY GROUP-FEDERAL ECOG HEM E1412 - RAND PHII OP LBL R2CHOP VS RC	93.395		HEM E1412 ECOG-FRONTI	168,293	
EMORY UNIVERSITY-CA180950-02 ECOG-ACRIN THORACIC INTEGRATED TRANSLATIONAL	93.395		5 U10 CA180950-02	(45)	
EMORY UNIVERSITY-CA180950-03 ECOG-ACRIN THORACIC INTEGRATED TRANSLATIONAL	93.395		5 U10 CA180950-03	103,143	
EMORY UNIVERSITY-CA180950-04:ECOG-ACRIN THORACIC MALIGNANCIES INTEGRATED	93.395		5 U10 CA180950-04	23,378	
FRED HUTCHINSON CANCER RESEARCH CENTER-CA118953-09:BMT 1380: CHRONIC GVHD RESPONSE MEAS	93.395		4 R01 CA118953-09	13,086	
FRED HUTCHINSON CANCER RESEARCH CENTER-CA118953-09:IMPROVING OUTCOMES ASSESSMENT IN CH	93.395		4 U01 CA118953-09	8,043	
MEMORIAL SLOAN-KETTERING CANCER CENTER-CA129243-09:TARGETS FOR THERAPY FOR CARCINOMAS O	93.395		5 P01 CA129243-09	59,805	
MEMORIAL SLOAN-KETTERING CANCER CENTER-CA129243-10:TARGETS FOR THERAPY FOR CARCINOMAS O	93.395		4 P01 CA129243-10	63,461	
NRG ONCOLOGY FOUNDATION-CA180868-03:NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER	93.395		5 U10 CA180868-03	7,500	
NRG ONCOLOGY FOUNDATION-CA180868-04:NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER	93.395		5 U10 CA180868-04	4,405	
NRG ONCOLOGY FOUNDATION-CA189867-02:NRG ONCOLOGY NCORP RESEARCH BASE	93.395		5 UG1 CA189867-02	4,407	
NRG ONCOLOGY FOUNDATION-CA189867-03:NRG ONCOLOGY NCORP RESEARCH BASE	93.395		5 UG1 CA189867-03	13,403	
OREGON HEALTH & SCIENCE UNIVERSITY-CA180888-02:SWOG NETWORK GROUP OPERATIONS CENTER OF	93.395		5 U10 CA180888-02	(87)	
OREGON HEALTH & SCIENCE UNIVERSITY-CA180888-03:SWOG NETWORK GROUP OPERATIONS CENTER OF	93.395		5 U10 CA180888-03	94,956	
OREGON HEALTH & SCIENCE UNIVERSITY-CA180888-04:SWOG NETWORK GROUP OPERATIONS CENTER NC	93.395		5 U10 CA180888-04	31,638	
RUBICON BIOTECHNOLOGY-CA192775:RUBICON - MODIFIED ANNEXIN V FOR IMMUNOSTIMULATION	93.395		1 R43 CA192775	68,058	
UNIVERSITY OF BERN-AI69923:NCI AIDS DEFINING CANCERS IN THE ERA OF COMBINED ANT	93.395		1 U01 AI69923	(8)	
VANDERBILT UNIVERSITY-CA116021-11 IMPROVED THERAPY FOR P53WT MELANOMA BY FUNCTION	93.395		2 R02 CA116021-11,12	(19)	
VANDERBILT UNIVERSITY-CA116021-12:IMPROVED THERAPY FOR P53WT MELANOMA BY FUNCTION	93.395		5 R01 CA116021-12	12,483	
VANDERBILT UNIVERSITY-CA116021-13:VU:IMPROVED THERAPY FOR P53WT MELANOMA	93.395		5 R01 CA116021-13	18,547	
VANDERBILT UNIVERSITY-CA121210-06:09 OVERCOMING ACQUIRED RESISTANCE TO EGFR INHIBI	93.395		5 R01 CA121210-09	6,039	7,620
VANDERBILT UNIVERSITY-CA131225-06:07 THE ROLE OF AURORA KINASE A IN UPPER GASTROIN	93.395		2 R01 CA131225-06	22	
VANDERBILT UNIVERSITY-CA160700-01:03 MULTIFUNCTIONAL NANOPARTICLES FOR IMAGE GUI	93.395		5 R01 CA160700-03	(1,447)	
VANDERBILT UNIVERSITY-CA166492-03 TARGETING RADIATION RESISTANCE IN GLIOBLASTOMA	93.395		1 R01 CA166492-01A1	46	
VANDERBILT UNIVERSITY-CA180847-03 VANDERBILT NETWORK LEAD ACADEMIC PARTICIPATING S	93.395		5 U01 CA180847-03	(75,803)	
VANDERBILT UNIVERSITY-CA181491-02 DUSP4 IN BREAST CANCER: TUMOR SUPPRESSOR BIOLOGY	93.395		4 R00 CA181491-02	298	
VANDERBILT UNIVERSITY-CA184387-02 EXPLOITING NOTCH INHIBITION AS A MECH TO OVERCOM	93.395		7 R21 CA184387-02	6,737	4,291
VANDERBILT UNIVERSITY-CA214043-01A1:MACROPHAGE-BASED OVARIAN CANCER IMMUNOTHERAPY	93.395		1 R01 CA214043-01A1	16,508	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
YALE UNIVERSITY-CA186689-02 VIKTRIY EARLY CLINICAL TRIALS CONSORTIUM	93.395		5 UM1 CA186689-02	(56)	
YALE UNIVERSITY-CA186689-03:VIKTRIY EARLY CLINICAL TRIALS CONSORTIUM(ECTC)	93.395		5 UM1 CA186689-03	120,498	1,311
YALE UNIVERSITY-CA186689-03S1:VIKTRIY-PC CONSORTIUM PHASE II SUPPLEMENT	93.395		3 UM1 CA186689-03S1	64,553	
YALE UNIVERSITY-CA186689-04:VIKTRIY EARLY CLINICAL TRIALS CONSORTIUM(ECTC)	93.395		1 UM1 CA186689-04	19,138	
YALE UNIVERSITY-CA186689-04:VIKTRIY-PC CONSORTIUM PHASE II SUPPLEMENT	93.395		3 UM1 CA186689-04	15,110	
Subtotal 93.395				**1,094,741**	**13,222**
MEMORIAL SLOAN-KETTERING CANCER CENTER-CA213274-01:COORDINATING CENTER FOR NCI SMALL CEL	93.396		1 U24 CA213274-01	4,651	
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON-CA194215-01A1:ADVANCING CANCER PHAR	93.396		1 U24 CA194215-01A1	101,054	
UNIVERSITY OF TOLEDO-CA202176-02:AN EPIGENETIC LINK FROM CXCL12-CXCR4 AXIS THROU	93.396		7 R21 CA202176-02	2,281	
UNIVERSITY OF VIRGINIA-CA166458-05:UVA: BLIMP-1 MEDIATED REGULATION OF CD8 TIL	93.396		5 R01 CA166458-05	8,980	
VANDERBILT UNIVERSITY-CA148934-01:5 EPHA2 RECEPTOR IN ENDOTHELIAL CELL-MEDIATED	93.396		5 R01 CA148934-05	(6,010)	
VANDERBILT UNIVERSITY-CA157781-01:5 EPITHELIAL IL4RALPHA REGULATES COLON TUMOR	93.396		1 R01 CA157781-01A1	(12)	
VANDERBILT UNIVERSITY-CA162433-01A1:4 THE P450 EPOXYGENASES AS PRO-ONCOGENIC ENZYM	93.396		1 R01 CA162433-01A1	1,085	
VANDERBILT UNIVERSITY-CA163499-THE ROLE OF MECHANOTRANSDUCTION IN PROGESSION OF TU	93.396		1 R01 CA163499-01A1	2,227	
VANDERBILT UNIVERSITY-CA163499-THE ROLE OF MECHANTRANSDUCTION IN PROGRESSION OF TU	93.396		1 R01 CA163499-01A1	79,958	
VANDERBILT UNIVERSITY-CA163563-01:03 ROLE OF EGFR LIGAND-CONTAINING EXOSOMES IN	93.396		5 R01 CA163563-03	(4,617)	
VANDERBILT UNIVERSITY-CA178030-03:REGULATION OF TRANSCRIPTION & TUMOR SUPPRESSION	93.396		5 R01 CA178030-03	64,707	
VANDERBILT UNIVERSITY-CA178589-02:INHIBITION OF PROLIFERATION BY LAMININ	93.396		5 R21 CA178589-02	10,551	
VANDERBILT UNIVERSITY-CA179514-03 SECRETED RNA DURING CRC PROGRESSION: BIOGENESIS	93.396		5 U19 CA179514-03	(938)	
VANDERBILT UNIVERSITY-CA187307-01:02 MOUSE MODEL OF INVASIVE COLON CANCER	93.396		1 R21 CA187307-01A1	62	
VANDERBILT UNIVERSITY-CA193219-01A1 THE ROLE OF AXL-ABL AXIS IN BARRETT'S CARCINOG	93.396		1 R01 CA193219-01A1	878	
VANDERBILT UNIVERSITY-CA196405-01 CELLULAR, MOLECULAR AND QUANTITATIVE IMAGING	93.396		1 U01 CA196405-01	14,240	9,070
VANDERBILT UNIVERSITY-CA197571-01:CANCER AND CONTEXT	93.396		1 R35 CA197571-01	6,719	
VANDERBILT UNIVERSITY-CA197571-02:CANCER AND CONTEXT	93.396		1 R35 CA197571-02	25,101	
VANDERBILT UNIVERSITY-CA202229-02:PHYSICAL DYNAMICS OF CANCER RESPONSE TO CHEMOTHE	93.396		5 U01CA202229-02	53,970	
VANDERBILT UNIVERSITY-CA34590-30:CHEMOKINE SIGNALS IN THE PREMETASTATIC NICHE INHI	93.396		5 R01 CA34590-32	36	
VANDERBILT UNIVERSITY-CA34590-33:CHEMOKINE SIGNALS IN THE PREMETASTATIC NICHE INHI	93.396		5 R01 CA34590-33	54,999	
VANDERBILT UNIVERSITY-CA46413-24:27 ROLE OF EGFR LIGANDS IN NEOPLASIA	93.396		5 R01 CA46413-27	(1,279)	
VANDERBILT UNIVERSITY-CA46413-28 ROLE OF EGFR LIGANDS IN NEOPLASIA	93.396		4 R01 CA46413-28	(224)	
VANDERBILT UNIVERSITY-CA64140-22:THE ROLE OF AML 1-ETO IN ACUTE LEUKEMIA	93.396		5 R01 CA64140-22	27,951	
VANDERBILT UNIVERSITY-CA69457-19S1 EMT REGULATION IN GASTROINTESTINAL - SUPPLEMENT	93.396		3 R01 CA69457-18S1	741	
VANDERBILT UNIVERSITY-CA93999-12A1:14 TARGETS OF GENE OVEREXPRESSION AT 17Q IN GAS	93.396		2 R01 CA93999-12A1	(17,620)	
Subtotal 93.396				**429,491**	**9,070**
DANA-FARBER CANCER INSTITUTE-CA168504-03: SPORE:DANA-FARBER/HARVARD CANCE CENTER SPORE	93.397		5 P50 CA168504-03	2,380	
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH-CA116201-09:MAYO CLINIC BREAST CANC	93.397		5 P50 CA116201-10	1,139	
VANDERBILT UNIVERSITY-CA153708-05S1:MEHARRY MEDICAL COLLEGE-CHC COMMUNITY NETWORKS	93.397		3 U54 CA153708-05S1	9,587	
VANDERBILT UNIVERSITY-CA163072-05 ADMIN - MMC,VICC & TSU: PARTNERS IN ELIMINATING	93.397		5 U54 CA163072-05	(39,209)	
VANDERBILT UNIVERSITY-CA68485-19 CANCER CTR SUPP GRANT: SENIOR LEADERS	93.397		2 P30 CA68485-19	(144,178)	
VANDERBILT UNIVERSITY-CA95103-14 SPORE IN GI CANCER - PROJECT 1	93.397		5 P50 CA95103-14	17,895	20,047

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-CA98131-13 SPORE IN BREAST CANCER - PROJECT 1	93.397		5 P50 CA98131-13	2,284	
Subtotal 93.397				**(150,102)**	**20,047**
MEHARRY MEDICAL COLLEGE-CA102209:MEDICAL STUDENT SUMMER PROGRAM - MATUSIK	93.398		2 R25 CA102209	6,993	
VANDERBILT UNIVERSITY-CA09592-28 MICROENVIRONMENTAL INFLUENCES IN CANCER	93.398		4 T32 CA09592-29	5,308	
VANDERBILT UNIVERSITY-CA09592-29S1:MICROENVIRONMENTAL INFLUENCES IN CANCER-BILL AG	93.398		3 T32 CA09592-29S1	845	
VANDERBILT UNIVERSITY-CA106183-11 SURGICAL ONCOLOGY TRAINING GRANT	93.398		2 T32 CA106183-11	(1)	
VANDERBILT UNIVERSITY-CA154267-05 CONDUCTING RESEARCH IN PEDIATRIC HEMATOLOGY/ONCO	93.398		5 T32 CA154267-05	(2,060)	
VANDERBILT UNIVERSITY-CA160056-04 VANDERBILT TRAINING PROGRAM IN MOLECULAR	93.398		5 R25 CA160056-04	(76,526)	
VANDERBILT UNIVERSITY-CA168936-04 ASSESSMENT OF TUMOR EARLY RESPONSE	93.398		4 K25 CA168936-04	4,526	
VANDERBILT UNIVERSITY-CA172294-01A1:03 UNRAVELING GENETIC DETERMINANTS OF LUNG CAN	93.398		1 K07 CA172294-03	(3,926)	(3,635)
VANDERBILT UNIVERSITY-CA172957-04 CANCER CELL SIGNALING THROUGH LIPIDS COMPLEXED	93.398		7 K01 CA172957-04	(39,086)	
VANDERBILT UNIVERSITY-CA184257-01:02 DNA REPAIR PATHWAYS IN TRIPLE NEGATIVE BREAST	93.398		5 K07 CA184257-02	31	
VANDERBILT UNIVERSITY-CA90625-15 VANDERBILT CLINICAL ONCOLOGY RESEARCH CAREER DEVE	93.398		5 K12 CA90625-15	(2,352)	
VANDERBILT UNIVERSITY-CA93240-14 TRAINING GRANT IN RADIATION BIOLOGY	93.398		5 T32 CA93240-14	(12,030)	
Subtotal 93.398				**(118,277)**	**(3,635)**
VANDERBILT UNIVERSITY-CA184352-01A1 MYC-INDUCED PATHWAYS IN B CELL LYMPHOMA INITIA	93.399		1 R21 CA184352-01A1	(219)	
Subtotal 93.399				**(219)**	
TN DEPARTMENT OF HEALTH-51472:SURVEILLANCE SERVICES - EIP INFRASTRUCTURE	93.521		51472:ST TN	167,394	
Subtotal 93.521				**167,394**	
VANDERBILT UNIVERSITY-IP00464-05S1 NEW VACCINE SURVEILLANCE NETWORK - PPH	93.533		3 U01 IP00464-05S1	72,606	
VANDERBILT UNIVERSITY-IP00464-05S1 NEW VACCINE SURVEILLANCE NETWORK - PPHF	93.533		3 U01 IP00464-05S1	(23,861)	
VANDERBILT UNIVERSITY-IP00464-05S2 ACUTE RESPIRATORY VIRAL SURVEILLANCE	93.533		3 U01 IP00464-05S2	138,678	30,208
VANDERBILT UNIVERSITY-IP00464-06 NEW VACCINE SURVEILLANCE NETWORK - PPH	93.533		6 U01 IP00464-06	187,730	
Subtotal 93.533				**375,154**	**30,208**
VANDERBILT UNIVERSITY-CMS331461-01 MID-SOUTH PRACTICE TRANSFORMATION NETWORK	93.638		1 L1 CMS 331461-01-00	3,140,469	413,530
Subtotal 93.638				**3,140,469**	**413,530**
VANDERBILT UNIVERSITY-DK105149-02:LASER-BASED MASS SPECTROMETRY ANALYSIS OF SINGLE	93.647		5 R33 DK105149-02	7,523	
Subtotal 93.647				**7,523**	
ACADEMYHEALTH-90CL0001/01-00:USING LOCAL DATA AND RESOURCES TO REDUCE INFA	93.727		90CL0001/01-00	90,855	
Subtotal 93.727				**90,855**	
TN DEPARTMENT OF HEALTH-50808:VANDERBILT DIABETES PREVENTION PROGRAM PILOT	93.757		ST TN 50808	20,999	
Subtotal 93.757				**20,999**	
BOSTON UNIVERSITY-HL126136-02 - FRAMINGHAM HEART STUDY	93.837		5 R01 HL126136-02	17,199	
BRIGHAM AND WOMEN'S HOSPITAL-5 R01 HL122225-02:IMPROVING QUALITY BY MAINTAINING ACCURAT	93.837		5 R01 HL122225-02	(10,042)	
BRIGHAM AND WOMEN'S HOSPITAL-HL112349-02 USING GENETICS FOR EARLY	93.837		5 P50 HL112349-02	40,452	
BRIGHAM AND WOMEN'S HOSPITAL-HL117713-03:EFFECT OF LOW DOSE METHOTREXATE - MTX A5314	93.837		5 R01 HL117713-03	85	
BRIGHAM AND WOMEN'S HOSPITAL-HL122225-03:IMPROVING QUALITY BY MAINTAINING ACCURATE	93.837		5 R01 HL122225-03	50,207	
BRIGHAM AND WOMEN'S HOSPITAL-HL123336-01: RANDOMIZED TRIAL TO PREVENT VASCULAR EVENTS-HI	93.837		1 U01 HL123336-01	17,212	
BRIGHAM AND WOMEN'S HOSPITAL-HL130163-01:INFLUENZA VACCINE TO EFFECTIVELY STOP CARDIO TH0	93.837		1 U01 HL130163-01	8,978	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
BRIGHAM AND WOMEN'S HOSPITAL-HL130163-02:INFLUENZA VACCINE TO EFFECTIVELY STOP CARDIO	93.837		5 U01 HL130163-02	10,613	
BRIGHAM AND WOMEN'S HOSPITAL-HL130163-02:INFLUENZA VACCINE TO EFFECTIVELY STOP CARDIO THO	93.837		5 U01 HL130163-02	8,550	
BRIGHAM AND WOMEN'S HOSPITAL-INFLUENZA VACCINE TO EFFECTIVELY STOP CARDIO THORACIC EVENT	93.837		1 U01 HL130163-01	7,213	
CHILDREN'S HOSPITAL OAKLAND RESEARCH INSTITUTE-HL69757-14 PHARMOCOGENETICS AND RISK OF CA	93.837		5 U19 HL69757-14	11,981	
CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER-HL10533-01A1: NATIONAL BIOLOGICAL SAMPLE AND	93.837		1 R24 HL10533-01A1	1,762	
CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER-HL127672-02:RLDC: TRAINING COMPONENT FOR MO	93.837		5 U54 HL127672-02	30,248	
CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER-HL127672-03:RLDC: MOLECULAR PATHWAY-DRIVEN	93.837		1 U54 HL127672-03	132,004	
CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER-HL131755-01A1:MULTICENTER INTERVENTIONAL LY	93.837		1 U01 HL131755-01A1	6,116	
DARTMOUTH COLLEGE-HL130828-01A1:INFORMATION EXTRACTION FROM :EMRS TO PREDICT	93.837		1 R01 HL130825-01A1	157,257	10,847
DUKE UNIVERSITY-HL105462-04:ISCHEMIA TRIAL - SDCC	93.837		5 U01 HL105462:04	57,106	
DUKE UNIVERSITY-HL105462-05:THE ISCHEMIA TRIAL-SDCC	93.837		4 U01 HL105462-05	55,487	
DUKE UNIVERSITY-HL117904-02 ISCHEMIA TRIAL - CKD - SDCC	93.837		5 U01 HL117904-02	16,491	
DUKE UNIVERSITY-HL117904-04:ISCHEMIA- CKD SDCC	93.837		4 U01 HL117904-04	12,588	
DUKE UNIVERSITY-HL84904-11:PROTOCOL TITLE: ENTRESTOTM (LCZ696) IN HOSPITALIZ	93.837		5 U10 HL84904-11	2,054	
EMORY UNIVERSITY-HL117721-03 EMORY CELLULAR AND MOLECULAR MECHANISMS	93.837		5 U01 HL117721-03	3,329	
HARVARD UNIVERSITY-HL132320-01:PROTEOMIC PATHWAY DISCOVERY IN CARDIOVASCULAR	93.837		1 R01 HL132320-01	20,544	
HARVARD UNIVERSITY-HL132320-02:PROTEOMIC PATHWAY DISCOVERY IN CARDIOVASCULAR	93.837		1 R01 HL132320-02	5,405	
INDIANA UNIVERSITY-HL123767-04:PULMONARY HYPERTENSION INITIATIVE. SUB-IN UNIV	93.837		1 R24 HL123767-02	72,372	
INDIANA UNIVERSITY-HL136986-01:B-LINES LUNG ULTRASOUND GUIDED ED MANAGEMENT	93.837		1 R34 HL136986-01	2,754	
INDIANA UNIVERSITY-PURDUE UNIVERSITY INDIANAPOLIS-HL126557-02:HIV, DEPRESSION, AND CARDIOVA	93.837		5 R01 HL126557-02	197,661	
JOHNS HOPKINS UNIVERSITY-HL108756: HYDROXYUREA - PREVENT CNS COMPLICATIONS - PATIENTS	93.837		1 R34 HL108756	(659)	
JOHNS HOPKINS UNIVERSITY-HL135114-01:HEPATOMA DERIVED GROWTH FACTOR IN PULMONARY HYPE	93.837		1 R01 HL135114-01	19,407	
KESTREL LABS, INC.-HL131165-01:PULSE OXIMETER INNOVATION TO MEASURE PULSUS	93.837		1 R43 HL131165-01	8,695	
MASSACHUSETTS GENERAL HOSPITAL-HL111821-05:COMPARATIVE EFFECTIVENESS OF POST-DISCHARGE S	93.837		4 R01 HL111821-05	16,892	
MASSACHUSETTS GENERAL HOSPITAL-HL18646-37: NEW APPROACHES TO CARDIOTHORACIC TOLERANCE I	93.837		5 P01 HL18646-37	30,902	
MASSACHUSETTS GENERAL HOSPITAL-HL18646-38:MASS GEN - NEW APPROACHES TO CARDIOTHORACIC	93.837		5 P01 HL18646-38	38,043	50
MEDICAL COLLEGE OF WISCONSIN-HL119747-03: TARGETED HIGHLY SENSITIVE, NON-INVASIVE CARDIAC	93.837		5 R01 HL119747-03	527	
MEDICAL COLLEGE OF WISCONSIN-HL119747-04:TARGETED HIGHLY SENSITIVE, NON-INVASIVE CARDIAC	93.837		5 R01 HL119747-04	27,618	
MOUNT HOLYOKE COLLEGE-HL107196-10 MOUNT HOLYOKE METHODS FOR HIGH DIMENSIONAL	93.837		7 R01 HL107196-10	1,319	
NATIONAL ASSOCIATION OF VETERANS' RESEARCH & EDUCATION FDNS-HL122735-01 SMALL HEAT SHOCK	93.837		1 R56 HL122735-01	4,326	
NATIONAL MARROW DONOR PROGRAM-BMT 0989 PROTOCOL 0701	93.837		5 U01 HL69294	23	
NEW ENGLAND RESEARCH INSTITUTES-HL68270; PEDIATRIC ECHOCARDIOGRAPHY Z-SCORE	93.837		1 U01 HL68270	20,979	
NEW YORK UNIVERSITY-HL105907-01: ISCHEMIA- INTERNATIONAL STUDY OF COMPARATIVE	93.837		1 U01 HL105907-01	1,010	
NORTHWESTERN UNIVERSITY-HL130502-01:MECHANICAL CIRCULATORY SUPPORT: MEASURES OF ADJU	93.837		1 R01 HL130502-01	13,342	1,658
NORTHWESTERN UNIVERSITY-HL130502-02:MECHANICAL CIRCULATORY SUPPORT:MEASURES OF ADJUS	93.837		5 R01 HL130502-02	4,287	
OHIO STATE UNIVERSITY-HL116533-03:THERAPEUTIC POTENTIAL FOR ALDOSTERONE INHIBITION	93.837		5 R01 HL116533-03	30,791	
OREGON HEALTH & SCIENCE UNIVERSITY-HL111033-04:IMPROVING SYNCOPE RISK STRATIFICATION IN OLD	93.837		4 R01 HL111033-04	23,400	
STANFORD UNIVERSITY-HL117913-02:THE NOTCH SIGNALING PATHWAY IN LARGE VESSEL VASC	93.837		1 RO1 HL117913-02	6,296	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-HL128044-02 PANNEXIN CHANNELS IN CARDIAC ARRHYTHMIA	93.837		7 R01 HL128044-02	83,225	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
UNIVERSITY OF ALABAMA AT BIRMINGHAM-HL128044-03:PANNEXIN CHANNELS IN CARDIAC ARRHYTHMIA	93.837		5 R01 HL128044-03	34,529	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-HL128563-02:CARDIOMYOCYTE-MEDIATED MECHANISMS OF I	93.837		7 R01 HL128563-02	13,734	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-HL128563-03:CARDIOMYOCYTE-MEDIATED MECHANISMS OF I	93.837		5 R01 HL128563-03	3,119	
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO-HL112827-01A1: PA-11-195: ECTOPIC FAT AND ATHEROSCL	93.837		1 K24 HL112827-01A1	1,374	
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO-HL126555-01 UCSF SUDDEN CARDIAC DEATH	93.837		1 R01 HL126555-01	282,874	161,650
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO-HL129856-01A1:PROTEIN BIOMARKERS FOR CVD PREDICTI	93.837		1 R01 HL129856-01A1	46,983	
UNIVERSITY OF CINCINNATI-HL127672 RLDC: MOLECULAR PATHWAY-DRIVEN DIAGNOSTICS & THERA	93.837		1 U54 HL127672 CINC	34,478	
UNIVERSITY OF CINCINNATI-HL127672:RLDC:PILOT PROJECT MOLECULAR PATHWAY-DRIVEN DIAGNOS	93.837		1 U54 HL127672 CINC	6,003	
UNIVERSITY OF ILLINOIS AT CHICAGO-HL92217-06: POSITIONAL CLONING AND CANDIDATE GENE APPROAC	93.837		5 R01 HL92217-06	85,299	21,410
UNIVERSITY OF KENTUCKY-HL134731-01:SERUM AMYLOID A, INFLAMMASOME ACTIVATION	93.837		1 R01 HL134731-01	1,071	
UNIVERSITY OF LOUISVILLE-HL127518:COLO-MIR: A PLASMA MICRORNA ASSAY WITH HIGH SPECIFI	93.837		1 U01 HL127518	6,743	
UNIVERSITY OF LOUISVILLE-HL127518:EXITE PROGRAM - COLO-MIR: A PLASMA MICRORNA	93.837		1 U01 HL127518	3,785	
UNIVERSITY OF MARYLAND-HL105198-10 VUMC/MARYLAND PAPI-2 STUDY	93.837		5 U01 HL105198-10	3,725	
UNIVERSITY OF MARYLAND-HL99997-07:FUNCTIONAL HETEROGENEITY IN CARDIAC PROGENITOR CE	93.837		5 U01 HL99997-08	49,132	
UNIVERSITY OF MICHIGAN-BMT 1566 LONG-TERM FOLLOW-UP & LENALIDOMIDE MAINTENANCE THER	93.837		NMDP BMT CTN 0702	5,163	
UNIVERSITY OF MICHIGAN-HL69330:INFRASTRUCTURE SUPPORT FOR BMT CTN	93.837		1 U10 HL69330	16,472	
UNIVERSITY OF MICHIGAN-HL6933015:INFRASTRUCTURE SUPPORT FOR BMT CTN: 2016-17	93.837		5 U01 HL6933015	16,355	
UNIVERSITY OF MICHIGAN-HL69330-15:VICC BMT 1662, SIROLIMUIS AND PREDNISONE IN PATIE	93.837		5 U01 HL69330-15	4,287	
UNIVERSITY OF MINNESOTA-HL123227-02 PERFUSION INJURY PROTECTION STRATEGIES DUING BAS	93.837		5 R01 HL123227-02	177,068	716
UNIVERSITY OF MINNESOTA-HL135300-01:CALORIC AND NON-CALORIC SWEETENERS AND THE DISTR	93.837		1 R21 HL135300-01	5,473	
UNIVERSITY OF MISSISSIPPI MEDICAL CENTER-HL126145-03:HBCU PRIDE PROGRAM	93.837		5 R25 HL126145-03	6,782	
UNIVERSITY OF MISSISSIPPI MEDICAL CENTER-HL133870-01A1:APTAMER PROTEOMICS OF CARDIOMETABO	93.837		1 R01 HL133870-01A1	6,244	
UNIVERSITY OF OKLAHOMA-HL128393-01:AUTOIMMUNE BASIS FOR POSTURAL TACHYCARDIA SYNDRO	93.837		1 R56 HL128393-01	85,225	
UNIVERSITY OF OKLAHOMA-HL128393-01A1:AUTOIMMUNE BASIS FOR POSTURAL TACHYCARDIA SYND	93.837		1 R01 HL128393-01A	42,055	
UNIVERSITY OF PENNSYLVANIA-HL115041-03:NOVEL METHODS FOR THE CONDUCT OF CLINICAL TRIALS	93.837		5 R01 HL115041-03	3,524	
UNIVERSITY OF PENNSYLVANIA-HL118018-03:MULTIMARKER RISK PREDICTION IN CANCER THERAPY CA	93.837		5 R01 HL118018-03	21,839	
UNIVERSITY OF PENNSYLVANIA-HL118018-04-MULTIMARKER RISK PREDICTION IN CANCER THERAPY CA	93.837		5 R01 HL118018-04	4,096	
UNIVERSITY OF PENNSYLVANIA-HL134905-01:ANASTROZOLE IN PULMONARY ARTERIAL:AIPH2-CC-CRM	93.837		R01 HL134905-01	1,996	
UNIVERSITY OF PITTSBURGH-HL123500-01A1:MINDING GOALS: AN INTERNET-ASSISTED MIND-BODY	93.837		1 R43 HL123500-01A1	(936)	
UNIVERSITY OF PITTSBURGH-HL123500-02:MINDING GOALS:AN INTERNET-ASSISTED MIND-BODY	93.837		1 R34 HL123500-02	24,907	
UNIVERSITY OF PITTSBURGH-HL129066-02:OUTSIDE-IN REGENERATION OF ABDOMINAL AORTIC ANEU	93.837		1 R21 HL129066-02	69,509	
UNIVERSITY OF ROCHESTER-HL96607: RAID - LATE SODIUM CURRENT BLOCKADE IN HIGH-RISK	93.837		1 U01 HL96607	(39,688)	
UNIVERSITY OF UTAH-HL107241 PULSE WAVE VELOCITY AND CENTRAL AORTIC PRESSURE	93.837		1 R01 HL107241	911	
VANDERBILT UNIVERSITY-HL07411-36:TRAINING IN CARDIOVASCULAR RESEARCH	93.837		2 T32 HL07411-36	19,050	
VANDERBILT UNIVERSITY-HL100398-07 PROJECT 1 OPTIMIZING CARDIO	93.837		5 U01 HL100398-07	7,071	
VANDERBILT UNIVERSITY-HL102780-04 OBESITY, SALT-SENSITIVITY, AND THE NATRIURETIC	93.837		7 R01 HL102780-04	(4,825)	(5,861)
VANDERBILT UNIVERSITY-HL103620-06 GROWING RIGHT ONTO WELLNESS (GROW): CHANGING EA	93.837		5 U01 HL103620-06	11,766	8,860
VANDERBILT UNIVERSITY-HL105334-05 DEVELOPMENTAL DETERMINANTS OF CARDIOVASCULAR DIS	93.837		5 T32 HL105334-05	(8,431)	
VANDERBILT UNIVERSITY-HL105731-01A1:2 METHODS TO REDUCE VEIN HARVEST INJURY	93.837		1 R01 HL105731-01A1	(285)	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-HL108173:05 FLECAINIDE FOR CATECHOLAMINERGIC POLYMORPHIC	93.837		5 R01 HL108173-05	1,067	4,676
VANDERBILT UNIVERSITY-HL109019-05 THE VANDERBILT EMERGENCY MEDICINE RESEARCH TRAIN	93.837		5 K12 HL109019-05	8,441	
VANDERBILT UNIVERSITY-HL109388-1:5 HEALTH LITERACY, HOSPITAL DISCHARGE, AND CARDIO	93.837		5 R01 HL109388-05	10,679	
VANDERBILT UNIVERSITY-HL111420-03:04 CARDIAC REPAIR BY REPROGRAMMING FIBROBLAST	93.837		7 K08 HL111420-03	11,362	
VANDERBILT UNIVERSITY-HL111516-01:04 VASCULAR FACTORS UNDERLYING ABNORMAL COG	93.837		1 R01 HL111516-04	(56,549)	
VANDERBILT UNIVERSITY-HL112746-03:04 IMPACT OF VITAMIN D	93.837		5 R01 HL112746-04	12,385	9,482
VANDERBILT UNIVERSITY-HL113039-02:04 CIRCULATING MICRORNAS CONTROL CHOLESTEROL	93.837		5 K22 HL113039-04	(499)	
VANDERBILT UNIVERSITY-HL114124-04 TNNI3K: A CARDIAC-SPECIFIC KINASE REGULATING IS	93.837		7 R01 HL114124-04	9,947	
VANDERBILT UNIVERSITY-HL115103-04:SEROTONERGIC RECEPTOR TARGETED THERAPY FOR DEGE	93.837		4 R01 HL115103-04	29,579	
VANDERBILT UNIVERSITY-HL116263-02 PROJ 1 HDL FUNCTION	93.837		5 P01 HL116263-02	(11,472)	
VANDERBILT UNIVERSITY-HL118386-01:03 TIE TEK MODULATION OF CARDIAC DEVELOPMENT	93.837		5 R01 HL118386-02	88	
VANDERBILT UNIVERSITY-HL118392-01:03 OPTIMAL DESIGN: CHALLENGE-RESPONSE - SHOTWELL	93.837		5 R01 HL118392-03	3,261	3,274
VANDERBILT UNIVERSITY-HL118952-01:03 REVISED SCN5A MUTATIONS AND DIALTED CARDIOMYO	93.837		5 R01 HL118952-03	(18)	
VANDERBILT UNIVERSITY-HL119234-01A1:02 HEART FAILURE IN CANCER PATIENTS	93.837		7 R01 HL119234-01A1	(231)	
VANDERBILT UNIVERSITY-HL121139-01:03 PROCESSING & PRESENTATION OF MINOR HISTOCOMPA	93.837		5 R01 HL121139-02	(21,258)	
VANDERBILT UNIVERSITY-HL121671-03 DIVERSE ROLES OF INTERLEUKIN 17 ISOFORMS IN THE	93.837		5 K08 HL121671-03	40	
VANDERBILT UNIVERSITY-HL122010-DECRYPTING VARIANTS OF UNCERTAIN SIGNIFICANCE IN	93.837		1 R01 HL122010	17,702	
VANDERBILT UNIVERSITY-HL122143-02 METABOLIC AND CD4+ T CELL DYSREGULATION	93.837		5 K23 HL122143-02	(74)	
VANDERBILT UNIVERSITY-HL122507-01:2 AUTONOMIC: ANGIOTENSIN -INTERACTIONS IN HYPER	93.837		1 K99 HL122507-02	(216)	
VANDERBILT UNIVERSITY-HL122847-01:02 SPLANCHNIC CIRCULATION AND BLOOD PRESSURE REG	93.837		5 R01 HL122847-02	99	
VANDERBILT UNIVERSITY-HL122904-03 RATIONAL INTEGRATION OF GENOMIC HEALTHCARE TESTI	93.837		5 U01 HL122904-03	45,868	31,617
VANDERBILT UNIVERSITY-HL123938-01:02 QUANTITATIVE ASSESSMENT- CARDIAC DISEASE	93.837		5 K23 HL123938-02	80	
VANDERBILT UNIVERSITY-HL124116-01A1 SIRTUIN 3 IMPAIRMENT AND SOD2 ACETYLATION	93.837		1 R01 HL124116-01A1	23	
VANDERBILT UNIVERSITY-HL124935-01:2 TOWARD MECHANISM-BASED APPROACH TO TREATING AF	93.837		1 R01 HL124935-02	38,814	42,922
VANDERBILT UNIVERSITY-HL125032-02 VU IMMUNE FUNCTION	93.837		5 R01 HL125032-02	65,662	65,669
VANDERBILT UNIVERSITY-HL125426-01:02 CARDIOVASCULAR CONSEQUENCES OF PEPTIDASE INHI	93.837		2 R01 HL125426-02	(245)	
VANDERBILT UNIVERSITY-HL125670-01A1 A RANDOMIZED, ED-BASED INTERVENTION TO IMPROVE	93.837		1 K23 HL125670-01A1	(96)	
VANDERBILT UNIVERSITY-HL125865-02 THE ROLE OF THE T CELL IN THE GENESIS OF HYPE	93.837		1 R01 HL125865-02	(55,898)	
VANDERBILT UNIVERSITY-HL126145-02:HBCU PRIDE	93.837		5 R25 HL126145-02	1,182	
VANDERBILT UNIVERSITY-HL127104-01A1 GROW BABY: IMPROVING MATERNAL GESTAT WEIGHT GA	93.837		1 K23 HL127104-01A1	(15)	
VANDERBILT UNIVERSITY-HL127130-01A1 ENHANCING INTER-FACILITY TRANSFER FOR PATIENTS	93.837		1 K23 HL127130-01A1	102	
VANDERBILT UNIVERSITY-HL127173-01A1MACROPHAGE SR-BI REGULATES AUTOPHAGY, ANGIOGENI	93.837		1 R01 HL127173-01A1	(3)	
VANDERBILT UNIVERSITY-HL127301-01A1 MENTORING IN TRANSLATIONAL RES IN INTERSTITIAL	93.837		1 K24 HL127301-01A1	(16,239)	
VANDERBILT UNIVERSITY-HL127368-01 CHARACTERIZING LIFE-SPAN SOCIOBEHAVIORAL DETERMI	93.837		1 R21 HL127368-01	18,223	18,223
VANDERBILT UNIVERSITY-HL128996-01 HDL-MICRORNA INTERCELLULAR COMMUNICATION	93.837		1 R01 HL128996-01	(206)	
VANDERBILT UNIVERSITY-HL130595-01 DNA-DAMAGE REPAIR IN PULMONARY FIBROSIS	93.837		1 K08 HL130595-01	(21,442)	
VANDERBILT UNIVERSITY-HL131911-01 ROLE OF GENETIC VARIANTS IN SUDDEN DEATH IN THE	93.837		1 U01 HL131911-01	(590)	
VANDERBILT UNIVERSITY-HL37675-22:24 REVISED REGULATION OF CARDIAC MYOCYTE DIFFEREN	93.837		5 R01 HL37675-24	(3,491)	
VANDERBILT UNIVERSITY-HL39006-27 IMMUNITY, INFLAMMATION AND HYPERTENSION	93.837		4 R01 HL39006-27	(150,123)	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-HL49989-18:21 MODULATION OF CARDIAC REPOLARIZATION	93.837		2 R01 HL49989-18	(6)	
VANDERBILT UNIVERSITY-HL56693-19 AUTONOMIC CARDIOVASCULAR REGULATION PROJECT 1 (PA	93.837		5 P01 HL56693-19	4,809	2,112
VANDERBILT UNIVERSITY-HL61688-19 SIGNALING MECHANISMS GOVERNING CARDIAC HYPERTROPH	93.837		5 R01 HL61688-18	4,765	
VANDERBILT UNIVERSITY-HL65962-14 PHARMACOGENOMICS OF ARRHYTHMIA THERAPY- KEY PERS	93.837		5 U19 HL65962-14	43,347	36,913
VANDERBILT UNIVERSITY-HL70715-09A1:11 PREVENTION OF VEIN GRAFT FAILURE	93.837		2 R01 HL70715-09A1	(22,103)	
VANDERBILT UNIVERSITY-HL71670-10:12 REVISED ARRHYTHMIA MECHANISMS IN SARCOMERIC CA	93.837		5 R01 HL71670-12	(35,925)	
VANDERBILT UNIVERSITY-HL79184-06A1:10 PHARMACOGENETICS OF ACE INHIBITOR-ASSOCIATED	93.837		5 R01 HL79184-10	(1,410)	
VANDERBILT UNIVERSITY-HL88635-08 REVISED CALSEQUESTRIN IN VENTRICULAR ARRHYTHMIA	93.837		5 R01 HL88635-08	(6,564)	
VANDERBILT UNIVERSITY-HL89385-01A3:05 ROLE OF OXIDATIVE STRESS IN POST-MI CARDIAC	93.837		1 R01 HL89385-05	2,469	
VANDERBILT UNIVERSITY-HL95813-01A2:4 REGULATION AND MAINTENANCE OF CARDIAC MUSCLE	93.837		1 R01 HL95813-01A2	7,897	
VANDERBILT UNIVERSITY-HL96844-01:05 PREAMYLOID OLIGOMERS AND SUSCEPTIBILITY TO	93.837		5 R01 HL96844-05	2,092	
VANDERBILT UNIVERSITY-HL98445-05 LONGITUDINAL CHANGES IN PERICARDIAL ADIPOSITY	93.837		7 R01 HL98445-05	488	(453)
VIRGINIA COMMONWEALTH UNIVERSITY-HL90586-05: VCU: ALLOSTERIC INHIBITORS OF COAGULATION PR	93.837		2 R01 HL90586-05	32,596	
WASHINGTON UNIVERSITY IN ST. LOUIS-HL118305-03:A MULTI-ETHNIC STUDY OF GENE-LIFESTYLE INTERAC	93.837		5 R01 HL118305-03	15,000	
WAYNE STATE UNIVERSITY-HL109090-03 CARDIAC BIOMARKER - PEDIATRIC CARDIOMYOPATHY	93.837		5 R01 HL109090-03	18,804	
WAYNE STATE UNIVERSITY-HL111459-04:GENOTYPE-PHENOTYPE ASSOCIATIONS IN PEDIATRIC	93.837		5 R01 HL111459-04	3,375	
WAYNE STATE UNIVERSITY-HL111459-05:GENOTYPE-PHENOTYPE ASSOCIATIONS IN PEDIATRIC	93.837		5 R01 HL111459-05	820	
Subtotal 93.837				**2,320,922**	**413,765**
CLEVELAND CLINIC FOUNDATION-HL125177-03:PULMONARY VASCULAR DISEASE PHENOMICS PROGRAM	93.838		1 U01 HL125177-03	8,251	
MASSACHUSETTS GENERAL HOSPITAL-HL123009-02: ROSE STUDY FOR PETAL NETWORK	93.838		5 U01 HL123009-02	241,964	224,525
MASSACHUSETTS GENERAL HOSPITAL-HL123009-03: PETAL NETWORK - CCC FOR NHLBI PREVENTION AND	93.838		5 U01 HL123009-03	195,686	
MASSACHUSETTS GENERAL HOSPITAL-HL123009-03:LOW TIDAL VOLUME UNIVERSAL SUPPORT-LOTUS FRUI	93.838		5 U01 HL123009-03	15,177	8,669
MASSACHUSETTS GENERAL HOSPITAL-HL123009-03:PETAL NETWORK CCC: VITAMIN D TO IMPROVE-VIOLE	93.838		5 U01 HL123009-03	18,699	
MASSACHUSETTS GENERAL HOSPITAL-HL123009-03:THE VIOLET POC VITAMIN D TESTING STUDY FOR PETA	93.838		5 U01 HL123009-03	1,942	
MASSACHUSETTS GENERAL HOSPITAL-HL123009-04:PETAL-CCC PREVENTION & EARLY TREATMENT OF ACU	93.838		5 U01 HL123009-04	37,905	
NORTHWESTERN UNIVERSITY-HL122477-03:LUNG FUNCTION DECLINE AND DISEASE RISK FROM YOUN	93.838		5 RO1 HL122477-03	45,976	
SEATTLE CHILDREN'S HOSPITAL-HL121067-01 PEDIATRIC RESPIRATORY ILLNESS INPATIENT MEASUREM	93.838		1 R01 HL121067-01	130,281	
UNIVERSITY OF COLORADO-HL121518-02 DATA FUSION:SUSTAINABLE, SCALABLE, OPEN SOURCE	93.838		5 U01 HL121518-02	13,179	
UNIVERSITY OF COLORADO-HL121518-03:DATA FUSION:A SUSTAINABLE, SCALABLE,OPEN SOURCE	93.838		5 U01 HL121518-03	38,558	
UNIVERSITY OF PENNSYLVANIA-1 R01 HL134015-01:APPROACHES TO GENETIC HETEROGENEITY OF OBS	93.838		1 R01 HL134015-01	3,022	
UNIVERSITY OF PENNSYLVANIA-HL113988-04:ESTROGEN SIGNALING IN PORTOPULMONARY HYPERTENSIO	93.838		5 R01 HL113988-04	(146)	
UNIVERSITY OF PENNSYLVANIA-HL113988-05:ESTROGEN SIGNALING IN PORTOPULMONARY HYPERTENSIO	93.838		5 R01 HL113988-05	1,715	
UNIVERSITY OF PENNSYLVANIA-HL87115-06A1 CLINICAL RISK FACTORS FOR PRIMARY GRAFT DYSFUCT	93.838		2 R01 HL087115-06A1	18,949	
VANDERBILT UNIVERSITY-HL102020-01:5 ROLE OF BMPR2 EXPRESSION IN HPAH; IMPLICATI	93.838		1 R01 HL102020-01A1	81	
VANDERBILT UNIVERSITY-HL105479-05 REGULATION OF FIBROTIC REMODELING BY THE AL	93.838		1 R01 HL105479-01A1	(372)	
VANDERBILT UNIVERSITY-HL108006-04:05 T CELL METABOLISM AS A DETERMINANT OF DIFFERE	93.838		7 R01 HL108006-04	89	
VANDERBILT UNIVERSITY-HL108800-04 PROJ1: HORMONAL, METABOLIC AND SIGNALING	93.838		5 P01 HL108800-04	(1,577)	
VANDERBILT UNIVERSITY-HL109977-05 PREGNANCY FOLATE STATUS & EARLY CHILDHOOD RESPIR	93.838		5 R01 HL109977-05	(8,574)	
VANDERBILT UNIVERSITY-HL111111-04 ALTERING SEDATION PARADIGMS TO IMPROVE BRAIN	93.838		5 R01 HL111111-04	3,344	3,837

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-HL111259-05 CAVEOLAR DEFECTS UNDERLIE GENETIC ORIG PAH-AIM 1	93.838		5 R01 HL111259-05	(79,939)	
VANDERBILT UNIVERSITY-HL112286-04 NRF2 AND RADIATION-INDUCED PULMONARY FIBROSIS	93.838		4 R01 HL112286-04	(61)	
VANDERBILT UNIVERSITY-HL119503-03 MECHANISMS OF PULMONARY FIBROSIS IN HERMANSKY-PU	93.838		1 R01 HL119503-01	69	
VANDERBILT UNIVERSITY-HL121174-02 METABOLIC REPROGRAMMING IN PULMONARY ARTERIAL	93.838		1 K08 HL121174-01A1	27	
VANDERBILT UNIVERSITY-HL122417-01:02 LIPID DEPOSITION IN THE RIGHT VENTRICLE IN PU	93.838		1 R01 HL122417-01A1	(60)	
VANDERBILT UNIVERSITY-HL122554-02 ROLE OF GENDER IN TH17-MEDIATED INFLAMMATION I	93.838		1 R01 HL122554-02	(19,658)	
VANDERBILT UNIVERSITY-HL123033-02 PREVENTION AND EARLY TREATMENT OF ACUTE LUNG IN	93.838		5 U01 HL123033-02	10,087	10,102
VANDERBILT UNIVERSITY-HL125212-02 A MOLECULAR PHENOTYPE OF COMBINED PULMONARY HYPE	93.838		5 U01 HL125212-02	67	
VANDERBILT UNIVERSITY-HL126176-01:02 THE GOLD STUDY: GOAL OF OPEN LUNG VEN- DONORS	93.838		1 R01 HL126176-01	54,591	53,518
VANDERBILT UNIVERSITY-HL126492-01:02 USING REAL WORLD DECISIONS TO DEVELOP A MODIF	93.838		1 R01 HL126492-01	3,389	
VANDERBILT UNIVERSITY-HL126671-02 HEMOGLOBIN IN ARDS: MEDIATOR AVEOLAR EPITHELIAL	93.838		5 R01 HL126671-02	28	
VANDERBILT UNIVERSITY-HL127102-01 BETA 1 INTEGRIN IN THE LUNG	93.838		1 K08 HL127102-01	6,539	
VANDERBILT UNIVERSITY-HL79937-08 ASTHMA AND NOCTURNAL HYPOXEMIA IN SICKLE CELL ANE	93.838		5 R01 HL79937-08	4,904	4,747
VANDERBILT UNIVERSITY-HL85317-06:09 EPITHELIAL-FIBROBLAST INTERACTIONS IN LUNG	93.838		5 R01 HL85317-09	3,124	802
VANDERBILT UNIVERSITY-HL87738-09 CLINICAL AND TRANSLATIONAL RESEARCH TRAINING PROG	93.838		5 T32 HL87738-09	(31,259)	
VANDERBILT UNIVERSITY-HL87738-10 CLINICAL AND TRANSLATIONAL RESEARCH TRAINING PROG	93.838		4 T32 HL87738-10	(1,025)	
VANDERBILT UNIVERSITY-HL94296-08 INTERDISCIPLINARY TRAINING PROGRAM IN LUNG RESEA	93.838		5 T32 HL94296-08	52,200	
VANDERBILT UNIVERSITY-HL95797-05A1:06 INTERVENTIONS AGAINST MOLECULAR ETIOLOGY OF	93.838		2 R01 HL95797-05A1	(10)	
Subtotal 93.838				**767,161**	**306,201**
EMORY UNIVERSITY-HL11721-04:CELLULAR AND MOLECULAR MECHANISMS OF ACUTE LUNG	93.839		5 U01 HL117721-04	40,039	
EMORY UNIVERSITY-HL117721-05:CELLULAR AND MOLECULAR MECHANISMS OF ACUTE LUNG	93.839		5 U01 HL117721-05	1,378	
NATIONAL MARROW DONOR PROGRAM-BMT 1049 PROTOCOL #0702	93.839		BMT 1049 PROTOCOL#070	2,660	
ST. JUDE HOSPITAL-HL133996-01:RE-AIMING AT HYDROXYUREA ADHERENCE FOR SICKLE CE	93.839		1 U01 HL133996-01	38,602	
UNIVERSITY OF ILLINOIS-HL111656: VASCULAR TARTGETING GENOMIC GENETIC STRATEGIES	93.839		1 R01 HL11156	91,159	
VANDERBILT UNIVERSITY-HL106812-05L06 DISTINCT CONTRIBUTIONS OF MTOR COMPLEXES 1 &	93.839		2 R01 HL106812-05A1	(3,364)	
VANDERBILT UNIVERSITY-HL114518-03 PREVENTING GASTRODUODENAL BLEEDING IN ORAL AN	93.839		1 R01 HL114518-01A1	(339)	
VANDERBILT UNIVERSITY-HL117676-01 FREE HEMOGLOBIN POTENTIATES PULMONARY VASCULAR	93.839		1 R21 HL117676-01	1,206	
VANDERBILT UNIVERSITY-HL58837-17 PHYSIOLOGY & MOLECULAR BIOLOGY OF FACTOR XI	93.839		2 R01 HL58837-17	(1,356)	
VANDERBILT UNIVERSITY-HL69765-14 IMMUNOBIOLOG OF BLOOD AND VASCULAR SYSTEMS	93.839		5 T32 HL69765-14	994	
VANDERBILT UNIVERSITY-HL71544-13 MECHANISMS OF STAPHYLOCOAGULASE-ACTIVATED BLOOD	93.839		2 R01 HL71544-11A1	4,086	4,123
VIRGINIA COMMONWEALTH UNIVERSITY-HL107152-05: CHEMISTRY AND BIOLOGY OF HEPARAN SULFATE	93.839		5 P01 HL107152--05	3,118	
VIRGINIA COMMONWEALTH UNIVERSITY-HL107152-06:CHEMISTRY AND BIOLOGY OF HEPARAN SULFATE	93.839		4 P01HL107152-06	38,776	
Subtotal 93.839				**216,961**	**4,123**
BRIGHAM AND WOMEN'S HOSPITAL-AR55557-06: PARTIAL MENISCECTOMY VS NON-OPERATIVE MANAGE	93.846		5 R01 AR55557-06	(5)	
BRIGHAM AND WOMEN'S HOSPITAL-AR55557-10:PARTIAL MENISCECTOMY VS. NONOPERATIVE MGMT IN	93.846		4 R01 AR55557-10	8,711	
PENNSYLVANIA STATE UNIVERSITY-AR68247-01:TARGETING RAS GENE PATHWAYS IN PSORIATIC ARTHRITI	93.846		1 R21 AR68247-01	4,027	
PENNSYLVANIA STATE UNIVERSITY-AR68247-02:TARGETING RAS GENE PATHWAYS IN PSORIATIC ARTHRITI	93.846		5 R21 AR68247-02	72,939	
UNIVERSITY OF IOWA-AR63381-03 FIBROMYALGIA ACTIVITY WITH TENS (FAST) STUDY	93.846		5 UM1 AR63381-03	42,611	
UNIVERSITY OF IOWA-AR63381-04:FIBROMYALGIA ACTIVITY WITH TENS(FAST) STUDY	93.846		5 UM1 AR63381-004	212,782	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
UNIVERSITY OF KENTUCKY-AR70620-02:EFFECTS OF SODIUM-DEPENDENT GLUCOSE CO-TRANSPORTE	93.846		1 R21 AR70620-01	32,818	
VANDERBILT UNIVERSITY-AR064772-BIOFILM DISPERSIVE GRAFTS TO IMPROVE HEALING OF CON	93.846		1 R01 AR64772-01A1	20,447	
VANDERBILT UNIVERSITY-AR63157-01:04 THE ROLES OF COLLAGEN AND WATER IN THE FRACTUR	93.846		1 R01 AR63157-01	(20,324)	
VANDERBILT UNIVERSITY-AR64768-01:03 DRUG-DRUG INTERACTIONS & PREVENTABLE ADVER	93.846		1 K23 AR64768-01	3,923	
VANDERBILT UNIVERSITY-AR66875-01A1:02 THE MECHANICAL PHENOTYPE OF FETAL FIBROBLA	93.846		1 R03 AR66875-02	(3,104)	
VANDERBILT UNIVERSITY-AR66971-01 HDL-MEDIATED TRANSFER OF MICRORNA REGULATES AUTOI	93.846		1 R21 AR66971-01	(16)	
VANDERBILT UNIVERSITY-AR67901-01:02 IMMUNE CELLS AND CYTOKINES MEDIATING FIBRODYSP	93.846		1 R21 AR67901-01	196	
VANDERBILT UNIVERSITY-AR68443-01 FUNCTIONAL IMPACT OF HDL TRANSPORT OF MIRNA IN RH	93.846		1 K23 AR68443-01	(24,723)	
VANDERBILT UNIVERSITY-DO NOT USE - CORRECT CENTER 4-04-386-0123	93.846		2 T32 AR59039-06A1	11,194	
WAKE FOREST UNIVERSITY-AR59105: THE STRENGTH TRAINING FOR ARTHRITIS TRIAL (START)	93.846		1 R01 AR59105	30,067	
WASHINGTON UNIVERSITY IN ST. LOUIS-AR60846-01A1 - REVISION ACL RECONSTRUCTION: A COMPARATI	93.846		1 R01 AR60846-01A1	130,932	
WASHINGTON UNIVERSITY IN ST. LOUIS-AR60846-04:REVISION ACL RECONSTRUCTION: A COMPARATIVE EF	93.846		2 R01 AR60846-04	11,316	
Subtotal 93.846				**533,791**	
BECKMAN RESEARCH INSTITUTE-VANDERBILT HUMAN ISLET QUALITY CONTROL CORE FACILITY (VQCCF)	93.847		1 UC4 DK98085-01	345,145	
CASE WESTERN RESERVE UNIVERSITY-DK101074-01 HEARING IMPAIRMENT IN LONG-TERM TYPE 1 DIABETE	93.847		1 DP3 DK101074-01	13,742	
CASE WESTERN RESERVE UNIVERSITY-DK104438-01 CASE WEST RESIDUAL BETA CELL FUNCTION IN PATIENT	93.847		1 DP3 DK104438-01	24,341	
CASE WESTERN RESERVE UNIVERSITY-DK94157-04 CASE WESTERN EPIDEMIOLOGY OF DIABETES INTERVEN	93.847		5 U01 DK94157-04	43,516	
CASE WESTERN RESERVE UNIVERSITY-DK94157-06:EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COM	93.847		4 U01 DK94157-06	196,499	
COLUMBIA UNIVERSITY-DK104309-02: COLUMBIA UNIV-GENETIC ORIGINS AND COMPLICATIONS	93.847		U 54 DK104309	78,815	
CUMBERLAND PHARMACEUTICALS, INC.-DK106779-01A1:A SIMPLE AND EFFECTIVE DIAGNOSTIC TEST FOR	93.847		1 R41 DK106779-01A1	87,506	
DUKE UNIVERSITY-DK94116-04 DECISION SUPPORT INTERVENTIONS TO IMPROVE RENAL	93.847		1 R34 DK94116-04	(2)	
EPIGEN BIOSCIENCES, INC.-DK105654-01A1:NOVEL INTEGRIN INHIBITORS FOR KIDNEY FIBROSIS	93.847		1 R43 DK105654-01A1	60,544	
GEORGE WASHINGTON UNIVERSITY-DK98246-04 GLYCEMIA REDUCTION APPROACHES IN DIABETES:A COM	93.847		5 U01 DK98246-04	2,498	
GEORGE WASHINGTON UNIVERSITY-DK98246-04 GLYCEMIA REDUCTOIN APPROACHES IN DIABET	93.847		5 U01 DK98246-04	155,347	
GEORGE WASHINGTON UNIVERSITY-DK98246-05:GLYCEMIA REDUCTION APPROACHES IN DIABETES:A COM	93.847		4 U01 DK98246-05	612,239	
GEORGIA REGENTS UNIVERSITY/MEDICAL COLLEGE OF GA-DK76169-09 IDENTIFICATION OF NOVEL OXYGEN	93.847		5 U24 DK076169-09	9,513	
GEORGIA REGENTS UNIVERSITY/MEDICAL COLLEGE OF GA-DK76169-10:NONINVASIVE EVALUATON OF DIA	93.847		5 U24 DK76169-10	23,171	
GEORGIA REGENTS UNIVERSITY/MEDICAL COLLEGE OF GA-DK76169-10:PROOF-OF-CONCEPT TESTING OF A	93.847		5 U24 DK76169-10	26,164	
GEORGIA REGENTS UNIVERSITY/MEDICAL COLLEGE OF GA-DK76169-11: AUGUSTA: DISSECTING BIOFILM FO	93.847		2 U24 DK76169-11	50,316	
GEORGIA REGENTS UNIVERSITY/MEDICAL COLLEGE OF GA-DK76169-11:DIACOMP PILOT & FEASIBILITY PRO	93.847		2 U24 DK76169-11	42,328	
GEORGIA REGENTS UNIVERSITY/MEDICAL COLLEGE OF GA-DK76169-11:DIACOMP PILOT AND FEASIBILITY S	93.847		2 U24 DK76169-11	34,651	
GEORGIA REGENTS UNIVERSITY/MEDICAL COLLEGE OF GA-DK76169-11:PILOT & FEASIBILITY OF LYMPHATIC	93.847		2 U24 DK76169-11	28,773	
GEORGIA REGENTS UNIVERSITY/MEDICAL COLLEGE OF GA-DK76169-11:TESTING LOXL2 INHIBITORS FOR A	93.847		2 U24 DK76169-11	14,243	
HARVARD UNIVERSITY-DK81572-08:METABOLOMIC PREDICTORS OF INSULIN RESISTANCE	93.847		2 R01 DK81572-08	115,968	
MASSACHUSETTS GENERAL HOSPITAL-DK81572-07:METABOLOMIC PREDICTORS OF INSULIN RESISTANCE	93.847		2 R01 DK81572-07	24,275	
NATIONWIDE CHILDREN'S HOSPITAL-DK100866-03:INTEGRATIVE PROTEOMICS & METABOLOMICS FOR PED	93.847		5 UM1 DK100866-03	1,749	
NORTHWESTERN UNIVERSITY-DK100754-02 FGF23 & MINERAL METABOLISM - ACUTE KIDNEY INJU	93.847		5 R21 DK100754-02	15,941	
PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE-DK97829-01: ISLET BIOLOGY IN CYSTIC FIBROSIS RELA	93.847		1 R01 DK97829-01	306,318	81,883
POTENTIA PHARMACEUTICALS, INC.-DK109870-01:REDUCING TIME, SAMPLE HANDLING, AND STAFF REQUI	93.847		1 R43 DK109870-01	31,324	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
RECOMBINETICS, INC.-DK109820-01:GENERATING A PORCINE MODEL FOR HUMAN MICROVILLUS	93.847		1 R43 DK109820-01	63,366	
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY-DK102934-01 ENDOSOMAL CONTROL OF MICROBE-HOS	93.847		1 R01 DK102934-01	55,752	
SEATTLE CHILDREN'S HOSPITAL-DK104936:GLUCAGON-LIKE PEPTIDE-1 AGONIST EFFECTS ON ENERGY	93.847		1 R01 DK104936-01A	198,795	
SILICON KIDNEY LLC-DK102240-01 IMPLANTABLE HEMODIALYZER FOR TRMT OF END STAGE	93.847		1 R43 DK102240-01	19,431	
SILICON KIDNEY LLC-DK104299-01 AN INTRAVASCULAR BIOARTIFICIAL PANC	93.847		1 R43 DK104299-01	50,438	
STANFORD UNIVERSITY-DK92241-01A1: MIND THE KIDNEYS	93.847		1 R01 DK92241-01A1	980	
UNIVERSITY OF CENTRAL FLORIDA-DK94900-05:UCF: ROLE OF ACTIVIN A SIGNALING IN ESOPHAGAL	93.847		7 R01 DK94900-05	30,409	
UNIVERSITY OF CHICAGO-DK98435-02 VIRAL INFECTIONS & CELIAC DISEASE PATHOGENESIS	93.847		5 R01 DK98435-02	3,959	
UNIVERSITY OF COLORADO-DK90964-06: INTERRUPTING THE VICIOUS CYCLE OF OBESITY	93.847		2 R24 DK90964-06	212,113	200
UNIVERSITY OF KENTUCKY-UNIV KY THE INSULIN/IGF-I AXIS IN DIABETIC OSTEOPATHY	93.847		7 R01 DK84045-04	21,915	
UNIVERSITY OF MINNESOTA-DK87919-04: SPRINT - AMBULATORY BLOOD PRESSURE MONITORING AN	93.847		5 K23 DK87919-04	760	
UNIVERSITY OF NORTH CAROLINA-DK100867-02 GDCN CLINICAL CENTER-ADVANCING CLINICAL RESEARCH	93.847		5 UM1 DK100867-02	10,157	
UNIVERSITY OF NORTH CAROLINA-DK100867-03S1:GDCN CLINICAL CENTER- ADVANCING CLINICAL RESEA	93.847		3 UM1 DK100867-03S1	(1,133)	
UNIVERSITY OF NORTH CAROLINA-DK100867-04:CLINICAL CENTER-ADVANCING CLINICAL RES - PATIENT	93.847		5 UM1 DK100867-04	45,286	
UNIVERSITY OF NORTH CAROLINA-DK100867-04:GDCN CLINICAL CENTER-ADVANCING CLINICAL RESEARCH	93.847		5 UM1 DK100867-04	23,668	
UNIVERSITY OF PENNSYLVANIA-DK105689-01A1:FORMATION AND MATURATION OF ENDOCRINE PANCREA	93.847		1 R01 DK105689-01A1	100,788	200
UNIVERSITY OF PENNSYLVANIA-DK105689-02:FORMATION AND MATURATION OF ENDOCRINE PANCREAS	93.847		1 R01 DK105689-02	129,842	200
UNIVERSITY OF PITTSBURGH-DK69103-08S1 REGULATION OF RENAL PROGENITOR CELLS IN REGENER	93.847		3 R01 DK69103-08S1	26,529	
UNIVERSITY OF PITTSBURGH-DK97084-01: ECTOPIC ADIPOSITY IN BLACK MEN WITH HIGH TYPE 2	93.847		1 R01 DK97084-01	85,668	
UNIVERSITY OF SOUTH FLORIDA-TRIALNET REVENUE CENTER- ONGOING OPERATIONS ASS. W/ TRIALNET	93.847		5 U01 DK85465-07	367,383	
UNIVERSITY OF TEXAS-DK38217-24A1:REGULATION OF THICK ASCENDING LIMB ACID-BASE TR	93.847		1 R01 DK38217-24A1	1,593	
UNIVERSITY OF TEXAS-DK38217-25:REGULATION OF THICK ASCENDING LIMB ACID-BASE TRAN	93.847		5 R01 DK38217-25	8,181	
UNIVERSITY OF WASHINGTON-DK99165-02:BIOLOGICAL DETERMINANTS OF PERITONEAL DIALYSIS	93.847		5 R01 DK99165-02	3,879	
VANDERBILT UNIVERSITY-DK07061-41 RESEARCH TRAINING IN DIABETES AND ENDOCRINOLOGY	93.847		5 T32 DK07061-41	(3,041)	
VANDERBILT UNIVERSITY-DK07383-36 SRTP - STIPENDS	93.847		5 T35 DK07383-36	(121)	
VANDERBILT UNIVERSITY-DK07563-28 MULTIDISCIPLINE TRAINING-MOLECULAR ENDOCRINOLOGY	93.847		5 T32 DK07563-28	462	
VANDERBILT UNIVERSITY-DK07563-29:MULTIDISCIPLINARY TRAINING IN MOLECULAR ENDOCRINO	93.847		4 T32 DK07563-29	2,917	
VANDERBILT UNIVERSITY-DK07569-26 RENAL BIOLOGY AND DISEASE TRAINING PROGRAM	93.847		2 T32 DK7569-26	(1,608)	
VANDERBILT UNIVERSITY-DK07673-22 TRAINING IN GASTROENTEROLOGY	93.847		5 T32 DK07673-22	(1,721)	
VANDERBILT UNIVERSITY-DK084246-06 BRUTON'S TYROSINE KINASE & IMM TOL IN TYPE1 DIA	93.847		2 R01 DK84246-06	12	
VANDERBILT UNIVERSITY-DK100431-01 ROLE OF FOREGUT IN NUTRIENT METABOLISM IN	93.847		1 R01 DK100431-01	953	
VANDERBILT UNIVERSITY-DK100533-02 MITOCHONDRIAL DYSFUNCTION IN CHRONIC KIDN	93.847		1 K23 DK100533-01	(23)	
VANDERBILT UNIVERSITY-DK100694-01A1:02 IMPROVING MEDICATION ADHERENCE AMONG UNDERS	93.847		5 R01 DK100694-02	7,635	598
VANDERBILT UNIVERSITY-DK101038-01 MAPPING SEROTONIN RECEPTORS IN LOWER URINARY	93.847		1 U01 DK101038-01	(4,603)	
VANDERBILT UNIVERSITY-DK101332-01A1:02 INDUCTION & EVOLUTION OF METAPLASIA-STOMACH	93.847		5 R01 DK101332-02	(4,398)	
VANDERBILT UNIVERSITY-DK101342-01A1:02 MITOCHONDRIAL DNA HAPLOGROUPS AND DIABETES-	93.847		1 R21 DK101342-02	9,311	9,311
VANDERBILT UNIVERSITY-DK101689-01A1:02 EARLY ONSET OBESITY AND COGNITIVE IMPAIRMEN	93.847		1 K23 DK101689-01A1	(8,085)	
VANDERBILT UNIVERSITY-DK101791-01A1 METABOLIC REPROGRAMMING IN ACUTE KIDNEY INJURY	93.847		1 R01 DK101791-01A1	(28,491)	
VANDERBILT UNIVERSITY-DK103067-01:02 NOVEL INTEGRATED ANALYSES OF HUMAN DIABETIC N	93.847		1 R24 DK103067-01	(2,899)	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-DK103831-01A1:SPATIO-TEMPORAL DISSECTION - MAIN	93.847		1 R01 DL103831-01A1	3,789	
VANDERBILT UNIVERSITY-DK103910-01A1 AFFERENT HYPERACTIVITY MECH IN OVERACTIVE BLAD	93.847		1 K23 DK103910-01A1	108	
VANDERBILT UNIVERSITY-DK103935-01:02 DETERMINING KEY ORGANIZATIONAL HEALTH COMMUNI	93.847		1 R01 DK103935-01A1	108	69
VANDERBILT UNIVERSITY-DK104211-01 MOLECULAR MECHANISMS OF PHYSIOLOGIC B-CELL GROWT	93.847		1 UC4 DK104211-01	281,722	273,646
VANDERBILT UNIVERSITY-DK104817-01 ICD8ALPHA CELLS AS NOVEL INNATE-TYPE LYMPHOID CE	93.847		1 R01 DK104817-01	775	
VANDERBILT UNIVERSITY-DK105149-02:LASER-BASED MASS SPECTROMETRY ANALYSIS OF SINGLE	93.847		5 R33 DK105149-02	22,612	
VANDERBILT UNIVERSITY-DK105371-01 NON-INVASIVE ASSESSMENT OF HUMAN BROWN ADIPOSE T	93.847		1 R01 DK105371-01	(20)	
VANDERBILT UNIVERSITY-DK105550-03EXPLOITING METABOLIC VULNERABILITIES OF CD4 T	93.847		5 R01 DK105550-03	11,567	12,998
VANDERBILT UNIVERSITY-DK105847-01:02 BILE DIVERSION: A SIMPLE AND EFFECTIVE METHOD	93.847		1 R01 DK105847-01	23,541	
VANDERBILT UNIVERSITY-DK106228-01A1 MICROTUBE REG-PANCREATIC BETA CELL-ANIMAL CARE	93.847		1 R01 DK106228-01A1	6,227	
VANDERBILT UNIVERSITY-DK106228-02:MICROTUBULE REGULATION OF PANCREATIC BETA CELL	93.847		5 RO1 DK106228-02	2,520	
VANDERBILT UNIVERSITY-DK106364-01A1:EFFECT OF LIVER GLYCOGEN CONTENT ON HYPOGLYCEM	93.847		1 R01 DK106364-01	13,214	
VANDERBILT UNIVERSITY-DK106472-01 MECHANISMS - CELLULAR ADAPTATION IN CYSTITIS	93.847		1 K08 DK106472-01	414	
VANDERBILT UNIVERSITY-DK106511-01 ENHANCING PATIENT ACTIVATION IN DIABETES CARE US	93.847		1 K23 DK106511-01	(2)	
VANDERBILT UNIVERSITY-DK106755-01: PANCREATIC SIGNATURES IN T2D MELLITUS-POWERS	93.847		1 R24 DK106755-01	27,852	27,812
VANDERBILT UNIVERSITY-DK108120-01:HIGH-RESOLUTION ANALYSIS OF JUVENILE PANCREAS	93.847		1 UC4 DK108120-01	216,349	180
VANDERBILT UNIVERSITY-DK108120-01S1:HIGH-RESOLUTION ANALYSIS OF JUVENILE HUMAN PAN	93.847		3 UC4 DK108120-01S1	9,028	
VANDERBILT UNIVERSITY-DK108352-01 INNATE AND ADAPTIVE IMMUNITY IN HIV-ASSOCIATED	93.847		1 R56 DK108352-01	(2,519)	(6,056)
VANDERBILT UNIVERSITY-DK18381-43 STUDIES ON THE STRUCTURE OF BASEMENT MEMBRANES	93.847		2 R01 DK18381-43	1,044	
VANDERBILT UNIVERSITY-DK20593-37 DRTC ADMINISTRATIVE COMPONENT	93.847		5 P30 DK20593-37	(10,440)	
VANDERBILT UNIVERSITY-DK38226-27 ROLE OF EICOSANOIDS IN RENAL FUNCTION-PROJECT 4	93.847		5 P01 DK38226-27	(1,079)	
VANDERBILT UNIVERSITY-DK48370-21 SMALL GTP BINDING PROTEINS IN GASTROINTESTINAL	93.847		2 R01 DK48370-19A1	77	
VANDERBILT UNIVERSITY-DK50435-16:19 ASCORBIC ACID FUNCTION AND METABOLISM	93.847		5 R01 DK050435-19	(5,595)	
VANDERBILT UNIVERSITY-DK51265-19:20 MECHANISMS OF EGFR ACTIVATION AND SIGNALING IN	93.847		2 R01 DK51265-19	(186,055)	
VANDERBILT UNIVERSITY-DK53620-11:14 H PYLORI INDUCED DNA DAMAGE AND IMMUNE DYSREG	93.847		2 R01 DK53620-11	14,040	
VANDERBILT UNIVERSITY-DK54902-16A1:INTEGRATED CONTROL OF MUSCLE GLUCOSE UPTAKE	93.847		2 R01 DK54902-16A1	38,060	
VANDERBILT UNIVERSITY-DK56942-10A1 RESOLUTION OF GLOMERULOSCLEROSIS	93.847		2 R01 DK56942-10A1	(16,450)	
VANDERBILT UNIVERSITY-DK58404-14 MOLECULAR AND CELLULAR BASIS - ADMIN CORE	93.847		5 P30 DK58404-14	(8,217)	
VANDERBILT UNIVERSITY-DK58587-10:13 HELICOBACTER PYLORI AND GASTROINTESTINAL BIO	93.847		5 R01 DK58587-13	3,708	
VANDERBILT UNIVERSITY-DK58697-9:11 BIOMAGNETIC CHARACTERIZATION OF GASTRIC/PHYSI	93.847		2 R01 DK58697-09A1	(1,259)	
VANDERBILT UNIVERSITY-DK59637-15:VANDERBILT MOUSE METABOLIC PHENOTYPING CENTER	93.847		5 U24 DK59637-15	81,260	
VANDERBILT UNIVERSITY-DK59637-16:VANDERBILT MOUSE METABOLIC PHENOTYPING CENTER	93.847		2 UC2 DK59637-16	251,708	
VANDERBILT UNIVERSITY-DK60667-13: VU: LIVER GLUCOSE FLUX IN OBESITY AND DIABETES	93.847		2 R01 DK60667-13	1,436	
VANDERBILT UNIVERSITY-DK65138-11 GLUCOSE MODIFICATION OF PROTEINS IN DIABETIC N	93.847		2 R01 DK65138-10	856	
VANDERBILT UNIVERSITY-DK69921-10:11 THE LAMININ RECEPTORS IN KIDNEY DEVELOPMENT	93.847		5 R01 DK69921-11	(286)	
VANDERBILT UNIVERSITY-DK70856-06:9 MOLECULAR CHARACTERISTICS OF THE APICAL RECYC	93.847		2 R01 DK70856-06	17,095	
VANDERBILT UNIVERSITY-DK75594-06 BETAL INTEGRIN AND RENAL TUBULOGENISIS	93.847		2 R01 DK75594-05	(31)	
VANDERBILT UNIVERSITY-DK76169-09:THE IMPACT OF BILE ACID FLUX ON INSULIN ACTION	93.847		5 U24 DK76169-09	12,712	
VANDERBILT UNIVERSITY-DK78158-06 REVISED NEURAL CREST CONTRIBUTIONS TO THE LOWER	93.847		5 R01 DK78158-06	193	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-DK81134-06:07 REGULATION OF INTESTINAL DEVELOPMENT BY A LACT	93.847		2 R01 DK81134-06A1	(895)	
VANDERBILT UNIVERSITY-DK81536-01A2:4 GLYCOLIPID-REACTIVE NKT CELLS, OBESITY AND IN	93.847		1 R01 DK81536-01A2	28,238	
VANDERBILT UNIVERSITY-DK82192-08 IMPACT OF ACUTE KIDNEY INJURY ON KIDNEY DISEASE P	93.847		5 U01 DK82192-08	236	
VANDERBILT UNIVERSITY-DK83187-01A2:4 STRUCTURE FUNCTION ANALYSIS OF INEGRINS ALPHA	93.847		1 R01 DK83187-01A2	(997)	
VANDERBILT UNIVERSITY-DK83264-01A2:5 PUBLIC-PRIVATE PARTNERSHIP ADDRESSING LITERAC	93.847		1 R18 DK83264-01A2	5,617	
VANDERBILT UNIVERSITY-DK85465-07 VANDERBILT UNIVERSITY: CLINICAL CENTER APPLICATI	93.847		5 U01 DK85465-07	4,345	
VANDERBILT UNIVERSITY-DK90304-03:05 DEVELOPING, VALIDATING, AND IMPLEMENTING A CKD	93.847		7 K23 DK90304-03	480	688
VANDERBILT UNIVERSITY-DK91748-01:3 RYGB IMPROVES METABOLISM BY INTERUPTING THE	93.847		1 R01 DK91748-01A1	(7,348)	(1,457)
VANDERBILT UNIVERSITY-DK92357-05 PROTEIN HANDLING BY RENAL TUBULE EPITHELIAL	93.847		7 K01 DK092357-02	50	
VANDERBILT UNIVERSITY-DK92986-05 CDTR ADMINISTRATIVE CORE	93.847		5 P30 DK92986-05	20,282	19,344
VANDERBILT UNIVERSITY-DK93501-01A1:4 KINASE MODULATION OF NA+-DEPENDENT CI-COUPLE	93.847		1 R01 DK93501-01A1	(30,389)	(29,670)
VANDERBILT UNIVERSITY-DK93660-03:05 NOVEL CELL THERAPY FOR ANEMIA OF CKD-TRANSFER	93.847		7 R01 DK93660-03	(65)	
VANDERBILT UNIVERSITY-DK94199-01:3 ISLET IMAGING WITH MONOCLONAL ANTIBODIES-PARENT	93.847		1 R01 DK94199-01	1,338	123
VANDERBILT UNIVERSITY-DK95761-01A1 INTEGRIN/TGF-BETA AXIS IN TUBULOINTERSTITIAL	93.847		1 R01 DK95761-01A1	(2,051)	
VANDERBILT UNIVERSITY-DK95785-03 ROLE OF RENAL MACROPHAGES IN RECOVERY FROM ACUT	93.847		1 R01 DK95785-01A1	(35,569)	
VANDERBILT UNIVERSITY-DK96994-01:03 ENDOGENOUS ALDOSTERONE & GLUCOSE HOMEOST	93.847		1 R01 DK96994-01A1	991	2,521
VANDERBILT UNIVERSITY-DK96999-04 UNDERGRADUATE RESEARCH INTERNSHIPS IN PATHOBIOLOG	93.847		3 R25 DK96999-04	(2,259)	
VANDERBILT UNIVERSITY-DK97332-01:04 ROLE OF CD148 TYROSINE PHOSPHASE IN DIABETIC N	93.847		1 R01 DK97332-01	29	
VANDERBILT UNIVERSITY-DK97706-01:USING SOCIAL LEARNING TO IMPROVE ADOLESCENT DIABE	93.847		1 DP3 DK97706-01	40,253	
VANDERBILT UNIVERSITY-DK99204-01:02 SELENIUM IN GASTROINTESTINAL INFLAMMATORY DISE	93.847		5 R01 DK99204-02	(14,152)	
VANDERBILT UNIVERSITY-DK99467-01:03 COLLAGEN IV NETOWRKS OF BASEMENT MEMBRANES	93.847		1 R01 DK99467-01	42	
VANDERBILT UNIVERSITY-HL117074-03 MICROBIAL INDUCTION OF SARCOIDOSIS CD4+ T CELL D	93.847		5 R01 HL117074-03	(45,949)	9,191
VIRTUAL DRUG DEVELOPMENT-DK104638-01 DEVELOPMENT OF COMPOUNDS TO PREVENT RHABDOMYOL	93.847		1 R41 DK104638-01	(26,460)	
VIRTUAL DRUG DEVELOPMENT-DK104638-01:DEVELOPMENT OF COMPOUNDS TO PREVENT RHABDOMYOL	93.847		1 R41 DK1046338-01	37,705	7,041
WASHINGTON UNIVERSITY IN ST. LOUIS-DK111175-01:ROLE OF CD36 IN NUTRIENT DELIVERY AND ITS DYSF	93.847		1 R01 DK111175-01	70,881	
WASHINGTON UNIVERSITY IN ST. LOUIS-DK96982-03:0TAUROURSODEOXYCHOLIC ACID FOR PROTEASE-INH	93.847		5 RO1 DK96982-03	12,625	
Subtotal 93.847				**4,638,024**	**408,824**
CLEVELAND CLINIC FOUNDATION-AR53684-10: PROGNOSIS AND PREDICTORS OF ACL RECONSTRUCTION:	93.853		2 R01 AR53684-10	417,547	
JOHNS HOPKINS UNIVERSITY-NS80824:NIH/JHU - MISTIE III-A PHASE III RANDOMIZED, OPEN LA	93.853		5 U01 NS80824	43,001	
MASSACHUSETTS GENERAL HOSPITAL-NS88312-01: NN104 RHAPSODY 3K3A-APC IN ISCHEMIC STROKE	93.853		U01 NS88312-01	16,385	
MASSACHUSETTS GENERAL HOSPITAL-NS88312-01:NN105 (AVN011)STUDY TO DETERMINE TOLERABILITY I	93.853		U01 NS88312-01	24,331	
MASSACHUSETTS GENERAL HOSPITAL-NS90259-02:PHASE 3 TRIAL OF INOSINE FOR PARKINSON'S DISEASE	93.853		1 U01 NS90259-02	17,876	
MASSACHUSETTS GENERAL HOSPITAL-STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND ACTIVITY OF	93.853		NN102: NEURONEXT	28,452	
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH-NS80168-03:CAROTID REVASCULARIZATIO	93.853		5 U01 NS80168-03	151	
MEDICAL COLLEGE OF WISCONSIN-NS35929-14:PRESURGICAL APPLICATIONS OF FMRI IN EPILEPSY	93.853		5 R01 NS35929-14	7,407	
MICHIGAN STATE UNIVERSITY-NS95656-01A1:BDNF RS6265 AND RESPONSE TO DOPAMINERGIC THERAP	93.853		1 R21 NS95656-01A1	12,993	
NEUROTARGETING, LLC-MH100007-03: A WEB-BASED PHYSIOLOGICAL BRAIN ATLAS FOR IMPLA	93.853		9 R42 MH100007-03	51,896	50,823
OPTIMA NEUROSCIENCE, INC.-NS64647-05A1:HIGH PERFORMANCE SEIZURE MONITORING AND ALERT	93.853		2 R44 NS64647-05A1	9,767	
OPTIMA NEUROSCIENCE, INC.-NS64647-06:HIGH PERFORMANCE SEIZURE MONITORING AND ALERT	93.853		2 R44 NS64647-06	60,538	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
THE EMMES CORPORATION-NS26835-01A1 - PLATELET-ORIENTED INHIBITION IN NEW TIA	93.853		1 U01 NS26835-01A	10,533	
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO-NS26835-01A1:PLATELET-ORIENTED INHIBITION IN NEW TI	93.853		1 U01 NS26835-01A1	3,795	
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO-NS92764-01A1:HIGH-DOSE ERYTHROPOIETIN FOR ASPHYXI	93.853		1 U01 NS92764-01A1	13,641	
UNIVERSITY OF CINCINNATI-NS92076-01A1:DEFUSE 3 ENDOVASCULAR THERAPY FOLLOWING IMAGING	93.853		1 U01 NS92076-01A1	10,402	
UNIVERSITY OF FLORIDA-NS82244-01: RLS: PATHOPHYSIOLOGY USING BTBD9 CONDITIONAL KNO	93.853		1 R01 NS82244-01	9,308	
UNIVERSITY OF PITTSBURGH-NS81041-03:APPROACHES AND DECISIONS FOR ACUTE PEDIATRIC TBI	93.853		5 U01 NS81041-03	6,196	
UNIVERSITY OF ROCHESTER-NS61799-03: DOUBLE BLIND RANDOMIZED TRIAL	93.853		5 U01 NS61799-03	14	
UNIVERSITY OF TENNESSEE-NS94595-01A1:EFFECTS OF MODIFIED ERYTHROPOIETIN ON COGNITION	93.853		1 R01 NS94595-01A1	17,210	
VANDERBILT UNIVERSITY-NS049251-08 MULTIMODAL REGISTRATION OF THE BRAINS-MAINCENTER	93.853		2 R01 NS49251-08/12	(18)	
VANDERBILT UNIVERSITY-NS058639-THE BIOLOGICAL BASIS OF DIFFUSION-RADIOLOGY	93.853		2 R01 NS58639-05/08	53,589	
VANDERBILT UNIVERSITY-NS087796-DEBULKING FRM WITHIN:A STEERABLE (SURG RESEARCH	93.853		1 R21 NS87796-01/02	(10)	
VANDERBILT UNIVERSITY-NS096238-01: VU: QUANTIFYING DIFFERENCES IN MTOR ACTIVITY	93.853		1 R01 NS96238-01	14,341	
VANDERBILT UNIVERSITY-NS096238-02:VU: QUANTIFYING DIFFERENCES IN MTOR ACTIVITY	93.853		5 R01 NS96238-02	3,947	
VANDERBILT UNIVERSITY-NS33300-21 GABA(A) RECEPTOR ASSEMBLY/TRAFF/FUNC AND EPILEPSY	93.853		4 R01 NS33300-21	(31,035)	
VANDERBILT UNIVERSITY-NS49251-10:MULTIMODAL REGISTRATION OF BRAIN-NEUROSURGERY	93.853		2 R01 NS49251-10	70,253	
VANDERBILT UNIVERSITY-NS65736-07 AUTONOMIC RARE DISEASE CLIN RESH CONSORT - ADMIN	93.853		2 U54 NS65736-07	57,325	97,350
VANDERBILT UNIVERSITY-NS66927-06:07 PATHOPHYSIOLOGY OF CONDUCTION BLOCK IN HNPP	93.853		5 R01 NS66927-07	(38,859)	
VANDERBILT UNIVERSITY-NS69909-01A1:05 REPRESENTATION OF NOCICEPTION IN SII	93.853		5 R01 NS69909-04	(737)	
VANDERBILT UNIVERSITY-NS69909-05 REPRESENTATION OF NOCICEPTION IN SII AND THALAMUS	93.853		4 R01 NS69909-05	(5,039)	
VANDERBILT UNIVERSITY-NS7491-15 TRAINING PROGRAM IN ION CHANNEL AND TRANSPORTER BI	93.853		5 T32 NS7491-15	10,528	
VANDERBILT UNIVERSITY-NS75270-05 MRI STRUCTURAL AND FUNCTIONAL CONNECTIVITY CHANGE	93.853		4 R01 NS75270-05	(201)	
VANDERBILT UNIVERSITY-NS78289-01A1:4 REGULATION OF NEUROGENESIS IN TSC BY MTORC1	93.853		5 R01 NS78289-03	3,342	
VANDERBILT UNIVERSITY-NS78291-04:CAMKIT, ENDOCANNABINOIDS, SYNAPTIC PLASTICIT	93.853		5 R01 NS78291-04	59,040	
VANDERBILT UNIVERSITY-NS78680-01A1:04 BIOPHYSICAL BASIS OF FUNCATIONAL CONNECTIVIT	93.853		5 R01 NS78680-04	(256)	
VANDERBILT UNIVERSITY-NS78828-01A1:4 CHARACTERIZING HEMODYNAMIC COMPENSATION AND	93.853		5 R01 NS78828-04	1,083	
VANDERBILT UNIVERSITY-NS80988-01A1:03 DOPAMINE EFFECTS ON MESOCORTICOLIMBIC FUNCT	93.853		5 K23 NS80988-03	(100,845)	
VANDERBILT UNIVERSITY-NS81492-02 SEROTONIN TRANSPORTER-MEDIATED REGULATION OF NE	93.853		1 R21 NS81492-01A1	(77)	
VANDERBILT UNIVERSITY-NS82635-01A1:03 ALTERED SYNAPSE FORMATION AND FUNCTION IN A	93.853		1 R01 NS82635-01A1	(9)	
VANDERBILT UNIVERSITY-NS83710-01 MTOR MODULATION OF MYELINATION	93.853		1 K08 NS83710-01	17	
VANDERBILT UNIVERSITY-NS86423-03:GAMMA-KETOADEHYDES IN EPILEPTOGENESIS	93.853		5 R01 NS86423-03	3,162	
VANDERBILT UNIVERSITY-NS86423-03:GAMMA-KETOALDEHYDES IN EPILEPTOGENEISIS	93.853		5 R01 NS86423-03	12,460	
VANDERBILT UNIVERSITY-NS86492-03 THE VANDERBILT STROKE TRIALS NETWORK	93.853		5 U10 NS86492-03	(66)	
VANDERBILT UNIVERSITY-NS92961-01A1 RESTING STATE CONNECTIVITY IN PRIMATE SPINAL CO	93.853		1 R01 NS92961-01A1	(37,012)	
VANDERBILT UNIVERSITY-NS93669-01A1 RESTING STATE CONNECTIVITY IN WHITE MATTER	93.853		1 R01 NS93669-01A1	(17,052)	
VANDERBILT UNIVERSITY-NS94041-01 PRIMARY PREVENTION OF STROKE IN CHILDREN WITH SCD	93.853		1 R01 NS94041-01	25,211	21,216
VANDERBILT UNIVERSITY-NS95291-09A1:COMPUTER-ASSISTED FUNCTIONAL NEUROSURGERY	93.853		9 R01 NS95291-09A1	129,720	
VANDERBILT UNIVERSITY-NS95291-09A1:DO NOT USE -USE 404-738-0123 INSTEAD	93.853		9 R01 NS95291	(121)	
VANDERBILT UNIVERSITY-NS96127-01 MRI-BASED QUANTITATIVE BRAIN OXYGEN METABOLISM ID	93.853		1 R01 NS96127-01	(2,064)	
Subtotal 93.853				**972,061**	**169,389**

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY-AI96299-07:CENTRAL AFRICA INTERNATI	93.855		2 U01 AI96299-07	74,561	
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON-AI109565-03: INT058A1 EXTEND: IMMUNE TOLERA	93.855		5 UM1 AI109565-03	41,730	
BRIGHAM AND WOMEN'S HOSPITAL-5 UM1 AI68636-10: ACTG-PF	93.855		5 UM1 AI68636-10	(876)	
BRIGHAM AND WOMEN'S HOSPITAL-AI106701-03:HUMAN DNA REPOSITORY SUPPORT LABORATORY	93.855		5 UM1 AI106701-03	94,877	
BRIGHAM AND WOMEN'S HOSPITAL-AI106701-04:HUMAN DNA REPOSITORY SUPPORT LABORATORY	93.855		5 UM1 AI106701-04	65,160	
BRIGHAM AND WOMEN'S HOSPITAL-AI68636-10: ACTG-PF	93.855		5 UM1 AI68636-10	232,501	
BRIGHAM AND WOMEN'S HOSPITAL-AI68636-10:ACTG-F GUARANTEED CORE FUNDS	93.855		5 UM1 AI68636-10	87,074	
BRIGHAM AND WOMEN'S HOSPITAL-AI68636-10:ACTG-PF GUARANTEED CORE FUNDS	93.855		5 UM1 AI68636-10	(3,291)	
BRIGHAM AND WOMEN'S HOSPITAL-AI68636-11: ACTG-PF	93.855		5 UM1 AI68636	183,283	
BRIGHAM AND WOMEN'S HOSPITAL-AI68636-11:ACTG-F GUARANTEED CORE FUNDS	93.855		5 UM1 AI68636-11	140,285	
CONSORTIUM OF EOSINOPHILIC GASTROINTESTINAL DISEASE RESEARCH-AI117804:TRAINING GRANT - CON	93.855		1 U54 AI17804	27,678	
DUKE UNIVERSITY-AI104681-02 PROVIDE: VACOMYCIN EXPOSURE, MRSA BLOOD INFECTIO	93.855		5 UM1 AI104681-02	7,841	
DUKE UNIVERSITY-AI104681-04:ARLG - ANTIBACTERIAL RESISTANCE	93.855		4 UM1 AI104681-04	24,103	
DUKE UNIVERSITY-AI104681-05:ANTIBACTERIAL RESISTANCE LEADERSHIP GROUP (ARLG)	93.855		4 UM1 AI104681-05	37,495	
FAMILY HEALTH INTERNATIONAL-AI68619:HIV PREVENTION TRIALS NETWORK (HPTN) LEADERSHIP	93.855		UM1 AI68619	75,037	
FAMILY HEALTH INTERNATIONAL-AI68619:HPTN 083 PROTOCOL FUNDING	93.855		UM1 AI68619	152,840	138,200
FRED HUTCHINSON CANCER RESEARCH CENTER-5 UM1 AI68614-11 - HVTN PROTOCOL FUNDING	93.855		5 UM1 AI68614-11	245,011	
FRED HUTCHINSON CANCER RESEARCH CENTER-AI68614-09: HVTN PROTOCOL FUNDING - PF	93.855		2 UM1 AI68614-09	(107)	
FRED HUTCHINSON CANCER RESEARCH CENTER-AI68614-10:HVTN 704/HPTN 085 PROTOCOL FUNDING (PF)	93.855		5 UM1 AI68614-10	277,190	
FRED HUTCHINSON CANCER RESEARCH CENTER-AI68614-10:HVTN INITIATIVES PROGRAM (HIP) - PILKINTO	93.855		5 UM1 AI68614-10	273	
FRED HUTCHINSON CANCER RESEARCH CENTER-AI68614-10:HVTN PROTOCOL FUNDING (PF)	93.855		5 UM1 AI68614-10	202,740	
FRED HUTCHINSON CANCER RESEARCH CENTER-AI68614-11: HVTN 704 / 085 AMP STUDY PROTOCOL FUND	93.855		5 UM1 AI68614-11	457,435	
FRED HUTCHINSON CANCER RESEARCH CENTER-AI68614-11:HVTN INITIATIVES PROGRAM (HIP) - PILKINTO	93.855		5 UM1 AI68614-11	26,974	
FRED HUTCHINSON CANCER RESEARCH CENTER-CA163438-06: BMT 1035 IMMUNE MEDIATED DISORDERS	93.855		U54 CA163438-06	(5,950)	
HARVARD UNIVERSITY-AI112339-01 NEW METHODS FOR DESIGN& EVALUATION OF LARGE HIV	93.855		1 R01 AI112339-01	24,408	
HENRY M. JACKSON FOUNDATION-AI121517-01:HELICOBACTER PYLORI CAGA TOXIN POLYMORPHISM	93.855		1 R21 AI121517-01	8,223	
INDIANA UNIVERSITY-PURDUE UNIVERSITY INDIANAPOLIS-AI89911-10:EAST AFRICA IEDEA REGIONAL CONS	93.855		5 U01 AI89911-10	21,732	
IQUITY LABS, INC.-AI12476601-01:LONG NON-CODING RNA SIGNATURES TO CLASSIFY MUL	93.855		1 R43 AI124766-01	48,808	
IQUITY LABS, INC.-AI129147-01:LONG NON-CODING RNA SIGNATURES TO DISINQUISH FIB	93.855		1 R43 AI129147-01	17,762	
JOHNS HOPKINS UNIVERSITY-AI68632-09:LOC-IMPAACT LEADERSHIP GROUP	93.855		2 UM1 AI68632-09	5,662	
JOHNS HOPKINS UNIVERSITY-AI68632-11:LOC-IMPAACT LEADERSHIP GROUP	93.855		2 UM1 AI68632-11	5,475	
JOHNS HOPKINS UNIVERSITY-AI69918-10 NORTH AMERICAN AIDS COLLABORATION ON RESEARCH	93.855		5 U01 AI69918-10	9,290	
JOHNS HOPKINS UNIVERSITY-AI69918-11:NORTH AMERICAN AIDS COLLABORATION ON RESEARCH	93.855		5 U01 AI69918-11	75,600	
MEHARRY MEDICAL COLLEGE-AI122960-01A1:MEHARRY: ROLE OF THE VIRAL CAPSID IN HIV-1	93.855		1 R56 AI122960-01A1	65,888	
NEW YORK UNIVERSITY-AI105129-03: NYU - CONTRIBUTION OF LUKED TO STAPHYLOCOCCUS	93.855		5 R01 AI105129-03	5,249	
NEW YORK UNIVERSITY-AI105129-04:CONTRIBUTION OF LUKED TO STAPHYLOCOCCUS PATHOBIO	93.855		5 R01 AI105129-04	6,222	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-AI109680-03: ANTIVIRAL DRUG DISCOVERY AND DEVELOPMEN	93.855		5 U19 AI109680-03	352,324	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-AI109680-04:ANTIVIRAL DRUG DISCOVERY AND DEVELOPMEN	93.855		5 U19 AI109680-04	79,447	
UNIVERSITY OF CALIFORNIA, BERKELEY-AI106695 PROTECTIVE IMMUNITY FOLLOWING DENGUE VIRUS NAT	93.855		1 P01 AI106695-01A1	22,093	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
UNIVERSITY OF CALIFORNIA, BERKELEY-AI106695-02:PROTECTIVE IMMUNITY FOLLOWING DENGUE VIRUS	93.855		1 P01 AI106695-02	285,836	
UNIVERSITY OF EDUARDO MONDLANE-AI112295-03:BACTEREMIA IN HIV-INFECTED CHILDREN U5, HOSPITA	93.855		1 R01 AI112295-03	44,110	
UNIVERSITY OF EDUARDO MONDLANE-AI12295-02:BACTEREMIA IN HIV INFECTED CHILDREN UNDER 5 YRS	93.855		1 R01 AI112295-02	7,269	
UNIVERSITY OF FLORIDA-AI103348-01: THE STRUCTURAL AND FUNCTIONAL BASIS OF HLA-ASSO	93.855		1 R01 AI103348-01	90,510	
UNIVERSITY OF HAWAII-AI89999-07:SELENOPROTEIN K MODULATES CALCIUM-DEPENDENT SIGNA	93.855		5 R01 AI89999-07	19,226	
UNIVERSITY OF MICHIGAN-SEXUAL MODULATIONS OF HIV-RELEVANT VAGINAL IMMUNITY	93.855		5 R01 AI94563-05	49,147	
UNIVERSITY OF NORTH CAROLINA-AI107731-03: MOLECULAR BASIS OF DENGUE VIRUS NEUTRALIZATION	93.855		5 R01 AI107731-03	506	
UNIVERSITY OF PITTSBURGH-AI85062-07A1:HOST DETERMINIANTS OF HUMAN METAPNEUMOVIRUS	93.855		2 R01 AI85062-07A1	19,306	
UNIVERSITY OF SOUTHERN CALIFORNIA-AI117211-02:USC: TRANSFERRIN COMBINATION THERAPY TO ADD	93.855		5 R01 AI117211-02	3,901	
UNIVERSITY OF TEXAS-AI109711-03:ADVANCEMENT OF TREATMENTS FOR EBOLA AND MARBURG	93.855		5 U19 AI109711-03	359,272	5,655
UNIVERSITY OF TEXAS-AI109711-04:ADVANCEMENT OF TREATMENTS FOR EBOLA AND WARBURG	93.855		5 U19 AI109711-04	104,322	
UNIVERSITY OF TEXAS-AI70412-10:IDENTIFYING AND COMPARING THE SHARED GENETIC RISK	93.855		5 U19 AI70412-10	111,505	
VANDERBILT UNIVERSITY-AI073843-06:07 PATHOBIOLOGY OF HEME INDUCIBLE TRANSPORTERS I	93.855		5 R01 AI73843-07	159	
VANDERBILT UNIVERSITY-AI07474-21 VANDERBILT INFECTION PATHOGENESIS AND EPIDEMIOLOG	93.855		2 T32 AI07474-21	(22,185)	
VANDERBILT UNIVERSITY-AI100700-01A1:4 THE ROLE OF OBESITY AND ADIPOCYTES IN IMMUNE	93.855		5 K23 AI100700-03	(6,181)	
VANDERBILT UNIVERSITY-AI101171-04 HOST-MEDIATED ZINC SEQUESTRATION DURING ACINET	93.855		4 R01 AI101171-04	200	
VANDERBILT UNIVERSITY-AI103038-01:04 KEY DETERMINANTS OF DENGUE VIRUS NEUTRALIZATI	93.855		1 K08 AI103038-04	257	
VANDERBILT UNIVERSITY-AI103834-01 HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES FOR RIF	93.855		1 R21 AI103834-01	215	
VANDERBILT UNIVERSITY-AI104336-04 CHRONIC GRAFT DESTRUCTION: INTERPLAY OF ALLO	93.855		4 U01 AI104336-04	89,932	89,749
VANDERBILT UNIVERSITY-AI104352-03 TUBERCULOSIS RISK & HIGHLY ACTIVE ANTIRETROVIR	93.855		1 K08 AI104352-01A1	(165)	
VANDERBILT UNIVERSITY-AI104779-01:03 DEVELOPMENT & VALIDATION OF A CLINICAL PREDIC	93.855		5 K23 AI104779-03	600	
VANDERBILT UNIVERSITY-AI104779-04 DEVELOPMENT AND VALIDATION OF A CLINICAL PREDICT	93.855		4 K23 AI104779-04	(2,159)	
VANDERBILT UNIVERSITY-AI106002-01:04 MOLECULAR DETERMINANTS OF CROSS-REACTIVE ANTI	93.855		1 R01 AI106002-01	(19,709)	
VANDERBILT UNIVERSITY-AI106420-01A1:02 FLUOROQUINOLONE RESISTANCE IN PATIENTS WITH	93.855		1 K08 AI106420-02	243	225
VANDERBILT UNIVERSITY-AI107052-01A1: TWO-COMPONENT SYSTEM INTERACTIONS A UROPATHOG	93.855		1 R01 AI107052-01A1	66	
VANDERBILT UNIVERSITY-AI108778-03:COPN MECHANISM AS A KEY TO UNDERSTAND TYPE THREE	93.855		5 R01 AI108778-03	9,959	
VANDERBILT UNIVERSITY-AI109690-01:02 NOVEL BIOCHEMICAL AND FUNCTIONAL TARGETS	93.855		1 R21 AI109690-01	171	
VANDERBILT UNIVERSITY-AI110527-01A1 TN-CFAR - ADMIN CORE	93.855		1 P30 AI110527-01A1	223,056	216,610
VANDERBILT UNIVERSITY-AI111820-01:03 PGI2 REGULATION OF TSLP-MEDIATED ALLERGIC INF	93.855		5 R01 AI111820-02	41	
VANDERBILT UNIVERSITY-AI112541-02:CHEMICAL BIOLOGY OF INFECTIOUS DISEASE(CBID)	93.855		5 T32 AI112541-02	8,954	
VANDERBILT UNIVERSITY-AI113107-02 HOST-PATHOGEN INTERACTIONS DURING OSTEOMYE	93.855		1 K08 AI113107-01	(60)	
VANDERBILT UNIVERSITY-AI113150-01:02 EVALUATING THE FUNCTIONAL ANTIBODY RESPONSE	93.855		5 K23 AI113150-02	(5)	
VANDERBILT UNIVERSITY-AI113292-01A1:02 FIT TO REMEMBER? B CELL METABOLIC 'FITNESS'	93.855		1 R01 AI113292-01A1	3,369	
VANDERBILT UNIVERSITY-AI114339-01 A COMPETITION BINDING ASSAY FOR IDENTIFYING NOVE	93.855		1 R01 AI1114339-01	(9)	
VANDERBILT UNIVERSITY-AI114816-01A1:02 VUMC-STRUCTURAL AND FUNCTIONAL BASIS CHKV	93.855		1 R01 AI114816-01A1	1,326	
VANDERBILT UNIVERSITY-AI115419-01:02 CHARACTERIZATION OF CD8A CELLS AS A NOVEL IMM	93.855		1 R21 AI115419-01	31	
VANDERBILT UNIVERSITY-AI117905-01 -ADMINCORE- STRUCTURE BASED DESIGN OF ANTIBODIES	93.855		1 U19 AI117905-01	97,534	118,338
VANDERBILT UNIVERSITY-AI118887-01 REOVIRUS ATTACHMENT MECHANISMS	93.855		1 R01 AI118887-01	45,796	45,504
VANDERBILT UNIVERSITY-AI119224-01 HIGH THROUGHPUT IDENTIFICATION OF TREG ACTIVATIN	93.855		1 R21 AI119224-01	(1,929)	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-AI121420-01 THE ROLE OF OVARIAN HORMONES ON ALLERGEN-MEDIATE	93.855		1 R21 AI121420-01	74	
VANDERBILT UNIVERSITY-AI121626-01A1:ENGINEERED NANOPARTICLES FOR PROTECTIVE SUBUNI	93.855		1 R21 AI121626-01A1	36,264	
VANDERBILT UNIVERSITY-AI32539-21:23 CELL BIOLOGY OF REOVIRUS INFECTION	93.855		5 R01 AI32539-22	14,228	14,229
VANDERBILT UNIVERSITY-AI38296-16S1: 17 SUPPL MOLUECULAR BASIS OF REOVIRUS PATHOGEN	93.855		4 R37 AI38296-16S1	582	
VANDERBILT UNIVERSITY-AI39657-17 STRUCTURE & FUNCTION OF HELICOBACTER PYLORI	93.855		2 R01 AI39657-16A1	39	
VANDERBILT UNIVERSITY-AI44924-14:15 IFN-GAMMA GENE REGULATION IN T CELLS AND NK CE	93.855		2 R01 AI44924-14	53	
VANDERBILT UNIVERSITY-AI69233-08 MECHANISM AND FUNCTION OF HEME-IRON UTILIZATIO	93.855		5 R01 AI69233-07	154	
VANDERBILT UNIVERSITY-AI69439-10 VANDERBILT HIV CLINICAL TRIALS UNIT ADMI	93.855		5 UM1 AI69439-10	495	
VANDERBILT UNIVERSITY-AI69923-10 CARIBBEAN, CENTRAL AND SOUTH AMERICA NETWORK FOR	93.855		5 U01 AI69923-10	194,541	228,054
VANDERBILT UNIVERSITY-AI76121-08 MECHANISM AND REGULATION OF HIV-1 UNCOATING	93.855		4 R01 AI76121-08	(4)	
VANDERBILT UNIVERSITY-AI77505-06A1:07 PHARMACOGENOMICS OF HIV THERAPY	93.855		2 R01 AI77505-06A1	66,998	52,748
VANDERBILT UNIVERSITY-AI91692-1:5 TOLL-LIKE RECEPTOR 2, VITAMIN D AND EXTRAPULMONA	93.855		5 K23 AI91692-04	(6,127)	
VANDERBILT UNIVERSITY-AI95202-05 CHILDHOOD INFECTIONS RESEARCH PROGRAM	93.855		5 T32 AI95202-05	(5,850)	
VANDERBILT UNIVERSITY-AI95227-05 HOST AND VIRAL DETERMINANTS OF INFANT AND CHILDHO	93.855		5 U19 AI95227-05	42,714	30,825
VANDERBILT UNIVERSITY-AI95755-03 STRUCTURAL MECHANISMS OF CLOSTRIDIUM DIFFICILE	93.855		5 R01 AI95755-02	8,056	
VANDERBILT UNIVERSITY-AI96186-05 IEDEA NETWORKS COORDINATING CENTER AT VANDERBILT	93.855		5 U01 AI96186-05	1,205	
WASHINGTON UNIVERSITY IN ST. LOUIS-AI73755-08S1:ANTIBODY-BASED PROTECTION AGAINST DE	93.855		3 R01 AI73755-08S1	36,330	
WASHINGTON UNIVERSITY IN ST. LOUIS-AI73755-09:ANTIBODY-BASED PROTECTION AGAINST DENGUE VIR	93.855		5 R01 AI73755-09	33,409	
Subtotal 93.855				**5,139,623**	**940,138**
UNIVERSITY OF KENTUCKY-AG46116-01A1: PAIN AND WELL-BEING IN OLDER WOMEN	93.856		1 R01 AG46116-01A1	13,341	
Subtotal 93.856				**13,341**	
CHILDREN'S HOSPITAL OF PHILADELPHIA-GM108807-01A1-02:LAMELLAR BODY BIOGENESIS IN HEALTJ AND	93.859		1 R01 GM108807-01A1-02	282,859	
CORNELL UNIVERSITY-GM105688-05:NOA-NATIONAL INFRASTRUCTURE FOR STANDARDIZED AND	93.859		5 R01 GM105688-05	99,211	
CORNELL UNIVERSITY-GM15688-04:NATIONAL INFRASTRUCTURE FOR STANDARDIZED AND PORT	93.859		7 R01 GM105688-04	579	
EAST TENNESSEE STATE UNIVERSITY-GM119197-01:TRAINING INNATE IMMUNITY: A NEW APPROACH TO T	93.859		1 R01 GM119197-01	244,622	
EMORY UNIVERSITY-GM111027-17A1 VIRAL AND CELLULAR DETERMINANTS OF HIV-1 ASSEM	93.859		9 R01 GM111027-17A1	11,191	
OREGON HEALTH & SCIENCE UNIVERSITY-GM116184-01:FXI AND SEPSIS	93.859		1 R01 GM116184-01	5,232	
OREGON HEALTH & SCIENCE UNIVERSITY-GM116184-02: FX AND SEPSIS	93.859		5 R01 GM116184-02	32,734	
PENNSYLVANIA STATE UNIVERSITY-GM105247-01: LINKING MODELS AND POLICY: USING ACTIVE ADAPTIV	93.859		1 R01 GM105247-01	65,871	140
UNIVERSITY OF ALABAMA AT BIRMINGHAM-GM118361-01:GENETIC REGULATION OF UNCONVENTIONAL P	93.859		1 R01 GM118361-01	24,225	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-GM118361-02:GENETIC REGULATION OF UNCONVENTIONAL P	93.859		5 R01 GM118361-02	9,544	
UNIVERSITY OF CINCINNATI-GM114640-01 (UNIV CINN) STRUCTURE-FUNCTION INVESTIGATION	93.859		1 R01 GM114640-01	162,382	15,574
UNIVERSITY OF PITTSBURGH-GM82251-09: PITTSBURGH CENTER FOR HIV PROTEIN INTERACTIONS	93.859		5 P50 GM82251-09	1,535	
UNIVERSITY OF PITTSBURGH-GM82251-10: PITTSBURGH CENTER FOR HIV PROTEIN INTERACTIONS	93.859		4 P50 GM82251-10	262,164	200
VANDERBILT UNIVERSITY-DK108159-01A1 METABOLITE PROFILES AND THE RISK OF DIABETES	93.859		1 R01 DK108159-01A1	(17,705)	
VANDERBILT UNIVERSITY-GM07569-39 CLINICAL PHARMACOLOGY TRAINING PROGRAM	93.859		5 T32 GM07569-39	(10,737)	
VANDERBILT UNIVERSITY-GM07628-39:TRAINING IN PHARMACOLOGICAL SCIENCES	93.859		3 T32 GM07628-39	3,059	
VANDERBILT UNIVERSITY-GM103859-01:02 INFORMATICS TOOLS FOR PHARMACOGENOMIC DISCOV	93.859		1 R01 GM103859-02	209,474	205,938
VANDERBILT UNIVERSITY-GM104306-01:03 AUGMENTATION OF INNATE ANTI-MICROBIAL IMMUNIT	93.859		5 R01 GM104306-03	38,494	8,211

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-GM106232-01:03 REVISED ALLOSTERIC MODULATORS OF THE GLUCAGON	93.859		5 R01 GM106232-02	(1,026)	
VANDERBILT UNIVERSITY-GM107947-01:02 ULTRA COMPACT POLARIZER PROBE - IMAGING METAB	93.859		1 R21 GM107947-02	1,895	
VANDERBILT UNIVERSITY-GM108554-02 TIPS: TRAINING IN PERIOPERATIVE SCIENCE	93.859		5 T32 GM108554-02	(2,734)	
VANDERBILT UNIVERSITY-GM109145-01:03 DRUG METABOLISM GENOTYPES IN CLINICAL PRACTIC	93.859		5 R01 GM109145-03	4,204	2,678
VANDERBILT UNIVERSITY-GM110469-01:02 SALIVARY CORTISOL AS A MARKER OF COMMUNITY-AC	93.859		1 K23 GM110469-01A1	7	
VANDERBILT UNIVERSITY-GM115305-01 IMPROVING PREDICTION OF DRUG ACTION-ADMIN CORE	93.859		1 P50 GM115305-01	(494,400)	(22,168)
VANDERBILT UNIVERSITY-GM115353-01 SERIAL, NON-INVASIVE MOLECULAR ANALYSIS OF EXHA	93.859		1 R01 GM115353-01	(721)	
VANDERBILT UNIVERSITY-GM117367-01 PREVENTION OF ENDOTHELIAL INJURY BY TOLL-LIKE RE	93.859		1 K08 GM117367-01	10	
VANDERBILT UNIVERSITY-GM117916-01:EXOSOME-FILOPODIA INTERACTIONS	93.859		1 R01 GM117916-01	4,405	
VANDERBILT UNIVERSITY-GM15431-48 RESEARCH CENTER FOR PHARM AND DRUG TOXIC PROJ 4	93.859		5 P01 GM15431-48	63,844	
VANDERBILT UNIVERSITY-GM66885-11:13 RESISTANCE OF BETA 2 MICROGLOBULIN NULL MICE T	93.859		5 R01 GM66885-11	1	
VANDERBILT UNIVERSITY-GM74771-05A1:8 KINASES IN ION COTRANSPORTER FUNCTION	93.859		2 R01 GM74771-05A1	(1,599)	
VANDERBILT UNIVERSITY-GM76592-09:CONVERGENCE OF THE COX-2 AND 5-LIPOXYGENASE PATHW	93.859		5 R01 GM76592-09	1,627	
VANDERBILT UNIVERSITY-LM07450-14 VANDERBILT BIOMEDICAL INFORMATICS TRAINING PGM	93.859		5 T15 LM07450-14	14,368	
VANDERBILT UNIVERSITY-LM07450-15:VANDERBILT BIOMEDICAL INFORMATICS TRAINING PROGRA	93.859		4 T15 LM07450-15	945	
Subtotal 93.859				**1,015,560**	**210,572**
DUKE UNIVERSITY-HD73984-05 DUKE STUDY OF OXYTOCIN IN AUTISM TO IMPROVE RECIP	93.865		7 U01 HD73984-05 DUKE	47,823	
DUKE UNIVERSITY-HD73984-06:STUDY OF OXYTOCIN IN AUTISM TO IMPROVE RECIPRO	93.865		5 U01 HD73984-06 DUKE	225,330	
GEORGE WASHINGTON UNIVERSITY-HD68541-02: MOMS2 OUTPATIENT - A FOLLOW UP OF CHILDREN EN	93.865		1 U01 HD68541-02	(122)	
GEORGE WASHINGTON UNIVERSITY-HD68541-05:MOMS 2 A FOLLOW-UP OF CHILDREN ENROLLED	93.865		5 U01 HD68541-05	14,849	
INDIANA UNIVERSITY-HD62484-02 PHARMACOGENETIC DETERMINANTS OF VINCRISTINE TO	93.865		1 R01 HD62484-02	8,631	
NATIONWIDE CHILDREN'S HOSPITAL-HD74736:MULTIMODAL EVALUATION OF SENSORY PROCESSING AND	93.865		7 K23 HD74736	151	
NATIONWIDE CHILDREN'S HOSPITAL-HD74736-04:MULTILMODAL EVALUATION OF SENSORY PROCESSING A	93.865		7 K23 HD74736-04	655	
NATIONWIDE CHILDREN'S HOSPITAL-HD81120-02:EARLY CHILDHOOD CONSTRAINT THERAPY FOR SENSORY	93.865		1 R01 HD81120-02	25,092	
NATIONWIDE CHILDREN'S HOSPITAL-HD81120-03:EARLY CHILDHOOD CONSTRAINT THERAPY FOR SENSORY	93.865		1 R01 HD81120-03	4,086	
STANFORD UNIVERSITY-HD84679-02:WEBINAR IMPLEMENTATION FOR THE SCIENCE OF ENHANCI	93.865		1 R01 HD84679-02	12,298	
TEXAS A & M UNIVERSITY-HD079625-01A1 ROLE OF MIR15A AND MIR34C IN PGE2 SIGNALING	93.865		1 R01 HD079625-01A1	13	
TEXAS A & M UNIVERSITY-HD79625-02:ROLE OF MIR15A AND MIR34C IN PGE2 SIGNALING	93.865		1 R01 HD79625-02	51,394	
TEXAS A & M UNIVERSITY-HD79625-03:ROLE OF MIR15A AND MIR34C IN PGE2 SIGNALING	93.865		1 R01 HD79625-03	9,684	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-HD61222-11 NATURAL HISTORY OF RETT SYNDROME, MECP2	93.865		2 U54 HD61222-11	321	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-HD61222-12:NATURAL HISTORY OF RETT SYNDROME, MECP2	93.865		5 U54 HD61222-12	13,671	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-HD61222-13:RETT SYNDROME, MECP2 DUPLICATIONS AND RE	93.865		5 U54 HD61222-13	50,911	
UNIVERSITY OF IOWA-HD87864-01:NEWBORN METABOLIC SCREENING FOR PREDICTION OF CHI	93.865		1 R21 HD87864-01	94,690	
UNIVERSITY OF MARYLAND-HD67126-05 AZITHROMYCIN TO PREVENT BPD IN UREAPLASMA-INFECTE	93.865		5 R01 HD67126-05	2,695	
UNIVERSITY OF NORTH CAROLINA-HD82127-02:BEHAVIORAL INFLEXIBILITY IN IDD OUTCOME MANAGEME	93.865		5 R01 HD82127-02	244,746	18,201
UNIVERSITY OF WISCONSIN-HD71089-05:SOCIAL PERCEPTION AND SOCIAL COMMUNICATION	93.865		4 R01 HD71089-05	76,631	9,734
VANDERBILT UNIVERSITY-HD00001-02 MTRNR1 AMINOGLYCOSIDE OTOTOXICITY OUTCOMES AND	93.865		1 K23 HD00001-01	874	
VANDERBILT UNIVERSITY-HD067254-01PREDICITNG LATE-EMERGING RD:NEUROBOLOGICAL AND CO	93.865		1 R01 HD067254-01/05	1,367	
VANDERBILT UNIVERSITY-HD075005-01A1 STRESS,PARENTING AND COGNITIVE FUNCTION	93.865		1 R21 HD075005-01A1	319	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-HD35684-14:16 PREDICTING PHENOTYPIC TRAJECTORIES IN (SOM)	93.865		5 R01 HD35684-14	8,724	
VANDERBILT UNIVERSITY-HD43483-14 BIRCWH - ADMIN (PARENT)	93.865		5 K12 HD43483-14	(8,069)	
VANDERBILT UNIVERSITY-HD44073-13:COGNITIVE AND NEURAL PROCESSES IN READING COMP	93.865		5 R01 HD44073-13	2,755	
VANDERBILT UNIVERSITY-HD53714-08:PREVENTING AND UNDERSTANDING MATHEMATICS DISABILI	93.865		5 R01 HD53714-08	14,034	
VANDERBILT UNIVERSITY-HD53714-09:PREVENTING & UNDERSTANDING MATHEMATICS DISABILITY	93.865		5 R01 HD53714-09	2,147	
VANDERBILT UNIVERSITY-HD59794-06:08 ROLE OF PARENT HEALTH LITERACY IN EARLY CHILD	93.865		5 R01 HD59794-08	247,723	247,913
VANDERBILT UNIVERSITY-HD60554-06A1 CONDUCTING CHILD HEALTH CARE RESEARCH IN	93.865		2 T32 HD60554-06A1	(1,466)	
VANDERBILT UNIVERSITY-HD64727-06A1;SLOS AND NEURAL OXIDATIVE STRESS	93.865		2 R01 HD064727-06A1	23,980	
VANDERBILT UNIVERSITY-HD68256-05 PREVENTING PREMATURITY AND POOR PREGNANCY OUTCOME	93.865		5 T32 HD68256-05	586	
VANDERBILT UNIVERSITY-HD74711-01 UNDERSTANDING THE GENETIC RISK UNDERLYING RACIAL	93.865		1 R01 HD74711-01	31,199	42,158
VANDERBILT UNIVERSITY-HD74711-03S1 UNDERSTANDING THE GENETIC RISK UNDERLYING RACIA	93.865		3 R01 HD74711-03S1	3,805	
VANDERBILT UNIVERSITY-HD75443-04:CORE A WORD PROBLEMS, LANGUAGE, AND COMORID LEARN	93.865		5 R24 HD75443-04	830	
VANDERBILT UNIVERSITY-HD75443-04:PROJ 1-WORD PROBLEMS, LANGUAGE, AND COMORBID LEAR	93.865		5 R24 HD75443-04	839	
VANDERBILT UNIVERSITY-HD76733-01A1:02 TIMING OF INGUINAL HERNIA REPAIR IN PREMATUR	93.865		1 R01 HD76733-01A1	31,760	31,108
VANDERBILT UNIVERSITY-HD76983-01:03 PREDICTING TREATMENT RESPONSE IN PEDIATRIC FU	93.865		5 R01 HD76983-02	8,474	8,474
VANDERBILT UNIVERSITY-HD80148-01A1 PAROUS MOUSE: A UNIQUE MODEL TO DEFINE UTERINE	93.865		1 R21 HD80148-01A1	(12,417)	
VANDERBILT UNIVERSITY-HD81121-02 DETECTING BIOCHEMICAL CHANGES IN THE PREGNANT MOU	93.865		1 R01 HD81121-01	(40)	
VANDERBILT UNIVERSITY-HD83211-01A1 E.K SHRIVER INTELLECTUAL DEVELOPMENT CORE A	93.865		1 U54 HD83211-01A1	(7)	
VANDERBILT UNIVERSITY-HD84500-01A1 MARKERS OF DISEASE PROGRESSION IN MECP2 DUPLICA	93.865		1 R01 HD84500-01A1	11,352	
VANDERBILT UNIVERSITY-HD87023-01 PATHOGENESIS, TARGETED THERAPEUTICS, AND NEW VAC	93.865		1 K12 HD87023-01	6,502	
VANDERBILT UNIVERSITY-HD89474-01:NEUROBIOLOGY AND TREATMENT OF READING DISABILITY	93.865		1 R01 HD89474-01	1,407	
WAKE FOREST UNIVERSITY-HD84606:BUILDING SOCIAL NETWORKS TO IMPROVE PHYSICAL ACT	93.865		1 R01 HD84606	14,101	
Subtotal 93.865				**1,274,328**	**357,588**
BROWN UNIVERSITY-AG44374-03:COST SHARING, USE, & OUTCOMES OF POST-ACUTE CARE	93.866		5 R01 AG44374-03	53,362	
MASSACHUSETTS GENERAL HOSPITAL-AG46149-04:BUILDING COMMUNITY CAPACITY FOR DISABILITY PREV	93.866		5 R01 AG46149-04	33,754	
NATIONAL BUREAU OF ECONOMIC RESEARCH, INC.-AG41794-04:ESTIMATING THE RETURNS TO MEDICAL C	93.866		2 R01 AG41794-04	119,361	
UNIVERSITY OF MARYLAND-AG37120-03 NON-INVASIVE TREATMENT OF ABDOMINAL AORTIC ANEUR	93.866		5 R01 AG37120-03	1	
UNIVERSITY OF MARYLAND-AG37120-04:NON-INVASIVE TREATMENT OF ABDOMINAL AORTIC ANEUR	93.866		5 R01 AG37120-04	118,280	
UNIVERSITY OF NEBRASKA MEDICAL CENTER OMAHA-AG37120-02 NON-INVASIVE TREATMENT OF ABDOMI	93.866		5 R01 AG37120-03	(13)	
UNIVERSITY OF NEBRASKA MEDICAL CENTER OMAHA-AG37120-04 : NON-INVASIVE TREATMENT OF ABDO	93.866		4 R01 AG37120-04	72,031	
UNIVERSITY OF VERMONT-AG50716-01A1:THE NICOTINIC CHOLINERGIC SYSTEM AND COGNITIVE	93.866		1 R01 AG50716-01A1	12,278	
VANDERBILT UNIVERSITY-AG33679-05 SYSTEMIC INFLAMMATION AND CENTRAL NERVOUS SYSTEM	93.866		7 R01 AG33679-05	(58)	
VANDERBILT UNIVERSITY-AG34962-04S2:05S1 CARDIAC FUNCTION AS A MECHANISM FOR MALADA	93.866		3 R01 AG34962-05	(1,190)	
VANDERBILT UNIVERSITY-AG34962-06 CARDIAC FUNCTION AS A MECHANISM FOR MALADAPTIVE B	93.866		4 R01 AG34962-06	1,131	
VANDERBILT UNIVERSITY-AG35117-01:4 THE MIND USA STUDY	93.866		1 R01 AG35117-01A1	15,277	25,571
VANDERBILT UNIVERSITY-AG35117-05 THE MIND USA STUDY	93.866		4 R01 AG35117-05	68,837	53,208
VANDERBILT UNIVERSITY-AG38471-1:5 COGNITIVE AND NEURAL CORRELATES OF THE PICTURE	93.866		5 R01 AG38471-05	(77)	
VANDERBILT UNIVERSITY-AG38481-03:05 ORGANIZATIONAL FACTORS & THE DELIVERY OF NURSI	93.866		7 K01 AG38481-05	4	
VANDERBILT UNIVERSITY-AG43458-03:DOPAMINERGIC NEUROMODULATION OF DECISION MA	93.866		1 R01 AG43458-03	267,116	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-AG43471-01A1:03 OPIOD SELECTIONS & THE RISK OF SERIOUS INF	93.866		5 R01 AG43471-03	6	
VANDERBILT UNIVERSITY-AG45085-02 ROLE OF ENDOTHELIAL AND BRAIN INJURY IN ACUTE	93.866		1 R03 AG45085-01A1	(7,241)	
VANDERBILT UNIVERSITY-AG45735-01A1:02 AGE-RELATED DIFFERENCES MEDICINE BUDGET	93.866		5 R21 AG45735-02	(23)	
VANDERBILT UNIVERSITY-AG45735-01A1:02 AGE-RELATED DIFFERENCES MEDICINE BUDGET	93.866		5 R21 AG45735-02	17,625	
VANDERBILT UNIVERSITY-AG46093-03 INSULIN RESISTANCE, VASCULAR REACTIVITY,	93.866		5 F32 AG46093-03	2,919	
VANDERBILT UNIVERSITY-AG47992-01A1 LONG-TERM NICOTINE TREATMENT OF MILD COGNITIVE	93.866		1 R01 AG47992-01A1	77,062	69,792
VANDERBILT UNIVERSITY-AG49332-01A1:DIFFERENCES IN PAIN BETWEEN ALZHEIMER'S DISEA	93.866		1 R21 AG49332-01A1	64,067	
VANDERBILT UNIVERSITY-AG55184-01:2-HYDROXYBENZYLAMINE FOR THE PREVENTION OF ALZHEI	93.866		1 R44 AG55184-01	100,905	
Subtotal 93.866				**1,015,414**	**148,571**
CHILDREN'S HOSPITAL OF PHILADELPHIA-EY21137:POSTNATAL GROWTH AND RETINOPATHY OF PREMATU	93.867		1 R01 EY21137	2,488	
CHILDREN'S HOSPITAL OF PHILADELPHIA-EY21137-05:POSTNATAL GROWTH AND RETINOPATHY OF PREMA	93.867		4 R01 EY21137-05	6,243	
EMORY UNIVERSITY-EY25553-01:INFANT APHAKIA TREATMENT STUDY - CLINICAL CENTERS	93.867		1 UG1 EY25553-01	5,719	
JAEB CENTER FOR HEALTH RESEARCH-EY11751-19:PEDIATRIC EYE DISEASE INVESTIGATOR GROUP	93.867		5 U10 EY11751-19	16,071	
JAEB CENTER FOR HEALTH RESEARCH-EY11751-20:PEDIATRIC EYE DISEASE INVESTIGATOR GROUP COORDIN	93.867		5 U10 EY11751-20	8,196	
JAEB CENTER FOR HEALTH RESEARCH-JAEB CENTER FOR HEALTH RSCH EY11751 STUDY	93.867		5 U10 EY11751-03	15,541	
PENNSYLVANIA STATE UNIVERSITY-EY23533 SCORE2 COMPARATIVE TRIAL (SCT)	93.867		1 U01 EY2353	1,837	
UNIVERSITY OF COLORADO-EY25333-01:02 FUNCTIONAL REVERSE THERMAL GEL RETINAL GANGLI	93.867		1 R21 EY25333-01	17,083	
UNIVERSITY OF MIAMI-EY12118-15:GENOMIC ARCHITECTURE OF PROGRESSION AND TREATMEN	93.867		5 R01 EY12118-15	19,152	
UNIVERSITY OF PITTSBURGH-HL129066-01:OUTSIDE IN REGENERATION OF ABDOMINAL AORTIC ANEU	93.867		1 R21 HL129066-01	9	
VANDERBILT UNIVERSITY-EY012018-19-20 MOLECULAR BASIS FOR LENS TRANSPARENCY	93.867		4 R01 EY-12018-19/20	(17)	
VANDERBILT UNIVERSITY-EY024036- QUANTITATIVE IMAGE ANALYSIS TECH FOR OPTIC-MAIN CT	93.867		1 R21 EY24036	637	
VANDERBILT UNIVERSITY-EY024036-QUANTITATIVE IMAGE ANAYSIS TECH - EYE INSTITUTE	93.867		1 R21 EY24036	15,119	
VANDERBILT UNIVERSITY-EY08126-27 CORE GRANT IN VISION RESEARCH - PARENT CENTER	93.867		5 P30 EY08126-27	(2,085)	
VANDERBILT UNIVERSITY-EY13760-11 REGULATION OF RETINAL PROGENITOR CELL PROPERTIES	93.867		7 R01 EY13760-11	(14,477)	
VANDERBILT UNIVERSITY-EY20496-01:05 INTERIEUKIN-6 AND RETINAL GANGLION CELL DEGE	93.867		5 R01 EY20496-05	19,374	
VANDERBILT UNIVERSITY-EY20894-04A1:05 MICROFIBRIL DEFICIENCY IN GLAUCOMA PATHOGEN	93.867		2 R01 EY20894-04A1	(61,608)	
VANDERBILT UNIVERSITY-EY22349-01:05 NOVEL THERAPY AND MECHANISMS IN GLAUCOMA	93.867		5 R01 EY22349-05	13,498	
VANDERBILT UNIVERSITY-EY22349-06 NOVEL THERAPY AND MECHANISMS IN GLAUCOMA	93.867		4 R01 EY22349-06	(10,872)	
VANDERBILT UNIVERSITY-EY22618-01A1:03 METABOLOMIC AND GENETIC INTERACTIONS IN AGE	93.867		1 R01 EY22618-01A1	(2,520)	
VANDERBILT UNIVERSITY-EY23240-01:03 MICROSTRUCTURAL CHARACTERIZATION OF THE OPTIC	93.867		5 R01 EY23240-02	(50,911)	
VANDERBILT UNIVERSITY-EY23397-01:03 IN VIVO MOLECULAR IMAGING OF THE RETINA	93.867		5 R01 EY23397-03	(1,765)	
VANDERBILT UNIVERSITY-EY23397-04 IN VIVO MOLECULAR IMAGING OF THE RETI	93.867		4 R01 EY23397-04	64,585	
VANDERBILT UNIVERSITY-EY23639-01:03 CALCINEURIN/NFAT SIGNALING AXIS-DIABETIC RETI	93.867		5 R01 EY23639-02	(535)	
VANDERBILT UNIVERSITY-EY24036-02:QUANTITATIVE IMAGE ANALYSIS TECHNIQUES	93.867		5 R21 EY24036-02	1,490	
VANDERBILT UNIVERSITY-EY24373-01A1 REGULATION OF EYE MORPHOGENESIS	93.867		1 R01 EY24373-01A1	(61,741)	
VANDERBILT UNIVERSITY-EY26176-01:GRAPHENE OPTOELECTRONIC PROBES FOR MAPPING	93.867		1 R21 EY26176-01	57,814	
Subtotal 93.867				**58,324**	
GROUP HEALTH-LM11366-02 SCALABLE & ROBUST CLINICAL TEXT DE-IDENTIFICATION	93.879		5 R01 LM11366-02	3,118	
PURDUE UNIVERSITY-LM11999-01: DETECTION OF POTENTIAL DRUG EFFECT SIGNALS FROM	93.879		1 R15 LM11999-01	38,847	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
VANDERBILT UNIVERSITY-LM09989-06 TECHNOLOGIES TO ENABLE PRIVACY IN BIOMEDICAL DATA	93.879		1 R01 LM09989-01A1	30,721	30,799
VANDERBILT UNIVERSITY-LM10207-05A1:06 AUTOMATED DETECTION OF ANOMALOUS ACCESSES TO	93.879		2 R01 LM10207-05A1	2,505	
VANDERBILT UNIVERSITY-LM10685-04:05 FROM GWAS TO PHEWAS: SCANNIN THE EMR PHENOME F	93.879		2 R01 LM10685-05	(117)	
VANDERBILT UNIVERSITY-LM11382-01:2 DEVELOPING NEW APPROACHES TO CHRONIC DISEASE	93.879		1 K22 LM11382-01	(864)	
VANDERBILT UNIVERSITY-LM11933-01A1 LEARNING PATTERNS OF COLLABORATION TO OPTIMIZE	93.879		1 K99 LM11933-01A1	(426)	
Subtotal 93.879				**73,784**	**30,799**
TN DEPARTMENT OF HEALTH-GR-15-45951-00: DIABETES PREVENTION	93.945		GR-15-45951-00	2,930	
Subtotal 93.945				**2,930**	
VANDERBILT UNIVERSITY-TW01035-15 VANDERBILT UNIVERISTY-CIDRZ AIDS INTERNATIONAL TR	93.989		5 D43 TW01035-15	(112)	
VANDERBILT UNIVERSITY-TW09348-04:VANDERBILT-ZAMBIA NETWORK FOR INNOVATION IN GLOB	93.989		5 D43 TW009348-04	4,409	
VANDERBILT UNIVERSITY-TW09348-05:VANDERBILT-ZAMBIA NETWORK FOR INNOVATION IN GLOBA	93.989		4 D43 TW09348-05	16,342	
VANDERBILT UNIVERSITY-TW09722-03 VU-MOZAMBIQUE COLLABOR RESEARCH ETHICS EDUCATION	93.989		5 R25 TW09722-03	9,087	8,733
VANDERBILT UNIVERSITY-TW09744-01A1 UNZA-VANDERBILT PARTNERSHIP-HIV-NUTRITION RESCH	93.989		1 D43 TW09744-01A1	3,134	2,788
VANDERBILT UNIVERSITY-TW09745-01A UEM PARTNERSHIP - RESEARCH IN SCIENCE MOZAMBIQUE	93.989		1 D43 TW09745-01A1	20,581	14,287
VANDERBILT UNIVERSITY-TW9337-04 VANDERBILT-EMORY-CORNELL-DUKE CONSORTIUM FOR GLOBA	93.989		5 R25 TW09337-04	245,840	235,734
Subtotal 93.989				**299,280**	**261,542**
ABT ASSOCIATES, INC.-TASK ORDER 1:EPIDEMIOLOGY OF NOVEL INFLUENZA VIRUS INFECTION	93.RD		GS-10F-0086K/BPA 200	807	
DUKE UNIVERSITY-200-2011-41276:TUBERCULOSIS EPIDEMILOGIC STUDIES CONSORTIUM	93.RD		200-2011-41276	74,930	
DUKE UNIVERSITY-ANTIBIOTIC SAFETY IN INFANTS WITH COMPLICATED INTRA-ABDOMINA	93.RD		HHSN27520120000031	15,647	
DUKE UNIVERSITY-CDC 200-2011-41276: TUBERCULOSIS EPIDEMILOGIC STUDIES CONSOR	93.RD		CDC 200-211-41276	118,275	79,440
DUKE UNIVERSITY-HHSO100201300009C: DUKE 212079: A PHASE 1 OPEN-LABEL MULTI-C	93.RD		HHSO100201300009C	4,348	
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC.-HHSN261201100100C: SEP2C: NCI 9111 - ST	93.RD		HHSN261201100100C	234	
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC.-NCI 8972 RANDOMIZED PHASE II TRIAL OF TI	93.RD		SEP2C HEM1151	19,240	
HARVARD PILGRIM HEALTH CARE-HHSF22301001T: YEAR 2 INFRASTRUCTURE TO#1	93.RD		HHSF2230101T	81,693	
HARVARD PILGRIM HEALTH CARE-HHSF22301001T:MAINTENANCE AND OPERATION FOR MEDICATION EXP	93.RD		HHSF22301001T	19,969	
HARVARD PILGRIM HEALTH CARE-HHSF22301001T:YEAR 3 INFRASTRUCTURE TO#1	93.RD		HHSF22301001T	150,039	
HARVARD PILGRIM HEALTH CARE-HHSF22301007T:KAWASAKI DISEASE AND PCV13 VACCINE	93.RD		HHSF22301007T	15,835	
HARVARD PILGRIM HEALTH CARE-HHSF22301012T-0024 SUPPORT WORKGROUP ACTIVITIES FOR TO 12	93.RD		HHSF22301012T-0024	1,491	
HARVARD PILGRIM HEALTH CARE-HHSF22301013T-0002: TO#13 MINI-SENTINAL; VTI VS, ORAL CLEFTS	93.RD		HHSF22301013T-0002	15,330	
HARVARD PILGRIM HEALTH CARE-HHSF223201400042I:HHSF22301002T:RISK OF NTD AMONG LIVE BIRTH	93.RD		HHSF223201400042I	60,163	
HARVARD UNIVERSITY-HHSF22301006T-005: IVIG TEE WORKPLANS MOD#2	93.RD		HHSF22301006T-005	841	
INTEGRAL MOLECULAR-HHSN272201400058C - INTEGRAL B-CELL EPITOPE DISCOVERY	93.RD		HHSN272201400058C	49,294	
INTEGRAL MOLECULAR-HHSN272201400058C:SUPP B-CELL EPITOPE DISCOVERY AND MECHANIS	93.RD		HHSN272201400058C:SUP	1,348,697	
LEIDOS BIOMEDICAL RESEARCH, INC.(FORMERLY SAIC-FREDERICK)-HHSN261200800001E:CONNECTING GE	93.RD		HHSN261200800001E	74,382	1,138
LEIDOS BIOMEDICAL RESEARCH, INC.(FORMERLY SAIC-FREDERICK)-HHSN261200800001E:LEIDOS 16X142 ID	93.RD		HHSN261200800001E	138,712	
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH-HHSN2612012000421:THE EFFECT OF CUR	93.RD		HHSN2612012000421	4,090	
NEW YORK UNIVERSITY-HHSN27220140 B CELL EPITOPE DISCOVERY AND MECHANISMS ANTIBOD	93.RD		HHSN27220140	31,226	
NORTHWESTERN UNIVERSITY-HHSN261201200035I:HHSN26100009:CANCER PREVENTION AGENT DEVEL	93.RD		HHSN261201200035I	7,114	
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION-13XS131: HHSN261200800001E - TCGA RADIOLOG	93.RD		HHSN261200800001E	1,889	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION-SAIC - 13XS029: HHSN261200800001E: NETWORK-	93.RD		HHSN261200800001E	84,239	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-HHSN26820090047C:SYSTOLIC BLOOD PRESSURE INTERVENTI	93.RD		HHSN268200900047C	15,739	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-HHSN272201100038C: CASG BASE PERIOD FIXED COST	93.RD		HHSN272201100038C	316	
UNIVERSITY OF ALABAMA AT BIRMINGHAM-HHSN27220110037C: CASG OPTION 2 PERIOD COST REIMBURS	93.RD		HHSN27220110037C	6,349	
UNIVERSITY OF MISSISSIPPI MEDICAL CENTER-HHSN268201300046C: JACKSON HEART STUDY - YEAR 4	93.RD		HHSN268201300046C YR4	35,469	
UNIVERSITY OF MISSISSIPPI MEDICAL CENTER-HHSN268201300046C: JACKSON HEART STUDY YR5	93.RD		HHSN268201300046C YR5	5,501	
UNIVERSITY OF UTAH-HHSN268200900046C SPRINT MRI AND MAIN SPRINT	93.RD		HHSN268200900046C	(26)	
UNIVERSITY OF UTAH-HHSN268200900046C: SPRINT CLINICAL CENTER NETWORK - CAPITAT	93.RD		HHSN268200900046C	(146)	
VANDERBILT UNIVERSITY-16X117 4A-WDR5-MLL1:INHIBITORS OF THE MYC-WDR5 INTERACTION	93.RD		16X117 4A-WDR5-MLL1	5,278	
VANDERBILT UNIVERSITY-HHSN268201400010C:DEVELOPMENT OF GAMMA-KETOALDEHYDE SCAVENG	93.RD		HHSN268201400010C	137,399	
VETERANS AFFAIRS-15FED1511233-002:TB TRIALS CONSORTIUM - ON CAMPUS	93.RD		15FED1511233-002	162,003	
VETERANS AFFAIRS-V688-2858: TB TRIALS CONSORTIUM - OFF CAMPUS	93.RD		V688-2858	360,798	310,515
VETERANS AFFAIRS-V688-2858: TB TRIALS CONSORTIUM - ON CAMPUS	93.RD		V688-2858	30,009	
WASHINGTON UNIVERSITY IN ST. LOUIS-HHSN272201400018C B-CELL EPITOPE - WUSTL	93.RD		HHSN272201400018C	156,772	
WASHINGTON UNIVERSITY IN ST. LOUIS-HHSN272201400018C WUSTL B-CELL EPITOPE MAPPING	93.RD		HHSN272201400018C	275,713	
Subtotal 93.RD				**3,509,657**	**391,093**
Total Department Of Health And Human Services				**44,987,189**	**5,709,675**
Department Of The Interior					
VANDERBILT UNIVERSITY-D15PC00304:PREMONITION: PREVENTATIVE MONITORING OF INFECTIOU	15.RD		D15PC00304	43,681	
Subtotal 15.RD				**43,681**	
Total Department Of The Interior				**43,681**	
Department Of The Treasury					
PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE-CE-12-11-4667: GENERATING CRITICAL PATIENT-CEN	21.RD		CE-12-11-4667	356,714	251,140
Subtotal 21.RD				**356,714**	**251,140**
Total Department Of The Treasury				**356,714**	**251,140**
Environmental Protection Agency					
VANDERBILT UNIVERSITY-83573601:EPA:VPROMPT	66.509		83573601:EPA	6,883	
VANDERBILT UNIVERSITY-83573601:VANDERBILT-PITTSBURGH RESOURCE FOR ORGANOTYPIC	66.509		83573601:VU/PITTSBURG	7,082	
VANDERBILT UNIVERSITY-83573601-VANDERBILT-PITTSBURGH RESOURCE-INFECTIOUS DISEASE	66.509		83573601-INFECTION DIS	7,020	
VANDERBILT UNIVERSITY-VANDERBILT-PITTSBURGH RESOURCE FOR ORGANOTYPIC MODELS FOR PR	66.509		EPA-VU SPONS BILLING A	11,035	
VANDERBILT UNIVERSITY-VANDERBILT-PITTSBURGH RESOURCE-OSBSTERICS&GYNECOLOGY	66.509		EPA 83573601-OB-BYN	202,976	
Subtotal 66.509				**234,995**	
Total Environmental Protection Agency				**234,995**	
National Aeronautics And Space Administration					
BAYLOR COLLEGE-CA03801:IMPROVING CARDIOVASCULAR RISK PREDICTION-BIOMARKERS	43.001		CA03801:NASA	1,847	
Subtotal 43.001				**1,847**	
BAYLOR COLLEGE-CA03801:IMPROVING CARDIOVASCULAR RISK PREDICTION-BIOMARKERS	43.002		CA03801:NASA	14,429	
Subtotal 43.002				**14,429**	
Total National Aeronautics And Space Administration				**16,276**	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
National Science Foundation					
VANDERBILT UNIVERSITY-CBET-1264462:INDIVIDUALIZED ADAPTIVE ROBOT-MEDIATED INTERVEN	47.041		CBET-1264462	6,814	
VANDERBILT UNIVERSITY-CBET-160520:LEVERAGING TOE DYNAMICS TO IMPROVE PROSTHETIC FE	47.041		CBET-1605200	5,187	
VANDERBILT UNIVERSITY-CREM: CONTINUUM ROBOTS MANIPULATION (OPTHALMOLOGY)	47.041		CMMI1537659 SUBCENTE	28,188	
VANDERBILT UNIVERSITY-PFI:AIR-TT: EXTERNAL STENTS TO PREVENT VEIN FAILURE IN DIALY	47.041		IIP1542996	8,685	
Subtotal 47.041				**48,874**	
JOHNS HOPKINS UNIVERSITY-NSF1329737:TWC:FRONTIER: COLLABORATIVE: ENABLING TRUSTWORTHY	47.070		NSF1329737	32,849	
VANDERBILT UNIVERSITY-CA186193:WIRELESS POINT OF CARE SENSOR FOR CONTINUOUS FLUID	47.070		R01 CA186193	19,308	
VANDERBILT UNIVERSITY-NRI: LARGE: COLLABORATIVE RESEARCH: UROLOGY SUBCENTER	47.070		IIS1327566 SUBCENTER	11,358	
Subtotal 47.070				**63,514**	
UNIVERSITY OF CALIFORNIA, SYSTEMWIDE-UC BERKELEY: GENOMIC DETERMINANTS OF PATHOGENICITY	47.074		UC BERKLEY	6,868	
UNIVERSITY OF PITTSBURGH-IOS-1649443:PITTSBURGH:CAREER: AN INTEGRATIVE APPROACH TO PR	47.074		IOS-1649443	657	
VANDERBILT UNIVERSITY-NSF IOS-1121758 IMMUNE MECHANISMS OF DISEASE RESISTANCE I	47.074		NSF IOS-1121758	(60)	
Subtotal 47.074				**7,465**	
US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION-OISE-15-61521-1:RHINOVIRUS GENOTYPING IN	47.079		US CRDF - 214062	11,718	6,257
US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION-OISE-9531011:IDENTIFYING INNOVATIVE BACTE	47.079		OISE-9531011	29,608	
Subtotal 47.079				**41,326**	**6,257**
Total National Science Foundation				**161,179**	**6,257**
Total Research and Development Cluster - Pass-Through Grantor				**49,404,597**	**6,056,183**
Total Research and Development Cluster				**346,161,352**	**49,847,179**
Medicaid Cluster - Pass-Through Grantor					
Department Of Health And Human Services					
TN BUREAU OF TENNCARE-46264:CLINICAL CENTER - PERINATAL NEWBORN AND OB/GYN	93.778		46264:TN-HIGH RISK PER	1,086,973	
TN BUREAU OF TENNCARE-CLINICAL CENTER - PERINATAL NEWBORN AND OB/GYN	93.778		PERINATAL NEWBORN AN	171,497	
TN DEPARTMENT OF FINANCE AND ADMINISTRATION-39861: ST OF TN:BEHAVIOR HEALTH SERVICES COE C	93.778		39861:ST TN	979,934	16,729
TN DEPARTMENT OF FINANCE AND ADMINISTRATION-39862:QUALITY AND SAFETY PROJECTS (CANS)	93.778		39862:ST TN	2,753,188	63,590
TN DEPARTMENT OF FINANCE AND ADMINISTRATION-GR-11-31880: EPSDT - CANS	93.778		GR-11-31880	405,898	
TN DEPARTMENT OF FINANCE AND ADMINISTRATION-GR-11-31880: EPSDT - COE	93.778		GR-11-31880	115,977	3,435
TN DEPARTMENT OF HEALTH-GR-15-42680:TIPQC-TN INITIATIVE PERINATAL QUALITY CARE	93.778		GR-15-42680-01: ST TN	432,562	
TN DEPARTMENT OF HEALTH-GR-15-42680-00 TIPQC-TN INITIATIVE PERINATAL QUALTY CARE	93.778		GR-15-42680-00	67,597	
UNIVERSITY OF MICHIGAN-M15ADM-16:IMPACT OF HEALTHY MICHIGAN PLAN ON UNCOMPENSATED	93.778		05 U05 M15ADM-16	16,378	
UNIVERSITY OF MICHIGAN-M15ADM-17:IMPACT OF HEALTHY MICHIGAN PLAN ON UNCOMPENSATED	93.778		05 U05 M15ADM-17	22,008	
Subtotal 93.778				**6,052,013**	**83,754**
Total Department Of Health And Human Services				**6,052,013**	**83,754**
Total Medicaid Cluster - Pass-Through Grantor				**6,052,013**	**83,754**
Total Medicaid Cluster				**6,052,013**	**83,754**
Special Education Cluster (IDEA) - Pass-Through Grantor					
Department Of Education					
TN DEPARTMENT OF EDUCATION-PROVIDE ACCESS TO THE VISUAL ENVIRONMENT (PAVE), 2015 - 2020	84.027	PAVE 7/2015 - 2020		369,274	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
TN DEPARTMENT OF EDUCATION-TREATMENT AND RESEARCH INSTITUTE FOR AUTISM SPECTRUM DISORD	84.027	STATE OF TN TRIAD		1,590,895	
VANDERBILT UNIVERSITY-46346/33136-01216:SECONDARY TRANSITION PLANNING PROJECT	84.027	46346/33136-01216		1,743	
VANDERBILT UNIVERSITY-H027A140052-14A:POSITIVE BEHAVIORAL INTERVENTIONS AND SUPPOR	84.027	H027A140052-14A		58,052	
VANDERBILT UNIVERSITY-H027A50052:SUPPORTING STRONG TRANSITIONS:PROFESSIONAL DEVEL	84.027	H027A50052		3,495	
Subtotal 84.027				**2,023,459**	
TN DEPARTMENT OF EDUCATION-49454:ST TN TRIAD-TREATMENT AND RESEARCH INSTITUTE FOR AUTIS	84.173	49454:ST TN		150,022	
TN DEPARTMENT OF EDUCATION-TN DOE 33136-00314 YR3: TRIAD TRAINING IN EARLY CHILDHOOD TE	84.173	TN DOE 33136-00314 YR3		9,033	
Subtotal 84.173				**159,055**	
Total Department Of Education				**2,182,514**	
Total Special Education Cluster (IDEA) - Pass-Through Grantor				**2,182,514**	
Total Special Education Cluster (IDEA)				**2,182,514**	
Other Awards - Direct Awards					
Department Of Education					
H325K160370 PREPARATION OF AUDIOLOGISTS, SPEECH-LAN	84.325	H325K160370		295,221	229,460
H325K160371 PROJECT GIFT-D-GRADUATE INSTRUCTION FOR	84.325	H325K160371		180,124	108,804
Subtotal 84.325				**475,344**	**338,264**
H326T150002 TENNESSEE DEAF-BLIND PROJECT (TNDB)	84.326	H326T150002		259,826	
Subtotal 84.326				**259,826**	
Total Department Of Education				**735,170**	**338,264**
Department Of Health And Human Services					
GH01943-01 SUPPORTING SUSTAINABLE IMPLEMENTATION OF HIV AND	93.067	1 NU2G GH01943-01		4,148,213	
Subtotal 93.067				**4,148,213**	
6 NU53DD000001-02-02 ENHANCING PUBLIC HEALTH SURVEILLANCE OF	93.073	6 NU53DD000001-02-02		356,654	
Subtotal 93.073				**356,654**	
MC30767-01-00 RURAL LEADERSHIP ED FOR NDRP FAMILIES BASE	93.110	7 T73MC30767-01-00		656,772	57,548
Subtotal 93.110				**656,772**	**57,548**
HA30750-01 RYAN WHITE PART D WICY COMPETING CONTINU	93.153	6 H12 HA30750-01		579,236	
Subtotal 93.153				**579,236**	
7H4BHS30752-01-00 POISON CONTROL STABILIZATION & EN	93.253	5 H4BHS15599-05-00		402,535	
Subtotal 93.253				**402,535**	
90DD0807-01-00 VANDERBILT KENNEDY CENTER FOR EXCELLENCE IN	93.632	90DD0807-01-00		86,476	
Subtotal 93.632				**86,476**	
HA30761-01-00 HIV EARLY INTERVENTION SERVICES -EIS-	93.918	7 H76 HA30761-01		548,598	
HA30761-02-00 HIV EARLY INTERVENTION SERVICES (EIS) PROGRAM,	93.918	5 H76 HA30761-02-00		109,007	
Subtotal 93.918				**657,605**	
Total Department Of Health And Human Services				**6,887,492**	**57,548**
Total Other Awards - Direct Awards				**7,622,662**	**395,812**
Other Awards - Pass-Through Grantor					

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
Agency For International Development					
FAMILY HEALTH INTERNATIONAL-AID-OAA-LA-13-00001: MOZAMBIQUE ASPIRES/SCIP EVALUATION	98.001	AID-OAA-LA-13-00001		269,105	
Subtotal 98.001				**269,105**	
Total Agency For International Development				**269,105**	
Department Of Education					
TN DEPARTMENT OF HUMAN SERVICES-34570-23917: EVALUATION, WORK ADJUSTMENT AND/OR EMPLOY	84.126	34570-23917 ST TN-FEDE		58,222	
TN DEPARTMENT OF HUMAN SERVICES-GR-10-28631: EVALUATION, WORK ADJUSTMENT AND/OR EMPLOY	84.126	GR-10-28631		15,206	
Subtotal 84.126				**73,429**	
TN DEPARTMENT OF EDUCATION-49954:TRIAD FAMILTY EDUCATION AND CONSULTATION SERV -WEST TN	84.181	49954:ST TN		279,967	
TN DEPARTMENT OF EDUCATION-49965:TRIAD/TEIS DIRECT FAMILY EDUCATION SERVICES MIDDLE TN	84.181	49965:ST TN		453,449	
Subtotal 84.181				**733,415**	
VANDERBILT UNIVERSITY-H325D140087 TRILL: TRAINING EXEMPLARY PRE-DOCTORAL RESEARCHE	84.325	H325D140087		9,168	
VANDERBILT UNIVERSITY-H325K120305 PREPARATION OF AUDIOLOGISTS, SPEECH-LANGUAGE	84.325	H325K120305-DOE		(488)	
VANDERBILT UNIVERSITY-H325K130226 PROJECT GIFT-D-GRADUATE INSTRUCTION FOR TEACHERS	84.325	H325K130226		(960)	
VANDERBILT UNIVERSITY-H325K140110:FOCUS AREA A:PREPARING EARLING CHILDHOOD SPECIAL	84.325	H325K140110		4,533	
VANDERBILT UNIVERSITY-H325K140110:FOCUS AREA A:PREPARING EARLY CHILDHOOD SPECIAL E	84.325	H325K140110		3,400	
Subtotal 84.325				**15,653**	
VANDERBILT UNIVERSITY-H326T130030 TENNESSEE DEAF-BLIND PROJECT (TNDB)	84.326	H326T130030		1,222	
Subtotal 84.326				**1,222**	
Total Department Of Education				**823,720**	
Department Of Health And Human Services					
FRIENDS OF THE GLOBAL HEALTH INITIATIVE IN NIGERIA-GH00922-03: ENGAGING INDIGENOUS ORGANIZA	93.067	3 U2G GH00922-03		20,584	
FRIENDS OF THE GLOBAL HEALTH INITIATIVE IN NIGERIA-GH00922-04:ENGAGING INDIGENOUS ORGANIZAT	93.067	5 U2G GH00922-04		20,683	
UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO-GH01270-02: STRENGTHENING MOZAMBICAN CAPACITY O	93.067	5 U2G GH01270-02		242,207	
Subtotal 93.067				**283,474**	
TN DEPARTMENT OF HEALTH-51265:POISON CONTROL,CHEMICAL AND ALL HAZARDS INCIDENT	93.069	51265:ST TN		49,912	
Subtotal 93.069				**49,912**	
VANDERBILT UNIVERSITY-DD01170-02 ENHANCING PUBLIC HEALTH SURVEILLANCE OF AUTISM SP	93.073	5 U53 DD01170-02		(907)	
Subtotal 93.073				**(907)**	
UNIVERSITY OF TENNESSEE-TRAINING AND IMPLEMENTATION OF TOP IN TENNESSEE CONGREGATE C	93.092	STATE OF TN - TOP		19,726	
Subtotal 93.092				**19,726**	
MASSACHUSETTS GENERAL HOSPITAL-MC11054-08:(AIR-P) AUTISM INTERVENTION RESEARCH NETWORK O	93.110	6 UA3 MC11054-08		27,107	
VANDERBILT UNIVERSITY-MC00050-16 VANDERBILT LEADERSHIP EDUCATION NEURODEVELOPMEN	93.110	5 T73 MC00050-16-00		11,789	9,087
Subtotal 93.110				**38,895**	**9,087**
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY-HA28686-02-01:AETC NATIONAL COORDINATING RESOU	93.145	6 U10 HA28686-02-01		14,680	
Subtotal 93.145				**14,680**	
VANDERBILT UNIVERSITY-HA24820-00 RYAN WHITE PART D WICY COMPETING CONTINUATION	93.153	2 H12 HA24820		2,863	
Subtotal 93.153				**2,863**	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
UNIVERSITY OF TENNESSEE-SAMSHA NCTSI CATEGORY III GRANT	93.243	UNIV OF TENNESSEE		21,600	
Subtotal 93.243				**21,600**	
TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE-31614-80217:PATHFINDER: DISA	93.630	31614-80217 ST TN		165,826	
TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE-PATHFINDER FY 2016: DISABILITY	93.630	STATE OF TN PATHFINDER		33,863	
Subtotal 93.630				**199,689**	
VANDERBILT UNIVERSITY-90DN0294-04:TENNESSEEWORKS PARTNERSHIP:CHANGING THE EMPLOYME	93.631	90DN0294-04		22,387	
VANDERBILT UNIVERSITY-90DN0294-05:TENNESSEEWORKS PARTNERSHIP: CHANGING THE EMPLOYM	93.631	90DN0294-05		69,691	
Subtotal 93.631				**92,079**	
TN DEPARTMENT OF CHILDREN'S SERVICES-42852:CPS ASSESSMENT TRACKING ACADEMY	93.658	42852:ST TN		189,902	36,350
TN DEPARTMENT OF CHILDREN'S SERVICES-CPS ASSESSMENT TRACK TRAINING ACADEMY	93.658	ST OF TN 35910-10211		22,048	
Subtotal 93.658				**211,950**	**36,350**
TN DEPARTMENT OF HEALTH-49551:TENNESSEE POISON CENTER - FEDERAL FUNDS	93.758	49551:ST TN		379,471	
Subtotal 93.758				**379,471**	
TN DEPARTMENT OF HEALTH-GR-16-47229: COORDINATION CENTER FOR EMS RADION COMMUNICATIO	93.889	GR-16-47229		42,837	
TN DEPARTMENT OF HEALTH-STATE OF TN POISON CONTROL-HOSPITAL BIOTERRORISM	93.889	GR-12-37671		42,073	
Subtotal 93.889				**84,911**	
METRO-NASH. AND DAVIDSON COUNTY,TENNESSEE-RYAN WHITE PART A PROGRAM OUTPATIENT	93.914	METRO HEALTH SERVICES		130,157	
METRO-NASH. AND DAVIDSON COUNTY,TENNESSEE-RYAN WHITE PART A PROGRAM OUTPATIENT AMBUL	93.914	METRO HEALTH SERVICES		459,980	
UNITED WAY OF TENNESSEE-RYAN WHITE PART A - MEDICAL CASE MANAGEMENT (MCM)	93.914	CCC/UNITED WAY AGREE		(244)	
Subtotal 93.914				**589,893**	
TN DEPARTMENT OF HEALTH-GR-15-44744-00 RYAN WHITE PART B	93.917	GR-15-44744-00		(1,068)	
TN DEPARTMENT OF HEALTH-GR-16-48966: RYAN WHITE PART B	93.917	GR-16-48966		618,874	
TN DEPARTMENT OF HEALTH-GR-17-53111-00:RYAN WHITE PART B	93.917	GR-17-53111-00:ST TN		212,147	
Subtotal 93.917				**829,952**	
VANDERBILT UNIVERSITY-HA24955-04 HIV EARLY INTERVENTION SERVICES -EIS- PROGRAM	93.918	6 H76 HA24955-04		31,686	
Subtotal 93.918				**31,686**	
TN DEPARTMENT OF HEALTH-54451: DATA LINKAGE INTERGRATION SERVICES	93.944	54451: ST TN		204	
Subtotal 93.944				**204**	
TN DEPARTMENT OF HEALTH-GR-14-37151-00: POISON CONTROL SERVICES	93.991	GR-14-37151-00: FY16		154,856	
Subtotal 93.991				**154,856**	
TN DEPARTMENT OF HEALTH-49293:CHILDREN AND YOUTH WITH SPECIAL HEALTH CARE NEEDS-FED	93.994	49293:ST TN		25,810	
TN DEPARTMENT OF HEALTH-CHILDREN AND YOUTH WITH SPECIAL HEALTH CARE NEEDS (CYSHCN)	93.994	34347-51316		14,958	
TN DEPARTMENT OF HEALTH-GR-15-41447-00: GENETIC SCREENING, TESTING, COUNSELING, EDUC	93.994	GR-15-41447-00		1,055,484	
Subtotal 93.994				**1,096,252**	
Total Department Of Health And Human Services				**4,101,185**	**45,437**
Nuclear Regulatory Commission					
VANDERBILT UNIVERSITY-NRC 3810948 VANDERBILT FELLOWSHIP NUCLEAR PROGRAM	77.006	NRC 3810948		(66)	
Subtotal 77.006				**(66)**	

Accompanying notes follow this Schedule

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards
Period Ended June 30, 2017 (April 29, 2016 - June 30, 2017)

Federal Grantor/Pass-through Grantor/Program or Cluster Title	CFDA Number	Award Number	Pass-through Entity Identification Number	Federal Expenditures	Passed to Sub-Recipients
Total Nuclear Regulatory Commission				(66)	
Total Other Awards - Pass-Through Grantor				5,193,944	45,437
Total Other Awards				12,816,607	441,249
Total Expenditures of Federal Awards				367,212,486	50,372,182

Accompanying notes follow this Schedule

VANDERBILT UNIVERSITY MEDICAL CENTER
NOTES TO THE SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE FOURTEEN MONTHS ENDED JUNE 30, 2017

1. Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (SEFA) includes the activity of Vanderbilt University Medical Center (VUMC) under programs of the federal government for the fourteen month period ended June 30, 2017. The information in the SEFA is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the schedules present only a selected portion of the operations of VUMC, they are not intended to, and do not, present the financial position, results of operations, changes in net assets, or cash flows of VUMC.

For purposes of the SEFA, federal awards include all grants, contracts and similar agreements entered into directly between VUMC and agencies and departments of the federal government and all subawards to VUMC by organizations pursuant to federal grants, contracts and similar agreements.

On April 29, 2016, Vanderbilt University ("VU") entered into a transaction to divest Vanderbilt University Medical Center ("VUMC"). As a result, VUMC became a separate legal entity, which is not under common governance with or controlled by VU. Further, VU is not financially responsible for VUMC indebtedness.

Vanderbilt University Medical Center (VUMC) has historically been part of the VU financial statement and Uniform Guidance audits, the last of which were for the period ended June 30, 2016, under EIN 62-0476822. From July 1, 2015 through April 29, 2016, VUMC was included with the FY16 VU financial statement and Uniform Guidance audit, retaining the low-risk auditee qualification. Subsequent to April 29, 2016, as a result of the legal separation described above, VUMC's initial separate financial statement audit and Uniform Guidance audit will be for the fourteen month period ending June 30, 2017. VUMC audit reports after the initial audit will be for the twelve month period, from July 1 through June 30.

All grants, contracts and similar agreements that were determined to be VUMC's on April 29, 2016 were relinquished as VU awards and reissued to the newly formed VUMC entity, which are included in the SEFA as Direct Awards subsequent to the divestiture date. The relinquished portion of the awards and closing activity, issued under VU's FEIN, are recorded in the SEFA as Pass-through awards from VU.

2. Summary of Significant Accounting Policies for the Schedule

For purposes of the Schedules, expenditures for federal programs are recognized on the accrual basis, which is consistent with generally accepted accounting principles.

Expenditures for federal awards of VUMC are determined using the cost accounting principles and procedures set forth in Uniform Guidance. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement.

Negative amounts represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. CFDA numbers and pass-through numbers are provided when available.

3. Facilities and Administrative Costs

Expenditures for certain federal awards of VUMC include facilities and administrative costs (indirect costs). Facilities and administrative costs allocated to such awards were based on redetermined fixed rates negotiated with VUMC's cognizant federal agency, the U.S. Department of Health and Human Services. Indirect costs and recoveries of those costs under sponsored programs are classified as unrestricted expenditures and revenues, respectively, in VUMC's financial statements. VUMC has elected not to use the 10-percent de minimis indirect cost rate allowed under the Uniform Guidance.

VUMC currently operates under a hospitals rate agreement, with an effective period through June 30, 2018.

Part II
Reports on Internal Control and Compliance

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

To the Board of Directors of
Vanderbilt University Medical Center

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Vanderbilt University Medical Center (the "Medical Center"), which comprise the consolidated balance sheet as of June 30, 2017, and the related consolidated statement of operations, statement of changes in net assets, and statement of cash flows for the fourteen months ended June 30, 2017, and the related notes to the financial statements, and have issued our report thereon dated December 7, 2017.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Medical Center's internal control over financial reporting ("internal control") to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Medical Center's internal control. Accordingly, we do not express an opinion on the effectiveness of the Medical Center's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Medical Center's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

PricewaterhouseCoopers LLP, 150 3rd Avenue South, Suite 1400, Nashville, TN 37201
T: (615) 503 2860, F: (615) 503 2870, www.pwc.com/us

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

December 7, 2017

Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the Uniform Guidance

To the Board of Directors of
Vanderbilt University Medical Center

Report on Compliance for Each Major Federal Program

We have audited Vanderbilt University Medical Center's (the "Medical Center") compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of the Medical Center's major federal programs for the fourteen months ended June 30, 2017. The Medical Center's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of the Medical Center's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the Medical Center's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the Medical Center's compliance.

Opinion on Each Major Federal Program

In our opinion, Vanderbilt University Medical Center complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the fourteen months ended June 30, 2017.

PricewaterhouseCoopers LLP, 150 3rd Avenue South, Suite 1400, Nashville, TN 37201
T: (615) 503 2860, F: (615) 503 2870, www.pwc.com/us

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs as item 2017-001. Our opinion on each major federal program is not modified with respect to this matter.

The Medical Center's response to the noncompliance finding identified in our audit is described in the accompanying management's corrective action plan. The Medical Center's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Management of the Medical Center is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the Medical Center's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Medical Center's internal control over compliance.

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

December 7, 2017

Part III
Findings

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF FINDINGS AND QUESTIONED COSTS
FOR THE FOURTEEN MONTHS ENDED JUNE 30, 2017

SECTION I – SUMMARY OF AUDITOR'S RESULTS

FINANCIAL STATEMENTS

Type of auditor's report issued:	Unmodified	
Internal control over financial reporting:		
♦ Material weakness(es) identified?	____ Yes	___X__ No
♦ Significant deficiency(ies) identified that are not considered to be material weakness(es)?	____ Yes	___X___None reported
♦ Noncompliance material to financial statements noted?	____ Yes	___X___No

FEDERAL AWARDS

Internal control over major programs:		
♦ Material weakness(es) identified?	_____Yes	___X__No
♦ Significant deficiency(ies) identified that are not considered to be material weakness(es)?	_____Yes	___X___None reported
Type of auditor's report issued on compliance for major programs:	Unmodified	
Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?	___X__Yes	_____No

IDENTIFICATION OF MAJOR PROGRAMS

CFDA Number(s)	**Name of Federal Program or Cluster**
Various	Research and Development Cluster
93.067	Global Aids
93.778	Medicaid Cluster

Dollar threshold used to distinguish between Type A and Type B programs: $3,000,000

Auditee qualified as low-risk auditee? ____Yes __X___ No

VUMC does not meet the criteria in CFR 200.520 to be a low-risk auditee as this is the first year that a single audit of VUMC has been performed. VUMC is a newly established legal entity in the current period.

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF FINDINGS AND QUESTIONED COSTS
FOR THE FOURTEEN MONTHS ENDED JUNE 30, 2017

SECTION II – FINANCIAL STATEMENT FINDINGS

No findings to be reported.

SECTION III – FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

Finding 2017-001 – Fixed Asset identification
Grantor: Various*
Program Name: Research and Development Cluster
Award Name: Various*
Award Year: Various*
Award Number: Various*
CFDA Number: Various*

*See Schedule of Expenditures of Federal Awards for awards within the Research and Development Cluster

Criteria
Section 200.313 (d) of the Uniform Guidance states the following: "Procedures for managing equipment (including replacement equipment), whether acquired in whole or in part under a Federal award, until disposition takes place will, as a minimum, meet the following requirements: (1) Property records must be maintained that include a description of the property, a serial number or other identification number, the source of funding for the property (including the FAIN), who holds title, the acquisition date, and cost of the property, percentage of Federal participation in the project costs for the Federal award under which the property was acquired, the location, use and condition of the property, and any ultimate disposition data including the date of disposal and sale price of the property. (2) A physical inventory of the property must be taken and the results reconciled with the property records at least once every two years. (3) A control system must be developed to ensure adequate safeguards to prevent loss, damage, or theft of the property. Any loss, damage, or theft must be investigated. (4) Adequate maintenance procedures must be developed to keep the property in good condition. (5) If the non-Federal entity is authorized or required to sell the property, proper sales procedures must be established to ensure the highest possible return.

Condition
Through our testing of internal controls over compliance requirements for Federal awards, we selected 40 assets to observe from the Fixed Asset subledger at year-end, out of a population of approximately 1,400 assets, with a gross and net cost of approximately $19.9 million and $15.5 million, respectively. Through our testing, it was noted that 4 of the 40 assets observed were not properly tagged in accordance with the entity's internal controls over the Equipment Compliance Requirement.

Cause
Missing or damaged fixed asset tags are identified either on an ad hoc basis by the responsible project team or as the result of the entity's bi-annual physical inventory of its property acquired using proceeds from a Federal award. Vanderbilt University Medical Center ("VUMC") was established as an independent legal organization on April 30, 2016 and VUMC established new policies and procedures related to fixed assets subsequent to the legal reorganization. The resulting policy requires the performance of a bi-annual physical inventory on a rotating basis covering all fixed assets over a two year period. The first physical inventory, subsequent to the legal reorganization, of fixed assets acquired with proceeds from Federal Awards will be completed during fiscal year ended June 30, 2018. Thus, it has been since fiscal year 2015 that a full physical inventory has been taken related to assets acquired using the proceeds from Federal Awards and certain assets' tags were either lost, destroyed, or damaged in the intervening period.

Effect
As VUMC uses fixed asset tags as a means of identifying individual assets acquired under a Federal award, missing fixed asset tags could lead to instances of noncompliance in the nature of use, condition, safeguarding, or disposition of assets acquired under Federal awards, as those assets would not be identifiable as being acquired with Federal funding.

Questioned Costs
None noted.

Recommendation
VUMC plans to perform the first bi-annual physical inventory of its property acquired under a Federal award, subsequent to the legal reorganization, during the fiscal year ended June 30, 2018 period, in accordance with the requirements of the Uniform Guidance. In addition to conducting this physical inventory, we recommend that VUMC implement a communication process for ensuring that missing or damaged fixed asset tags are timely replaced in periods between the entity's bi-annual physical inventory observations.

Management's Response
Please refer to VUMC's Management's Views and Correction Action Plan for additional details.

VANDERBILT UNIVERSITY MEDICAL CENTER
SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS
FOR THE FOURTEEN MONTHS ENDED JUNE 30, 2017

Not applicable, as this is the first year that a single audit of Vanderbilt University Medical Center has been performed.

December 7, 2017

2017-001 – Fixed Asset Identification

Management Views and Corrective Action Plan

Management agrees that there were limited instances of missing fixed asset tags on equipment acquired under a Federal award. Missing tags may lead to instances of noncompliance in the nature of use, condition, safeguarding, or disposition of assets acquired under Federal awards, as those assets may not be identifiable as being acquired with Federal funding.

To strengthen this control VUMC will conduct a physical inventory of all fixed assets acquired under a Federal award during fiscal year 2018, replacing all missing fixed asset tags. In addition, VUMC will document communication protocols between fixed asset physical inventory dates to ensure that any missing or destroyed tags are replaced.

Contact person:
Scott Phillips, Vice President of Finance and Controller
(scott.t.phillips@vumc.org; tel. 615-875-9078)